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“Inflammatory Diseases – A Modern Perspective” represents an extended and 
thoroughly revised collection of papers on inflammation. This book explores a wide 
range of topics relevant to inflammation and inflammatory diseases while its main 
objective is to help in understanding the molecular mechanism and a concrete review 
of inflammation. One of the interesting things about this book is its diversity in topics 
which include pharmacology, medicine, rational drug design, microbiology and 
biochemistry. Each topic focuses on inflammation and its related disease thus giving a 
unique platform which integrates all the useful information regarding inflammation. 
About the Contents 
Chapter 1 contains an introduction to Urinary trypsin inhibitor (UTI), a serine protease 
inhibitor which is found to be a good therapeutic option for endotoxin-related 
inflammatory disorders such as DIC, acute lung injury in targeted mice model. 
Chapter 2 concerns structure based molecule design approaches and comparative 
docking studies of various hnps-PLA2 indole inhibitor derivatives. In this study they 
proved that molecule 13h could be a novel anti-inflammatory drug. 
Chapter 3 formally supports a model wherein Th1 and IL-17+ T cells mechanistically 
interact and collaboratively contribute to BD skin pathogenesis. This is found to be a 
beneficial for further study in Behcet’s disease skin lesions 
Chapter 4 contains a review of the most Activate Protein C role in inflammatory 
disease 
Chapter 5 is devoted to the formal theory of role and expression TrkA receptor in the 
pulmonary hypertension. This chapter well explains the importance of TrkA receptor. 
Chapter 6 concerns review of cytokines, their major role in chronic inflammatory 
diseases and cancers and it also elucidates challenge and significance of the 
cytokinome profile. 
Chapter 7 examines Periodontal Inflammation as Risk Factor for Pancreatic Diseases. It 




Chapter 8 is entirely devoted to Polyunsaturated fatty acids. It well explains that they 
play critical roles in physiologic and pathophysiologic processes involving the immune 
system and have the ability to alter cellular responses as free fatty acids, most interest is 
on the properties of the array of metabolic products which they generate. These form a 
regulatory network which either down or up-regulates the inflammatory reaction. 
Chapter 9 concerns the importance of asthma especially scientific knowledge which 
can help to address how and why this condition occurs and may contribute to a better 
understanding of the classification of each asthma patient. 
Chapter 10 is discussion of the functional and structural characterization of AC0T7 in 
macrophages and their role in inflammation. 
Chapter 11 contains interesting observations of dietary n-3 PUFA and n-3 PUFA-rich 
food such as salmon which plays crucial role to reduce inflammatory bowel disease. 
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Urinary Trypsin Inhibitor, an  
Alternative Therapeutic Option  
for Inflammatory Disorders  
Ken-ichiro Inoue1 and Hirohisa Takano2 
1Department of Public Health and Molecular Toxicology,  
School of Pharmacy, Kitasato University, Tokyo 
2Kyoto University Graduate School of Enginnering,  
Department of Environmental Engineering, Kyoto 
 Japan 
1. Introduction  
Urinary trypsin inhibitor (UTI), a serine protease inhibitor, has been widely (and sometimes 
experiencely) used as a supportive drug for patients with inflammatory disorders such as 
pancreatitis, shock, and disseminated intravascular coagulation (DIC). Also, previous in 
vitro studies have demonstrated that serine protease inhibitors may have anti-inflammatory 
properties at sites of inflammation. However, the therapeutic effects of UTI in vivo remain 
unclarified, since commercial UTI have been developed to act against human, with the 
activity and selectivity toward the relevant animal UTI being less characterized. In this 
review, we introduce the roles of UTI mainly in experimental endotoxin 
(lipopolysaccharide: LPS)-related inflammatory disorders using UTI-deficient (-/-) and 
corresponding wild-type (WT) mice. Our experiments employing genetic approach suggest 
that endogenous UTI can serve protection against the systemic inflammatory response and 
subsequent organ injury induced by LPS, at least partly, through the inhibition of 
proinflammatory cytokine and chemokine expression, which provide important in vivo 
evidence and understanding about a protective role of UTI in inflammatory conditions. 
Using genetically targeted mice selectively lacking UTI, UTI has been evidenced to provide 
an attractive “rescue” therapeutic option for endotoxin-related inflammatory disorders such 
as DIC, acute lung injury, and acute liver injury. 
2. General characteristics of UTI and clinical utility 
UTI, also referred to as ulinastatin, HI-30, ASPI, or bikunin, is an acidic glycoprotein with a 
molecular weight of 30 kDa by SDS-polyacrylamide gel electrophoresis. UTI is a multivalent 
Kunitz-type serine protease inhibitor found in human urine and blood [1]. It is composed of 
143 amino acid residues and its sequence includes two Kunitz-type domains (Fig. 1). UTI is 
produced by hepatocytes as a precursor in which UTI is linked to α1-microgloblin [2, 3]. In 
hepatocytes, different types of UTI-containing proteins are formed by the assembly of UTI 
with one or two of the three evolutionarily related heavy chains (HC) 1, HC 2, and HC 3, 
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through a chondroitin sulfate chain [4]; these proteins comprise inter-α-inhibitor (IαI) 
family members, including IαI, pre-α-inhibitor (PαI), inter-α-like inhibitor (IαLI), and 
free UTI. IαI, pαI, and IαLI are composed of HC1 + HC2 + UTI, HC3 + UTI, and HC2 + 
UTI, respectively [5, 6]. Its specific activity was 2,613 U/mg protein, one unit being the 
amount necessary to inhibit the activity of 2μg trypsin (3,200 NFU/mg, Canada Packers) by 
50% [7]. During inflammation, UTI is cleaved from IαI family proteins through proteolytic 
cleavage by neutrophil elastase in the peripheral circulation or at the inflammatory site [8-
11]. Therefore, plasma UTI has been considered to be one of the acute phase reactions and 
indeed, the plasma UTI level and its gene expression alter in severe inflammatory 
conditions [9]. Further, UTI is rapidly released into urine when infection occurs and is an 
excellent inflammatory marker, constituting most of the urinary anti-trypsin activity [12]. 
Various serine proteases such as trypsin, thrombin, chymotrypsin, kallikrein, plasmin, 
 
 
Fig. 1. Molecular structure of urinary trypsin inhibitor (UTI). 
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chymotrypsin, kallikrein, plasmin, elastase, cathepsin, and Factors IXa, Xa, XIa, and XlIa are 
inhibited by UTI [13, 14]. Furthermore, UTI can reportedly suppress urokinase-type 
plasminogen activator (uPA) expression through the inhibition of protein kinase C (PKC) 
[15, 16]. UTI appears to prevent organ injury by inhibiting the activity of these proteases [17, 
18]. Based on the multivalent nature of protease inhibition, clinically, UTI is widely used, 
especially in Japan, to treat acute pancreatitis including post-endoscopic retrograde 
cholangiopancreatography pancreatitis, in which proteases are thought to play a 
pathophysiological role [19]; however, current understanding as for the target 
mechanisms/pathways remains limited. 
3. Anti-inflammatory potential of UTI in in vitro, in vivo, and humans 
Beyond its inhibition of inflammatory proteases mentioned above, UTI exhibits anti-
inflammatory activity and suppresses the infiltration of neutrophils and release of elastase 
and chemical mediators from them [11, 20, 21]. Likewise, UTI reportedly inhibits the 
production of tumor necrosis factor (TNF)-α[22, 23] and interleukin (IL)-1 [23] in LPS-
stimulated human monocytes and LPS- or neutrophil elastase-stimulated IL-8 gene 
expression in HL60 cells [24] or bronchial epithelial cells [25] in vitro. Matsuzaki et al. 
demonstrated that UTI inhibits LPS-induced TNF-α and subsequent IL-1β and IL-6 
induction by macrophages, at least partly, through the suppression of mitogen-activated 
protein kinase (MAPK) signaling pathways such as ERK1/2, JNK, and p38 in vitro [26]. 
Nakatani and colleagues demonstrated that UTI inhibits neutrophil-mediated endothelial 
cell injury in vitro, suggesting that UTI can act directly/indirectly on neutrophils and 
suppress the production and secretion of activated elastase from them [21]. Furthermore, 
UTI down-regulates stimulated arachidonic acid metabolism such as thromboxane B2 
production in vitro [27], which plays a role in the pathogenesis of sepsis [28]. 
A large number of in vivo reports have provided evidence that UTI protects against 
pathological traits related to septic shock induced by gram-negative bacteria: UTI reduces 
LPS-elicited circulatory failure such as hypotension, lactic acidosis, and hyperglycemia [29-
31] through modulating TNF-α production via the inhibition of early growth response factor 
(Egr)-1 in monocytes and pulmonary induction of inducible nitric oxide synthase (iNOS) 
[29] and reduces mortality caused by sepsis [32]. Also, UTI can alleviate coagulatory 
disturbance accompanied by sepsis such as an increase in the serum level of fibrinogen and 
fibrinogen degradation products [33]. Likewise, UTI has a protective effect against ischemia-
reperfusion injury in the liver [35], kidney [36], heart [37], and lung [38] in vivo via the 
actions of its radical scavenging elements [39]. As for its mechanism, UTI reduces C-X-C 
chemotactic molecule production during liver ischemia/reperfusion in vivo [40]. In humans, 
prepump administration (5,000 U/kg) of UTI reportedly improves cardiopulmonary 
bypass-induced hemodynamic instability and pulmonary dysfunction through the 
attenuation of IL-6 and IL-8 production/release in humans [41]. Also, UTI can inhibit 
coagulatory activation accompanied by severe inflammation such as tissue factor (TF) 
expression on monocytes in vitro and in vivo [33] as well as coagulation and fibrinolysis 
during surgery in humans [42].     
Koizumi et al. have shown that UTI prevents experimental crescentic glomerulonephritis in 
rats, at least in part, by inhibiting the intraglomerular infiltration of inflammatory cells [50]. 
Interestingly, Tsujimura and colleagues reported a case of infectious interstitial pneumonia 
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associated with mixed connective tissue disease, in whom the bolus infusion of UTI improved 
the pathology [52]. Also, Komori et al. illustrated that UTI improves peripheral microcirculation 
and relieves bronchospasm associated with systemic anaphylaxis in rabbits [53].  
Moreover, UTI has been shown to down-regulate the expression of the cancer metastasis-
associated molecules uPA and uPA receptor (uPAR) possibly through MAPK- dependent 
signaling cascades in vitro and in vivo [61, 62]. In addition, UTI has anti-inflammatory effects 
against several forms of malignancy in vitro [58, 63]. These studies suggest that UTI is a 
candidate anti-cancer drug, although further studies are required in the future.  
4. In vivo mouse model supporting role of UTI in physiologic and pathologic 
conditions 
4.1 Generation of UTI-gene knockout mouse 
To further investigate the physiobiological functions of UTI in vivo, we generated UTI (-/-) 
mice [64]. UTI (-/-) mice were produced as follows: a targeting vector was designed to 
disrupt the exons encoding UTI, leaving the exons encoding α1m intact. Germline 
transmission was observed in 3 chimeric male mice derived from 3 independent targeted ES 
clones. We generated mice that were homozygous for the mutant UTI gene (UTI [-/-] mice) 
by intercrossing the heterozygous mice. Under specific pathogen-free conditions, UTI (-/-) 
mice were born and developed normally. They grew to a normal body size and showed no 
apparent behavioral abnormalities. A histological study of various organs revealed no 
apparent differences between wild-type (WT) and UTI (-/-) mice. The ages at vaginal 
opening during postnatal development and the estrous cycle of UTI (-/-) female mice 
determined by the vaginal smear method were also normal [64].   
Thereafter, we conducted a series of studies on the role of UTI in the inflammation related to 
LPS using the UTI (-/-) mice.  
4.2 Protective role of UTI in systemic inflammation  
In a study [65], both UTI (-/-) and wild-type (C57/BL6: WT) mice were injected 
intraperitoneally (i.p.) with vehicle or LPS at a dose of 1 mg/kg body weight. Evaluation of 
the coagulatory and fibrinolytic parameters and white blood cell (WBC) counts at 72 hours 
after i.p. challenge showed that fibrinogen levels were significantly greater in LPS- than in 
vehicle-challenged mice with the same genotypes. In the presence of LPS, however, they 
were also significantly higher in UTI (-/-) than in WT mice. WBC counts significantly 
decreased after LPS challenge in UTI (-/-) mice. In the presence of LPS, the prothrombin 
time was significantly shorter in UTI (-/-) than in WT mice. Furthermore, histopathological 
changes in the lung, kidney, and liver of both genotypes after LPS challenge revealed severe 
neutrophilic inflammation in UTI (-/-) lungs challenged with LPS, whereas little neutrophilic 
infiltration was found in LPS-treated WT mice. The overall trend was similar regarding 
findings in the kidney and liver.  
The protein expression levels of proinflammatory molecules such as macrophage 
chemoattractant protein (MCP)-1 in the lungs, MCP-1 and keratinocyte-derived 
chemoattractant (KC) in the kidneys, and IL-1β, macrophage inflammatory protein (MIP)-2, 
MCP-1, and KC in the livers, were significantly greater in UTI (-/-) than in WT mice after 
LPS challenge. These results indicate that UTI protects against systemic inflammation 
induced by the intraperitoneal administration of LPS, at least partly, through the inhibition 
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of proinflamatory cytokine production/release [65], suggesting that UTI may be therapeutic 
against sepsis in humans.  
4.3 Protective role of UTI in acute lung inflammation  
A previous study showed that UTI improves acute lung injury in vivo [66]; however, no 
evidence has been reported using a genetic approach. In another series of studies [67, 68], 
therefore, UTI (-/-) and WT mice were intratracheally treated with vehicle or LPS 
(125μg/kg), and sacrificed 24 hours later. In both genotypes, LPS treatment induced 
significant increases in the numbers of total cells and neutrophils in bronchoalveolar lavage 
(BAL) fluid as compared with vehicle treatment, which was significantly greater in UTI (-/-) 
than in WT mice. Also, UTI (-/-) mice showed a significantly greater increase in the lung 
water content when compared to WT mice following LPS treatment. Lung specimens 
stained with hematoxylin and eosin 24 hours after intratracheal instillation showed that, in 
the presence of LPS, WT mice showed the moderate infiltration of neutrophils, whereas in 
UTI (-/-) mice, LPS treatment led to the marked recruitment of neutrophils and interstitial 
edema. LPS treatment induced a significant elevation of the protein levels of IL-1β, MIP-1α, 
MCP-1, and KC in lung homogenates when compared to vehicle treatment in both 
genotypes; however, in the presence of LPS, the expression was higher in UTI (-/-) than in 
WT mice. Furthermore, immunohistochemical examination showed that, in the presence of 
LPS, immunoreactive 8-hydroxy-2’-deoxyguanosine was detected in the lungs of both 
genotypes of mice, but the staining was more prominent in UTI (-/-) than in WT mice. In 
addition, immunoreactive nitrotyrosine was strongly detected only in UTI (-/-) mice 
challenged with LPS. Quantitative gene expression analyses of lung homogenates after 
intratracheal challenge showed that, compared to vehicle treatment, LPS treatment resulted 
in a significant elevation of gene expression for iNOS in both genotypes of mice; however, in 
the presence of LPS, the expression was higher in UTI (-/-) than in WT mice. These results 
indicate that UTI also protects against acute lung inflammation induced by the intratracheal 
administration of LPS, at least in part, via the local suppression of proinflammatory 
cytokines [67] and oxidative stress [68], suggesting that UTI may be a therapeutical tool for 
acute lung injury in humans. 
4.4 Protective role of UTI in acute liver inflammation   
One study has shown that plasma UTI levels increase in patients with acute hepatitis and 
markedly decrease in those with fulminant hepatitis, suggesting that the plasma UTI level is 
closely linked to the severity of liver damage [69]. Further, the plasma UTI level is reportedly 
correlated with the degree of liver damage in patients with chronic liver diseases such as liver 
cirrhosis and hepatocellular carcinoma [70]. In a liver inflammation and coagulatory 
disturbance model induced by LPS (3μg/kg) and D-galactosamine (800 mg/kg: LPS/D-GalN), 
LPS/D-GalN treatment caused severe liver injury characterized by neutrophilic inflammation, 
hemorrhagic change, necrosis, and apoptosis, which was more prominent in UTI (-/-) than in 
WT mice [71]. In both genotypes of mice, interestingly, LPS/D-GalN challenge caused 
elevations of aspartate amino-transferase and alanine amino-transferase, prolongation of the 
prothrombin and activated partial thromboplastin time, and decreases in fibrinogen and 
platelet counts, as compared with vehicle challenge. These changes, however, were 
significantly greater in UTI (-/-) than in WT mice. Circulatory levels of TNF-α and interferon 
(IFN)-γ were also greater in UTI (-/-) than in WT mice after LPS/D-GalN challenge. These 
results suggest that UTI protects against severe liver injury and subsequent coagulatory 
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associated with mixed connective tissue disease, in whom the bolus infusion of UTI improved 
the pathology [52]. Also, Komori et al. illustrated that UTI improves peripheral microcirculation 
and relieves bronchospasm associated with systemic anaphylaxis in rabbits [53].  
Moreover, UTI has been shown to down-regulate the expression of the cancer metastasis-
associated molecules uPA and uPA receptor (uPAR) possibly through MAPK- dependent 
signaling cascades in vitro and in vivo [61, 62]. In addition, UTI has anti-inflammatory effects 
against several forms of malignancy in vitro [58, 63]. These studies suggest that UTI is a 
candidate anti-cancer drug, although further studies are required in the future.  
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conditions 
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mice [64]. UTI (-/-) mice were produced as follows: a targeting vector was designed to 
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transmission was observed in 3 chimeric male mice derived from 3 independent targeted ES 
clones. We generated mice that were homozygous for the mutant UTI gene (UTI [-/-] mice) 
by intercrossing the heterozygous mice. Under specific pathogen-free conditions, UTI (-/-) 
mice were born and developed normally. They grew to a normal body size and showed no 
apparent behavioral abnormalities. A histological study of various organs revealed no 
apparent differences between wild-type (WT) and UTI (-/-) mice. The ages at vaginal 
opening during postnatal development and the estrous cycle of UTI (-/-) female mice 
determined by the vaginal smear method were also normal [64].   
Thereafter, we conducted a series of studies on the role of UTI in the inflammation related to 
LPS using the UTI (-/-) mice.  
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In a study [65], both UTI (-/-) and wild-type (C57/BL6: WT) mice were injected 
intraperitoneally (i.p.) with vehicle or LPS at a dose of 1 mg/kg body weight. Evaluation of 
the coagulatory and fibrinolytic parameters and white blood cell (WBC) counts at 72 hours 
after i.p. challenge showed that fibrinogen levels were significantly greater in LPS- than in 
vehicle-challenged mice with the same genotypes. In the presence of LPS, however, they 
were also significantly higher in UTI (-/-) than in WT mice. WBC counts significantly 
decreased after LPS challenge in UTI (-/-) mice. In the presence of LPS, the prothrombin 
time was significantly shorter in UTI (-/-) than in WT mice. Furthermore, histopathological 
changes in the lung, kidney, and liver of both genotypes after LPS challenge revealed severe 
neutrophilic inflammation in UTI (-/-) lungs challenged with LPS, whereas little neutrophilic 
infiltration was found in LPS-treated WT mice. The overall trend was similar regarding 
findings in the kidney and liver.  
The protein expression levels of proinflammatory molecules such as macrophage 
chemoattractant protein (MCP)-1 in the lungs, MCP-1 and keratinocyte-derived 
chemoattractant (KC) in the kidneys, and IL-1β, macrophage inflammatory protein (MIP)-2, 
MCP-1, and KC in the livers, were significantly greater in UTI (-/-) than in WT mice after 
LPS challenge. These results indicate that UTI protects against systemic inflammation 
induced by the intraperitoneal administration of LPS, at least partly, through the inhibition 
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of proinflamatory cytokine production/release [65], suggesting that UTI may be therapeutic 
against sepsis in humans.  
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than in WT mice. Also, UTI (-/-) mice showed a significantly greater increase in the lung 
water content when compared to WT mice following LPS treatment. Lung specimens 
stained with hematoxylin and eosin 24 hours after intratracheal instillation showed that, in 
the presence of LPS, WT mice showed the moderate infiltration of neutrophils, whereas in 
UTI (-/-) mice, LPS treatment led to the marked recruitment of neutrophils and interstitial 
edema. LPS treatment induced a significant elevation of the protein levels of IL-1β, MIP-1α, 
MCP-1, and KC in lung homogenates when compared to vehicle treatment in both 
genotypes; however, in the presence of LPS, the expression was higher in UTI (-/-) than in 
WT mice. Furthermore, immunohistochemical examination showed that, in the presence of 
LPS, immunoreactive 8-hydroxy-2’-deoxyguanosine was detected in the lungs of both 
genotypes of mice, but the staining was more prominent in UTI (-/-) than in WT mice. In 
addition, immunoreactive nitrotyrosine was strongly detected only in UTI (-/-) mice 
challenged with LPS. Quantitative gene expression analyses of lung homogenates after 
intratracheal challenge showed that, compared to vehicle treatment, LPS treatment resulted 
in a significant elevation of gene expression for iNOS in both genotypes of mice; however, in 
the presence of LPS, the expression was higher in UTI (-/-) than in WT mice. These results 
indicate that UTI also protects against acute lung inflammation induced by the intratracheal 
administration of LPS, at least in part, via the local suppression of proinflammatory 
cytokines [67] and oxidative stress [68], suggesting that UTI may be a therapeutical tool for 
acute lung injury in humans. 
4.4 Protective role of UTI in acute liver inflammation   
One study has shown that plasma UTI levels increase in patients with acute hepatitis and 
markedly decrease in those with fulminant hepatitis, suggesting that the plasma UTI level is 
closely linked to the severity of liver damage [69]. Further, the plasma UTI level is reportedly 
correlated with the degree of liver damage in patients with chronic liver diseases such as liver 
cirrhosis and hepatocellular carcinoma [70]. In a liver inflammation and coagulatory 
disturbance model induced by LPS (3μg/kg) and D-galactosamine (800 mg/kg: LPS/D-GalN), 
LPS/D-GalN treatment caused severe liver injury characterized by neutrophilic inflammation, 
hemorrhagic change, necrosis, and apoptosis, which was more prominent in UTI (-/-) than in 
WT mice [71]. In both genotypes of mice, interestingly, LPS/D-GalN challenge caused 
elevations of aspartate amino-transferase and alanine amino-transferase, prolongation of the 
prothrombin and activated partial thromboplastin time, and decreases in fibrinogen and 
platelet counts, as compared with vehicle challenge. These changes, however, were 
significantly greater in UTI (-/-) than in WT mice. Circulatory levels of TNF-α and interferon 
(IFN)-γ were also greater in UTI (-/-) than in WT mice after LPS/D-GalN challenge. These 
results suggest that UTI protects against severe liver injury and subsequent coagulatory 
 
Inflammatory Diseases – A Modern Perspective 8 
disturbance induced by LPS/D-GalN, which was mediated, at least partly, through the 
suppression of TNF-α production along with its anti-protease activity [71]. Furthermore, after 
LPS/D-GalN challenge, protein levels of IL-1β, TNF-α, IFN-γ, MIP-1α, and MCP-1 in the lung 
homogenates were elevated in both genotypes, but to a greater extent in UTI (-/-) than in WT 
mice. The IFN-γ level was also significantly greater in LPS/D-GalN-challenged UTI (-/-) than 
in other mice. These results indicate that UTI protects against the local inflammatory response 
accompanied by severe liver injury, which supports its anti-inflammatory properties in vivo 
[72], implicating a therapeutic potential of UTI in fulminant hepatitis in humans. In this 
regard, Nobuoka and colleagues have recently implicated UTI in normal liver regeneration 
using UTI (-/-) mice via the regulation of systemic (serum) levels of cytokines such as IL-6 and 
IL-10 and chemokines such as MCP-1 and MIP-1α [73].  
5. Concluding remarks 
As described above, UTI protects against endotoxin-related inflammatory diseases’ 
pathology and subsequent organ damage induced by LPS in mice, at least partly, via the 
regulation of neutrophil-derived proteases such as elastase, proinflammatory cytokines and 
chemokines such as IL-1β, MIP-1α, MCP-1, and KC and oxidative stress (Fig. 2). Our  
 
 
Fig. 2. Schematic representation of the protective role of UTI against endotoxin-related 
inflammation in mice. Our data suggest that UTI protects against: 1) endothelial 
activation/damage, 2) proinflammatory cytokine and chemokine production/release, 3) 
fibrinogen synthesis, 4) neutrophil recruitment into organs, and/or 5) organ injury. 
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consecutive in vivo results provide direct and novel molecular evidence for the “rescue” 
therapeutic potential of UTI against endotoxin-related inflammatory diseases such as DIC, 
acute lung injury, and acute liver injury. 
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1. Introduction  
Phospholipase A2 (PLA2) catalyzes the hydrolysis of the SN-2 acyl ester linkage of 
phospholipids and producing fatty acids and lysophospholipids. Their activity is one of the 
rate-limiting steps in the formation of arachidonic acid and in the synthesis of leukotrienes 
and prostaglandins. These prostaglandins have vital role in carcinogenesis. In the present 
study structure based drug design approach has applied to the hnps-PLA2 inhibitors. It can 
be concluded that indole-3-acetamide derivative molecule 13 h was showing better 
interaction with the active site of hnps-PLA2. The comparative in silico ADME studies 
proved that 13h molecule could be a potential anticancer drug. Phospholipase is an enzyme 
that converts phospholipids into fatty acid and other lipophillic-substances. There are four 
major classes of Phospholipase, termed A, B, C and D. These classes are distinguished by the 
catalyzing type of reactions. Phospholipase A has two subtypes: Phospholipase A1 which 
cleaves the SN-1 acyl chain and Phospholipase A2 which cleaves the SN-2 acyl chain. 
2. Material and method 
Ligand fit (Discovery studio 2.1) software was used for molecular docking studies 
(Venkatachalam, C.M. et al. 2003). It is based on a cavity detection algorithm and Monte 
Carlo conformational search algorithm for generating ligand poses consistent with the 
active site shape. The crystal structure of hnps-PLA2 (1DB4) complex with potent indole 
inhibitor was determined and used in structure based drug design (Schevitz RW et al 
1995). The PDB structure 1DB4 was chosen for our study has 2.20 A° resolution and has 
RMSD value below 2 Aº. 
2.1 Ligand and receptor preparation 
The hnps-PLA2 inhibitors, 74 indole-3-acetic acid derivatives (Robert D. Dillard et al 1996) 
were sketched. The structure of all molecules used in the present study was designed on the 
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basis of the reported scaffold and the substituent table from NCBI pubchem. The Generic 
drugs with diverse scaffolds were downloaded from pubchem library. The Hydrogen Bonds 
were added and CHARMm force field was applied to all molecules. 
The crystal structure of hnps-PLA2 protein (1DB4) was downloaded from the PDB. After 
applying CHARMm force field macro molecule hnps-PLA2 was assigned as receptor. 
The receptor cavity was searched using flood filling algorithm and partition site was 
adjusted for the better fitments of molecule in the partition site of receptor. The 
comparative docking studies for all 100 molecules were performed. The determination of 
the ligand binding affinity was calculated using Ligscore1, Ligscore2 and Dock score 
were used to estimate the ligand-binding energies.In the present study ADME Tox 
software was used to study the toxicity of hnps-PLA2 inhibitors.We have used top ten 
ranked dock molecule of hnps-PLA2 for the present study.The Hydrogen Bonds were 
added and CHARMm force field was applied to all molecules and the ADME properties 
were calculated. 
3. Result and analysis 
In the present study we have taken generic drugs with diverse scaffolds and indole 
inhibitors of hnps- PLA2 which were biologically tested and synthesized (Robert D. Dillard 
et al 1996). The structure based studies of the molecules described above were carried out 
using Discovery Studio. The RMSD value between the top ten ranked (based on docked 
energy) reference molecules and hnp-SPLA2 was reported around 2Aº.  
Table 1 had shown the different score values of top ranked ligands against hnsp-SPLA2 
receptor. The score values include Ligscore1 and Ligscore 2 which is based on protein-
ligand affinity energy (Krammer et al 2005). It has been observed that Ligscore1 (6.16), 
Ligscore2 (7.06) were found highest for the 13 h molecule in comparison with the other 100 
molecules. During the study it has been observed that molecule 13 h which was found 
highest docked energy score 80.47 has high inhibitory concentration (IC50 .03 uM) which 
proved that the drugs found most effective in prior experimental studies was also giving 
high dock scores.  
It has been reported that indole inhibitors when substituted with additional alkyl group at 
different positions of indole the efficacy of the compound had increased towards hnps-PLA2 
(Lin et al 2003). In the present study the molecules having indole ring proved more efficient 
when substituting with other additional groups on indole ring. In comparison with the 
binding affinity of the other molecules it has been observed that indole-3- derivatives were 
found most effective scaffold. The top 7 Ranked docked molecules had indole ring and a 
additional acid side chain on the fifth position with acid group (13h (80.47 J/mol), 41 (71.59 
J/mol), 2n (70.59 J/mol), 71 (70.48 J/mol), 7i (68.14 J/mol), 16b (67.71 J/mol), 60a (67.71 
J/mol) ) It has been observed that indole-3-acetamides series molecule possessed potency 
and selectivity as inhibitors of hnps-PLA2 (Robert D. Dillard et al 1996). It was observed that 
the top 6 docked molecules (molecule 13h (80.47 J/mol), 41 (71.59 J/mol), 71 (70.48 J/mol), 
7i (68.14 J/mol), 16b (67.71 J/mol), 60a (67.71 J/mol) ) had 3-acetamide side chain at Indole 
ring. The molecule 13 h had oxy propyl phosphonic acid group on fifth position which had 
shown strong hydrogen bonding formation with the active site residue histidine of hnp-
SPLA2 receptor.(Fig 1). 
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Fig. 1. Molecule 13h showing hydrogen bonding with histidine 
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Fig. 1. Molecule 13h showing hydrogen bonding with histidine 
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Fig. 3. Molecule 41 showing similarties with mol 13h 
The structural similarity of two top ranked dock score molecules suggested that both had 
3-indole acetamide ring as basic scaffold and phosphonic acid group which was attached 
to fifth position of indole and a benzyl ring which was attached to first position of 
indole.(Fig 2,3) 
The top ten ranked dock molecules were chosen for ADME analysis. The ADME properties 
of 13h were found very satisfactory. The aqueous solubility value was found within optimal 
range-(4.028) whereas the molecule indomethcin (3.24), indoprofen (3.54) was found not 
good solubility value. The molecule 16b, 7i, 71, 60a had poor (3) intestinal absorption level 
whereas molecule 13 h had very good (0) intestinal absorption level. The Plasma protein 
binding was found more than  90% for molecule 13 h  but it was reported more than 95% for 
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the molecule 41 and 2n. The Blood Brain Penetration Level for molecule 13h was found to be 
extremely low (4) level and the cytochrome P450 enzyme (1) level was not found to be 
inhibited by molecule 13 h. Thus comparing with the other molecules ADME properties 13 h 








Name LigScore1 LigScore2 DOCK_SCORE
13h 6.16 7.06 80.47 
Bendazac 2.79 2.97 71.766 
41 6 6.62 71.496 
2n 3.33 2.89 70.596 
71 5.64 6.39 70.48 
7i 6.14 6.27 68.147 
16b 4.27 5.19 67.71 
60a 4.88 6.63 67.487 
Indometacin 3.54 4.26 66.921 
Indoprofen 2.86 2.85 66.375 
13f 5.81 6.9 65.9 
4n 4.76 5.46 65.728 
7o 5.47 5.84 65.64 









Table 1. Sketched molecules with Best dock score 
4. Conclusion 
In the present study it can be concluded that Indole derivative molecule 13 h is proved to 
better molecule in terms of experimental studies, molecular interaction with hnp-SPLA2 
receptor and computational ADME studies. So the present study proved that hnps-PLA2 
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based inhibitor molecule 13 h (Fig 4) could be a better substitute for NSAID (Non-steroid 

















Fig. 4. Showing alternate pathway for inflammation 
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1. Introduction 
Behçet's disease (BD) is a vasculitis characterized by oral, genital ulcers and uveitis with 
varying other manifestations associated with vascular inflammation. Additional target 
organ, including vascular, neurological, and gastrointestinal manifestations, were added to 
the disease spectrum [Yazici et al., 2003]. The etiology of BD is considered to be a complex 
systemic vasculitis, caused by T-helper-1 (Th1) cytokine skewed neutrophilic and 
lymphohistiocytic inflammation [Suzuki et al., 2006; Kulaber et al., 2007; Koarada et al., 
2004; Keller et al., 2005].  
The pathogenesis of BD is still unclear, but immune dysfunction, viral and bacterial agents, 
such as Staphylococcus spp. and herpes simplex virus, have been postulated [Onder et al., 
2001]. Cytokines play crucial roles in the inflammatory responses in BD [Hamzaoui et al., 
2002; Direskeneli et al., 2003]. BD as many autoimmune diseases are considered to be T cell-
regulated diseases, further classified as Th1-mediated diseases, with Th1-like diseases 
featuring a high production of IFN-. However, this classification fails to explain the 
involvement of inflammatory cells as seen in many autoimmune/inflammatory diseases. A 
unifying feature of the inflammation observed in BD is the nonspecific hyperreactivity of 
tissue to minor trauma, termed the skin pathergy reaction (SPR), which remains the most 
diagnostically relevant lesion in BD patients, where an exaggerated inflammatory response 
develops in the skin of BD patients that is characterized by dermal infiltration of activated 
dentritic cells (DCs) and the presence of a Th1-type immunological cascade [Melikoglu et al., 
2006]. The immunohistochemistry of patients with sterile, pustular skin eruptions in the 
context of a systemic autoinflammatory disease revealed a substantially denser, lymphocyte 
rich cell infiltrate (mainly CD4+ and some CD8+ T cells than in normal skin). The majority of 
T cells detected were immigrating, inflammatory T cells, as they expressed CCR6, the 
receptor for CCL20 (MIP-3) [Keller et al., 2005].  
Studies show that CD4+ IL-17+ and CD8+ IL-17+ T cells (Th17) play an active role in 
inflammation and autoimmune diseases in murine systems [Komiyama et al., 2006; Bettelli 
et al., 2007; Kryczek et al. 2007], and have never been studied in skin lesions from BD 
patients. The question addressed in this study is why Th1 and Th17 cells often colocalized in 
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pathological environments and what is the mechanism and pathological relevance of this 
colocalization. We studied skin lesions from BD patients. Previous studies implicated Th1 
cells promoting cytokine in skin lesions from BD patients [Melikoglu et al., 2006].  
In the current investigation, we explored the phenotype and function of IL-17-secreting T 
cells in BD and healthy skin, and the factors supporting their trafficking to and induction in 
lesional skin. Specifically, we show that IFN- is demonstrated as a potent promoter of IL-
17+ T cell trafficking, induction, and function. Our observations support a model wherein 
Th1 and IL-17+ T cells mechanistically interact and collaboratively contribute to BD skin 
pathogenesis. 
2. Materials and methods 
2.1 Patients skin testing, and tissue samples 
The study was approved by the Ethical Committee of our University. A total of 12 patients 
with active BD (3 females, 9 males) fulfilling the International Study Group Criteria for BD 
[ISG. 1990] were enrolled into this study. BD patients were aged: 39 years (range 26-47 
years) and the mean disease duration were 76 months (range 10-132 months). Disease 
activity was evaluated according to published criteria [Lawton & Bhakta, 2004]. Of 12 
patients, all had oral ulcerations, 8 had genital ulcers, 6 had erythema  nodosum, 10 had 
papulopustular lesions, 8 had arthritis, 7 had uveitis, 6 had deep venous thrombosis, and 11 
had a positive skin pathergy reaction (SPR). Consistent with previous published reports, 
there were no demographic or clinical differences discernible between BD patients with a 
positive or negative SPR in our study [Krause et al., 2000].  
The skin lesions were scored [Diri et al., 2001]: 0 = no lesions; 1 = 1-5 lesions; 2 = 6-10 
lesions; 3 = 11-15 lesions; 4 = 16-20 lesions; and 5 = more than 20 lesions. Table I describes 
BD patients with skin lesions. Patients were treated with steroids and colchicines. Seven 
donors of healthy human skin were included in this study. Punch-biopsy specimens (4 
mm) were obtained from affected skin (pustular eruption) and were divided in two equal 
parts, one for T cell elution and one for RT-PCR analysis. All skin biopsy samples were 
obtained with a circular dermal punch after injection of 1% lidocaine solution into the 
hypodermis. Biopsy samples were snap frozen directly in liquid nitrogen for mRNA 
extraction and RT-PCR analysis.  
2.2 Immune cell isolation  
Single cell suspensions were prepared from PBMC and skin tissue samples. Skin biopsy 
samples were incubated in 50 U/ml dispase  (BD Biosciences) at 37°C for 90 min. The skin 
portions were then cut into 1-mm pieces and digested in collagenase for 2 h at room 
temperature. Single cell suspensions of epidermal portions were generated by incubation in 
Cell Dissociation buffer (Invitrogen) at 37°C for 2 h. Skin explant cultures of T cells from 
skin biopsies were prepared as described by Clark et al. [Clark et al., 2006]. 
Immune cells including T cells and CD14+ or CD11c+ myeloid APCs were enriched using 
paramagnetic beads (StemCell Technologies) and sorted from stained single cell 
suspensions using a high-speed cell sorter (FACSAria; BD Immunocytometry Systems) as 
described by Curiel et al [Curiel et al., 2003]. Cell purity was >98% as confirmed by flow 
cytometry (LSR II; BD Immunocytometry Systems). CD14+ or CD11c+ myeloidAPCs were 
used to stimulate T cells as indicated. 
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2.3 APC activation and cytokine production  
Fresh peripheral blood CD11c+ APCs (0.5 x 106/ml) were incubated for 72 h with or without 
recombinant human IFN- (200 ng/ml; R&D Systems). These cells were washed and used 
for T cell stimulation or activated for 12 h with LPS (1 µg/ml; Sigma-Aldrich) or incubated 3 
days (1 x 106 cells/ml) in the presence of LPS to detect cytokine levels in supernatants. All 
Abs were from R&D Systems. 
2.4 T cell culture system 
Myeloid APCs were cocultured with peripheral blood T cells in ratios from 1:3 to 1:10 
(0.5 x 106 T cells/ml) for 4 days in the presence of anti-CD3 (2.5 - 5 µg/ml) and anti-
CD28 (1.2 - 2.5 µg/ml) mAbs (BD Biosciences). Different cytokines and neutralizing 
antibodies (Abs) or their combinations including IL-1 (2.5 ng/ml), IL-1β (2.5 ng/ml), IL-23 
(10 ng/ml), anti-IL-4 (1 µg/ml), anti-IFN- (2 µg/ml), anti-IL-1 (1 µg/ml anti-IL-1R plus 1 
µg/ml anti-IL-1) were used as indicated (all from R&D Systems). Cells were subjected to 
flow cytometric phenotyping, intracellular cytokine staining, and transcript detection by 
real-time PCR. Culture supernatants were collected for detection of IL-17 by ELISA (R&D 
Systems). For flow cytometry analysis, cells were first stained extracellularly with specific 
monoclonal antibodies (Abs), then fixed and permeabilized with Perm/Fix solution 
(eBioscience), and finally stained intracellularly with specific Abs against the indicated 
cytokines (BD Biosciences). Samples were acquired on a LSR II (BD Biosciences) and 
data were analyzed with DIVA software (BD Biosciences). 
2.5 Migration assays  
Migration assays were performed in a Transwell system with a polycarbonate membrane of 
6.5 mm diameter with a 3-µm pore size as described  by Curiel et al. [Curiel et al., 2004]. 
Purified T cell subsets were added to the upper chamber, and CCL20 (5 ng/ml; R&D 
Systems) was added to the lower chamber. After 4 h of incubation at 37°C, the phenotype 
and number of T cells in the upper and lower chambers was determined by FACS. 
2.6 Quantification of gene expression  
Quantitative real-time PCR was performed on control and lesional  skin samples from 12 BD 
patients and 7 normal healthy controls as we have recently reported [Hamzaoui et al., 2008]. 
Quantification of gene expression in the cultured myeloid APCs was performed as 
described by Kryczek et al [Kryczek et al., 2007]. The gene transcripts were quantified in a 
MasterCycler RealPlex system (Eppendorf Scientific) and expressed as mRNA quantities 
normalized to GAPDH levels. 
2.7 Immunohistochemistry 
Skin biopsy samples were stained with anti-CD4 or anti-CD8 Ab as described [Hamzaoui et 
al., 2008]. The staining was detected using the one-step avidin-biotin complex technique (BD 
Pharmingen). 
2.8 Statistical calculations  
The Wilcoxon rank-sum test was used to determine pairwise differences and the 2 test used 
to determine differences between groups. A value for p < 0.05 was considered as significant. 
Differences in phenotype of T cell subsets were tested with the paired Student’s t test. 
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Correlation was tested by Spearman’s test. All statistical analysis was done on Statistical 
software (StatSoft). 
3. Results 
3.1 IL-17+ T cells are increased in BD skin lesions 
We investigated the distribution of CD4+ and CD8+ IL-17+ T cells in BD-skin lesions and in 
healthy donors [Figure 1A and Figure 1B]. High levels of CD3+ IL-17+ T cells were observed 
in active BD compared to healthy control skin. The highest percentage of CD4+ and CD8+ IL-
17+ T cells were observed in BD-skin lesions. Notably, we observed an increased number of 
CD8+ IL-17+ T cells in BD-skin [Figure 1B]. We further analyzed the expression of IFN- and 
IL-17 per single cell level. Interestingly, 40–60% IL-17+ T cells coexpressed  IFN- in the BD-
skin [Figure 1C].  
The data demonstrate the prevalence, phenotype, and distribution of IL-17+ T cells in 
patients with BD, and indicate that BD-skin lesions is an environment containing abundant 
IL-17+ T cells including Th17 cells and CD8+ IL-17+ T cells. 
 
   
 
Fig. 1. IL-17+ T cells in BD skin lesions.  
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Skin biopsy from healthy donors and patients with Behcet’s disease (BD) were stained with 
specific antibodies as described in Materials and Methods. IL-17+ T cells were analyzed with 
FACS. (A): Results show mean percentage of IL-17+ T cells in T cells. Error bar indicates 
SD. Representative dot plots are shown. Total number of IL-17+ T cells in the skin. Total 
number of IL-17+ T cells was calculated by multiplying the percentage of IL-17+ T cells by 
the absolute number of T cells/mm2 of skin, as determined previously [51]. Results shown 
are mean number ± SD, for n = 12 BD patients and 7 healthy donors. (B): Coexpression of IL-
17 and IFN- on IL-17+ T cells. Single cell suspensions were made from skin tissues in 
healthy donors and patients with BD. The expression of IFN- and IL-17 were analyzed by 
intracellular cytokine staining gated on CD3+ T cells. (C): Total numbers of CD4+ and 
CD8+ IL-17+ T cell subsets are shown as mean number ± SD.  
3.2 IFN-+ T cells in patients with BD 
As BD was related as Th1 disease, we examined the distribution of CD4+, CD8+, and IFN-
+ T cells in BD-skin lesion. Consistent with previous reports [9], we observed a large 
number of CD4+ and CD8+ T cells in BD skin lesion [9; 20]. The distribution of CD4+ and 
CD8+ IFN-+ T cells is similar for T cells expressing IFN- and IL-17 in BD-skin. High 
levels of IFN-+ T cells [BD: 180.08 ± 62.46 cells/ mm2; HC: 25.71 ± 14.05 cells/ mm2; P = 
0.0001][Figure 2A] and IFN- transcripts [BD: 27.75 ± 6.98 relative IFNmRNA expression 
(10-3); HC: 4.5 ± 1.87 relative IFNmRNA expression (10-3); P = 0.0001] [Figure 2B] 
were also detected in BD skin lesions compared to healthy controls.  
 
 
Fig. 2. IFN-+ T cells in BD skin lesions. [A] and [B]: IFN-+ T cells in BD lesions. 
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Correlation was tested by Spearman’s test. All statistical analysis was done on Statistical 
software (StatSoft). 
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the absolute number of T cells/mm2 of skin, as determined previously [51]. Results shown 
are mean number ± SD, for n = 12 BD patients and 7 healthy donors. (B): Coexpression of IL-
17 and IFN- on IL-17+ T cells. Single cell suspensions were made from skin tissues in 
healthy donors and patients with BD. The expression of IFN- and IL-17 were analyzed by 
intracellular cytokine staining gated on CD3+ T cells. (C): Total numbers of CD4+ and 
CD8+ IL-17+ T cell subsets are shown as mean number ± SD.  
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CD45+CD3+ T cells were analyzed by FACS in cell suspensions obtained from healthy skin 
and BD skin lesions. [A]:  IFN-+ T cells were analyzed by FACS and quantified in the skin. 
Results shown are the mean number of cells/mm2 of skin ± SD for n = 5 healthy donors. [B]: 
Expression of IFN- in skin from healthy donors and patients with BD. IFN- was quantified 
by real-time PCR. Results shown are mean value of relative expression ± SD for 12 BD 
patients and 7 healthy donors.  
3.3 Myeloid APCs induce IL-17+ T cells 
We sorted both CD14+ and CD11c+ myeloid APCs from peripheral blood and skin lesions 
from BD patients and healthy donors [Figure 3A]. CD14+ and CD11c+ myeloid APCs induced 
similar levels of Th17 cells [Figure 3B]. Then we investigated the potential role for 
myeloid APCs in inducing IL-17+ T cells [Figure 3C]. Interestingly, APCs from BD peripheral 
blood and skin lesions were significantly more efficient than those from healthy donors in 
inducing IL-17 production [Figure 3C]. Myeloid APCs induced both CD4+ and CD8+ IL-17+ T 
cells [Figure 3D]. We performed similar experiments with responder T cells from 
normal donors and BD patients. Our data indicate that BD myeloid APCs potently induce IL-
17+ T cells, and may thereby stimulate and maintain the IL-17+ T cell pool in BD patients. 
 
 
   
Fig. 3. Behçet’s disease (BD) myeloid APCs stimulate IL-17+ T cell expansion. 
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Myeloid APCs (CD45+CD14+) were analyzed by FACS in cell suspensions obtained from 
healthy skin and BD skin lesions. [A]: One representative dot plot of CD14+ leukocytes from 
the skin of a healthy donor and a patient with BD. Total number of CD3+ or CD14+ cells is 
indicated. [B]: Myeloid APCs were analyzed by FACS and quantified in the skin. Results 
shown are mean number of cells/mm2 of skin ± SD for 5 BD patients and 4 healthy 
controls. [C and D]: BD myeloid APCs induce IL-17+ T cells. Normal peripheral blood T cells 
were stimulated for 5 days with myeloid APCs derived from skin and blood of healthy 
donors or patients with BD in the presence of anti-CD3 and anti-CD28. [C]: IL-17 was 
detected in the culture supernatants. Results shown are mean ± SD, for the same number of 
BD patients and controls.   
3.4 IFN- induces myeloid APCs to stimulate IL-17+ T cells 
We next studied why BD myeloid APCs are potent inducers of IL-17+ T cells. The 
contribution of IFN- was investigated, as IFN- is increased in serum of BD patients 
[Hamzaoui et al., 2007]. IFN+ T cells are enriched in BD skin lesions as reported in 
Figure 2 and all studies implicated IFN- (Th1 cells) in BD pathogenesis. To test the 
hypothesis that IFN- may program myeloid APCs to stimulate IL-17+ T cells, CD11+ cells 
from the blood of donors were conditioned with IFN- and tested for their capacity to 
induce IL-17+ T cells. IFN profoundly increased the capacity of CD11c+ cells to elicit IL-
17+ T cells [Figure 4A, B, and C]. We also conditioned peripheral blood myeloid APCs 
from BD patients with exogenous IFN-, and observed that IFN- was able to further 
enhance the ability of healthy controls and BD myeloid APCs to induce IL-17-secreting T 
cells [Figure 4]. The data suggest that IFN- released by BD T cells may condition myeloid 





Fig. 4. IFN- induces BD- APCs to stimulate IL-17+ T cells. 
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Healthy control (A) or BD patients (B) blood-derived ex vivo CD11c+ cells were conditioned 
for 72 h with or without IFN-, and then cultured with normal T cells for 5 days in the 
presence of anti-CD3 and anti-CD28. [A]: IL-17+ T cells were detected by FACS. Results 
shown are mean percentage ± SD of IL-17+ T cells in T cells. (C): IL-17 was measured in the 
supernatants by ELISA. Results shown are mean percentage ± SD of IL-17. Five patients 
with BD and 4 healthy controls were investigated. 
3.5 CCR6+ IL-17+ T cells and CCL20 in Behçet’s disease 
We examined how IL-17+ T cells traffic to the BD skin environment. We found that 
CD4+ and CD8+ IL-17+ T cells derived from BD skin lesions highly expressed CCR6 
[Figure 5A and B]. We therefore asked whether IL-17+ T cells could migrate 
toward CCL20, the ligand for CCR6. We observed that T cells efficiently migrated in 
response to CCL20, and that the migrating cells were enriched for IL-17+ T cells (from 
0.2% IL-17– cells in the upper chamber to 18% IL-17+ T cells in the lower chamber) [Figure 
5C]. We further tested the role of IFN- in CCL20 production. We observed that 
IFN stimulated CCL20 production from CD11c+ APCs [Figure 5D].  High levels of 
CCL20 mRNA were detected in lesional BD skin [Figure 5E]. The data suggest that IFN-
 derived from BD T cells induces CCL20 and promotes homing of IL-17+ T cells to the BD 
environment. In addition to CCR6, we observed that BD- IL-17+ T cells highly expressed 
CD103 as compared with IL-17– T cells [Figure 5F]. CD103 may play a specific role in IL-
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Fig. 5. CCR6+ IL-17+ T cells and CCL20 in the BD environment. 
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Healthy control (A) or BD patients (B) blood-derived ex vivo CD11c+ cells were conditioned 
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presence of anti-CD3 and anti-CD28. [A]: IL-17+ T cells were detected by FACS. Results 
shown are mean percentage ± SD of IL-17+ T cells in T cells. (C): IL-17 was measured in the 
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with BD and 4 healthy controls were investigated. 
3.5 CCR6+ IL-17+ T cells and CCL20 in Behçet’s disease 
We examined how IL-17+ T cells traffic to the BD skin environment. We found that 
CD4+ and CD8+ IL-17+ T cells derived from BD skin lesions highly expressed CCR6 
[Figure 5A and B]. We therefore asked whether IL-17+ T cells could migrate 
toward CCL20, the ligand for CCR6. We observed that T cells efficiently migrated in 
response to CCL20, and that the migrating cells were enriched for IL-17+ T cells (from 
0.2% IL-17– cells in the upper chamber to 18% IL-17+ T cells in the lower chamber) [Figure 
5C]. We further tested the role of IFN- in CCL20 production. We observed that 
IFN stimulated CCL20 production from CD11c+ APCs [Figure 5D].  High levels of 
CCL20 mRNA were detected in lesional BD skin [Figure 5E]. The data suggest that IFN-
 derived from BD T cells induces CCL20 and promotes homing of IL-17+ T cells to the BD 
environment. In addition to CCR6, we observed that BD- IL-17+ T cells highly expressed 
CD103 as compared with IL-17– T cells [Figure 5F]. CD103 may play a specific role in IL-








Th17 Trafficking Cells in Behcet's Disease Skin Lesions 
 
35 
         
 
       
 
Fig. 5. CCR6+ IL-17+ T cells and CCL20 in the BD environment. 
 
Inflammatory Diseases – A Modern Perspective 
 
36
[A,B]: BD-IL-17+ T cells highly express CCR6. Expression of CCR6 was determined by FACS 
on IL-17+ and IL-17–T cells in BD skin. Results shown are mean of CCR6+ T cells in IL-17+ T 
cells or IL-17– T cells ± SD for 5 healthy donors and 6 BD patients. (*): P < 0.05 compared 
with IL-17– T cells. [C]: IL-17+ T cells migrate in response to CCL20. Migration assay was 
performed as described in Materials and Methods. The migrated T cells were subjected to 
intracellular staining for IL-17. The percentage of IL-17+ T cells in the upper and lower 
chambers is shown. [D]: IFN-γ induces CCL20 production. Blood CD11c+ cells were 
stimulated for 3 days with or without IFN- γ. CCL20 was detected by ELISA in the 
supernatants. Results shown are mean value ± SD for 8 healthy controls. (*): P < 0.05 
compared with control. [E]: High expression of CCL20 in BD skin. CCL20 transcript was 
quantified by real-time PCR. Results shown are mean value of relative 1 expression ± SD for 
5 healthy donors. (*): P = 0.004 compared with healthy skin control. [F]: High expression of 
CD103 on BD IL-17+ T cells. CD103 expression was determined by FACS on IL-17+ and IL-
17– T cell subsets. Results shown are mean ± SD of CD103+ T cells in each T cell subset, for 5 
healthy donors. (*): P < 0.05 compared with IL-17– T cells. One representative dot plot of BD 
CD103+ IL-17+ T cells is shown gated each on CD4+ and CD8+ T cells. 
3.6 Functional characterization of CD8+IL-17+ and CD4+IL-17+ cells from BD-skin 
lesions 
The ability of CD8+IL-17+ and CD4+IL-17+ cells-producing T cells derived from BD-skin 
lesions to proliferate in response to TCR-mediated stimulation was also assessed. For this 
purpose, CCR6-sorted and expanded cells were challenged with anti-CD3/CD28 mAb. A 
well-characterized Th17 line was used as a control. The response of the Th17 cells from the 
BD-skin lesions was significantly increased to those of the CD8+IL-17+ and CD4+IL-17+ T 
cells derived from healthy controls [Figure 6].  
 
 
Fig. 6. Proliferative response of BD-skin-derived CD8+IL-17+ and CD4+IL-17+ T cells and a 
Th17 cell line. 
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Proliferative responses of CD8+IL-17+ and CD4+IL-17+ T cells from BD patients were more 
important than in healthy controls. Columns represent mean ± SD values (n=8) of 
proliferative response and asterisks, statistical significance [*]: P < 0.05.  
4. Discussion 
In this report we have investigated the phenotype and function of IL-17+ T cells in skin 
healthy controls and BD patients with skin lesions. We show that CD3+ T cells expressing 
IL-17 were increased in BD-skin lesions compared to skin biopsies from healthy controls. 
CD3+ IL-17+ T cells (Th17) are postulated to play a role in inflammatory/autoimmune 
pathogenesis [Wilson et al., 2007; Zaba et al., 2007; Murphy et al., 2003; Aggarwal et al., 
2003]. Recent data from Melikoglu et al [Melikoglu et al., 2006] reported increased cytokines 
(IFN-, IL-12 p40, IL-15), chemokines (MIP3-, IP-10, Mig, and iTac), and adhesion 
molecules (ICAM-1, VCAM-1) in the skin of BD patients with SPR+ but not in the skin of 
normal controls. These results suggested that BD patients experience marked cellular influx 
into the injury site, leading to an exaggerated lymphoid Th1-type response. Our results 
agree the inflammatory state in skin BD patient; our present results added a Th17-type 
response. We show that both CD4+ and CD8+ T cells express IL-17 in BD-skin lesions. We 
observed high levels of CD8+ IL-17+ T cells in the BD skin lesions. CD8+ IL-17+ T cells are 
ideally positioned to respond to potential keratinocyte autoantigens on HLA class I 
molecules. CD8+ IL-17+ T cells have been genetically implicated in skin lesions from 
autoimmune/inflammatory diseases [Nair et al., 206]. Our observations support the 
hypothesis that CD8+ IL-17+ T cells are critical mediators of the persistently altered 
epidermal growth and differentiation and the local inflammation that is characteristic of BD 
skin lesions. CD8+ IL-17+ T cells were observed in cancers [12] and in psoriasis [Kryczek et 
al., 2008]. Our data provide the first evidence that CD8+ IL-17+ T cells are important in BD as 
observed in autoimmune/inflammatory diseases [Wilson et al., 2007]. The presence of 
CD8+ T cells is necessary for the epidermal hyperproliferative response [Conrad et al., 2007].   
We characterized the phenotype of skin BD lesions IL-17+ T cells: CD103+CCR6+ IL-17+ T 
cells are effector T cells often found in environments with chronic inflammation 
[Gudjonsson et al. 2004; Krolls et al., 2006]. IL-17+ T cells highly express CD103, which may 
facilitate trafficking of IL-17+ cells into inflammatory tissues [Conrad et al., 2007; Pauls et al., 
2001]. We confirm that BD skin is an environment enriched with CCL20, and show that 
CCL20 is triggered by IFN- in myeloid APCs. We reported that BD Th1 cells are one of the 
major sources of IFN-, as reported recently [Hamzaoui et al., 2007], and that IL-17+ T cells 
efficiently migrate toward a CCL20-enriched BD environment via CCR6. Our data lead us to 
propose a first mode of potential interaction between Th1 and IL-17+ T cells in BD: IFN-
 derived from Th1 cells promotes trafficking of IL-17+ T cells to the environment BD 
lesions through the induction and maintenance of local CCL20 production. 
Regarding the contribution of epidermal CD8+IL-17+ cells to the pathogenesis of BD skin 
lesions, we have proved that CD4+IL-17+ and CD8+IL-17+ proliferate and secrete cytokines 
efficiently in response to CD3/TCR-mediated stimulation and to certain mediators. In 
Behcet’s disease, high mRNA levels of IL-8, IFN-, IL-12, IL-10, and MCP-1were found in 
lesional skin and pathergy sites [Melikoglu et al., 2006].  
CD4+CD25+ regulatory T (Treg) cells were found increased in the peripheral circulation of 
BD patients [Hamzaoui, 2007]. Treg cells and interleukin 17 (IL-17)-producing T helper 
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[A,B]: BD-IL-17+ T cells highly express CCR6. Expression of CCR6 was determined by FACS 
on IL-17+ and IL-17–T cells in BD skin. Results shown are mean of CCR6+ T cells in IL-17+ T 
cells or IL-17– T cells ± SD for 5 healthy donors and 6 BD patients. (*): P < 0.05 compared 
with IL-17– T cells. [C]: IL-17+ T cells migrate in response to CCL20. Migration assay was 
performed as described in Materials and Methods. The migrated T cells were subjected to 
intracellular staining for IL-17. The percentage of IL-17+ T cells in the upper and lower 
chambers is shown. [D]: IFN-γ induces CCL20 production. Blood CD11c+ cells were 
stimulated for 3 days with or without IFN- γ. CCL20 was detected by ELISA in the 
supernatants. Results shown are mean value ± SD for 8 healthy controls. (*): P < 0.05 
compared with control. [E]: High expression of CCL20 in BD skin. CCL20 transcript was 
quantified by real-time PCR. Results shown are mean value of relative 1 expression ± SD for 
5 healthy donors. (*): P = 0.004 compared with healthy skin control. [F]: High expression of 
CD103 on BD IL-17+ T cells. CD103 expression was determined by FACS on IL-17+ and IL-
17– T cell subsets. Results shown are mean ± SD of CD103+ T cells in each T cell subset, for 5 
healthy donors. (*): P < 0.05 compared with IL-17– T cells. One representative dot plot of BD 
CD103+ IL-17+ T cells is shown gated each on CD4+ and CD8+ T cells. 
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cells (TH17) carry out opposite functions, the former maintaining self-tolerance and the 
latter being involved in inflammation and autoimmunity [Deknuydt et al., 2009]. Several 
recent studies have indicated the existence of a close interplay between Treg and Th17 cells 
in regulating some autoimmune diseases. Whereas murine Treg cells suppress both Th1 and 
Th2 cells, in BD patients they enhance IL-17 secretion, likely through production of TGF-β 
[Mangan et al., 2006; Veldhoen et al., 2006].  Interplay between Treg cells and CD4+ IL-17+ 
cells have to be investigated in BD patients [Hamzaoui et al., 2011a; 2011b].  Memory Treg 
actually showed a more pronounced proficiency to give rise to Th17 cells than conventional 
memory CD4+ T cells, suggesting that they may be at least partially committed towards the 
TH17 differentiation pathway. This is consistent with the fact that memory Treg populations 
contain high proportions of cells expressing CCR6, the receptor of macrophage 
inflammatory protein3α (MIP-3/CCL20) that has been shown to characterize the TH17 
lineage [Acosta-Rodriguez et al., 2007; Tosello et al., 2008].  
The findings reported in the present study have several implications. First, one can imagine 
a scenario in which, during skin BD inflammation, Treg cells stimulated by APC activated 
by microbial products participate to innate immunity and transiently down-regulate 
suppressor functions, to allow the development of adaptive immunity. In a second scenario, 
sustained induction of Treg into Th17 cells in vivo will likely occur under defined permissive 
conditions, such as those that have been reported to lead to autoimmune/inflammatory 
reactions including chronic inflammation in the presence of interleukin (IL)-1 and IL-2. IL-1 
was highly expressed in BD [Bilginer et al., 2010; Kôtter et al., 2005].  
There are <1% CD4+ and <0.5% CD8+ IL-17+ T cells in peripheral blood of healthy humans 
[Kryczek et al., 2007]. Peripheral blood of active BD patients exhibited high levels of Th17 
cells in their peripheral circulation [Hamzaoui et al., 2002; Direskeneli et al.; 2003; Hamzaoui 
et al., 2011] and in cerebrospinal fluid [Hamzaoui et al., 2011]. High levels of Th17, CD4+ IL-
17+ and CD8+ IL-17+ T cells are observed in BD inflammatory skin. How does this induction 
occur? In addition to migration from peripheral blood, IL-17+ T cells may be induced 
within the BD lesions environment. It has been reported that myeloid cell-derived genes 
contribute to pathogenic manifestations in inflammatory diseases [Haider et al., 2008; 
Szegedi et al., 2003]. We demonstrate that myeloid APCs including macrophages and 
myeloid dendritic cells potently induce human IL-17+ T cells. Our observation may also 
explain why   IL-17+ T cells are often found in inflammatory tissues and organs. In support 
of this concept, we show that myeloid APCs isolated from BD patients potently stimulate IL-
17+ T cells.  Increased circulating IFN- [Szegedi et al.,2003] may activate circulating 
APCs, allowing them to enter tissue and promote expansion of IL-17+ T cells. Th1 cells can 
suppress Th17 cell differentiation through IFN- [Kolls et al., 2004; Weaver et al., 2006; 
Teunissen et al., 1998].  
IFN- triggers myeloid APCs to produce IL-1 and IL-23, and in turn induce IL-17+ T cells 
[Kryczek et al 2008]. Our data therefore demonstrate the potential mode of 
interaction between Th1 and IL-17+ T cells in BD skin lesions: IFN- derived from Th1 cells 
promotes IL-17+ T cell development through IL-1 and IL-23 in the skin lesion environment 
in Behcet disease. Therefore, IFN- may possibly play dual roles in regulating the IL-17+ T 
cell pool: IFN- targets APCs to initiate and promote Th17 polarization [Teunissen et al., 
1998; Kolls et al., 2004; Szabo et al., 1998] to suppress Th17 polarization. 
In summary, we show that IFN- may promote trafficking, induction, and function of IL-
17+ T cells in patients with BD. This study clarify the interaction between Th1 and Th17 cells, 
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challenges the view that Th1 cells suppress Th17 cell development, and suggests a 
collaborative contribution of Th1 and Th17 to autoimmune/inflammatory diseases. 
Ongoing research is addressing this aspect as well as attempting to define better whether 
CD8+ IL-17+ lymphocytes act as cytotoxic cells (Tc17 cells) which contribute to initiate, 
stabilize, or inhibit the BD process in the skin.  
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1. Introduction 
Protein C is a vitamin K–dependent zymogen, discovered in 1976 in bovine plasma (Stenflo, 
1976). It is derived from the human PROC gene on chromosome 2 (2q13-q14) which contains 
9 exons (Rezaie, 1993). Post-translational modifications include -hydroxylation at Asp71, 
N-linked glycosylation at residues 97, 248, 313 and 329 and γ-carboxylation of 9 glutamic 
acid residues which forms the Gla domain at the amino terminus. Human protein C is 62kD 
protein and consists of 419 amino acids. The four major moieties that make up the protein C 
molecule are a Gla domain, two epidermal growth factor (EGF)- like regions, a small 
activation peptide, and an active serine protease domain (Griffin, 2005). Mature 62 000 Da 
human protein C is cleaved by a furin-like endoprotease that releases Lys156–Arg157 before 
secretion from liver cells. Protein C is activated on the endothelial surface when thrombin 
binds to thrombomodulin and cleaves protein C’s activation peptide. This conversion to 
activated protein C (APC) is augmented by endothelial cell protein C receptor (EPCR) 
(Fukudome & Esmon, 1994). Protein C circulates in plasma at 70 nM whereas APC is present 
in much lower concentrations (40 pM  or ~ 2.3 ng/mL) (Gruber & Griffin, 1992).   
APC was  first recognized as an anticoagulant. In the presence of its cofactor, protein S, APC 
degrades the coagulation factors Va and VIIIa and inhibits thrombin generation. The light 
chain provides anticoagulant activity by having highly specific protein–protein interactions 
with factors Va and VIIIa followed by proteolytic inactivation of factor Va by cleavage at 
Arg (506) and Arg (306) and of factor VIIIa by cleavage at Arg (336) and Arg (562) (Zlokovic 
& Griffin, 2011). In addition, APC promotes fibrinolysis by binding to plasminogen activator 
inhibitor which prevents inhibition of plasminogen conversion to plasmin. The significance 
of APC as an anticoagulant is reflected by the findings that deficiencies in protein C result in 
severe familial disorders of thrombosis (Baker & Bick, 1999). Replenishment of protein 
C/APC in patients with systemic or local hypercoagulation can reverse the abnormality.   
2. Anti-inflammatory and cytoprotective functions of APC 
In addition to its anticoagulant activity, APC exerts a broad range of cytoprotective  and 
anti-inflammatory actions described below.  
 4 
Anti-Inflammatory Actions of the  
Anticoagulant, Activated Protein C  
Christopher John Jackson and Meilang Xue 
Sutton Arthritis Research Laboratories, Department of Rheumatology, 
Institute of Bone and Joint Research, Kolling Institute,  
University of Sydney at Royal North Shore Hospital, St Leonards  
Australia  
1. Introduction 
Protein C is a vitamin K–dependent zymogen, discovered in 1976 in bovine plasma (Stenflo, 
1976). It is derived from the human PROC gene on chromosome 2 (2q13-q14) which contains 
9 exons (Rezaie, 1993). Post-translational modifications include -hydroxylation at Asp71, 
N-linked glycosylation at residues 97, 248, 313 and 329 and γ-carboxylation of 9 glutamic 
acid residues which forms the Gla domain at the amino terminus. Human protein C is 62kD 
protein and consists of 419 amino acids. The four major moieties that make up the protein C 
molecule are a Gla domain, two epidermal growth factor (EGF)- like regions, a small 
activation peptide, and an active serine protease domain (Griffin, 2005). Mature 62 000 Da 
human protein C is cleaved by a furin-like endoprotease that releases Lys156–Arg157 before 
secretion from liver cells. Protein C is activated on the endothelial surface when thrombin 
binds to thrombomodulin and cleaves protein C’s activation peptide. This conversion to 
activated protein C (APC) is augmented by endothelial cell protein C receptor (EPCR) 
(Fukudome & Esmon, 1994). Protein C circulates in plasma at 70 nM whereas APC is present 
in much lower concentrations (40 pM  or ~ 2.3 ng/mL) (Gruber & Griffin, 1992).   
APC was  first recognized as an anticoagulant. In the presence of its cofactor, protein S, APC 
degrades the coagulation factors Va and VIIIa and inhibits thrombin generation. The light 
chain provides anticoagulant activity by having highly specific protein–protein interactions 
with factors Va and VIIIa followed by proteolytic inactivation of factor Va by cleavage at 
Arg (506) and Arg (306) and of factor VIIIa by cleavage at Arg (336) and Arg (562) (Zlokovic 
& Griffin, 2011). In addition, APC promotes fibrinolysis by binding to plasminogen activator 
inhibitor which prevents inhibition of plasminogen conversion to plasmin. The significance 
of APC as an anticoagulant is reflected by the findings that deficiencies in protein C result in 
severe familial disorders of thrombosis (Baker & Bick, 1999). Replenishment of protein 
C/APC in patients with systemic or local hypercoagulation can reverse the abnormality.   
2. Anti-inflammatory and cytoprotective functions of APC 
In addition to its anticoagulant activity, APC exerts a broad range of cytoprotective  and 
anti-inflammatory actions described below.  
 
Inflammatory Diseases – A Modern Perspective 46
2.1 Inflammation 
Independent of its effect on coagulation, APC has potent anti-inflammatory properties 
(Joyce, 2001; Mosnier & Griffin, 2003) associated with a decrease in pro-inflammatory 
cytokines and a reduction of leukocyte recruitment. Joyce et al (Joyce, 2001) have shown that 
APC directly suppresses expression of p50 and p52 nuclear factor (NF)-B  subunits in 
human umbilical vein endothelial cells. The NF-B pathway is important for the expression 
of a wide variety of inflammatory genes including tumor necrosis factor (TNF)-α and cell 
adhesion molecules that are associated with diseases ranging from inflammation to cancer 
(Li & Verma, 2002). Direct inhibition of NF-B is sufficient to block symptoms of many 
inflammatory diseases so these inhibitors have potential therapeutic value (Bell, 1915; Li & 
Verma, 2002; Calzado, 1914; Calzado, 2007). APC inhibits the expression and activation of 
NF-B in unstimulated and stimulated monocytes (White, 2000; Xue, 2007; Yuksel, 2002), 
keratinocytes (Xue, 2004), endothelial cells (Franscini, 2004). APC also suppresses 
inflammation in vivo by inhibition of NF-B (Cheng, 2006). In addition, APC has the ability 
to upregulate and activate matrix metalloproteinase (MMP)-2 (Nguyen, 2000; Xue, 2004), a 
MMP with anti-inflammatory properties (Itoh, 2002; McQuibban, 2002) and to suppress 
gelatinase B  (Cheng, 2006; Xue, 2007), a MMP associated with many inflammatory 
conditions (Itoh, 2002; Ram, 2006). During acute inflammation, plasma APC levels are 
diminished (Liaw, 2004) and inflammatory cytokines such as interleukin (IL)-1β and TNF-α, 
as well as endotoxin, can attenuate thrombomodulin and EPCR expression which further 
reduces the ability of endothelial cells to generate APC. Acute inflammation is exacerbated 
in mice genetically predisposed to a severe protein C deficiency (Lay, 2007).  
APC also regulates the immuno/inflammatory response. Monocytes treated with APC 
decrease the release of tissue factor (Toltl, 2008), the pro-inflammatory cytokines TNF-α 
(Grey, 1994), IL-1β, IL-6, and & IL-8 (Stephenson, 2006). Additionally, APC induces the 
release of the anti-inflammatory cytokine IL-10 from monocytes (Toltl, 2008). 
APC targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice (Kerschen, 
2010).  Expression of EPCR in mature murine immune cells is limited to a subset of CD8+ 
conventional dendritic cells.  Adoptive transfer of splenic CD11chiPDCA-1- dendritic cells 
from wild-type mice into animals with hematopoietic EPCR deficiency restored the 
therapeutic efficacy of APC, whereas transfer of EPCR-deficient CD11chi dendritic cells or 
wild-type CD11chi dendritic cells depleted of EPCR+ cells did not. These data reveal an 
essential role for EPCR and PAR1 on hematopoietic cells, identify EPCR-expressing 
dendritic immune cells as a critical target of APC therapy, and document EPCR-
independent anti-inflammatory effects of APC on innate immune cells. 
2.2 Cell proliferation and apoptosis 
APC induces growth of cultured human umbilical vein endothelial cells (HUVEC) (Uchiba, 
2004). In smooth muscle cells, APC elicits an increase in [(3)H]-thymidine incorporation 
(Bretschneider, 2007) and enhances proliferation and migration of human skin keratinocytes 
(Xue, 2005). Consistent with the stimulatory effects on cell growth, APC displays strong 
anti-apoptotic properties. APC decreases sepsis-induced apoptosis resulting from increased 
p21 and p53 proteins in mice (Sakar, 2007) and modulates Bcl-2 and Bax and inhibits 
caspase-3 and -8  activity which results in inhibition of apoptosis in a number of cell types 
(Joyce, 2001). During hypoxic stress of brain endothelial cells, APC inhibits p53, reduces pro-
apoptotic Bax and maintains levels of protective Bcl-2 protein, thereby preventing the 
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stimulation of the intrinsic apoptotic pathway (Cheng, 2003). In human skin keratinocytes, 
APC prevents cell apoptosis via inhibition of caspase-3 activation (Xue, 2004) and in 
podocytes, APC protects against  glucose-induced apoptosis both in vitro and in vivo 
(Isermann, 2007). APC inhibits bisphosphonate-induced endothelial cell death via EPCR-
induced inactivation of caspase-3 and NF-κB, and also suggests that APC has the potential 
to be a therapeutic drug in various vascular diseases induced by endothelial cell damage 
(Seol, 2011). 
2.3 Barrier stabilization 
Endothelial cells normally form a dynamically regulated stable barrier at the blood-tissue 
interface, and breakdown of this barrier is a key pathogenic factor in inflammatory 
disorders, such as sepsis. APC boosts the barrier via at least two different mechanisms.  
First, APC enhances sphingosine-1-phosphate (S-1-P) production, which signals through its 
G-protein coupled receptor to stabilize the cytoskeleton and reduce endothelial permeability 
(Feistritzer & Riewald, 2005; Finigan, 2005). Second, APC utilizes the angiopoietin 
(Ang)/Tie2 axis to promote endothelial barrier function (Minhas, 2010). APC significantly 
up-regulates gene and protein expression of Tie2 and Ang1 in a dose (0.01-10 µg/ml) and 
time (0.5 h – 24 h) dependent manner in HUVEC, whilst it markedly inhibits Ang2 with an 
IC50 of ~ 0.1 µg/ml. HUVEC permeability, measured using Evans blue dye transfer, is 
significantly reduced in the presence of APC and, in concordance, the tight junction 
associated protein, zona occludens (ZO)-1, is up regulated and localized peripherally 
around cells, compared to control. Smooth muscle cell migration towards APC-stimulated 
HUVEC is elevated compared to unstimulated cells. Blocking antibodies and small 
interfering (si) RNA treatment, compared to isotype or scrambled siRNA controls, show that 
APC requires three receptors, endothelial protein C receptor (EPCR), protease activated 
receptor (PAR)-1 and Tie2 to perform all these barrier stabilization functions (Minhas, 2010). 
We have shown that HUVEC produce protein C that acts through novel mediators to 
enhance their own functional integrity (Xue, 2010). When endogenous protein C or its 
receptor, EPCR, is suppressed by si RNA, HUVEC proliferation is decreased and apoptosis 
elevated. Interestingly, protein C or EPCR siRNA significantly increases HUVEC 
permeability, which occurs via a reduction of the Ang1/Ang2 ratio and inhibition of the 
peripheral localization of the tight junction protein, ZO-1. In addition, protein C or EPCR 
siRNA inhibits type IV collagen and MMP-2, providing the first evidence that protein C 
contributes to vascular basement membrane formation (Xue, 2010). Barrier stabilization is 
more effective when APC is derived endogenously and functions in an autocrine manner, 
than when the source of APC is exogenous (Feistritzer, 2006). 
The barrier protective effect of APC is also relevant to epidermal keratinocytes (Xue, 2011).  
In response to APC, Tie2, a tyrosine kinase receptor, is rapidly activated within 30 minutes, 
and relocates to cell-cell contacts. APC also increases junction proteins ZO-1, claudin-1 and 
VE-cadherin. Inhibition of Tie2 by its peptide inhibitor or small interfering RNA abolished 
the barrier protective effect of APC (Xue, 2011).   
3. APC cellular signalling  
APC exerts its anti-inflammatory, cyto-protective and barrier stabilization effects by acting 
on receptors which initiates cellular signaling, as described below. 
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3.1 EPCR and PARs 
Many of the cyto-protective actions of APC are mediated through EPCR, which itself is 
anti-inflammatory (Esmon, 2004). This receptor binds protein C and APC with similar 
affinity (Fukudome & Esmon, 1994), and protein C can be converted to APC whilst 
remaining bound to EPCR. EPCR is a type I transmembrane protein which shares 
homology with the major histocompatibility class 1/CD1 family of proteins involved in 
the immune response. EPCR was discovered on endothelial cells, however EPCR was 
subsequently found on some leukocytes (Esmon, 2004) and is strongly expressed by the 
basal layer of keratinocytes in skin epidermis as well as in cultured keratinocytes (Xue, 
2005). Recent studies show that EPCR has important physiological functions. For example, 
over-expression of EPCR protects transgenic mice from endotoxin-induced injury (Li, 
2005) and EPCR is essential for normal embryonic development as deletion of the EPCR 
gene in mice is lethal by embryonic day 10 (Gu, 2002).  
Recently, EPCR has been identified as a marker of certain stem cells in mice (Balazs, 2006; 
Kent, 2009).  EPCR is expressed at high levels within the bone marrow in hematopoietic 
stem cells (HSCs). Mouse bone marrow cells isolated on the basis of EPCR expression alone 
are highly enriched HSCs, showing levels of engraftment in vivo comparable to that of stem 
cells purified using the most effective conventional methods (Balazs, 2006). Moreover, they 
showed that hematopoietic stem cell activity is always associated with EPCR-expressing 
cells (Balazs, 2006). In addition, high EPCR-expressing cells are observed in basal-like 
tumours in breast cancer (Park, 2010).  
EPCR does not mediate cell signalling, but acts as a homing receptor to allow APC to cleave 
PAR-1 (Riewald, 2002). The PARs are G-protein coupled receptors found on most cells. The 
four known PARs are activated via proteolytic cleavage by various proteases that results in 
an intra-molecular tethered ligand that triggers activation  of a G protein and subsequent 
intracellular signalling (Coughlin, 2000). Thrombin activates PAR-1, PAR-3, and PAR-4, 
whereas other serine proteases, including APC (Riewald, 2002). but not thrombin, activate 
PAR-2. Subsequent functional activity of APC cleavage of PAR-2 is yet to be fully 
elucidated, although our experiments indicate that APC acts through PAR-2 to promote 
wound healing in mice (Julovi et al, personal communication) . While the majority of 
reports cast PAR-2 as pro-inflammatory, others show that PAR-2 agonists are beneficial in 
several mouse models that involve inflammation or ischemia (Milia, 2002). Among the 
PARs, PAR-1 is most widely expressed and has been most extensively studied. APC 
bound to EPCR can activate PAR-1 and promote the anti-inflammatory and anti-apoptotic 
actions of APC (Riewald, 2002). 
Both thrombin and APC can cleave PAR-1 at identical locations. Thrombin cleavage causes 
platelet activation, increases vascular permeability, activates NF-B and elevates 
inflammatory cytokines, all of which promote an inflammatory response. Unexpectedly, 
when APC cleaves PAR-1, its actions are directly opposite to that of thrombin. APC strongly 
inhibits vascular permeability, activation of NF-B, endothelial adhesion molecule 
expression, cytokine production and monocyte migration (Riewald, 2002).  Studies using 
endothelial cells and other cell types show that when APC activates PAR-1 in an EPCR-
dependent manner, it causes alterations in gene expression profiles and exerts direct anti-
apoptotic effects (Guo, 2004; Joyce, 2001). However, compared to thrombin, APC is 
relatively inefficient and requires ~104 higher concentration (Kuliopulos, 1999) to cleave 
PAR-1. This has raised doubts about the possibility of APC having a physiological effect by 
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acting through PAR-1. Bae et al (Bae, 2007) have partially solved this issue by showing that 
APC cleaves PAR-1 on lipid rafts in endothelial cells. They subsequently identified a novel 
pathway whereby EPCR is associated with caveolin-1 in lipid rafts in endothelial cells (Bae, 
2007). These discrete, cholesterol and sphingolipid enriched microdomains of the cell 
membrane provide a protective compartment for APC to act in isolation. When APC 
binds to EPCR in the lipid raft, caveolin-1 is replaced with PAR-1 which couples with the 
pertussis toxin sensitive Gi-protein to initiate a protective signalling pathway. In contrast, 
when thrombin cleaves PAR-1 outside the lipid raft signalling occurs via Gq and/or 
G12/13 which exert inflammatory effects.  Interestingly, if EPCR is occupied on the lipid 
raft, even thrombin, can induce activation of the Gi protein and mimic the protective 
effects of APC (Bae, 2007).  
3.2 Epidermal growth factor receptor (EGFR) and Tie2 
In normal epidermis, EGFR is important for autocrine growth of this renewing tissue, 
suppression of terminal differentiation, promotion of cell survival, and regulation of cell 
migration during epidermal morphogenesis. In wounded skin, EGFR is momentarily up-  
 
 
Fig. 1. Proposed signal pathway for APC’s protective role on barrier function in confluent 
keratinocytes. APC binds to EPCR which cleaves PAR-1. G protein transactivates EGFR 
which may further transactivate Tie2 receptor, although the mechanism of activation is 
unclear. This triple receptor action results in increased ZO-1 and phosphorylation of Akt via 
PI3K and inhibition of ERK, leading to an increase in keratinocyte survival and barrier 
function. From (Xue, 2011). 
 
Inflammatory Diseases – A Modern Perspective 48
3.1 EPCR and PARs 
Many of the cyto-protective actions of APC are mediated through EPCR, which itself is 
anti-inflammatory (Esmon, 2004). This receptor binds protein C and APC with similar 
affinity (Fukudome & Esmon, 1994), and protein C can be converted to APC whilst 
remaining bound to EPCR. EPCR is a type I transmembrane protein which shares 
homology with the major histocompatibility class 1/CD1 family of proteins involved in 
the immune response. EPCR was discovered on endothelial cells, however EPCR was 
subsequently found on some leukocytes (Esmon, 2004) and is strongly expressed by the 
basal layer of keratinocytes in skin epidermis as well as in cultured keratinocytes (Xue, 
2005). Recent studies show that EPCR has important physiological functions. For example, 
over-expression of EPCR protects transgenic mice from endotoxin-induced injury (Li, 
2005) and EPCR is essential for normal embryonic development as deletion of the EPCR 
gene in mice is lethal by embryonic day 10 (Gu, 2002).  
Recently, EPCR has been identified as a marker of certain stem cells in mice (Balazs, 2006; 
Kent, 2009).  EPCR is expressed at high levels within the bone marrow in hematopoietic 
stem cells (HSCs). Mouse bone marrow cells isolated on the basis of EPCR expression alone 
are highly enriched HSCs, showing levels of engraftment in vivo comparable to that of stem 
cells purified using the most effective conventional methods (Balazs, 2006). Moreover, they 
showed that hematopoietic stem cell activity is always associated with EPCR-expressing 
cells (Balazs, 2006). In addition, high EPCR-expressing cells are observed in basal-like 
tumours in breast cancer (Park, 2010).  
EPCR does not mediate cell signalling, but acts as a homing receptor to allow APC to cleave 
PAR-1 (Riewald, 2002). The PARs are G-protein coupled receptors found on most cells. The 
four known PARs are activated via proteolytic cleavage by various proteases that results in 
an intra-molecular tethered ligand that triggers activation  of a G protein and subsequent 
intracellular signalling (Coughlin, 2000). Thrombin activates PAR-1, PAR-3, and PAR-4, 
whereas other serine proteases, including APC (Riewald, 2002). but not thrombin, activate 
PAR-2. Subsequent functional activity of APC cleavage of PAR-2 is yet to be fully 
elucidated, although our experiments indicate that APC acts through PAR-2 to promote 
wound healing in mice (Julovi et al, personal communication) . While the majority of 
reports cast PAR-2 as pro-inflammatory, others show that PAR-2 agonists are beneficial in 
several mouse models that involve inflammation or ischemia (Milia, 2002). Among the 
PARs, PAR-1 is most widely expressed and has been most extensively studied. APC 
bound to EPCR can activate PAR-1 and promote the anti-inflammatory and anti-apoptotic 
actions of APC (Riewald, 2002). 
Both thrombin and APC can cleave PAR-1 at identical locations. Thrombin cleavage causes 
platelet activation, increases vascular permeability, activates NF-B and elevates 
inflammatory cytokines, all of which promote an inflammatory response. Unexpectedly, 
when APC cleaves PAR-1, its actions are directly opposite to that of thrombin. APC strongly 
inhibits vascular permeability, activation of NF-B, endothelial adhesion molecule 
expression, cytokine production and monocyte migration (Riewald, 2002).  Studies using 
endothelial cells and other cell types show that when APC activates PAR-1 in an EPCR-
dependent manner, it causes alterations in gene expression profiles and exerts direct anti-
apoptotic effects (Guo, 2004; Joyce, 2001). However, compared to thrombin, APC is 
relatively inefficient and requires ~104 higher concentration (Kuliopulos, 1999) to cleave 
PAR-1. This has raised doubts about the possibility of APC having a physiological effect by 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 49 
acting through PAR-1. Bae et al (Bae, 2007) have partially solved this issue by showing that 
APC cleaves PAR-1 on lipid rafts in endothelial cells. They subsequently identified a novel 
pathway whereby EPCR is associated with caveolin-1 in lipid rafts in endothelial cells (Bae, 
2007). These discrete, cholesterol and sphingolipid enriched microdomains of the cell 
membrane provide a protective compartment for APC to act in isolation. When APC 
binds to EPCR in the lipid raft, caveolin-1 is replaced with PAR-1 which couples with the 
pertussis toxin sensitive Gi-protein to initiate a protective signalling pathway. In contrast, 
when thrombin cleaves PAR-1 outside the lipid raft signalling occurs via Gq and/or 
G12/13 which exert inflammatory effects.  Interestingly, if EPCR is occupied on the lipid 
raft, even thrombin, can induce activation of the Gi protein and mimic the protective 
effects of APC (Bae, 2007).  
3.2 Epidermal growth factor receptor (EGFR) and Tie2 
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suppression of terminal differentiation, promotion of cell survival, and regulation of cell 
migration during epidermal morphogenesis. In wounded skin, EGFR is momentarily up-  
 
 
Fig. 1. Proposed signal pathway for APC’s protective role on barrier function in confluent 
keratinocytes. APC binds to EPCR which cleaves PAR-1. G protein transactivates EGFR 
which may further transactivate Tie2 receptor, although the mechanism of activation is 
unclear. This triple receptor action results in increased ZO-1 and phosphorylation of Akt via 
PI3K and inhibition of ERK, leading to an increase in keratinocyte survival and barrier 
function. From (Xue, 2011). 
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regulated and is a major contributor to the proliferative and migratory aspects of wound re-
epithelialization. EGFR is able to regulate cell adhesion, expression of matrix degrading 
proteinases, and cell migration to provide a vital contribution to the migratory and invasive 
potential of keratinocytes (Hudson & McCawley, 1998). APC appears to act through EGFR 
to regulate  lymphocyte migration (Feistritzer, 2006) and wound healing (Xue, 2007). When 
keratinocytes are stimulated with APC, the expression and phosphorylation of EGFR is 
markedly increased and conversely when cells are treated with protein C siRNA, the 
phosphorylated form of EGFR in cell lysates is inhibited by more than 50% (Xue, 2007). 
Using dual immunofluorescent staining, we found that both EPCR and activated EGFR are 
co-localized in basal and suprabasal keratinocytes in the epidermis, which is identical to 
protein C localization in skin epidermis (Xue, 2007).  Furthermore, APC does not activate 
Tie2 through its major ligand, Ang-1, in keratinocytes, but instead acts by binding to EPCR, 
cleaving PAR-1 and trans-activating EGFR followed by transactivation of Tie2 (Figure 1). 
When activation of Akt, but not ERK, is inhibited, the barrier protective effect of APC on 
keratinocytes is abolished. Another report has indicated that, extracellularly, APC engages 
EPCR, PAR-1, and EGFR in order to increase the invasiveness of MDA-MB-231 cells 
(Gramling, 2010). 
3.3 Other receptors 
EPCR-independent signaling components of the APC pathway have been identified in 
monocytes. Apolipoprotein E receptor 2 (ApoER2) binding of APC results in 
phosphorylation of Dab1 and activation of the PI3K and Akt pathway resulting in decreased 
tissue factor release from monocytes (Yang, 2009).  
The efficacy of APC in murine endotoxemia is dependent on integrin CD11b. Genetic 
inactivation of CD11b, PAR1, or sphingosine kinase-1, but not EPCR, abolished the ability of 
APC to suppress the macrophage inflammatory response in vitro. Using a LPS-induced 
mouse model of lethal endotoxemia, Cao et al (Cao, 2010) showed that APC administration 
reduced the mortality of wild-type mice, but not CD11b-deficient mice. 
 
Receptor Significant Finding Year Reference 
Tie2 
APC increases angiopoietin to activate 
Tie2 in endothelial cells 
APC activates PAR-1 which 





CD11b APC acts through Cd11b in macrophages 2009 (Cao, 2010) 
ApoER2 ApoER2 acts independent of EPCR and PAR-1 to phosphorylate Dab-1 2008 (Yang, 2009) 
EGFR APC phosphorylates EGFR in HUVEC 2005 (Montiel, 2005) 
PAR-3 Prevention of neuronal cell apoptosis 2004 (Guo, 2004) 
PAR-2 APC bound EPCR supports cleavage of PAR-2 2002 (Riewald, 2002) 
EPCR/PAR-1 APC bound EPCR cleaves PAR-1 resulting in APCs effects 2002 (Riewald, 2002) 
Table 1. Cell receptors that APC acts through to exert its anti-inflammatory and 
cytoprotective effects. 
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3.4 Intracellular signaling 
The transcription factors, NF-B and the AP-1 complex, a transcriptionally active 
heterodimer of Fos and Jun proteins, regulate the expression of genes involved in immune 
and inflammatory responses. They play a pivotal role in the regulation of inflammation 
(Carmi & Razin, 2007). APC prevents activation of NF-B and AP-1 stimulated by LPS and 
endotoxin in human monocytes. The MAP kinase pathway is a prerequisite for growth 
factor stimulated mitogenesis in many cell types. Three major downstream MAP kinase 
cascades are mitogen- activated ERK1/2 and stress/cytokine-activated p38 and c-Jun N-
terminal kinases. APC induces cell proliferation via activation of the ERK1/2 pathway in 
endothelial cells (Uchiba, 2004). Similarly, stimulation of smooth muscle cells with APC 
induces a synergistic effect on ERK-1/2 phosphorylation and DNA synthesis (Bretschneider, 
2007). In human keratinocytes, blocking protein C expression or inhibiting its binding to 
EPCR/EGFR decreases the phosphorylation of ERK1/2 but increases p38 activation. 
Furthermore, inhibition of ERK completely abolishes APC’s stimulatory effect on 
proliferation. These results indicate that keratinocyte-derived protein C promotes cell 
growth in an autocrine manner via EPCR, EGFR and activation of ERK1/2 (Xue, 2007).  
Furthermore, when activation of Akt, but not ERK, is inhibited, the barrier protective effect 
of APC on keratinocytes is abolished. Thus, APC activates Tie2, which selectively enhances 
the PI3K/Akt signalling to stimulate junctional complexes and reduce keratinocyte 
permeability (Xue, 2011). 
4. APC in inflammatory disease 
APC has therapeutic benefit in a number of other diseases, through its anticoagulant, anti-
apoptotic, anti-inflammatory activities and positive effects on cell growth, migration and 
barrier stabilization, summarized in Figure 2. The following sections detail evidence for the 
potential beneficial effects of APC in a number of disorders associated with abnormal auto-
immune/inflammatory responses. 
4.1 Sepsis 
Severe sepsis is a very serious condition characterized physiologically by an aberrant 
systemic inflammatory response and microvascular dysfunction. Low levels of endogenous 
protein C provokes endotoxic (Levi, 2003) and septic responses (Ganopolsky & Castellino, 
2004). In human sepsis, there is a reduction in circulating  APC which appears to be due to 
both decreased levels of protein C, with  protein C levels strongly inversely correlating with 
sepsis prognosis (Fisher, Jr. & Yan, 2000) and decreased activation of protein C to APC 
(Liaw, 2004). Evidence from the PROWESS and ENHANCE clinical trials suggests that 
administration of recombinant human APC (drotrecogin alfa) reduces mortality in a subset 
of patients with severe sepsis (Bernard, 2004; Bernard, 2001; Marti-Carvajal, 2003).  It is 
indicated for use in patients with sepsis involving acute organ dysfunction who have a high 
risk of death. Two recent case reports provide evidence that APC may also be useful to treat 
multi-organ failure resulting from severe malaria (Kendrick, 2006; Srinivas, 2007). However, 
there is evidence that APC may cause bleeding in some patients, especially children and 
patients who have undergone recent surgery (Marti-Carvajal, 2007). The therapeutic effect 
and controversies of APC in severe sepsis has been extensively reviewed (Griffin, 2002; 
O'Brien, 2006; Short, 2006). Commercial preparations of recombinant APC (Xigris, Ely Lilly, 
Indianapolis) are readily available and FDA approved. 
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induces a synergistic effect on ERK-1/2 phosphorylation and DNA synthesis (Bretschneider, 
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Severe sepsis is a very serious condition characterized physiologically by an aberrant 
systemic inflammatory response and microvascular dysfunction. Low levels of endogenous 
protein C provokes endotoxic (Levi, 2003) and septic responses (Ganopolsky & Castellino, 
2004). In human sepsis, there is a reduction in circulating  APC which appears to be due to 
both decreased levels of protein C, with  protein C levels strongly inversely correlating with 
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and controversies of APC in severe sepsis has been extensively reviewed (Griffin, 2002; 
O'Brien, 2006; Short, 2006). Commercial preparations of recombinant APC (Xigris, Ely Lilly, 
Indianapolis) are readily available and FDA approved. 
 
Inflammatory Diseases – A Modern Perspective 52
Endogenous APC signaling is critical to protection of mice from LPS-induced septic shock 
(Xu, 2009). Many mechanisms have been described, but the exact manner in which APC 
affects sepsis patients is unclear. Therapeutic APC can regulate neutrophil migration and 
extravasation by direct engagement of β1 and β3 integrins (Elphick, 2009), suppress 
macrophage activation dependent on integrin CD11b/CD18 (Kerschen, 2010), control 
maturation and activation of CD8+ DCs dependent on EPCR (Kerschen, 2010), and 
neutralize late-stage inflammatory mediators by degrading nuclear histones from apoptotic 
cells (Xu, 2009).  
A recent Cochrane review suggested that APC should not be used for treating patients with 
severe sepsis or septic shock and that APC is associated with a higher risk of bleeding 
(Marti-Carvajal, 2011). Unless additional RCTs provide evidence of a treatment effect, 
policy-makers, clinicians and academics have been advised not promote the use of APC 
(Marti-Carvajal, 2011). Nonetheless, new reports continue to show that patients with septic 
shock who were treated with APC had a reduced in-hospital mortality compared with those 
not treated with APC (Sadaka, 2011). 
 
Fig. 2. The diverse biological effects of APC. APC exerts numerous molecular effects which 
lead to cellular responses which cause protective effects in a number of diseases. Ang= 
angiopoietin; EGFR= epidermal growth factor receptor; IL=interleukin; MMP=matrix 
metalloproteinase; TGF=transforming growth factor; TNF=tumour necrosis factor-α; 
ZO=zona occludens; Bcl=B-cell lymphoma; BAX=Bcl-2–associated X protein.  
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4.2 Spinal cord injury (SCI)  
SCI can be induced by a physical insult resulting in an inflammatory response that leads to 
tissue destruction and life-long disabilities. Therapeutic intervention in SCI is largely being 
directed at reducing or alleviating inflammation (Okajima, 2004). In rat models, the 
inflammatory response occurs due to infiltration by neutrophils and release of TNF- 
(Taoka, 2000). Taoka et al (Taoka, 1997) demonstrated that a P-selectin mediated interaction 
between activated neutrophils and endothelial cells may be a critical step in endothelial cell 
damage leading to spinal cord injury in rats. These authors (Taoka, 1998) originally showed 
that rats subjected to compression-trauma induced SCI and treated with APC have a 
marked reduction in motor disturbances (Taoka, 1998), however, 12 years later this paper 
was retracted by the authors (2011). APC significantly reduces motor disturbances and 
micro-infarctions of the spinal cord in rats subjected to ischemia/reperfusion-induced SCI 
(Hirose, 2000). The increased tissue levels of TNF- and neutrophils in the injured part of 
the spinal cord were significantly reduced in animals that received APC. 
APC has direct neuroprotective effects, independent of its anticoagulant activity (Zlokovic, 
2005). In a rabbit model of ischemic spinal cord injury, APC eases the functional deficits and 
increases the number of motor neurons (Yamauchi, 2006). Interestingly, APC induces 
insulin-like growth factor (IGF)-1, IGF-1 receptor and the downstream p-Akt which might 
partially explain the neuroprotective effects of APC after transient spinal cord ischemia in 
rabbit. 
4.3 Brain injury and stroke 
Elevated plasma protein C levels are linked to a lower incidence of ischemic stroke in 
humans (Folsom, 1999) and conversely, lower circulating APC levels are found in patients 
with post-infection ischemic stroke compared to the control subjects (Macko, 1996). These 
data imply that the protein C pathway may protect against stroke. In a murine model of 
focal cerebral ischemia, APC significantly improved cerebral blood flow in the ischemic 
hemisphere and markedly reduced the volume of brain injury caused by middle cerebral 
vein occlusion. These effects were dependent on EPCR and PAR-1 and seemingly 
independent of APC’s anticoagulant effects  (Fernandez, 2003; Guo, 2004; Shibata, 2001). 
APC directly prevents apoptosis in hypoxic human brain endothelium through inhibition of 
p53, normalization of the pro-apoptotic Bax/Bcl-2 ratio, and reduction of caspase-3 
signalling (Guo, 2004). APC's cytoprotection of endothelial cells in vitro requires EPCR and 
PAR-1(Guo, 2004; Mosnier & Griffin, 2003).  APC can also directly protect perturbed 
neurons from cell injury and apoptosis. In vitro, APC reduces apoptosis in mouse cortical 
neurons treated with N-methyl-D-aspartate (NMDA) and staurosporine (Guo, 2004). 
Interestingly, PAR-1 and PAR-3 are required for this effect. Intra-cerebral APC infusion 
dose-dependently reduces NMDA excitotoxic injury in mice (Guo, 2004). Overall, APC 
maintains the patency of ischemic vasculature by inhibiting hypoxia-induced endothelial 
cell apoptosis and also directly protects the integrity and functionality of the neuronal 
network. 
Periventricular leukomalacia is the dominant form of brain injury in premature infants, 
characterized by white matter injury. The underlying pathogenic mechanisms include 
hypoperfusion, procoagulant activity, apoptotic cell death, microglial activation and 
inflammation associated with maternal and/or fetal infection (Genc, 2006). They 
hypothesized that APC, which modulates many of these processes, is a promising 
therapeutic agent for periventricular leukomalacia. 
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4.2 Spinal cord injury (SCI)  
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(Taoka, 2000). Taoka et al (Taoka, 1997) demonstrated that a P-selectin mediated interaction 
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damage leading to spinal cord injury in rats. These authors (Taoka, 1998) originally showed 
that rats subjected to compression-trauma induced SCI and treated with APC have a 
marked reduction in motor disturbances (Taoka, 1998), however, 12 years later this paper 
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(Hirose, 2000). The increased tissue levels of TNF- and neutrophils in the injured part of 
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insulin-like growth factor (IGF)-1, IGF-1 receptor and the downstream p-Akt which might 
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rabbit. 
4.3 Brain injury and stroke 
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humans (Folsom, 1999) and conversely, lower circulating APC levels are found in patients 
with post-infection ischemic stroke compared to the control subjects (Macko, 1996). These 
data imply that the protein C pathway may protect against stroke. In a murine model of 
focal cerebral ischemia, APC significantly improved cerebral blood flow in the ischemic 
hemisphere and markedly reduced the volume of brain injury caused by middle cerebral 
vein occlusion. These effects were dependent on EPCR and PAR-1 and seemingly 
independent of APC’s anticoagulant effects  (Fernandez, 2003; Guo, 2004; Shibata, 2001). 
APC directly prevents apoptosis in hypoxic human brain endothelium through inhibition of 
p53, normalization of the pro-apoptotic Bax/Bcl-2 ratio, and reduction of caspase-3 
signalling (Guo, 2004). APC's cytoprotection of endothelial cells in vitro requires EPCR and 
PAR-1(Guo, 2004; Mosnier & Griffin, 2003).  APC can also directly protect perturbed 
neurons from cell injury and apoptosis. In vitro, APC reduces apoptosis in mouse cortical 
neurons treated with N-methyl-D-aspartate (NMDA) and staurosporine (Guo, 2004). 
Interestingly, PAR-1 and PAR-3 are required for this effect. Intra-cerebral APC infusion 
dose-dependently reduces NMDA excitotoxic injury in mice (Guo, 2004). Overall, APC 
maintains the patency of ischemic vasculature by inhibiting hypoxia-induced endothelial 
cell apoptosis and also directly protects the integrity and functionality of the neuronal 
network. 
Periventricular leukomalacia is the dominant form of brain injury in premature infants, 
characterized by white matter injury. The underlying pathogenic mechanisms include 
hypoperfusion, procoagulant activity, apoptotic cell death, microglial activation and 
inflammation associated with maternal and/or fetal infection (Genc, 2006). They 
hypothesized that APC, which modulates many of these processes, is a promising 
therapeutic agent for periventricular leukomalacia. 
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4.4 Alzheimer’s disease 
Alzheimer’s disease is characterized by elevated levels of amyloid β peptide (Aβ) in the 
brain that are associated with neuronal and vascular toxicity and is the major cause of 
dementia with advancing age. Inflammation, Aβ deposition in the brain parenchyma and 
vessels, blood–brain barrier dysfunction, oxidative stress, formation of advanced end 
glycation products and endothelial and neural cell death have all been implicated in the 
pathogenesis of Alzheimer’s disease (Zlokovic, 2005). It has been proposed that APC could 
be useful in treating Alzheimer’s disease, since it has anti-inflammatory, anti-oxidant, 
profibrinolytic, neurovascular protectant and pro-angiogenic properties (Genc, 2007). 
Furthermore, APC exerts anti-inflammatory and anti-apoptotic activities directly on 
endothelial and neural cells (Griffin, 2006). APC protects against neurovascular injury in 
experimental stroke models, protects endothelial barrier integrity and decreases fibrin 
deposition (Griffin, 2006). Similar to its anti-inflammatory effect on other cells, APC may 
inhibit the activation status of the microglia that plays a key role in neuroinflammation.  
4.5 Acute kidney injury 
In a rat model of endotoxemia, rat APC significantly improved peritubular capillary flow 
and reduced leukocyte adhesion and rolling, 3 hours after treatment with LPS (Gupta, 2007). 
After 24 hr, APC treatment significantly improved renal blood flow. In addition, APC 
modulated the renin-angiotensin system by reducing mRNA expression levels of 
angiotensin converting enzyme-1, angiotensinogen in the kidney (Gupta, 2007). Thus, APC 
can suppress LPS-induced acute renal failure by modulating factors involved in vascular 
inflammation.  
Ischemia/reperfusion-induced renal injury is an important pathologic mechanism leading 
to acute renal failure (Thadhani, 1996).  In a rat model, intravenous administration of APC 
markedly reduces ischemia/reperfusion -induced renal dysfunction and tubular necrosis, 
whereas heparin or inactive APC has no effect (Mizutani, 2000). Furthermore, APC 
significantly inhibited the ischemia/reperfusion -induced decrease in renal tissue blood 
flow, the increase in the vascular permeability, and renal levels of TNF-, IL-8, and 
myeloperoxidase. Leukocytopenia produced effects similar to those of APC. These findings 
strongly suggested that APC has a protective effect against ischemia/reperfusion-induced 
renal injury by inhibiting activation of leukocytes rather than inhibiting coagulation 
(Okajima, 2004). Recently, Isemann et al (Isermann, 2007) have shown that APC protects 
against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.  In a rat 
model of sepsis by cecal ligation and puncture (CLP), treatment with APC significantly 
inhibited sepsis-induced elevations in creatinine, LDH levels, and improved renal 
architecture. Furthermore, sepsis-induced inhibition of interferon (INF)-γ and increase in IL-
1β and IL-10 were attenuated by APC treatment. The authors suggested that APC confers a 
survival advantage by reducing systemic inflammation and, in doing so, preserves organ 
function (Keller, 2011). 
4.6 Lung disorders 
In a mouse model of acute lung injury, APC inhalation attenuates LPS-induced 
amplification of neutrophils and macrophages in bronchoalveolar lavage fluid as well as 
VCAM-1 protein levels in lung tissue (Kotanidou, 2006). In a murine model of asthma, 
inhalation of APC significantly inhibits the expression of T helper 2 (Th2) cytokines, IgE, 
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eosinophilic inflammation, and hyper-responsiveness in bronchiolar lavage fluid (Yuda, 
2004). Electromobility shift assays show that translation of signal transducer and activator of 
transcription 6 (STAT6) and NF-B to the nucleus is reduced in lung samples from mice 
treated with inhaled APC. Although APC is thought to have a short half-life of ~ 20 mins, it 
can be detected in mice bronchoalveolar lavage fluid 24 h after inhalation. Thus, APC 
inhalation might offer a long-acting alternative route of administration to the lungs to 
attenuate pulmonary inflammation in acute lung injury.  
It is unclear whether APC has any beneficial effect in humans with inflammatory lung 
diseases. Nick et al (Nick, 2004) performed a double-blinded, placebo-controlled study of 
APC in a human model of endotoxin-induced pulmonary inflammation and showed that 
APC significantly reduced leukocyte accumulation to the airspaces, independent of 
pulmonary cytokine or chemokine release. Bronchoalveolar lavage fluid neutrophils of 
patients receiving APC demonstrated decreased chemotaxis ex vivo but no change in 
cytokine release, cell survival, or apoptosis. The major components of the protein C 
pathway, including thrombomodulin, protein C and EPCR are all expressed by human 
airway epithelial cells (Hataji, 2002). Activation of protein C is reduced in sputum of 
patients with bronchial asthma compared to control subjects, which may contribute to 
exacerbation of the inflammatory response in the airway of asthmatic patients  (Hataji, 
2002). However, Schouten et al (Schouten, 2011) showed that endogenous protein C has 
strong effects on the host response to lethal influenza A infection, on the one hand inhibiting 
pulmonary coagulopathy and inflammation, but on the other hand facilitating neutrophil 
influx and protein leak and accelerating mortality. 
4.7 Acute pancreatitis 
Acute pancreatitis is a local inflammatory process that leads to a systemic inflammatory 
response and multiple organ failure (Kirschenbaum & Astiz, 2005). Disseminated 
intravascular coagulation and thromboembolism are related to overall morbidity of this 
disease which provides a setting in which APC could play a therapeutic role. Ottesen et al 
(Ottesen, 1999) found  a decrease in levels of protein C in animals with acute pancreatitis. In 
a rodent model of pancreatitis (Alsfasser, 2006), treatment with APC reduces inflammation 
in the pancreas and lungs and significantly improves survival compared to controls (86% vs 
38%; P=.05). This animal model exhibits severe consumptive coagulopathy, however APC’s 
anti-coagulation properties did not worsen this condition. In another study, when APC was 
given 6 hours after the induction of pancreatitis, it significantly reduced acinar necrosis, 
tissue edema, fat necrosis, IL-6 and TNF-α and inflammatory infiltration compared to 
controls. Inhibition of expression of pancreatic p38 MAPK and JNK and upregulation of 
ERK1/2 expression by APC treatment protects against pancreatic injury, thus ameliorating 
severity of the disease (Chen, 2007).  
4.8 Type 1 Diabetes (T1D) 
T1D is a chronic progressive autoimmune disease that affects genetically prone individuals. 
The physiological destruction of -cells is a crucial event for disease onset (Mathis, 2001). 
Inflammation and auto-immunity play an important role in the destruction of pancreatic 
islet -cells in T1D, with apoptosis being the dominant form of -cell death in both animal 
models of diabetes and humans. Replacement of the -cells by transplantation of islet cells is 
a radical therapy for human T1D. A major problem with this therapy is the large loss of 
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inhibit the activation status of the microglia that plays a key role in neuroinflammation.  
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1β and IL-10 were attenuated by APC treatment. The authors suggested that APC confers a 
survival advantage by reducing systemic inflammation and, in doing so, preserves organ 
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eosinophilic inflammation, and hyper-responsiveness in bronchiolar lavage fluid (Yuda, 
2004). Electromobility shift assays show that translation of signal transducer and activator of 
transcription 6 (STAT6) and NF-B to the nucleus is reduced in lung samples from mice 
treated with inhaled APC. Although APC is thought to have a short half-life of ~ 20 mins, it 
can be detected in mice bronchoalveolar lavage fluid 24 h after inhalation. Thus, APC 
inhalation might offer a long-acting alternative route of administration to the lungs to 
attenuate pulmonary inflammation in acute lung injury.  
It is unclear whether APC has any beneficial effect in humans with inflammatory lung 
diseases. Nick et al (Nick, 2004) performed a double-blinded, placebo-controlled study of 
APC in a human model of endotoxin-induced pulmonary inflammation and showed that 
APC significantly reduced leukocyte accumulation to the airspaces, independent of 
pulmonary cytokine or chemokine release. Bronchoalveolar lavage fluid neutrophils of 
patients receiving APC demonstrated decreased chemotaxis ex vivo but no change in 
cytokine release, cell survival, or apoptosis. The major components of the protein C 
pathway, including thrombomodulin, protein C and EPCR are all expressed by human 
airway epithelial cells (Hataji, 2002). Activation of protein C is reduced in sputum of 
patients with bronchial asthma compared to control subjects, which may contribute to 
exacerbation of the inflammatory response in the airway of asthmatic patients  (Hataji, 
2002). However, Schouten et al (Schouten, 2011) showed that endogenous protein C has 
strong effects on the host response to lethal influenza A infection, on the one hand inhibiting 
pulmonary coagulopathy and inflammation, but on the other hand facilitating neutrophil 
influx and protein leak and accelerating mortality. 
4.7 Acute pancreatitis 
Acute pancreatitis is a local inflammatory process that leads to a systemic inflammatory 
response and multiple organ failure (Kirschenbaum & Astiz, 2005). Disseminated 
intravascular coagulation and thromboembolism are related to overall morbidity of this 
disease which provides a setting in which APC could play a therapeutic role. Ottesen et al 
(Ottesen, 1999) found  a decrease in levels of protein C in animals with acute pancreatitis. In 
a rodent model of pancreatitis (Alsfasser, 2006), treatment with APC reduces inflammation 
in the pancreas and lungs and significantly improves survival compared to controls (86% vs 
38%; P=.05). This animal model exhibits severe consumptive coagulopathy, however APC’s 
anti-coagulation properties did not worsen this condition. In another study, when APC was 
given 6 hours after the induction of pancreatitis, it significantly reduced acinar necrosis, 
tissue edema, fat necrosis, IL-6 and TNF-α and inflammatory infiltration compared to 
controls. Inhibition of expression of pancreatic p38 MAPK and JNK and upregulation of 
ERK1/2 expression by APC treatment protects against pancreatic injury, thus ameliorating 
severity of the disease (Chen, 2007).  
4.8 Type 1 Diabetes (T1D) 
T1D is a chronic progressive autoimmune disease that affects genetically prone individuals. 
The physiological destruction of -cells is a crucial event for disease onset (Mathis, 2001). 
Inflammation and auto-immunity play an important role in the destruction of pancreatic 
islet -cells in T1D, with apoptosis being the dominant form of -cell death in both animal 
models of diabetes and humans. Replacement of the -cells by transplantation of islet cells is 
a radical therapy for human T1D. A major problem with this therapy is the large loss of 
 
Inflammatory Diseases – A Modern Perspective 56
viability of islet cells during the procedure. APC’s strong anti-inflammatory and anti-
apoptotic properties appear to be beneficial in preventing destruction of islet cells. 
Exogenous administration of APC significantly reduces loss of functional islet mass after 
intraportal transplantation in diabetic mice (Contreras, 2004). Animals given APC exhibit 
better glucose control, higher glucose disposal rates and higher arginine-stimulated acute 
insulin release (Contreras, 2004). These effects are associated with a reduction in plasma 
proinsulin, intrahepatic fibrin deposition, and islet apoptosis early after the transplant. APC 
treatment is also associated with a significant reduction of proinflammatory cytokine release 
and prevents endothelial cell activation and dysfunction. This study suggests that APC 
therapy will improve the take-rate of the transplanted islet cells and thus decrease the 
number of the  cells required for human pancreatic islet transplantation (Contreras, 2004).  
Interestingly, plasma levels of protein C/APC are reduced in humans with T1D (Gruden, 
1997; Vukovich & Schernthaner, 1986). In addition, soluble EPCR, which binds to APC 
and inhibits its activity, is increased in T1D (Wu, 2000). These data together indicate that 
circulating APC activity is markedly reduced in T1D. Whether replenishment of APC 
levels will benefit patients with T1D is yet to be resolved. However, APC exhibits great 
potential in preventing glucose-induced apoptosis in endothelial cells and podocytes 
(Isermann, 2007). 
4.9 Rheumatoid Arthritis (RA) 
RA is a chronic autoimmune disease characterized by persistent inflammation of multiple 
synovial joints which results in progressive tissue destruction of bone and cartilage. Protein 
C/APC is present in RA synovial tissues and co-localizes with MMP-2 in endothelial and 
synovial lining cells (Buisson-Legendre, 2004). EPCR is also strongly expressed by synovial 
tissue in patients with RA and co-localizes with CD68 positive staining cells, indicating that 
these cells are largely macrophage/monocytes (Xue, 2007). Inhibiting the activation of 
monocytes/macrophages reduces the severity of arthritis in patients with RA and in animal 
models of RA (Bondeson, 1999; Kwasny-Krochin, 2002). APC inhibits activation of normal 
monocytes by preventing their migration and production of proinflammatory 
cytokines/chemokines, such as TNF- and macrophage migration inhibitory factor levels 
(Schmidt-Supprian, 2000). When monocytes from RA patients are pre-treated with APC, 
their migration towards monocyte chemoattractant protein-1 (MCP-1) is inhibited in a dose-
dependent manner (Xue, 2007). Pre-incubation of these cells with RCR252, an antibody 
which blocks APC binding to EPCR, abolishes this inhibitory effect of APC, indicating that 
APC acts through EPCR to inhibit the chemotactic response of RA monocytes.  MMP-9 
regulation may be at least one downstream effector of APC’s inhibition of monocyte 
migration. When added to purified monocytes from RA patients, APC dose-dependently 
inhibits the production of MMP-9 (Xue, 2007). MMP-9 not only allows cell migration but 
also exerts direct pro-inflammatory effects, such as activation of cytokines which would 
enhance the beneficial effect of APC in RA.  
NF-B is activated in synovium from RA patients (Marok, 1996) and in cultured RA 
synovial fibroblasts (Fujisawa, 1996). Inhibition of NF-B activity strongly reduces the 
severity of disease in animal models of arthritis by inhibiting leukocyte infiltration 
(Blackwell, 2004). High levels of NF-B activity are present in RA monocytes under basal 
conditions. APC (20 g/ml) dramatically inhibits the active form of NF-B in both control 
and LPS stimulated monocytes from RA patients. Downstream of NF-B is one of the most 
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potent inflammatory cytokines in RA, TNF- (Xue, 2007). Specific inhibition of TNF- 
using biological agents such as the monoclonal antibody, Adalimumab (marketed as 
Humira), is proving very successful in treating moderate to severe RA in adults who have 
had a poor response to other anti-rheumatic drugs. Monocytes/macrophages are the 
primary source of TNF- which, after release, promotes the proinflammatory activity of 
these and other surrounding cells. APC significantly decreases TNF- both in control and 
LPS-stimulated RA monocytes (Xue, 2007). Thus, APC may mimic the action of the 
“biological” agents, through inhibition of TNF-. However, by acting on multiple targets, 
APC may be more effective. 
4.10 Cancer  
APC can activate signaling molecules to promote MDA-MB-231 breast cancer cell and 
endothelial cell motility (Gramling, 2010). However, accumulating evidence suggests that 
the APC pathway limits cancer progression. Acquired protein C deficiency is observed in 
cancer patients, especially in patients using certain types of chemotherapy (Feffer, 1989; 
Mewhort-Buist, 2008; Rogers, 1988; Woodley-Cook, 2006).  The  loss of expression of 
thrombomodulin (or increase in its soluble form), a receptor required to convert protein C to 
APC, on cancer cells correlates with advanced stage and poor prognosis (Hanly, 2006; Hanly 
& Winter, 2007; Lindahl, 1993). Low levels of thrombomodulin also increase the invasive 
ability of cancer cells in vitro (Matsushita, 1998) and is significantly correlated with a high 
relapse rate in breast cancer (Kim, 1997). It is likely that low thrombomodulin levels induce 
metastasis due to reduced endogenous APC levels, although several alternative mechanisms 
have also been proposed (Hanly & Winter, 2007). Additionally, EPCR, the specific receptor 
for APC is detected in several cell lines derived from various types of cancer (Van Sluis, 
2010). For example, EPCR is expressed on human breast cancer cells, with an extremely high 
frequency (Tsuneyoshi, 2001). EPCR on the vascular wall inhibits cancer cell adhesion and 
transmigration (Bezuhly, 2009; Lindahl, 1993). Finally, significant resistance to APC was 
found in women with a lymph-node-positive breast carcinoma (Bezuhly, 2009; Lindahl, 
1993; Nijziel, 2003). In a mouse model, endogenous APC has been found to limit cancer cell 
extravasation via sphingosine-1-phosphate receptor-1 and VE-cadherin-dependent vascular 
barrier enhancement. Van Sluis et al (Van Sluis, 2011) showed that in the absence of 
endogenous APC, fibrinogen depletion does not prevent cancer cell dissemination and 
secondary tumor formation in immune-competent mice. Overall, they show that 
endogenous APC is essential for immune-mediated cancer cell elimination (Van Sluis, 2011). 
The exact mechanisms on how about prevents cancer are not clear. However, recently, a 
number of studies have shown that activation of PAR1 are involved in limiting of tumour 
cell migration and  invasion/metastasis in vitro and in vivo (Kamath, 2001; Nierodzik, 1998; 
Villares, 2011) and intact barrier function can effectively prevent tumour cell migration and  
metastasis. APC can enhance both endothelial and epithelial barrier functions via activation 
of PAR1 which may partly explain the underlying mechanisms(Minhas, 2010; Xue, 2011). 
4.11 Skin injuries 
Chronic wounds are a common health problem. There are many different factors which lead 
to a chronic wound, including advancing age, persistent inflammatory stimuli, tissue 
hypoxia, diabetes mellitus, immunodeficiency, a smoking history or the use of certain 
medications, but they can affect patients at any race or economic background. The common 
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potent inflammatory cytokines in RA, TNF- (Xue, 2007). Specific inhibition of TNF- 
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secondary tumor formation in immune-competent mice. Overall, they show that 
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cell migration and  invasion/metastasis in vitro and in vivo (Kamath, 2001; Nierodzik, 1998; 
Villares, 2011) and intact barrier function can effectively prevent tumour cell migration and  
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Chronic wounds are a common health problem. There are many different factors which lead 
to a chronic wound, including advancing age, persistent inflammatory stimuli, tissue 
hypoxia, diabetes mellitus, immunodeficiency, a smoking history or the use of certain 
medications, but they can affect patients at any race or economic background. The common 
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types of chronic wounds include: peripheral ulcers, which are the most frequent cause of 
lower limb amputation in patients with type I and type II diabetes (Levin, 1993); decubitus 
ulcers, a result of prolonged, unrelieved pressure over a bony prominence and venous stasis 
ulcers, where venous congestion of the lower extremities results in local hypoxia (Trent, 
2005).  With the current diabetes epidemic and increasing aging population, chronic wounds 
are a serious concern to the health system. They require dedicated care including regular 
dressings, frequent clinic appointments and when complications arise, hospital admission 
potentially requiring surgery or even amputation. The “state-of-the-art” treatments for 
chronic wounds are expensive and have limited success. Cutaneous wound repair can be 
divided into a series of overlapping phases including formation of fibrin clot, inflammatory 
response, granulation tissue formation, which includes re-epithelialization and 
angiogenesis, and matrix remodeling. Re-epithelialization is an important component of 
wound repair as it serves to restore the barrier function of skin. Newly formed blood vessels 
provide nutrition and oxygen to the growing tissue and allow leukocytes to enter the site of 
injury. A chronic wound or ulcer occurs when the co-coordinated cellular and biochemical 
response to injury are disrupted.  
 
 
Fig. 3. APC treatment used in conjunction with topical negative pressure (TNP) to treat a 
recalcitrant orthopaedic wound present for 2 years. APC and TNP were applied on day 0 
and twice a week until day 19. Day 0 shows exposed bone (arrow) and day 7 shows healthy 
granulation tissue covering bone. Wound is fully healed by day 28 and remained healed at 8 
months follow-up. Taken from Wijewardana et al, Int J Lower Extrem Wounds in press, 
2011. 
The role of inflammation in wound healing is under debate. Many researchers believe that 
the inflammatory phase is vital for wound healing to proceed, however, there is evidence to 
suggest otherwise. Whereas normal adult healing results in a fibrous scar, early fetal 
wounds which have very little, if any, inflammatory response, exhibit scarless healing with 
complete restoration of the normal skin architecture. Scar formation exacerbates when 
inflammation is provoked in fetal wounds, suggesting that the absence of inflammation 
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contributes to the rapid and flawless repair of these wounds (Szpaderska & DiPietro, 2005). 
Compared to dermal wounds, oral wounds have substantially lower levels of macrophage, 
neutrophil, and T-cell infiltration and heal rapidly with minimal inflammation and often 
with minimal scar formation (Szpaderska, 2003). Redd et al  (Redd, 2004) studied wound 
healing in the PU.1 null mouse, which is genetically incapable of raising an inflammatory 
response because several haematopoietic lineages, including macrophages and 
neutrophils, are absent or severely delayed in their differentiation. Wounds in these 
animals rapidly repair with increased vascularity at the wound site and faster 
reepithelialisation of the wound surface, as well as being scarless (Redd, 2004). They 
hypothesised that the lower the level of some growth factors in adult wounds the closer it 
would mimic scar-free healing in the embryo. This is relevant to many chronic wounds 
which are often associated with excess inflammation and become locked in this 
inflammatory phase. Thus, APC’s anti-inflammatory effects may actually benefit, rather 
than hinder, the healing of chronic wounds. 
Keratinocytes and endothelial cells are two major cell types in skin and play critical roles in 
the healing of skin injury. Keratinocytes of the epidermis provide the major cellular 
component of the outermost barrier to the environment. When the skin is broken, a critical 
response is triggered to restore its protective function. Within 24 hours of wounding, 
keratinocytes from the wound margins begin to migrate and invade the wound bed, where 
they proliferate to form the new epithelium. We have shown that protein C is produced by 
skin keratinocytes, especially those in the basal layer (Xue, 2007). This endogenous protein C 
is activated on the cell surface, with the resulting APC stimulating a wound healing 
phenotype in keratinocytes (Xue, 2005; Xue, 2007). Furthermore, the autocrine actions of 
APC are necessary for normal keratinocyte growth and function (Xue, 2007).  APC 
stimulates proliferation, MMP-2 activity, migration and prevents apoptosis in skin 
keratinocytes, all vital processes of re-epithelialization (Xue, 2005; Xue, 2004). Endothelial 
migration and proliferation are vital to generate new blood vessels for wound healing. APC 
stimulates endothelial cell proliferation and induces tube-like structure formation in vitro 
(Uchiba, 2004) and cell migration (Brueckmann, 2003). In the chick chorioallantoic 
membrane (CAM) assay, APC stimulates angiogenesis and re-epithelialization. In vivo, APC 
induces corneal angiogenesis in a mouse model (Uchiba, 2004). APC also stimulates the 
proliferation of smooth muscle cells (Bretschneider, 2007), which would contribute to the 
formation of mature blood vessels.  In a full-thickness rat skin-healing model, a single 
topical application of APC enhances wound healing compared to saline control at least 
partly via stimulating angiogenesis and re-epithelialisation (Jackson, 2005). 
Recent evidence suggests that APC will be effective in humans with chronic wounds. An 
open label pilot study was conducted on 4 patients whose wounds were not improving, 
despite standard wound treatment for 4 months or greater (Whitmont, 2008). APC was 
applied topically to wounds once weekly for 4 weeks. All 4 patients showed rapid positive 
response to treatment which was maintained during a 4 month follow-up period. Overall, 
there was more than 80% reduction in wound size. The treatment was well tolerated with no 
significant side effects or complications experienced. In another recent study, APC treatment 
was used in conjunction with topical negative pressure (TNP), to treat recalcitrant long-
standing orthopaedic wounds (Wijewardana et al, Combination of activated protein C and 
topical negative pressure vacuum therapy rapidly regenerates granulation tissue over 
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healing in the PU.1 null mouse, which is genetically incapable of raising an inflammatory 
response because several haematopoietic lineages, including macrophages and 
neutrophils, are absent or severely delayed in their differentiation. Wounds in these 
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reepithelialisation of the wound surface, as well as being scarless (Redd, 2004). They 
hypothesised that the lower the level of some growth factors in adult wounds the closer it 
would mimic scar-free healing in the embryo. This is relevant to many chronic wounds 
which are often associated with excess inflammation and become locked in this 
inflammatory phase. Thus, APC’s anti-inflammatory effects may actually benefit, rather 
than hinder, the healing of chronic wounds. 
Keratinocytes and endothelial cells are two major cell types in skin and play critical roles in 
the healing of skin injury. Keratinocytes of the epidermis provide the major cellular 
component of the outermost barrier to the environment. When the skin is broken, a critical 
response is triggered to restore its protective function. Within 24 hours of wounding, 
keratinocytes from the wound margins begin to migrate and invade the wound bed, where 
they proliferate to form the new epithelium. We have shown that protein C is produced by 
skin keratinocytes, especially those in the basal layer (Xue, 2007). This endogenous protein C 
is activated on the cell surface, with the resulting APC stimulating a wound healing 
phenotype in keratinocytes (Xue, 2005; Xue, 2007). Furthermore, the autocrine actions of 
APC are necessary for normal keratinocyte growth and function (Xue, 2007).  APC 
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stimulates endothelial cell proliferation and induces tube-like structure formation in vitro 
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formation of mature blood vessels.  In a full-thickness rat skin-healing model, a single 
topical application of APC enhances wound healing compared to saline control at least 
partly via stimulating angiogenesis and re-epithelialisation (Jackson, 2005). 
Recent evidence suggests that APC will be effective in humans with chronic wounds. An 
open label pilot study was conducted on 4 patients whose wounds were not improving, 
despite standard wound treatment for 4 months or greater (Whitmont, 2008). APC was 
applied topically to wounds once weekly for 4 weeks. All 4 patients showed rapid positive 
response to treatment which was maintained during a 4 month follow-up period. Overall, 
there was more than 80% reduction in wound size. The treatment was well tolerated with no 
significant side effects or complications experienced. In another recent study, APC treatment 
was used in conjunction with topical negative pressure (TNP), to treat recalcitrant long-
standing orthopaedic wounds (Wijewardana et al, Combination of activated protein C and 
topical negative pressure vacuum therapy rapidly regenerates granulation tissue over 
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exposed bone to heal recalcitrant orthopaedic wounds, in press, 2011, Int J Lower Extrem 
Wounds). One example is a 47 year old male with no significant co-morbidities who had 
tibial and fibula fractures following an assault and being hit in the leg by a baseball bat, 2 
years prior to presentation. The fractures required open reduction and fixation with plates 
and screws. Two months post-operatively he developed an infection and breakdown of the 
wound. He was started on antibiotic treatment and had wash out of the wound and 
scraping of the bone which showed osteomyelitis. Antibiotic treatment was continued but 
failed to control the infection so all metal-ware was removed and the wound was debrided. 
There was malunion of the bone and after 3 months the plates and screws were replaced 
and the wound was covered with a fasciocutaneous flap. After one month, he again 
developed infection and breakdown of the flap. For the following year he had continued 
treatment with antibiotics, conventional and TNP dressings, however the wound remained 
non-healing. He was then treated with APC plus topical negative pressure and after 7 days a 
layer of healthy granulation tissue covered the bone and almost filled the entire wound 
space (Figure 3). By day 10 re-epithelialization had occurred on top of the dermis around the 
perimeter of the wound and by day 19 the wound had completely healed. Follow up at 8 
month showed the wound had continued to remain intact 
By dampening inflammation and accelerating angiogenesis and re-epithellialisation, APC 
is also likely to minimize scar formation, which holds great potential for burn victims and 
those susceptible to keloid scarring. Patients with burn injuries and inhalation trauma 
have a significant increase in thrombin generation in the airways compared with control 
patients, as reflected by increased lavage fluid levels of thrombin-antithrombin complexes 
and fibrin degradation products, and decreased lavage fluid levels of APC and 
antithrombin (Hofstra, 2011).  
5. Engineered protein C/APC 
The stereospecific interactions of APC with factors Va and VIIIa involve both the APC 
enzymatic active-site region and residues that are not part of the immediate APC active site. 
These residues are termed ‘exosites’ on the APC active enzyme surface and can be mutated 
to diminish the anticoagulant activity of APC without altering the cell-signaling activity of 
the molecule (Bae, 2007; Gale, 2002; Kerschen, 2007; Mosnier, 2004). Replacement of a cluster 
of five positively charged residues by alanine residues (ie. 5A-APC) on the top surface of the 
APC heavy-chain protease domain restructures this crucial positively charged exosite, 
causing >98% loss of the anticoagulant activity of human APC while leaving intact APC cell-
signaling activities on different cell types within the neurovascular unit (Mosnier, 2007; 
Mosnier, 2009). Replacement of three of these five residues (i.e. lysine residues 191–193) by 
three alanine residues produces the 3K3A-APC variant  (Deane, 2009; Guo, 2009; Wang, 
2009) which has a similar effect to the 5A-APC variant, causing loss of >92% of APC 
anticoagulant activity. These engineered variants provide APC for therapeutic purposes in 
which the risk of serious bleeding caused by the anticoagulant activity of APC is diminished 
while the cytoprotective effects of APC are preserved. In preclinical animal models of ALS 
(Zhong, 2009), stroke (Guo, 2009; Wang, 2009), brain injury (Walker, 2010) and sepsis 
{Kerschen, 2007 KERSCHEN2007 /id} and cytoprotective function (Ni, 2011) these APC 
variants show beneficial effects that were equivalent to, or sometimes greater than, the wild-
type recombinant APC. Bir et al (Bir, 2011) demonstrated that 5A-APC could attenuate lung 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 61 
damage caused by P. aeruginosa in critically ill patients. In addition, 5A-APC inhibits the 
inflammatory response of conventional dendritic cells independent of EPCR and suppresses 
IFN-gamma production by natural killer-like dendritic cells (Kerschen, 2010).  Recently, an 
APC variant (APC-L38D/N329Q) was generated with minimal anticoagulant activity, but 5-
fold enhanced endothelial barrier protective function and 30-fold improved anti-apoptotic 
function when compared with wild type APC (Ni, 2011).  
An APC variant with minimal cell-signaling activity but with substantially increased 
anticoagulant activity, E149A-APC, has been useful for proof of concept studies and for 
antithrombotic indications (Mosnier, 2009). E149A-APC has superior antithrombotic activity 
in a mouse model of arterial thrombosis compared to wt-APC, but has no benefit in an 
endotoxemia sepsis model where wild type (wt)-APC or the 5A-APC variant reduced 
mortality {Kerschen, 2007 KERSCHEN2007 /id} (Mosnier, 2009). 
6. Conclusion 
APC, an anticoagulant with anti-inflammatory, anti-apoptotic, proliferative and barrier 
stabilization properties, has not only emerged as a therapeutic agent for use in selected 
patients with severe sepsis, but also appears to have considerable benefit in chronic wounds 
and a number of other autoimmune/inflammatory diseases. The in vitro, preclinical and 
limited clinical data for these diseases indicate that APC holds a remarkable promise. 
Further insights into the mechanisms of action of APC will be required for the translation of 
preclinical study results to the bedside. 
More than three decades since the discovery of APC, we are only beginning to learn of its 
biological diversity. The clinical evidence for APC as a treatment for severe sepsis is 
perplexing (Marti-Carvajal, 2007; Marti-Carvajal, 2011). Strong evidence indicates that APC 
will benefit other disorders involving various organ injuries including kidney injury, spinal 
cord injury, respiratory function and stroke. Blinded and controlled clinical trials will 
elucidate its clinical protective effects in these disorders. With the recent discovery that the 
largest organ of the body, the skin, positively responds to APC, it is likely that APC will 
accelerate healing of skin injuries and disorders.    
7. References 
Retraction for yuji taoka et Al., (2011). "activated protein C reduces the severity of 
compression-induced spinal cord injury in rats by inhibiting activation of 
leukocytes". J.Neurosci. Vol.31, No.23, pp. 8697 
Alsfasser, G., Warshaw, A.L., Thayer, S.P., Antoniu, B., Laposata, M., Lewandrowski, K.B., 
& Fernandez-del, C.C. (2006). Decreased inflammation and improved survival with 
recombinant human activated protein C treatment in experimental acute 
pancreatitis. Arch.Surg. Vol.141, No.7, pp. 670-676 
Bae, J.S., Yang, L., Manithody, C., & Rezaie, A.R. (2007). Engineering a disulfide bond to 
stabilize the calcium binding loop of activated protein C eliminates its 
anticoagulant but not protective signaling properties. J.Biol.Chem. Vol.282, No.35, 
pp.25493-25500 
Bae, J.S., Yang, L., Manithody, C., & Rezaie, A.R. (2007). The ligand occupancy of endothelial 
protein C receptor switches the protease-activated receptor 1-dependent signaling 
 
Inflammatory Diseases – A Modern Perspective 60
exposed bone to heal recalcitrant orthopaedic wounds, in press, 2011, Int J Lower Extrem 
Wounds). One example is a 47 year old male with no significant co-morbidities who had 
tibial and fibula fractures following an assault and being hit in the leg by a baseball bat, 2 
years prior to presentation. The fractures required open reduction and fixation with plates 
and screws. Two months post-operatively he developed an infection and breakdown of the 
wound. He was started on antibiotic treatment and had wash out of the wound and 
scraping of the bone which showed osteomyelitis. Antibiotic treatment was continued but 
failed to control the infection so all metal-ware was removed and the wound was debrided. 
There was malunion of the bone and after 3 months the plates and screws were replaced 
and the wound was covered with a fasciocutaneous flap. After one month, he again 
developed infection and breakdown of the flap. For the following year he had continued 
treatment with antibiotics, conventional and TNP dressings, however the wound remained 
non-healing. He was then treated with APC plus topical negative pressure and after 7 days a 
layer of healthy granulation tissue covered the bone and almost filled the entire wound 
space (Figure 3). By day 10 re-epithelialization had occurred on top of the dermis around the 
perimeter of the wound and by day 19 the wound had completely healed. Follow up at 8 
month showed the wound had continued to remain intact 
By dampening inflammation and accelerating angiogenesis and re-epithellialisation, APC 
is also likely to minimize scar formation, which holds great potential for burn victims and 
those susceptible to keloid scarring. Patients with burn injuries and inhalation trauma 
have a significant increase in thrombin generation in the airways compared with control 
patients, as reflected by increased lavage fluid levels of thrombin-antithrombin complexes 
and fibrin degradation products, and decreased lavage fluid levels of APC and 
antithrombin (Hofstra, 2011).  
5. Engineered protein C/APC 
The stereospecific interactions of APC with factors Va and VIIIa involve both the APC 
enzymatic active-site region and residues that are not part of the immediate APC active site. 
These residues are termed ‘exosites’ on the APC active enzyme surface and can be mutated 
to diminish the anticoagulant activity of APC without altering the cell-signaling activity of 
the molecule (Bae, 2007; Gale, 2002; Kerschen, 2007; Mosnier, 2004). Replacement of a cluster 
of five positively charged residues by alanine residues (ie. 5A-APC) on the top surface of the 
APC heavy-chain protease domain restructures this crucial positively charged exosite, 
causing >98% loss of the anticoagulant activity of human APC while leaving intact APC cell-
signaling activities on different cell types within the neurovascular unit (Mosnier, 2007; 
Mosnier, 2009). Replacement of three of these five residues (i.e. lysine residues 191–193) by 
three alanine residues produces the 3K3A-APC variant  (Deane, 2009; Guo, 2009; Wang, 
2009) which has a similar effect to the 5A-APC variant, causing loss of >92% of APC 
anticoagulant activity. These engineered variants provide APC for therapeutic purposes in 
which the risk of serious bleeding caused by the anticoagulant activity of APC is diminished 
while the cytoprotective effects of APC are preserved. In preclinical animal models of ALS 
(Zhong, 2009), stroke (Guo, 2009; Wang, 2009), brain injury (Walker, 2010) and sepsis 
{Kerschen, 2007 KERSCHEN2007 /id} and cytoprotective function (Ni, 2011) these APC 
variants show beneficial effects that were equivalent to, or sometimes greater than, the wild-
type recombinant APC. Bir et al (Bir, 2011) demonstrated that 5A-APC could attenuate lung 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 61 
damage caused by P. aeruginosa in critically ill patients. In addition, 5A-APC inhibits the 
inflammatory response of conventional dendritic cells independent of EPCR and suppresses 
IFN-gamma production by natural killer-like dendritic cells (Kerschen, 2010).  Recently, an 
APC variant (APC-L38D/N329Q) was generated with minimal anticoagulant activity, but 5-
fold enhanced endothelial barrier protective function and 30-fold improved anti-apoptotic 
function when compared with wild type APC (Ni, 2011).  
An APC variant with minimal cell-signaling activity but with substantially increased 
anticoagulant activity, E149A-APC, has been useful for proof of concept studies and for 
antithrombotic indications (Mosnier, 2009). E149A-APC has superior antithrombotic activity 
in a mouse model of arterial thrombosis compared to wt-APC, but has no benefit in an 
endotoxemia sepsis model where wild type (wt)-APC or the 5A-APC variant reduced 
mortality {Kerschen, 2007 KERSCHEN2007 /id} (Mosnier, 2009). 
6. Conclusion 
APC, an anticoagulant with anti-inflammatory, anti-apoptotic, proliferative and barrier 
stabilization properties, has not only emerged as a therapeutic agent for use in selected 
patients with severe sepsis, but also appears to have considerable benefit in chronic wounds 
and a number of other autoimmune/inflammatory diseases. The in vitro, preclinical and 
limited clinical data for these diseases indicate that APC holds a remarkable promise. 
Further insights into the mechanisms of action of APC will be required for the translation of 
preclinical study results to the bedside. 
More than three decades since the discovery of APC, we are only beginning to learn of its 
biological diversity. The clinical evidence for APC as a treatment for severe sepsis is 
perplexing (Marti-Carvajal, 2007; Marti-Carvajal, 2011). Strong evidence indicates that APC 
will benefit other disorders involving various organ injuries including kidney injury, spinal 
cord injury, respiratory function and stroke. Blinded and controlled clinical trials will 
elucidate its clinical protective effects in these disorders. With the recent discovery that the 
largest organ of the body, the skin, positively responds to APC, it is likely that APC will 
accelerate healing of skin injuries and disorders.    
7. References 
Retraction for yuji taoka et Al., (2011). "activated protein C reduces the severity of 
compression-induced spinal cord injury in rats by inhibiting activation of 
leukocytes". J.Neurosci. Vol.31, No.23, pp. 8697 
Alsfasser, G., Warshaw, A.L., Thayer, S.P., Antoniu, B., Laposata, M., Lewandrowski, K.B., 
& Fernandez-del, C.C. (2006). Decreased inflammation and improved survival with 
recombinant human activated protein C treatment in experimental acute 
pancreatitis. Arch.Surg. Vol.141, No.7, pp. 670-676 
Bae, J.S., Yang, L., Manithody, C., & Rezaie, A.R. (2007). Engineering a disulfide bond to 
stabilize the calcium binding loop of activated protein C eliminates its 
anticoagulant but not protective signaling properties. J.Biol.Chem. Vol.282, No.35, 
pp.25493-25500 
Bae, J.S., Yang, L., Manithody, C., & Rezaie, A.R. (2007). The ligand occupancy of endothelial 
protein C receptor switches the protease-activated receptor 1-dependent signaling 
 
Inflammatory Diseases – A Modern Perspective 62
specificity of thrombin from a permeability-enhancing to a barrier-protective 
response in endothelial cells. Blood. Vol.110, No.12, pp. 3909-3916 
Bae, J.S., Yang, L., & Rezaie, A.R. (2007). Receptors of the protein C activation and activated 
protein C signaling pathways are colocalized in lipid rafts of endothelial cells. 
Proc.Natl.Acad.Sci.U.S.A. Vol.104, No.8, pp. 2867-2872 
Baker, W.F. & Bick, R.L. (1999). Treatment of hereditary and acquired thrombophilic 
disorders. Semin.Thromb.Hemostasis. Vol.25, No.4, pp. 387-405 
Balazs, A.B., Fabian, A.J., Esmon, C.T., & Mulligan, R.C. (2006). Endothelial protein C 
receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone 
marrow. Blood. Vol.107, No.6, pp. 2317-2321 
Bernard, G.R., Margolis, B.D., Shanies, H.M., Ely, E.W., Wheeler, A.P., Levy, H., Wong, K., & 
Wright, T.J. (2004). Extended Evaluation of Recombinant Human Activated Protein 
C United States Trial (ENHANCE US): A Single-Arm, Phase 3B, Multicenter Study 
of Drotrecogin Alfa (Activated) in Severe Sepsis. Chest. Vol.125, No.6, pp. 2206-2216 
Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., 
Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., & Fisher, C.J. (2001). 
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. 
New Engl. J Med. Vol.344, No.10, pp. 699-709 
Bezuhly, M., Cullen, R., Esmon, C.T., Morris, S.F., West, K.A., Johnston, B., & Liwski, R.S. 
(2009). Role of activated protein C and its receptor in inhibition of tumor 
metastasis. Blood. Vol.113, No.14, pp. 3371-3374 
Bir, N., Lafargue, M., Howard, M., Goolaerts, A., Roux, J., Carles, M., Cohen, M.J., Iles, K.E., 
Fernandez, J.A., Griffin, J.H., & Pittet, J.F. (2011). Cytoprotective-selective Activated 
Protein C Attenuates P. aeruginosa-induced Lung Injury in Mice. Am.J.Respir.Cell 
Mol.Biol. Epub ahead of print 
Blackwell, N.M., Sembi, P., Newson, J.S., Lawrence, T., Gilroy, D.W., & Kabouridis, P.S. 
(2004). Reduced infiltration and increased apoptosis of leukocytes at sites of 
inflammation by systemic administration of a membrane-permeable IkappaBalpha 
repressor. Arthritis Rheum. Vol.50, No.8, pp. 2675-2684 
Bondeson, J., Browne, K.A., Brennan, F.M., Foxwell, B.M.J., & Feldmann, M. (1999). Selective 
Regulation of Cytokine Induction by Adenoviral Gene Transfer of I{kappa}B{alpha} 
into Human Macrophages: Lipopolysaccharide-Induced, But Not Zymosan-
Induced, Proinflammatory Cytokines Are Inhibited, But IL-10 Is Nuclear Factor-
{kappa}B Independent. J. Immunol. Vol.162, No.5, pp. 2939-2945 
Bretschneider, E., Uzonyi, B., Weber, A.A., Fischer, J.W., Pape, R., Lotzer, K., & Schror, K. 
(2007). Human vascular smooth muscle cells express functionally active endothelial 
cell protein C receptor. Circ.Res. Vol.100, No.2, pp. 255-262 
Brueckmann, M., Marx, A., Martin, W.H., Liebe, V., Lang, S., Kaden, J.J., Zieger, W., 
Borggrefe, M., Huhle, G., & Konstantin, H.K. (2003). Stabilization of monocyte 
chemoattractant protein-1-mRNA by activated protein C. Thromb.Haemost. Vol.89, 
No.1, pp. 149-160 
Buisson-Legendre, N., Smith, S., March, L., & Jackson, C. (2004). Elevation of activated 
protein C in synovial joints in rheumatoid arthritis and its correlation with matrix 
metalloproteinase 2. Arthritis Rheum. Vol.50, No.7, pp. 2151-2156 
Calzado, M.A., Bacher, S., & Schmitz, M.L. (2007). NF-kappaB inhibitors for the treatment of 
inflammatory diseases and cancer. Curr.Med.Chem. Vol.14, No.3, pp.367-376 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 63 
Calzado, M.A., Bacher, S., & Schmitz, M.L. (2007). NF-kappaB inhibitors for the treatment of 
inflammatory diseases and cancer. Curr.Med.Chem. Vol.14, No.3, pp. 367-376 
Cao, C., Gao, Y., Li, Y., Antalis, T.M., Castellino, F.J., & Zhang, L. (2010). The efficacy of 
activated protein C in murine endotoxemia is dependent on integrin CD11b. J. Clin 
Invest. Vol.120, No.6, pp. 1971-1980 
Carmi, I. & Razin, E. (2007). The role played by key transcription factors in activated mast 
cells. Immunol.Rev. Vol.217:280-91., No.280-291 
Chen, P., Zhang, Y., Qiao, M., & Yuan, Y. (2007). Activated protein C, an anticoagulant 
polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-
activated protein kinases. J.Gastroenterol. Vol.42, No.11, pp. 887-896 
Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., Fukudome, K., & 
Zlokovic, B.V. (2003). Activated protein C blocks p53-mediated apoptosis in 
ischemic human brain endothelium and is neuroprotective. Nat.Med. Vol.9, No.3, 
pp. 338-342 
Cheng, T., Petraglia, A.L., Li, Z., Thiyagarajan, M., Zhong, Z., Wu, Z., Liu, D., Maggirwar, 
S.B., Deane, R., Fernandez, J.A., LaRue, B., Griffin, J.H., Chopp, M., & Zlokovic, 
B.V. (2006). Activated protein C inhibits tissue plasminogen activator-induced 
brain hemorrhage. Nat. Med. Vol.12, No.11, pp. 1278-1285 
Contreras, J.L., Eckstein, C., Smyth, C.A., Bilbao, G., Vilatoba, M., Ringland, S.E., Young, C., 
Thompson, J.A., Fernandez, J.A., Griffin, J.H., & Eckhoff, D.E. (2004). Activated 
protein C preserves functional islet mass after intraportal transplantation: a novel 
link between endothelial cell activation, thrombosis, inflammation, and islet cell 
death. Diabetes. Vol.53, No.11, pp. 2804-2814 
Coughlin, S.R. (2000). Thrombin signalling and protease-activated receptors [In Process 
Citation]. Nature. Vol.407, No.6801, pp. 258-264 
Deane, R., LaRue, B., Sagare, A.P., Castellino, F.J., Zhong, Z., & Zlokovic, B.V. (2009). 
Endothelial protein C receptor-assisted transport of activated protein C across the 
mouse blood-brain barrier. J.Cereb.Blood Flow Metab. Vol.29, No.1, pp. 25-33 
Elphick, G.F., Sarangi, P.P., Hyun, Y.M., Hollenbaugh, J.A., Ayala, A., Biffl, W.L., Chung, 
H.L., Rezaie, A.R., McGrath, J.L., Topham, D.J., Reichner, J.S., & Kim, M. (2009). 
Recombinant human activated protein C inhibits integrin-mediated neutrophil 
migration. Blood. Vol.113, No.17, pp. 4078-4085 
Esmon, C.T. (2004). Crosstalk between inflammation and thrombosis. Maturitas. Vol.47, 
No.4, pp. 305-314 
Esmon, C.T. (2004). Structure and functions of the endothelial cell protein C receptor. Crit 
Care Med. Vol.32, No.5 Suppl, pp. S298-S301 
Feffer, S.E., Carmosino, L.S., & Fox, R.L. (989). Acquired protein C deficiency in patients 
with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. 
Cancer. Vol.63, No.7, pp. 1303-1307 
Feistritzer, C., Mosheimer, B.A., Sturn, D.H., Riewald, M., Patsch, J.R., & Wiedermann, C.J. 
(2006). Endothelial protein C receptor-dependent inhibition of migration of human 
lymphocytes by protein C involves epidermal growth factor receptor. J.Immunol. 
Vol.176, No.2, pp. 1019-1025 
Feistritzer, C. & Riewald, M. (2005). Endothelial barrier protection by activated protein C 
through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. 
Blood. Vol.105, No.8, pp. 3178-3184 
 
Inflammatory Diseases – A Modern Perspective 62
specificity of thrombin from a permeability-enhancing to a barrier-protective 
response in endothelial cells. Blood. Vol.110, No.12, pp. 3909-3916 
Bae, J.S., Yang, L., & Rezaie, A.R. (2007). Receptors of the protein C activation and activated 
protein C signaling pathways are colocalized in lipid rafts of endothelial cells. 
Proc.Natl.Acad.Sci.U.S.A. Vol.104, No.8, pp. 2867-2872 
Baker, W.F. & Bick, R.L. (1999). Treatment of hereditary and acquired thrombophilic 
disorders. Semin.Thromb.Hemostasis. Vol.25, No.4, pp. 387-405 
Balazs, A.B., Fabian, A.J., Esmon, C.T., & Mulligan, R.C. (2006). Endothelial protein C 
receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone 
marrow. Blood. Vol.107, No.6, pp. 2317-2321 
Bernard, G.R., Margolis, B.D., Shanies, H.M., Ely, E.W., Wheeler, A.P., Levy, H., Wong, K., & 
Wright, T.J. (2004). Extended Evaluation of Recombinant Human Activated Protein 
C United States Trial (ENHANCE US): A Single-Arm, Phase 3B, Multicenter Study 
of Drotrecogin Alfa (Activated) in Severe Sepsis. Chest. Vol.125, No.6, pp. 2206-2216 
Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., 
Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., & Fisher, C.J. (2001). 
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. 
New Engl. J Med. Vol.344, No.10, pp. 699-709 
Bezuhly, M., Cullen, R., Esmon, C.T., Morris, S.F., West, K.A., Johnston, B., & Liwski, R.S. 
(2009). Role of activated protein C and its receptor in inhibition of tumor 
metastasis. Blood. Vol.113, No.14, pp. 3371-3374 
Bir, N., Lafargue, M., Howard, M., Goolaerts, A., Roux, J., Carles, M., Cohen, M.J., Iles, K.E., 
Fernandez, J.A., Griffin, J.H., & Pittet, J.F. (2011). Cytoprotective-selective Activated 
Protein C Attenuates P. aeruginosa-induced Lung Injury in Mice. Am.J.Respir.Cell 
Mol.Biol. Epub ahead of print 
Blackwell, N.M., Sembi, P., Newson, J.S., Lawrence, T., Gilroy, D.W., & Kabouridis, P.S. 
(2004). Reduced infiltration and increased apoptosis of leukocytes at sites of 
inflammation by systemic administration of a membrane-permeable IkappaBalpha 
repressor. Arthritis Rheum. Vol.50, No.8, pp. 2675-2684 
Bondeson, J., Browne, K.A., Brennan, F.M., Foxwell, B.M.J., & Feldmann, M. (1999). Selective 
Regulation of Cytokine Induction by Adenoviral Gene Transfer of I{kappa}B{alpha} 
into Human Macrophages: Lipopolysaccharide-Induced, But Not Zymosan-
Induced, Proinflammatory Cytokines Are Inhibited, But IL-10 Is Nuclear Factor-
{kappa}B Independent. J. Immunol. Vol.162, No.5, pp. 2939-2945 
Bretschneider, E., Uzonyi, B., Weber, A.A., Fischer, J.W., Pape, R., Lotzer, K., & Schror, K. 
(2007). Human vascular smooth muscle cells express functionally active endothelial 
cell protein C receptor. Circ.Res. Vol.100, No.2, pp. 255-262 
Brueckmann, M., Marx, A., Martin, W.H., Liebe, V., Lang, S., Kaden, J.J., Zieger, W., 
Borggrefe, M., Huhle, G., & Konstantin, H.K. (2003). Stabilization of monocyte 
chemoattractant protein-1-mRNA by activated protein C. Thromb.Haemost. Vol.89, 
No.1, pp. 149-160 
Buisson-Legendre, N., Smith, S., March, L., & Jackson, C. (2004). Elevation of activated 
protein C in synovial joints in rheumatoid arthritis and its correlation with matrix 
metalloproteinase 2. Arthritis Rheum. Vol.50, No.7, pp. 2151-2156 
Calzado, M.A., Bacher, S., & Schmitz, M.L. (2007). NF-kappaB inhibitors for the treatment of 
inflammatory diseases and cancer. Curr.Med.Chem. Vol.14, No.3, pp.367-376 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 63 
Calzado, M.A., Bacher, S., & Schmitz, M.L. (2007). NF-kappaB inhibitors for the treatment of 
inflammatory diseases and cancer. Curr.Med.Chem. Vol.14, No.3, pp. 367-376 
Cao, C., Gao, Y., Li, Y., Antalis, T.M., Castellino, F.J., & Zhang, L. (2010). The efficacy of 
activated protein C in murine endotoxemia is dependent on integrin CD11b. J. Clin 
Invest. Vol.120, No.6, pp. 1971-1980 
Carmi, I. & Razin, E. (2007). The role played by key transcription factors in activated mast 
cells. Immunol.Rev. Vol.217:280-91., No.280-291 
Chen, P., Zhang, Y., Qiao, M., & Yuan, Y. (2007). Activated protein C, an anticoagulant 
polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-
activated protein kinases. J.Gastroenterol. Vol.42, No.11, pp. 887-896 
Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., Fukudome, K., & 
Zlokovic, B.V. (2003). Activated protein C blocks p53-mediated apoptosis in 
ischemic human brain endothelium and is neuroprotective. Nat.Med. Vol.9, No.3, 
pp. 338-342 
Cheng, T., Petraglia, A.L., Li, Z., Thiyagarajan, M., Zhong, Z., Wu, Z., Liu, D., Maggirwar, 
S.B., Deane, R., Fernandez, J.A., LaRue, B., Griffin, J.H., Chopp, M., & Zlokovic, 
B.V. (2006). Activated protein C inhibits tissue plasminogen activator-induced 
brain hemorrhage. Nat. Med. Vol.12, No.11, pp. 1278-1285 
Contreras, J.L., Eckstein, C., Smyth, C.A., Bilbao, G., Vilatoba, M., Ringland, S.E., Young, C., 
Thompson, J.A., Fernandez, J.A., Griffin, J.H., & Eckhoff, D.E. (2004). Activated 
protein C preserves functional islet mass after intraportal transplantation: a novel 
link between endothelial cell activation, thrombosis, inflammation, and islet cell 
death. Diabetes. Vol.53, No.11, pp. 2804-2814 
Coughlin, S.R. (2000). Thrombin signalling and protease-activated receptors [In Process 
Citation]. Nature. Vol.407, No.6801, pp. 258-264 
Deane, R., LaRue, B., Sagare, A.P., Castellino, F.J., Zhong, Z., & Zlokovic, B.V. (2009). 
Endothelial protein C receptor-assisted transport of activated protein C across the 
mouse blood-brain barrier. J.Cereb.Blood Flow Metab. Vol.29, No.1, pp. 25-33 
Elphick, G.F., Sarangi, P.P., Hyun, Y.M., Hollenbaugh, J.A., Ayala, A., Biffl, W.L., Chung, 
H.L., Rezaie, A.R., McGrath, J.L., Topham, D.J., Reichner, J.S., & Kim, M. (2009). 
Recombinant human activated protein C inhibits integrin-mediated neutrophil 
migration. Blood. Vol.113, No.17, pp. 4078-4085 
Esmon, C.T. (2004). Crosstalk between inflammation and thrombosis. Maturitas. Vol.47, 
No.4, pp. 305-314 
Esmon, C.T. (2004). Structure and functions of the endothelial cell protein C receptor. Crit 
Care Med. Vol.32, No.5 Suppl, pp. S298-S301 
Feffer, S.E., Carmosino, L.S., & Fox, R.L. (989). Acquired protein C deficiency in patients 
with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. 
Cancer. Vol.63, No.7, pp. 1303-1307 
Feistritzer, C., Mosheimer, B.A., Sturn, D.H., Riewald, M., Patsch, J.R., & Wiedermann, C.J. 
(2006). Endothelial protein C receptor-dependent inhibition of migration of human 
lymphocytes by protein C involves epidermal growth factor receptor. J.Immunol. 
Vol.176, No.2, pp. 1019-1025 
Feistritzer, C. & Riewald, M. (2005). Endothelial barrier protection by activated protein C 
through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. 
Blood. Vol.105, No.8, pp. 3178-3184 
 
Inflammatory Diseases – A Modern Perspective 64
Feistritzer, C., Schuepbach, R.A., Mosnier, L.O., Bush, L.A., Di, C.E., Griffin, J.H., & Riewald, 
M. (2006). Protective signaling by activated protein C is mechanistically linked to 
protein C activation on endothelial cells. J. Biol. Chem. Vol.281, No.29, pp. 20077-
20084 
Fernandez, J.A., Xu, X., Liu, D., Zlokovic, B.V., & Griffin, J.H. (2003). Recombinant murine-
activated protein C is neuroprotective in a murine ischemic stroke model. Blood 
Cells Mol.Dis. Vol.30, No.3, pp. 271-276 
Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., Camp, S.M., Ye, S.Q., 
& Garcia, J.G. (2005). Activated protein C mediates novel lung endothelial barrier 
enhancement: Role of sphingosine 1-phosphate receptor transactivation. 
J.Biol.Chem. Vol.280, No.17, pp.17286-17293 
Fisher, C.J., Jr. & Yan, S.B. (2000). Protein C levels as a prognostic indicator of outcome in 
sepsis and related diseases. Crit Care Med. Vol.28, No.9 Suppl, pp. S49-S56 
Folsom, A.R., Rosamond, W.D., Shahar, E., Cooper, L.S., Aleksic, N., Nieto, F.J., Rasmussen, 
M.L., & Wu, K.K. (1999). Prospective study of markers of hemostatic function with 
risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study 
Investigators. Circulation. Vol.100, No.7, pp. 736-742 
Franscini, N., Bachli, E.B., Blau, N., Leikauf, M.S., Schaffner, A., & Schoedon, G. (2004). Gene 
expression profiling of inflamed human endothelial cells and influence of activated 
protein C. Circulation. Vol.110, No.18, pp. 2903-2909 
Fujisawa, K., Aono, H., Hasunuma, T., Yamamoto, K., Mita, S., & Nishioka, K. (1996). 
Activation of transcription factor NF-kappa B in human synovial cells in response 
to tumor necrosis factor alpha. Arthritis Rheum. Vol.39, No.2, pp. 197-203 
Fukudome, K. & Esmon, C.T. (1994). Identification, cloning, and regulation of a novel 
endothelial cell protein c activated protein c receptor. J. Biol. Chem. Vol.269, No.42, 
pp. 26486-26491 
Gale, A.J., Tsavaler, A., & Griffin, J.H. (2002). Molecular characterization of an extended 
binding site for coagulation factor Va in the positive exosite of activated protein C. 
J. Biol. Chem. Vol.277, No.32, pp. 28836-28840 
Ganopolsky, J.G. & Castellino, F.J. (2004). A Protein C Deficiency Exacerbates Inflammatory 
and Hypotensive Responses in Mice During Polymicrobial Sepsis in a Cecal 
Ligation and Puncture Model. Am. J. Pathol. Vol.165, No.4, pp. 1433-1446 
Genc, K. (2007). The rationale for activated protein C treatment in perinatal white matter 
injury. Med.Hypotheses. Vol.68, No.6, pp. 1418-1419 
Genc, K. (2007). Activated protein C: therapeutic implications for Alzheimer's disease. Med 
Hypotheses. Vol.69, No.3, pp. 701-702 
Gramling, M.W., Beaulieu, L.M., & Church, F.C. (2010). Activated protein C enhances cell 
motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular 
signal transduction. Exp.Cell Res. Vol.316, No.3, pp. 314-328 
Grey, S.T., Tsuchida, A., Hau, H., Orthner, C.L., Salem, H.H., & Hancock, W.W. (1994). 
Selective inhibitory effects of the anticoagulant activated protein C on the 
responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol 
ester. J. Immunol. Vol.153, No.8, pp. 3664-3672 
Griffin, J.H., Fernandez, J.A., Gale, A.J., & Mosnier, L.O. (2005). Activated protein C. 
J.Thromb.Haemost.2007.Vol.5,No.suppl 1, pp.73-80. 
Griffin, J.H., Fernandez, J.A., Mosnier, L.O., Liu, D., Cheng, T., Guo, H., & Zlokovic, B.V. 
(2006). The promise of protein C. Blood Cells Mol.Dis. Vol.36, No.2, pp. 211-216 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 65 
Griffin, J.H., Zlokovic, B., & Fernandez, J.A. (2002). Activated protein C: potential therapy 
for severe sepsis, thrombosis, and stroke. Semin.Hematol. Vol.39, No.3, pp. 197-205 
Gruber, A. & Griffin, J.H. (1992). Direct detection of activated protein C in blood from 
human subjects. Blood. Vol.79, No.9, pp. 2340-2348 
Gruden, G., Olivetti, C., Cavallo-Perin, P., Bazzan, M., Stella, S., Tamponi, G., & Pagano, G. 
(1997). Activated protein C resistance in type I diabetes. Diabetes Care. Vol.20, No.3, 
pp. 424-425 
Gu, J.M., Crawley, J.T.B., Ferrell, G., Zhang, F., Li, W., Esmon, N.L., & Esmon, C.T. (2002). 
Disruption of the Endothelial Cell Protein C Receptor Gene in Mice Causes 
Placental Thrombosis and Early Embryonic Lethality. J. Biol. Chem. Vol.277, No.45, 
pp. 43335-43343 
Guo, H., Gu, F., Li, W., Zhang, B., Niu, R., Fu, L., Zhang, N., & Ma, Y. (2009). Reduction of 
protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. 
J.Neurochem. Vol.109, No.1, pp. 203-213 
Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H., & 
Zlokovic, B.V. (2004). Activated protein C prevents neuronal apoptosis via protease 
activated receptors 1 and 3. Neuron. Vol.41, No.4, pp. 563-572 
Guo, H., Singh, I., Wang, Y., Deane, R., Barrett, T., Fernandez, J.A., Chow, N., Griffin, J.H., & 
Zlokovic, B.V. (2009). Neuroprotective activities of activated protein C mutant with 
reduced anticoagulant activity. Eur J Neurosci. Vol.29, No.6, pp. 1119-1130 
Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H., & 
Zlokovic, B.V. (2004). Activated Protein C Prevents Neuronal Apoptosis via 
Protease Activated Receptors 1 and 3. Neuron. Vol.41, No.4, pp. 563-572 
Gupta, A., Rhodes, G.J., Berg, D.T., Gerlitz, B., Molitoris, B.A., & Grinnell, B.W. (2007). 
Activated protein C ameliorates LPS-induced acute kidney injury and 
downregulates renal INOS and angiotensin 2. Am.J.Physiol. Renal Physiol. Vol.293, 
No.1, pp. F245-F254 
Hanly, A.M., Redmond, M., Winter, D.C., Brophy, S., Deasy, J.M., Bouchier-Hayes, D.J., & 
Kay, E.W. (2006). Thrombomodulin expression in colorectal carcinoma is protective 
and correlates with survival. Br J Cancer. Vol.94, No.9, pp. 1320-1325 
Hanly, A.M. & Winter, D.C. (2007). The role of thrombomodulin in malignancy. Semin 
Thromb Hemost. Vol.33, No.7, pp. 673-679 
Hataji, O., Taguchi, O., Gabazza, E.C., Yuda, H., Fujimoto, H., Suzuki, K., & Adachi, Y. 
(2002). Activation of protein C pathway in the airways. Lung. Vol.180, No.1, pp. 47-
59 
Hirose, K., Okajima, K., Taoka, Y., Uchiba, M., Tagami, H., Nakano, K., Utoh, J., Okabe, H., 
& Kitamura, N. (2000). Activated protein C reduces the ischemia/reperfusion-
induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg. 
Vol.232, No.2, pp. 272-280 
Hofstra, J.J., Vlaar, A.P., Knape, P., Mackie, D.P., Determann, R.M., Choi, G., van Der, P.T., 
Levi, M., & Schultz, M.J. (2011). Pulmonary Activation of Coagulation and 
Inhibition of Fibrinolysis After Burn Injuries and Inhalation Trauma. J Trauma. 
Epub ahead of print 
Hudson, L.G. & McCawley, L.J. (1998). Contributions of the epidermal growth factor 
receptor to keratinocyte motility. Microsc.Res.Tech. Vol.43, No.5, pp. 444-455 
Isermann, B., Vinnikov, I.A., Madhusudhan, T., Herzog, S., Kashif, M., Blautzik, J., Corat, 
M.A.F., Zeier, M., Blessing, E., Oh, J., Gerlitz, B., Berg, D.T., Grinnell, B.W., 
 
Inflammatory Diseases – A Modern Perspective 64
Feistritzer, C., Schuepbach, R.A., Mosnier, L.O., Bush, L.A., Di, C.E., Griffin, J.H., & Riewald, 
M. (2006). Protective signaling by activated protein C is mechanistically linked to 
protein C activation on endothelial cells. J. Biol. Chem. Vol.281, No.29, pp. 20077-
20084 
Fernandez, J.A., Xu, X., Liu, D., Zlokovic, B.V., & Griffin, J.H. (2003). Recombinant murine-
activated protein C is neuroprotective in a murine ischemic stroke model. Blood 
Cells Mol.Dis. Vol.30, No.3, pp. 271-276 
Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., Camp, S.M., Ye, S.Q., 
& Garcia, J.G. (2005). Activated protein C mediates novel lung endothelial barrier 
enhancement: Role of sphingosine 1-phosphate receptor transactivation. 
J.Biol.Chem. Vol.280, No.17, pp.17286-17293 
Fisher, C.J., Jr. & Yan, S.B. (2000). Protein C levels as a prognostic indicator of outcome in 
sepsis and related diseases. Crit Care Med. Vol.28, No.9 Suppl, pp. S49-S56 
Folsom, A.R., Rosamond, W.D., Shahar, E., Cooper, L.S., Aleksic, N., Nieto, F.J., Rasmussen, 
M.L., & Wu, K.K. (1999). Prospective study of markers of hemostatic function with 
risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study 
Investigators. Circulation. Vol.100, No.7, pp. 736-742 
Franscini, N., Bachli, E.B., Blau, N., Leikauf, M.S., Schaffner, A., & Schoedon, G. (2004). Gene 
expression profiling of inflamed human endothelial cells and influence of activated 
protein C. Circulation. Vol.110, No.18, pp. 2903-2909 
Fujisawa, K., Aono, H., Hasunuma, T., Yamamoto, K., Mita, S., & Nishioka, K. (1996). 
Activation of transcription factor NF-kappa B in human synovial cells in response 
to tumor necrosis factor alpha. Arthritis Rheum. Vol.39, No.2, pp. 197-203 
Fukudome, K. & Esmon, C.T. (1994). Identification, cloning, and regulation of a novel 
endothelial cell protein c activated protein c receptor. J. Biol. Chem. Vol.269, No.42, 
pp. 26486-26491 
Gale, A.J., Tsavaler, A., & Griffin, J.H. (2002). Molecular characterization of an extended 
binding site for coagulation factor Va in the positive exosite of activated protein C. 
J. Biol. Chem. Vol.277, No.32, pp. 28836-28840 
Ganopolsky, J.G. & Castellino, F.J. (2004). A Protein C Deficiency Exacerbates Inflammatory 
and Hypotensive Responses in Mice During Polymicrobial Sepsis in a Cecal 
Ligation and Puncture Model. Am. J. Pathol. Vol.165, No.4, pp. 1433-1446 
Genc, K. (2007). The rationale for activated protein C treatment in perinatal white matter 
injury. Med.Hypotheses. Vol.68, No.6, pp. 1418-1419 
Genc, K. (2007). Activated protein C: therapeutic implications for Alzheimer's disease. Med 
Hypotheses. Vol.69, No.3, pp. 701-702 
Gramling, M.W., Beaulieu, L.M., & Church, F.C. (2010). Activated protein C enhances cell 
motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular 
signal transduction. Exp.Cell Res. Vol.316, No.3, pp. 314-328 
Grey, S.T., Tsuchida, A., Hau, H., Orthner, C.L., Salem, H.H., & Hancock, W.W. (1994). 
Selective inhibitory effects of the anticoagulant activated protein C on the 
responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol 
ester. J. Immunol. Vol.153, No.8, pp. 3664-3672 
Griffin, J.H., Fernandez, J.A., Gale, A.J., & Mosnier, L.O. (2005). Activated protein C. 
J.Thromb.Haemost.2007.Vol.5,No.suppl 1, pp.73-80. 
Griffin, J.H., Fernandez, J.A., Mosnier, L.O., Liu, D., Cheng, T., Guo, H., & Zlokovic, B.V. 
(2006). The promise of protein C. Blood Cells Mol.Dis. Vol.36, No.2, pp. 211-216 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 65 
Griffin, J.H., Zlokovic, B., & Fernandez, J.A. (2002). Activated protein C: potential therapy 
for severe sepsis, thrombosis, and stroke. Semin.Hematol. Vol.39, No.3, pp. 197-205 
Gruber, A. & Griffin, J.H. (1992). Direct detection of activated protein C in blood from 
human subjects. Blood. Vol.79, No.9, pp. 2340-2348 
Gruden, G., Olivetti, C., Cavallo-Perin, P., Bazzan, M., Stella, S., Tamponi, G., & Pagano, G. 
(1997). Activated protein C resistance in type I diabetes. Diabetes Care. Vol.20, No.3, 
pp. 424-425 
Gu, J.M., Crawley, J.T.B., Ferrell, G., Zhang, F., Li, W., Esmon, N.L., & Esmon, C.T. (2002). 
Disruption of the Endothelial Cell Protein C Receptor Gene in Mice Causes 
Placental Thrombosis and Early Embryonic Lethality. J. Biol. Chem. Vol.277, No.45, 
pp. 43335-43343 
Guo, H., Gu, F., Li, W., Zhang, B., Niu, R., Fu, L., Zhang, N., & Ma, Y. (2009). Reduction of 
protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. 
J.Neurochem. Vol.109, No.1, pp. 203-213 
Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H., & 
Zlokovic, B.V. (2004). Activated protein C prevents neuronal apoptosis via protease 
activated receptors 1 and 3. Neuron. Vol.41, No.4, pp. 563-572 
Guo, H., Singh, I., Wang, Y., Deane, R., Barrett, T., Fernandez, J.A., Chow, N., Griffin, J.H., & 
Zlokovic, B.V. (2009). Neuroprotective activities of activated protein C mutant with 
reduced anticoagulant activity. Eur J Neurosci. Vol.29, No.6, pp. 1119-1130 
Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H., & 
Zlokovic, B.V. (2004). Activated Protein C Prevents Neuronal Apoptosis via 
Protease Activated Receptors 1 and 3. Neuron. Vol.41, No.4, pp. 563-572 
Gupta, A., Rhodes, G.J., Berg, D.T., Gerlitz, B., Molitoris, B.A., & Grinnell, B.W. (2007). 
Activated protein C ameliorates LPS-induced acute kidney injury and 
downregulates renal INOS and angiotensin 2. Am.J.Physiol. Renal Physiol. Vol.293, 
No.1, pp. F245-F254 
Hanly, A.M., Redmond, M., Winter, D.C., Brophy, S., Deasy, J.M., Bouchier-Hayes, D.J., & 
Kay, E.W. (2006). Thrombomodulin expression in colorectal carcinoma is protective 
and correlates with survival. Br J Cancer. Vol.94, No.9, pp. 1320-1325 
Hanly, A.M. & Winter, D.C. (2007). The role of thrombomodulin in malignancy. Semin 
Thromb Hemost. Vol.33, No.7, pp. 673-679 
Hataji, O., Taguchi, O., Gabazza, E.C., Yuda, H., Fujimoto, H., Suzuki, K., & Adachi, Y. 
(2002). Activation of protein C pathway in the airways. Lung. Vol.180, No.1, pp. 47-
59 
Hirose, K., Okajima, K., Taoka, Y., Uchiba, M., Tagami, H., Nakano, K., Utoh, J., Okabe, H., 
& Kitamura, N. (2000). Activated protein C reduces the ischemia/reperfusion-
induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg. 
Vol.232, No.2, pp. 272-280 
Hofstra, J.J., Vlaar, A.P., Knape, P., Mackie, D.P., Determann, R.M., Choi, G., van Der, P.T., 
Levi, M., & Schultz, M.J. (2011). Pulmonary Activation of Coagulation and 
Inhibition of Fibrinolysis After Burn Injuries and Inhalation Trauma. J Trauma. 
Epub ahead of print 
Hudson, L.G. & McCawley, L.J. (1998). Contributions of the epidermal growth factor 
receptor to keratinocyte motility. Microsc.Res.Tech. Vol.43, No.5, pp. 444-455 
Isermann, B., Vinnikov, I.A., Madhusudhan, T., Herzog, S., Kashif, M., Blautzik, J., Corat, 
M.A.F., Zeier, M., Blessing, E., Oh, J., Gerlitz, B., Berg, D.T., Grinnell, B.W., 
 
Inflammatory Diseases – A Modern Perspective 66
Chavakis, T., Esmon, C.T., Weiler, H., Bierhaus, A., & Nawroth, P.P. (2007). 
Activated protein C protects against diabetic nephropathy by inhibiting endothelial 
and podocyte apoptosis. Nat Med. Vol.13, No.11, pp. 1349-1358 
Itoh, T., Matsuda, H., Tanioka, M., Kuwabara, K., Itohara, S., & Suzuki, R. (2002). The role of 
matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced 
arthritis. J.Immunol. Vol.169, No.5, pp. 2643-2647 
Jackson, C.J., Xue, M., Thompson, P., Davey, R.A., Whitmont, K., Smith, S., Buisson-
Legendre, N., Sztynda, T., Furphy, L.J., Cooper, A., Sambrook, P., & March, L. 
(2005). Activated protein C prevents inflammation yet stimulates angiogenesis to 
promote cutaneous wound healing. Wound.Repair Regen. Vol.13, No.3, pp. 284-294 
Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B., & Grinnell, B.W. (2001). Gene expression 
profile of antithrombotic protein c defines new mechanisms modulating 
inflammation and apoptosis. J.Biol.Chem. Vol.276, No.14, pp. 11199-11203 
Kamath, L., Meydani, A., Foss, F., & Kuliopulos, A. (2001). Signaling from protease-
activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer 
Res. Vol.61, No.15, pp. 5933-5940 
Keller, S.A., Moore, C.C., Evans, S.L., McKillop, I.H., & Huynh, T. (2011). Activated protein 
C alters inflammation and protects renal function in sepsis. J Surg.Res. Vol.168, 
No.1, pp. e103-e109 
Kendrick, B.J., Gray, A.G., Pickworth, A., & Watters, M.P. (2006). Drotrecogin alfa 
(activated) in severe falciparum malaria. Anaesthesia. Vol.61, No.9, pp. 899-902 
Kent, D.G., Copley, M.R., Benz, C., Wohrer, S., Dykstra, B.J., Ma, E., Cheyne, J., Zhao, Y., 
Bowie, M.B., Zhao, Y., Gasparetto, M., Delaney, A., Smith, C., Marra, M., & Eaves, 
C.J. (2009). Prospective isolation and molecular characterization of hematopoietic 
stem cells with durable self-renewal potential. Blood. Vol.113, No.25, pp. 6342-6350 
Kerschen, E., Hernandez, I., Zogg, M., Jia, S., Hessner, M.J., Fernandez, J.A., Griffin, J.H., 
Huettner, C.S., Castellino, F.J., & Weiler, H. (2010). Activated protein C targets 
CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 
Vol.120, No.9, pp. 3167-3178 
Kerschen, E.J., Fernandez, J.A., Cooley, B.C., Yang, X.V., Sood, R., Mosnier, L.O., Castellino, 
F.J., Mackman, N., Griffin, J.H., & Weiler, H. (2007). Endotoxemia and sepsis 
mortality reduction by non-anticoagulant activated protein C. J Exp Med. Vol.204, 
No.10, pp. 2439-2448 
Kim, S.J., Shiba, E., Ishii, H., Inoue, T., Taguchi, T., Tanji, Y., Kimoto, Y., Izukura, M., & 
Takai, S. (1997). Thrombomodulin is a new biological and prognostic marker for 
breast cancer: an immunohistochemical study. Anticancer Res. Vol.17, No.3C, pp. 
2319-2323 
Kirschenbaum, L. & Astiz, M. (2005). Acute pancreatitis: a possible role for activated protein 
C? Crit Care. Vol.9, No.3, pp. 243-244 
Kotanidou, A., Loutrari, H., Papadomichelakis, E., Glynos, C., Magkou, C., Armaganidis, A., 
Papapetropoulos, A., Roussos, C., & Orfanos, S.E. (2006). Inhaled activated protein 
C attenuates lung injury induced by aerosolized endotoxin in mice. 
Vascul.Pharmacol. Vol.45, No.2, pp. 134-140 
Kuliopulos, A., Covic, L., Seeley, S.K., Sheridan, P.J., Helin, J., & Costello, C.E. (1999). 
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, 
and implications for thrombolytic therapy. Biochemistry. Vol.38, No.14, pp. 4572-
4585 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 67 
Kwasny-Krochin, B., Bobek, M., Kontny, E., Gluszko, P., Biedron, R., Chain, B.M., Maslinski, 
W., & Marcinkiewicz, J. (2002). Effect of taurine chloramine, the product of 
activated neutrophils, on the development of collagen-induced arthritis in DBA 1/J 
mice. Amino.Acids. Vol.23, No.4, pp. 419-426 
Lay, A.J., Donahue, D., Tsai, M.J., & Castellino, F.J. (2007). Acute inflammation is 
exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood. 
Vol.109, No.5, pp. 1984-1991 
Levi, M., Dorffler-Melly, J., Reitsma, P., Buller, H., Florquin, S., van der Poll, T., & Carmeliet, 
P. (2003). Aggravation of endotoxin-induced disseminated intravascular 
coagulation and cytokine activation in heterozygous protein-C-deficient mice. 
Blood. Vol.101, No.12, pp. 4823-4827 
Levin, M.E. (1993). Diabetic foot ulcers: pathogenesis and management. J.ET Nurs. Vol.20, 
No.5, pp. 191-198 
Li, Q. & Verma, I.M. (2002). NF-kappaB regulation in the immune system. Nat.Rev.Immunol. 
Vol.2, No.10, pp. 725-734 
Li, W., Zheng, X., Gu, J., Hunter, J., Ferrell, G.L., Lupu, F., Esmon, N.L., & Esmon, C.T. 
(2005). Overexpressing endothelial cell protein C receptor alters the hemostatic 
balance and protects mice from endotoxin. J Thromb.Haemost. Vol.3, No.7, pp. 1351-
1359 
Liaw, P.C., Esmon, C.T., Kahnamoui, K., Schmidt, S., Kahnamoui, S., Ferrell, G., Beaudin, S., 
Julian, J.A., Weitz, J.I., Crowther, M., Loeb, M., & Cook, D.J. (2004). Patients with 
severe sepsis vary markedly in their ability to generate activate protein C. Blood. 
Vol.104, No,13, pp 3958-3964 
Lindahl, A.K., Boffa, M.C., & Abildgaard, U. (1993). Increased plasma thrombomodulin in 
cancer patients. Thromb Haemost. Vol.69, No.2, pp. 112-114 
Macko, R.F., Ameriso, S.F., Gruber, A., Griffin, J.H., Fernandez, J.A., Barndt, R., Quismorio, 
F.P., Jr., Weiner, J.M., & Fisher, M. (1996). Impairments of the protein C system and 
fibrinolysis in infection-associated stroke. Stroke. Vol.27, No.11, pp. 2005-2011 
Marok, R., Winyard, P.G., Coumbe, A., Kus, M.L., Gaffney, K., Blades, S., Mapp, P.I., Morris, 
C.J., Blake, D.R., Kaltschmidt, C., & Baeuerle, P.A. (1996). Activation of the 
transcription factor nuclear factor-kappa-b in human inflamed synovial tissue. 
Arthritis Rheum. Vol.39, No.4, pp. 583-591 
Marti-Carvajal, A., Salanti, G., & Cardona, A.F. (2003). Human recombinant activated 
protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.5,CD004388 
Marti-Carvajal, A., Salanti, G., & Cardona, A.F. (2007). Human recombinant activated 
protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.3, CD004388 
Marti-Carvajal, A.J., Sola, I., Lathyris, D., & Cardona, A.F. (2011). Human recombinant 
activated protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.4,.CD004388 
Mathis, D., Vence, L., & Benoist, C. (2001). [beta]-Cell death during progression to diabetes. 
Nature. Vol.414, No.6865, pp. 792-798 
Matsushita, Y., Yoshiie, K., Imamura, Y., Ogawa, H., Imamura, H., Takao, S., Yonezawa, S., 
Aikou, T., Maruyama, I., & Sato, E. (1998). A subcloned human esophageal 
squamous cell carcinoma cell line with low thrombomodulin expression showed 
increased invasiveness compared with a high thrombomodulin-expressing clone--
thrombomodulin as a possible candidate for an adhesion molecule of squamous 
cell carcinoma. Cancer Lett. Vol.127, No.1-2, pp. 195-201 
 
Inflammatory Diseases – A Modern Perspective 66
Chavakis, T., Esmon, C.T., Weiler, H., Bierhaus, A., & Nawroth, P.P. (2007). 
Activated protein C protects against diabetic nephropathy by inhibiting endothelial 
and podocyte apoptosis. Nat Med. Vol.13, No.11, pp. 1349-1358 
Itoh, T., Matsuda, H., Tanioka, M., Kuwabara, K., Itohara, S., & Suzuki, R. (2002). The role of 
matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced 
arthritis. J.Immunol. Vol.169, No.5, pp. 2643-2647 
Jackson, C.J., Xue, M., Thompson, P., Davey, R.A., Whitmont, K., Smith, S., Buisson-
Legendre, N., Sztynda, T., Furphy, L.J., Cooper, A., Sambrook, P., & March, L. 
(2005). Activated protein C prevents inflammation yet stimulates angiogenesis to 
promote cutaneous wound healing. Wound.Repair Regen. Vol.13, No.3, pp. 284-294 
Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B., & Grinnell, B.W. (2001). Gene expression 
profile of antithrombotic protein c defines new mechanisms modulating 
inflammation and apoptosis. J.Biol.Chem. Vol.276, No.14, pp. 11199-11203 
Kamath, L., Meydani, A., Foss, F., & Kuliopulos, A. (2001). Signaling from protease-
activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer 
Res. Vol.61, No.15, pp. 5933-5940 
Keller, S.A., Moore, C.C., Evans, S.L., McKillop, I.H., & Huynh, T. (2011). Activated protein 
C alters inflammation and protects renal function in sepsis. J Surg.Res. Vol.168, 
No.1, pp. e103-e109 
Kendrick, B.J., Gray, A.G., Pickworth, A., & Watters, M.P. (2006). Drotrecogin alfa 
(activated) in severe falciparum malaria. Anaesthesia. Vol.61, No.9, pp. 899-902 
Kent, D.G., Copley, M.R., Benz, C., Wohrer, S., Dykstra, B.J., Ma, E., Cheyne, J., Zhao, Y., 
Bowie, M.B., Zhao, Y., Gasparetto, M., Delaney, A., Smith, C., Marra, M., & Eaves, 
C.J. (2009). Prospective isolation and molecular characterization of hematopoietic 
stem cells with durable self-renewal potential. Blood. Vol.113, No.25, pp. 6342-6350 
Kerschen, E., Hernandez, I., Zogg, M., Jia, S., Hessner, M.J., Fernandez, J.A., Griffin, J.H., 
Huettner, C.S., Castellino, F.J., & Weiler, H. (2010). Activated protein C targets 
CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 
Vol.120, No.9, pp. 3167-3178 
Kerschen, E.J., Fernandez, J.A., Cooley, B.C., Yang, X.V., Sood, R., Mosnier, L.O., Castellino, 
F.J., Mackman, N., Griffin, J.H., & Weiler, H. (2007). Endotoxemia and sepsis 
mortality reduction by non-anticoagulant activated protein C. J Exp Med. Vol.204, 
No.10, pp. 2439-2448 
Kim, S.J., Shiba, E., Ishii, H., Inoue, T., Taguchi, T., Tanji, Y., Kimoto, Y., Izukura, M., & 
Takai, S. (1997). Thrombomodulin is a new biological and prognostic marker for 
breast cancer: an immunohistochemical study. Anticancer Res. Vol.17, No.3C, pp. 
2319-2323 
Kirschenbaum, L. & Astiz, M. (2005). Acute pancreatitis: a possible role for activated protein 
C? Crit Care. Vol.9, No.3, pp. 243-244 
Kotanidou, A., Loutrari, H., Papadomichelakis, E., Glynos, C., Magkou, C., Armaganidis, A., 
Papapetropoulos, A., Roussos, C., & Orfanos, S.E. (2006). Inhaled activated protein 
C attenuates lung injury induced by aerosolized endotoxin in mice. 
Vascul.Pharmacol. Vol.45, No.2, pp. 134-140 
Kuliopulos, A., Covic, L., Seeley, S.K., Sheridan, P.J., Helin, J., & Costello, C.E. (1999). 
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, 
and implications for thrombolytic therapy. Biochemistry. Vol.38, No.14, pp. 4572-
4585 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 67 
Kwasny-Krochin, B., Bobek, M., Kontny, E., Gluszko, P., Biedron, R., Chain, B.M., Maslinski, 
W., & Marcinkiewicz, J. (2002). Effect of taurine chloramine, the product of 
activated neutrophils, on the development of collagen-induced arthritis in DBA 1/J 
mice. Amino.Acids. Vol.23, No.4, pp. 419-426 
Lay, A.J., Donahue, D., Tsai, M.J., & Castellino, F.J. (2007). Acute inflammation is 
exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood. 
Vol.109, No.5, pp. 1984-1991 
Levi, M., Dorffler-Melly, J., Reitsma, P., Buller, H., Florquin, S., van der Poll, T., & Carmeliet, 
P. (2003). Aggravation of endotoxin-induced disseminated intravascular 
coagulation and cytokine activation in heterozygous protein-C-deficient mice. 
Blood. Vol.101, No.12, pp. 4823-4827 
Levin, M.E. (1993). Diabetic foot ulcers: pathogenesis and management. J.ET Nurs. Vol.20, 
No.5, pp. 191-198 
Li, Q. & Verma, I.M. (2002). NF-kappaB regulation in the immune system. Nat.Rev.Immunol. 
Vol.2, No.10, pp. 725-734 
Li, W., Zheng, X., Gu, J., Hunter, J., Ferrell, G.L., Lupu, F., Esmon, N.L., & Esmon, C.T. 
(2005). Overexpressing endothelial cell protein C receptor alters the hemostatic 
balance and protects mice from endotoxin. J Thromb.Haemost. Vol.3, No.7, pp. 1351-
1359 
Liaw, P.C., Esmon, C.T., Kahnamoui, K., Schmidt, S., Kahnamoui, S., Ferrell, G., Beaudin, S., 
Julian, J.A., Weitz, J.I., Crowther, M., Loeb, M., & Cook, D.J. (2004). Patients with 
severe sepsis vary markedly in their ability to generate activate protein C. Blood. 
Vol.104, No,13, pp 3958-3964 
Lindahl, A.K., Boffa, M.C., & Abildgaard, U. (1993). Increased plasma thrombomodulin in 
cancer patients. Thromb Haemost. Vol.69, No.2, pp. 112-114 
Macko, R.F., Ameriso, S.F., Gruber, A., Griffin, J.H., Fernandez, J.A., Barndt, R., Quismorio, 
F.P., Jr., Weiner, J.M., & Fisher, M. (1996). Impairments of the protein C system and 
fibrinolysis in infection-associated stroke. Stroke. Vol.27, No.11, pp. 2005-2011 
Marok, R., Winyard, P.G., Coumbe, A., Kus, M.L., Gaffney, K., Blades, S., Mapp, P.I., Morris, 
C.J., Blake, D.R., Kaltschmidt, C., & Baeuerle, P.A. (1996). Activation of the 
transcription factor nuclear factor-kappa-b in human inflamed synovial tissue. 
Arthritis Rheum. Vol.39, No.4, pp. 583-591 
Marti-Carvajal, A., Salanti, G., & Cardona, A.F. (2003). Human recombinant activated 
protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.5,CD004388 
Marti-Carvajal, A., Salanti, G., & Cardona, A.F. (2007). Human recombinant activated 
protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.3, CD004388 
Marti-Carvajal, A.J., Sola, I., Lathyris, D., & Cardona, A.F. (2011). Human recombinant 
activated protein C for severe sepsis. Cochrane.Database.Syst.Rev. Vol.4,.CD004388 
Mathis, D., Vence, L., & Benoist, C. (2001). [beta]-Cell death during progression to diabetes. 
Nature. Vol.414, No.6865, pp. 792-798 
Matsushita, Y., Yoshiie, K., Imamura, Y., Ogawa, H., Imamura, H., Takao, S., Yonezawa, S., 
Aikou, T., Maruyama, I., & Sato, E. (1998). A subcloned human esophageal 
squamous cell carcinoma cell line with low thrombomodulin expression showed 
increased invasiveness compared with a high thrombomodulin-expressing clone--
thrombomodulin as a possible candidate for an adhesion molecule of squamous 
cell carcinoma. Cancer Lett. Vol.127, No.1-2, pp. 195-201 
 
Inflammatory Diseases – A Modern Perspective 68
McQuibban, G.A., Gong, J.H., Wong, J.P., Wallace, J.L., Clark-Lewis, I., & Overall, C.M. 
(2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins 
generates CC chemokine receptor antagonists with anti-inflammatory properties in 
vivo. Blood. Vol.100, No.4, pp. 1160-1167 
Mewhort-Buist, T.A., Liaw, P.C., Patel, S., Atkinson, H.M., Berry, L.R., & Chan, A.K. (2008). 
Treatment of endothelium with the chemotherapy agent vincristine affects 
activated protein C generation to a greater degree in newborn plasma than in adult 
plasma. Thromb Res. Vol.122, No.3, pp. 418-426 
Milia, A.F., Salis, M.B., Stacca, T., Pinna, A., Madeddu, P., Trevisani, M., Geppetti, P., & 
Emanueli, C. (2002). Protease-activated receptor-2 stimulates angiogenesis and 
accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. 
Circ.Res. Vol.91, No.4, pp. 346-352 
Minhas, N., Xue, M., Fukudome, K., & Jackson, C.J. (2010). Activated protein C utilizes the 
angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J. Vol.24, 
No.3, pp. 873-881 
Mizutani, A., Okajima, K., Uchiba, M., & Noguchi, T. (2000). Activated protein C reduces 
ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte 
activation. Blood. Vol.95, No.12, pp. 3781-3787 
Montiel, M., de la Blanca, E.P., & Jimenez, E. (2005). Angiotensin II induces focal adhesion 
kinase/paxillin phosphorylation and cell migration in human umbilical vein 
endothelial cells. Biochem.Biophys.Res.Commun. Vol.327, No.4, pp. 971-978 
Mosnier, L.O., Gale, A.J., Yegneswaran, S., & Griffin, J.H. (2004). Activated protein C 
variants with normal cytoprotective but reduced anticoagulant activity. Blood. 
Vol.104, No.6, pp 1740-1744 
Mosnier, L.O. & Griffin, J.H. (2003). Inhibition of staurosporine-induced apoptosis of 
endothelial cells by activated protein C requires protease-activated receptor-1 and 
endothelial cell protein C receptor. Biochem.J. Vol.373, No.Pt 1, pp. 65-70 
Mosnier, L.O., Yang, X.V., & Griffin, J.H. (2007). Activated protein C mutant with minimal 
anticoagulant activity, normal cytoprotective activity, and preservation of 
thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. 
J.Biol.Chem. Vol.282, No.45, pp. 33022-33033 
Mosnier, L.O., Zampolli, A., Kerschen, E.J., Schuepbach, R.A., Banerjee, Y., Fernandez, J.A., 
Yang, X.V., Riewald, M., Weiler, H., Ruggeri, Z.M., & Griffin, J.H. (2009). 
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. 
Blood. Vol.113, No.23, pp. 5970-5978 
Nguyen, M., Arkell, J., & Jackson, C.J. (3000). Activated protein C directly activates human 
endothelial gelatinase A. J. Biol. Chem.Vol.275, No.13, pp. 9095-9098 
Ni, A.F., O'Donnell, J.S., Johnson, J.A., Brown, L., Gleeson, E.M., Smith, O.P., & Preston, R.J. 
(2011). Activated protein C N-linked glycans modulate cytoprotective signaling 
function on endothelial cells. J. Biol. Chem. Vol.286, No.2, pp. 1323-1330 
Nick, J.A., Coldren, C.D., Geraci, M.W., Poch, K.R., Fouty, B.W., O'Brien, J., Gruber, M., 
Zarini, S., Murphy, R.C., Kuhn, K., Richter, D., Kast, K.R., & Abraham, E. (2004). 
Recombinant human activated protein C reduces human endotoxin-induced 
pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. Vol.104, 
No.13, pp 3878-3885 
Nierodzik, M.L., Chen, K., Takeshita, K., Li, J.J., Huang, Y.Q., Feng, X.S., D'Andrea, M.R., 
ndrade-Gordon, P., & Karpatkin, S. (1998). Protease-activated receptor 1 (PAR-1) is 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 69 
required and rate-limiting for thrombin-enhanced experimental pulmonary 
metastasis. Blood. Vol.92, No.10, pp. 3694-3700 
Nijziel, M.R., van, O.R., Christella, M., Thomassen, L.G., van Pampus, E.C., Hamulyak, K., 
Tans, G., & Rosing, J. (2003). Acquired resistance to activated protein C in breast 
cancer patients. Br.J Haematol. Vol.120, No.1, pp. 117-122 
O'Brien, L.A., Gupta, A., & Grinnell, B.W. (2006). Activated protein C and sepsis. Front 
Biosci. Vol.11, No.1, pp. 676-698 
Okajima, K. (2004). Regulation of inflammatory responses by activated protein C: the 
molecular mechanism(s) and therapeutic implications. Clin.Chem.Lab Med. Vol.42, 
No.2, pp. 132-141 
Ottesen, L.H., Bladbjerg, E.M., Osman, M., Lausten, S.B., Jacobsen, N.O., Gram, J., & Jensen, 
S.L. (1999). Protein C activation during the initial phase of experimental acute 
pancreatitis in the rabbit. Dig.Surg. Vol.16, No.6, pp. 486-495 
Park, S.Y., Lee, H.E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010). Heterogeneity for 
Stem CellGÇôRelated Markers According to Tumor Subtype and Histologic Stage 
in Breast Cancer. Clin. Cancer Res. Vol.16, No.3, pp. 876-887 
Ram, M., Sherer, Y., & Shoenfeld, Y. (2006). Matrix metalloproteinase-9 and autoimmune 
diseases. J Clin Immunol. Vol.26, No.4,  pp. 299-307 
Redd, M.J., Cooper, L., Wood, W., Stramer, B., & Martin, P. (2004). Wound healing and 
inflammation: embryos reveal the way to perfect repair. Philos.Trans.R.Soc.Lond B 
Biol.Sci. Vol.359, No.1445, pp. 777-784 
Rezaie, A.R., Neuenschwander, P.F., Morrissey, J.H., & Esmon, C.T. (1993). Analysis of the 
functions of the first epidermal growth factor-like domain of factor X. J.Biol.Chem. 
Vol.268, No.11, pp. 8176-8180 
Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., & Ruf, W. (2002). Activation of 
endothelial cell protease activated receptor 1 by the protein C pathway. Science. 
Vol.296, No.5574, pp. 1880-1882 
Rogers, J.S., Murgo, A.J., Fontana, J.A., & Raich, P.C. (1988). Chemotherapy for breast cancer 
decreases plasma protein C and protein S. J Clin Oncol. Vol.6, No.2, pp. 276-281 
Sadaka, F., O'Brien, J., Migneron, M., Stortz, J., Vanston, A., & Taylor, R.W. (2011). Activated 
protein C in septic shock: a propensity-matched analysis. Crit Care. Vol.15, No.2, 
pp. R89- 
Sakar, A., Vatansever, S., Sepit, L., Ozbilgin, K., & Yorgancioglu, A. (2007). Effect of 
recombinant human activated protein C on apoptosis-related proteins. Eur.J 
Histochem. Vol.51, No.2, pp. 103-109 
Schmidt-Supprian, M., Murphy, C., While, B., Lawler, M., Kapurniotu, A., Voelter, W., 
Smith, O., & Bernhagen, J. (2000). Activated protein C inhibits tumor necrosis factor 
and macrophage migration inhibitory factor production in monocytes. Eur Cytokine 
Netw. Vol.11, No.3, pp. 407-413 
Schouten, M., de Boer, J.D., van der Sluijs, K.F., Roelofs, J.J., van, '., V, Levi, M., Esmon, C.T., 
& van Der, P.T. (2011). Impact of Endogenous Protein C on Pulmonary Coagulation 
and Injury During Lethal H1N1 Influenza in Mice. Am J Respir.Cell Mol Biol. Vol.44, 
No.3, pp. 377-383 
Seol, J.W., Lee, Y.J., Jackson, C.J., Sambrook, P.N., & Park, S.Y. (2011). Activated protein C 
inhibits bisphosphonate-induced endothelial cell death via the endothelial protein 
C receptor and nuclear factor-kappaB pathways. Int J Mol Med. Vol.27, No.6, pp. 
835-840 
 
Inflammatory Diseases – A Modern Perspective 68
McQuibban, G.A., Gong, J.H., Wong, J.P., Wallace, J.L., Clark-Lewis, I., & Overall, C.M. 
(2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins 
generates CC chemokine receptor antagonists with anti-inflammatory properties in 
vivo. Blood. Vol.100, No.4, pp. 1160-1167 
Mewhort-Buist, T.A., Liaw, P.C., Patel, S., Atkinson, H.M., Berry, L.R., & Chan, A.K. (2008). 
Treatment of endothelium with the chemotherapy agent vincristine affects 
activated protein C generation to a greater degree in newborn plasma than in adult 
plasma. Thromb Res. Vol.122, No.3, pp. 418-426 
Milia, A.F., Salis, M.B., Stacca, T., Pinna, A., Madeddu, P., Trevisani, M., Geppetti, P., & 
Emanueli, C. (2002). Protease-activated receptor-2 stimulates angiogenesis and 
accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. 
Circ.Res. Vol.91, No.4, pp. 346-352 
Minhas, N., Xue, M., Fukudome, K., & Jackson, C.J. (2010). Activated protein C utilizes the 
angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J. Vol.24, 
No.3, pp. 873-881 
Mizutani, A., Okajima, K., Uchiba, M., & Noguchi, T. (2000). Activated protein C reduces 
ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte 
activation. Blood. Vol.95, No.12, pp. 3781-3787 
Montiel, M., de la Blanca, E.P., & Jimenez, E. (2005). Angiotensin II induces focal adhesion 
kinase/paxillin phosphorylation and cell migration in human umbilical vein 
endothelial cells. Biochem.Biophys.Res.Commun. Vol.327, No.4, pp. 971-978 
Mosnier, L.O., Gale, A.J., Yegneswaran, S., & Griffin, J.H. (2004). Activated protein C 
variants with normal cytoprotective but reduced anticoagulant activity. Blood. 
Vol.104, No.6, pp 1740-1744 
Mosnier, L.O. & Griffin, J.H. (2003). Inhibition of staurosporine-induced apoptosis of 
endothelial cells by activated protein C requires protease-activated receptor-1 and 
endothelial cell protein C receptor. Biochem.J. Vol.373, No.Pt 1, pp. 65-70 
Mosnier, L.O., Yang, X.V., & Griffin, J.H. (2007). Activated protein C mutant with minimal 
anticoagulant activity, normal cytoprotective activity, and preservation of 
thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. 
J.Biol.Chem. Vol.282, No.45, pp. 33022-33033 
Mosnier, L.O., Zampolli, A., Kerschen, E.J., Schuepbach, R.A., Banerjee, Y., Fernandez, J.A., 
Yang, X.V., Riewald, M., Weiler, H., Ruggeri, Z.M., & Griffin, J.H. (2009). 
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. 
Blood. Vol.113, No.23, pp. 5970-5978 
Nguyen, M., Arkell, J., & Jackson, C.J. (3000). Activated protein C directly activates human 
endothelial gelatinase A. J. Biol. Chem.Vol.275, No.13, pp. 9095-9098 
Ni, A.F., O'Donnell, J.S., Johnson, J.A., Brown, L., Gleeson, E.M., Smith, O.P., & Preston, R.J. 
(2011). Activated protein C N-linked glycans modulate cytoprotective signaling 
function on endothelial cells. J. Biol. Chem. Vol.286, No.2, pp. 1323-1330 
Nick, J.A., Coldren, C.D., Geraci, M.W., Poch, K.R., Fouty, B.W., O'Brien, J., Gruber, M., 
Zarini, S., Murphy, R.C., Kuhn, K., Richter, D., Kast, K.R., & Abraham, E. (2004). 
Recombinant human activated protein C reduces human endotoxin-induced 
pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. Vol.104, 
No.13, pp 3878-3885 
Nierodzik, M.L., Chen, K., Takeshita, K., Li, J.J., Huang, Y.Q., Feng, X.S., D'Andrea, M.R., 
ndrade-Gordon, P., & Karpatkin, S. (1998). Protease-activated receptor 1 (PAR-1) is 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 69 
required and rate-limiting for thrombin-enhanced experimental pulmonary 
metastasis. Blood. Vol.92, No.10, pp. 3694-3700 
Nijziel, M.R., van, O.R., Christella, M., Thomassen, L.G., van Pampus, E.C., Hamulyak, K., 
Tans, G., & Rosing, J. (2003). Acquired resistance to activated protein C in breast 
cancer patients. Br.J Haematol. Vol.120, No.1, pp. 117-122 
O'Brien, L.A., Gupta, A., & Grinnell, B.W. (2006). Activated protein C and sepsis. Front 
Biosci. Vol.11, No.1, pp. 676-698 
Okajima, K. (2004). Regulation of inflammatory responses by activated protein C: the 
molecular mechanism(s) and therapeutic implications. Clin.Chem.Lab Med. Vol.42, 
No.2, pp. 132-141 
Ottesen, L.H., Bladbjerg, E.M., Osman, M., Lausten, S.B., Jacobsen, N.O., Gram, J., & Jensen, 
S.L. (1999). Protein C activation during the initial phase of experimental acute 
pancreatitis in the rabbit. Dig.Surg. Vol.16, No.6, pp. 486-495 
Park, S.Y., Lee, H.E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010). Heterogeneity for 
Stem CellGÇôRelated Markers According to Tumor Subtype and Histologic Stage 
in Breast Cancer. Clin. Cancer Res. Vol.16, No.3, pp. 876-887 
Ram, M., Sherer, Y., & Shoenfeld, Y. (2006). Matrix metalloproteinase-9 and autoimmune 
diseases. J Clin Immunol. Vol.26, No.4,  pp. 299-307 
Redd, M.J., Cooper, L., Wood, W., Stramer, B., & Martin, P. (2004). Wound healing and 
inflammation: embryos reveal the way to perfect repair. Philos.Trans.R.Soc.Lond B 
Biol.Sci. Vol.359, No.1445, pp. 777-784 
Rezaie, A.R., Neuenschwander, P.F., Morrissey, J.H., & Esmon, C.T. (1993). Analysis of the 
functions of the first epidermal growth factor-like domain of factor X. J.Biol.Chem. 
Vol.268, No.11, pp. 8176-8180 
Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., & Ruf, W. (2002). Activation of 
endothelial cell protease activated receptor 1 by the protein C pathway. Science. 
Vol.296, No.5574, pp. 1880-1882 
Rogers, J.S., Murgo, A.J., Fontana, J.A., & Raich, P.C. (1988). Chemotherapy for breast cancer 
decreases plasma protein C and protein S. J Clin Oncol. Vol.6, No.2, pp. 276-281 
Sadaka, F., O'Brien, J., Migneron, M., Stortz, J., Vanston, A., & Taylor, R.W. (2011). Activated 
protein C in septic shock: a propensity-matched analysis. Crit Care. Vol.15, No.2, 
pp. R89- 
Sakar, A., Vatansever, S., Sepit, L., Ozbilgin, K., & Yorgancioglu, A. (2007). Effect of 
recombinant human activated protein C on apoptosis-related proteins. Eur.J 
Histochem. Vol.51, No.2, pp. 103-109 
Schmidt-Supprian, M., Murphy, C., While, B., Lawler, M., Kapurniotu, A., Voelter, W., 
Smith, O., & Bernhagen, J. (2000). Activated protein C inhibits tumor necrosis factor 
and macrophage migration inhibitory factor production in monocytes. Eur Cytokine 
Netw. Vol.11, No.3, pp. 407-413 
Schouten, M., de Boer, J.D., van der Sluijs, K.F., Roelofs, J.J., van, '., V, Levi, M., Esmon, C.T., 
& van Der, P.T. (2011). Impact of Endogenous Protein C on Pulmonary Coagulation 
and Injury During Lethal H1N1 Influenza in Mice. Am J Respir.Cell Mol Biol. Vol.44, 
No.3, pp. 377-383 
Seol, J.W., Lee, Y.J., Jackson, C.J., Sambrook, P.N., & Park, S.Y. (2011). Activated protein C 
inhibits bisphosphonate-induced endothelial cell death via the endothelial protein 
C receptor and nuclear factor-kappaB pathways. Int J Mol Med. Vol.27, No.6, pp. 
835-840 
 
Inflammatory Diseases – A Modern Perspective 70
Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F., Griffin, J.H., & Zlokovic, 
B.V. (2001). Anti-inflammatory, antithrombotic, and neuroprotective effects of 
activated protein C in a murine model of focal ischemic stroke. Circulation. Vol.103, 
No.13, pp. 1799-1805 
Short, M.A., Schlichting, D., & Qualy, R.L. (2006). From bench to bedside: a review of the 
clinical trial development plan of drotrecogin alfa (activated). Curr.Med.Res.Opin. 
Vol.22, No.12, pp. 2525-2540 
Srinivas, R., Agarwal, R., & Gupta, D. (2007). Severe sepsis due to severe falciparum malaria 
and leptospirosis co-infection treated with activated protein C. Malar.J. Vol.6, No.6, 
pp.42 
Stenflo, J. (1976). A new vitamin K-dependent protein. Purification from bovine plasma and 
preliminary characterization. J.Biol.Chem. Vol.251, No.2, pp. 355-363 
Stephenson, D.A., Toltl, L.J., Beaudin, S., & Liaw, P.C. (2006). Modulation of monocyte 
function by activated protein C, a natural anticoagulant. J.Immunol. Vol.177, No.4, 
pp. 2115-2122 
Szpaderska, A.M. & DiPietro, L.A. (2005). Inflammation in surgical wound healing: friend or 
foe? Surgery. Vol.137, No.5, pp. 571-573 
Szpaderska, A.M., Zuckerman, J.D., & DiPietro, L.A. (2003). Differential injury responses in 
oral mucosal and cutaneous wounds. J.Dent.Res. Vol.82, No.8, pp. 621-626 
Taoka, Y., Okajima, K., Uchiba, M., & Johno, M. (2000). Neuroprotection by recombinant 
thrombomodulin. Thromb Haemost. Vol.83, No.3, pp. 462-468 
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Harada, N., Johno, M., & Naruo, M. 
(1998). Activated protein C reduces the severity of compression-induced spinal 
cord injury in rats by inhibiting activation of leukocytes. J Neurosci. Vol.18, No.4, 
pp. 1393-1398 
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Kushimoto, S., Johno, M., Naruo, M., 
Okabe, H., & Takatsuki, K. (1997). Role of neutrophils in spinal cord injury in the 
rat. Neuroscience. Vol.79, No.4, pp. 1177-1182 
Thadhani, R., Pascual, M., & Bonventre, J.V. (1996). Acute renal failure. N.Engl.J.Med. 
Vol.334, No.22, pp. 1448-1460 
Toltl, L.J., Beaudin, S., & Liaw, P.C. (2008). Activated protein C up-regulates IL-10 and 
inhibits tissue factor in blood monocytes. J.Immunol. Vol.181, No.3, pp. 2165-2173 
Trent, J.T., Falabella, A., Eaglstein, W.H., & Kirsner, R.S. (2005). Venous ulcers: 
pathophysiology and treatment options. Ostomy.Wound Manage. Vol.51, No.5, pp. 
38-54 
Tsuneyoshi, N., Fukudome, K., Horiguchi, S., Ye, X., Matsuzaki, M., Toi, M., Suzuki, K., & 
Kimoto, M. (2001). Expression and anticoagulant function of the endothelial cell 
protein C receptor (EPCR) in cancer cell lines. Thromb Haemost. Vol.85, No.2, pp. 
356-361 
Uchiba, M., Okajima, K., Oike, Y., Ito, Y., Fukudome, K., Isobe, H., & Suda, T. (2004). 
Activated protein C induces endothelial cell proliferation by mitogen-activated 
protein kinase activation in vitro and angiogenesis in vivo. Circ Res. Vol.95, No.1, 
pp. 34-41 
Van Sluis, G.L., Bruggemann, L.W., Esmon, C.T., Kamphuisen, P.W., Richel, D.J., Buller, 
H.R., Van Noorden, C.J., & Spek, C.A. (2011). Endogenous activated protein C is 
essential for immune-mediated cancer cell elimination from the circulation. Cancer 
Lett. Vol.306, No.1, pp. 106-110 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 71 
Van Sluis, G.L., Buller, H.R., & Spek, C.A. (2010). The role of activated protein C in cancer 
progression. Thromb Res. Vol.125 Suppl 2, No.S138-S142 
Villares, G.J., Zigler, M., Dobroff, A.S., Wang, H., Song, R., Melnikova, V.O., Huang, L., 
Braeuer, R.R., & Bar-Eli, M. (2011). Protease activated receptor-1 inhibits the 
Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. 
Proc Natl Acad Sci U.S.A. Vol.108, No.2, pp. 626-631 
Vukovich, T.C. & Schernthaner, G. (1986). Decreased protein C levels in patients with 
insulin-dependent type I diabetes mellitus. Diabetes. Vol.35, No.5, pp. 617-619 
Walker, C.T., Marky, A.H., Petraglia, A.L., Ali, T., Chow, N., & Zlokovic, B.V. (2010). 
Activated protein C analog with reduced anticoagulant activity improves 
functional recovery and reduces bleeding risk following controlled cortical impact. 
Brain Res. Vol.1347, No.125-131 
Wang, Y., Thiyagarajan, M., Chow, N., Singh, I., Guo, H., Davis, T.P., & Zlokovic, B.V. 
(2009). Differential neuroprotection and risk for bleeding from activated protein C 
with varying degrees of anticoagulant activity. Stroke. Vol.40, No.5, pp. 1864-1869 
White, B., Schmidt, M., Murphy, C., Livingstone, W., O'Toole, D., Lawler, M., O'Neill, L., 
Kelleher, D., Schwarz, H.P., & Smith, O.P. (2000). Activated protein C inhibits 
lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-
kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 
monocytic cell line. Br.J.Haematol. Vol.110, No.1, pp. 130-134 
Whitmont, K., Reid, I., Tritton, S., March, L., Xue, M., Lee, M., Fulcher, G., Sambrook, P., 
Slobedman, E., Cooper, A., & Jackson, C. (2008). Treatment of chronic leg ulcers 
with topical activated protein C. Arch.Dermatol. Vol.144, No.11, pp. 1479-1483 
Woodley-Cook, J., Shin, L.Y., Swystun, L., Caruso, S., Beaudin, S., & Liaw, P.C. (2006). 
Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant 
pathway. Mol Cancer Ther. Vol.5, No.12, pp. 3303-3311 
Wu, J., Zhou, Z., Ye, S., Dai, H., Ma, L., Xu, X., & Li, X. (2000). [Detection of soluble 
endothelial protein C receptor (sEPCR) in patients with CHD, DM and SLE]. 
Zhonghua Xue.Ye.Xue.Za Zhi. Vol.21, No.9, pp. 472-474 
Xu, J., Ji, Y., Zhang, X., Drake, M., & Esmon, C.T. (2009). Endogenous activated protein C 
signaling is critical to protection of mice from lipopolysaccaride-induced septic 
shock. J Thromb Haemost. Vol.7, No.5, pp. 851-856 
Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C.T., Semeraro, F., Taylor, F.B., 
Esmon, N.L., Lupu, F., & Esmon, C.T. (2009). Extracellular histones are major 
mediators of death in sepsis. Nat Med. Vol.15, No.11, pp. 1318-1321 
Xue, M., Campbell, D., Sambrook, P.N., Fukudome, K., & Jackson, C.J. (2005). Endothelial 
protein C receptor and protease-activated receptor-1 mediate induction of a 
wound-healing phenotype in human keratinocytes by activated protein C. J. Invest. 
Dermatol. Vol.125, No.6, pp. 1279-1285 
Xue, M., Chow, S.O., Dervish, S., Chan, Y.K., Julovi, S.M., & Jackson, C.J. (2011). Activated 
protein C enhances human keratinocyte barrier integrity via sequential activation 
of epidermal growth factor receptor and Tie2. J. Biol. Chem. Vol.286, No.8, pp. 6742-
6750 
Xue, M., March, L., Sambrook, P.N., Fukudome, F., & Jackson, C.J. (2007). Endothelial 
protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and 
mediates the anti-inflammatory effects of activated protein C in RA monocytes. 
Ann.Rheum.Dis. Vol.66, No.12, pp.1574-1580 
 
Inflammatory Diseases – A Modern Perspective 70
Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F., Griffin, J.H., & Zlokovic, 
B.V. (2001). Anti-inflammatory, antithrombotic, and neuroprotective effects of 
activated protein C in a murine model of focal ischemic stroke. Circulation. Vol.103, 
No.13, pp. 1799-1805 
Short, M.A., Schlichting, D., & Qualy, R.L. (2006). From bench to bedside: a review of the 
clinical trial development plan of drotrecogin alfa (activated). Curr.Med.Res.Opin. 
Vol.22, No.12, pp. 2525-2540 
Srinivas, R., Agarwal, R., & Gupta, D. (2007). Severe sepsis due to severe falciparum malaria 
and leptospirosis co-infection treated with activated protein C. Malar.J. Vol.6, No.6, 
pp.42 
Stenflo, J. (1976). A new vitamin K-dependent protein. Purification from bovine plasma and 
preliminary characterization. J.Biol.Chem. Vol.251, No.2, pp. 355-363 
Stephenson, D.A., Toltl, L.J., Beaudin, S., & Liaw, P.C. (2006). Modulation of monocyte 
function by activated protein C, a natural anticoagulant. J.Immunol. Vol.177, No.4, 
pp. 2115-2122 
Szpaderska, A.M. & DiPietro, L.A. (2005). Inflammation in surgical wound healing: friend or 
foe? Surgery. Vol.137, No.5, pp. 571-573 
Szpaderska, A.M., Zuckerman, J.D., & DiPietro, L.A. (2003). Differential injury responses in 
oral mucosal and cutaneous wounds. J.Dent.Res. Vol.82, No.8, pp. 621-626 
Taoka, Y., Okajima, K., Uchiba, M., & Johno, M. (2000). Neuroprotection by recombinant 
thrombomodulin. Thromb Haemost. Vol.83, No.3, pp. 462-468 
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Harada, N., Johno, M., & Naruo, M. 
(1998). Activated protein C reduces the severity of compression-induced spinal 
cord injury in rats by inhibiting activation of leukocytes. J Neurosci. Vol.18, No.4, 
pp. 1393-1398 
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Kushimoto, S., Johno, M., Naruo, M., 
Okabe, H., & Takatsuki, K. (1997). Role of neutrophils in spinal cord injury in the 
rat. Neuroscience. Vol.79, No.4, pp. 1177-1182 
Thadhani, R., Pascual, M., & Bonventre, J.V. (1996). Acute renal failure. N.Engl.J.Med. 
Vol.334, No.22, pp. 1448-1460 
Toltl, L.J., Beaudin, S., & Liaw, P.C. (2008). Activated protein C up-regulates IL-10 and 
inhibits tissue factor in blood monocytes. J.Immunol. Vol.181, No.3, pp. 2165-2173 
Trent, J.T., Falabella, A., Eaglstein, W.H., & Kirsner, R.S. (2005). Venous ulcers: 
pathophysiology and treatment options. Ostomy.Wound Manage. Vol.51, No.5, pp. 
38-54 
Tsuneyoshi, N., Fukudome, K., Horiguchi, S., Ye, X., Matsuzaki, M., Toi, M., Suzuki, K., & 
Kimoto, M. (2001). Expression and anticoagulant function of the endothelial cell 
protein C receptor (EPCR) in cancer cell lines. Thromb Haemost. Vol.85, No.2, pp. 
356-361 
Uchiba, M., Okajima, K., Oike, Y., Ito, Y., Fukudome, K., Isobe, H., & Suda, T. (2004). 
Activated protein C induces endothelial cell proliferation by mitogen-activated 
protein kinase activation in vitro and angiogenesis in vivo. Circ Res. Vol.95, No.1, 
pp. 34-41 
Van Sluis, G.L., Bruggemann, L.W., Esmon, C.T., Kamphuisen, P.W., Richel, D.J., Buller, 
H.R., Van Noorden, C.J., & Spek, C.A. (2011). Endogenous activated protein C is 
essential for immune-mediated cancer cell elimination from the circulation. Cancer 
Lett. Vol.306, No.1, pp. 106-110 
 
Anti-Inflammatory Actions of the Anticoagulant, Activated Protein C 71 
Van Sluis, G.L., Buller, H.R., & Spek, C.A. (2010). The role of activated protein C in cancer 
progression. Thromb Res. Vol.125 Suppl 2, No.S138-S142 
Villares, G.J., Zigler, M., Dobroff, A.S., Wang, H., Song, R., Melnikova, V.O., Huang, L., 
Braeuer, R.R., & Bar-Eli, M. (2011). Protease activated receptor-1 inhibits the 
Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. 
Proc Natl Acad Sci U.S.A. Vol.108, No.2, pp. 626-631 
Vukovich, T.C. & Schernthaner, G. (1986). Decreased protein C levels in patients with 
insulin-dependent type I diabetes mellitus. Diabetes. Vol.35, No.5, pp. 617-619 
Walker, C.T., Marky, A.H., Petraglia, A.L., Ali, T., Chow, N., & Zlokovic, B.V. (2010). 
Activated protein C analog with reduced anticoagulant activity improves 
functional recovery and reduces bleeding risk following controlled cortical impact. 
Brain Res. Vol.1347, No.125-131 
Wang, Y., Thiyagarajan, M., Chow, N., Singh, I., Guo, H., Davis, T.P., & Zlokovic, B.V. 
(2009). Differential neuroprotection and risk for bleeding from activated protein C 
with varying degrees of anticoagulant activity. Stroke. Vol.40, No.5, pp. 1864-1869 
White, B., Schmidt, M., Murphy, C., Livingstone, W., O'Toole, D., Lawler, M., O'Neill, L., 
Kelleher, D., Schwarz, H.P., & Smith, O.P. (2000). Activated protein C inhibits 
lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-
kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 
monocytic cell line. Br.J.Haematol. Vol.110, No.1, pp. 130-134 
Whitmont, K., Reid, I., Tritton, S., March, L., Xue, M., Lee, M., Fulcher, G., Sambrook, P., 
Slobedman, E., Cooper, A., & Jackson, C. (2008). Treatment of chronic leg ulcers 
with topical activated protein C. Arch.Dermatol. Vol.144, No.11, pp. 1479-1483 
Woodley-Cook, J., Shin, L.Y., Swystun, L., Caruso, S., Beaudin, S., & Liaw, P.C. (2006). 
Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant 
pathway. Mol Cancer Ther. Vol.5, No.12, pp. 3303-3311 
Wu, J., Zhou, Z., Ye, S., Dai, H., Ma, L., Xu, X., & Li, X. (2000). [Detection of soluble 
endothelial protein C receptor (sEPCR) in patients with CHD, DM and SLE]. 
Zhonghua Xue.Ye.Xue.Za Zhi. Vol.21, No.9, pp. 472-474 
Xu, J., Ji, Y., Zhang, X., Drake, M., & Esmon, C.T. (2009). Endogenous activated protein C 
signaling is critical to protection of mice from lipopolysaccaride-induced septic 
shock. J Thromb Haemost. Vol.7, No.5, pp. 851-856 
Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C.T., Semeraro, F., Taylor, F.B., 
Esmon, N.L., Lupu, F., & Esmon, C.T. (2009). Extracellular histones are major 
mediators of death in sepsis. Nat Med. Vol.15, No.11, pp. 1318-1321 
Xue, M., Campbell, D., Sambrook, P.N., Fukudome, K., & Jackson, C.J. (2005). Endothelial 
protein C receptor and protease-activated receptor-1 mediate induction of a 
wound-healing phenotype in human keratinocytes by activated protein C. J. Invest. 
Dermatol. Vol.125, No.6, pp. 1279-1285 
Xue, M., Chow, S.O., Dervish, S., Chan, Y.K., Julovi, S.M., & Jackson, C.J. (2011). Activated 
protein C enhances human keratinocyte barrier integrity via sequential activation 
of epidermal growth factor receptor and Tie2. J. Biol. Chem. Vol.286, No.8, pp. 6742-
6750 
Xue, M., March, L., Sambrook, P.N., Fukudome, F., & Jackson, C.J. (2007). Endothelial 
protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and 
mediates the anti-inflammatory effects of activated protein C in RA monocytes. 
Ann.Rheum.Dis. Vol.66, No.12, pp.1574-1580 
 
Inflammatory Diseases – A Modern Perspective 72
Xue, M., March, L., Sambrook, P.N., & Jackson, C.J. (2007). Differential regulation of matrix 
metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: 
relevance to inflammation in rheumatoid arthritis. Arthritis Rheum. Vol.56, No.9, 
pp. 2864-2874 
Xue, M., Minhas, N., Chow, S.O., Dervish, S., Sambrook, P.N., March, L., & Jackson, C.J. 
(2010). Endogenous protein C is essential for the functional integrity of human 
endothelial cells. Cell Mol Life Sci. Vol.67, No.9, pp.1537-1546 
Xue, M., Thompson, P., Kelso, I., & Jackson, C. (2004). Activated protein C stimulates 
proliferation, migration and wound closure, inhibits apoptosis and upregulates 
MMP-2 activity in cultured human keratinocytes. Exp Cell Res. Vol.299, No.1, pp. 
119-127 
Xue, M., Campbell, D., & Jackson, C.J. (2007). Protein C is an autocrine growth factor for 
human skin keratinocytes. J. Biol. Chem. Vol.282, No.18, pp. 13610-13616 
Yamauchi, T., Sakurai, M., Abe, K., Takano, H., & Sawa, Y. (2006). Neuroprotective effects of 
activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 
receptor, and its downstream signal phosphorylated serine-threonine kinase after 
spinal cord ischemia in rabbits. Stroke. Vol.37, No.4, pp. 1081-1086 
Yang, X.V., Banerjee, Y., Fernandez, J.A., Deguchi, H., Xu, X., Mosnier, L.O., Urbanus, R.T., 
de Groot, P.G., White-Adams, T.C., McCarty, O.J., & Griffin, J.H. (2009). Activated 
protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 
cells. Proc. Nat. Acad. Sci. U.S.A. Vol.106, No.1, pp. 274-279 
Yuda, H., Adachi, Y., Taguchi, O., Gabazza, E.C., Hataji, O., Fujimoto, H., Tamaki, S., 
Nishikubo, K., Fukudome, K., D'Alessandro-Gabazza, C.N., Maruyama, J., 
Izumizaki, M., Iwase, M., Homma, I., Inoue, R., Kamada, H., Hayashi, T., Kasper, 
M., Lambrecht, B.N., Barnes, P.J., & Suzuki, K. (2004). Activated protein C inhibits 
bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood. 
Vol.103, No.6, pp. 2196-2204 
Yuksel, M., Okajima, K., Uchiba, M., Horiuchi, S., & Okabe, H. (2002). Activated protein C 
inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by 
inhibiting activation of both nuclear factor-kappa B and activator protein-1 in 
human monocytes. Thromb.Haemost. Vol.88, No.2, pp. 267-273 
Zhong, Z., Ilieva, H., Hallagan, L., Bell, R., Singh, I., Paquette, N., Thiyagarajan, M., Deane, 
R., Fernandez, J.A., Lane, S., Zlokovic, A.B., Liu, T., Griffin, J.H., Chow, N., 
Castellino, F.J., Stojanovic, K., Cleveland, D.W., & Zlokovic, B.V. (2009). Activated 
protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting 
SOD1 in motor neurons and microglia cells. J. Clin. Invest. Vol.119, No.11, pp. 3437-
3449 
Zlokovic, B.V. (2005). Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends 
Neurosci. Vol.28, No.4, pp. 202-208 
Zlokovic, B.V. & Griffin, J.H. (2011). Cytoprotective protein C pathways and implications for 
stroke and neurological disorders. Trends Neurosci. Vol.34, No.4, pp. 198-209 
Part 5 
Role of TrkA Receptor in Inflammation 
 
Inflammatory Diseases – A Modern Perspective 72
Xue, M., March, L., Sambrook, P.N., & Jackson, C.J. (2007). Differential regulation of matrix 
metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: 
relevance to inflammation in rheumatoid arthritis. Arthritis Rheum. Vol.56, No.9, 
pp. 2864-2874 
Xue, M., Minhas, N., Chow, S.O., Dervish, S., Sambrook, P.N., March, L., & Jackson, C.J. 
(2010). Endogenous protein C is essential for the functional integrity of human 
endothelial cells. Cell Mol Life Sci. Vol.67, No.9, pp.1537-1546 
Xue, M., Thompson, P., Kelso, I., & Jackson, C. (2004). Activated protein C stimulates 
proliferation, migration and wound closure, inhibits apoptosis and upregulates 
MMP-2 activity in cultured human keratinocytes. Exp Cell Res. Vol.299, No.1, pp. 
119-127 
Xue, M., Campbell, D., & Jackson, C.J. (2007). Protein C is an autocrine growth factor for 
human skin keratinocytes. J. Biol. Chem. Vol.282, No.18, pp. 13610-13616 
Yamauchi, T., Sakurai, M., Abe, K., Takano, H., & Sawa, Y. (2006). Neuroprotective effects of 
activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 
receptor, and its downstream signal phosphorylated serine-threonine kinase after 
spinal cord ischemia in rabbits. Stroke. Vol.37, No.4, pp. 1081-1086 
Yang, X.V., Banerjee, Y., Fernandez, J.A., Deguchi, H., Xu, X., Mosnier, L.O., Urbanus, R.T., 
de Groot, P.G., White-Adams, T.C., McCarty, O.J., & Griffin, J.H. (2009). Activated 
protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 
cells. Proc. Nat. Acad. Sci. U.S.A. Vol.106, No.1, pp. 274-279 
Yuda, H., Adachi, Y., Taguchi, O., Gabazza, E.C., Hataji, O., Fujimoto, H., Tamaki, S., 
Nishikubo, K., Fukudome, K., D'Alessandro-Gabazza, C.N., Maruyama, J., 
Izumizaki, M., Iwase, M., Homma, I., Inoue, R., Kamada, H., Hayashi, T., Kasper, 
M., Lambrecht, B.N., Barnes, P.J., & Suzuki, K. (2004). Activated protein C inhibits 
bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood. 
Vol.103, No.6, pp. 2196-2204 
Yuksel, M., Okajima, K., Uchiba, M., Horiuchi, S., & Okabe, H. (2002). Activated protein C 
inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by 
inhibiting activation of both nuclear factor-kappa B and activator protein-1 in 
human monocytes. Thromb.Haemost. Vol.88, No.2, pp. 267-273 
Zhong, Z., Ilieva, H., Hallagan, L., Bell, R., Singh, I., Paquette, N., Thiyagarajan, M., Deane, 
R., Fernandez, J.A., Lane, S., Zlokovic, A.B., Liu, T., Griffin, J.H., Chow, N., 
Castellino, F.J., Stojanovic, K., Cleveland, D.W., & Zlokovic, B.V. (2009). Activated 
protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting 
SOD1 in motor neurons and microglia cells. J. Clin. Invest. Vol.119, No.11, pp. 3437-
3449 
Zlokovic, B.V. (2005). Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends 
Neurosci. Vol.28, No.4, pp. 202-208 
Zlokovic, B.V. & Griffin, J.H. (2011). Cytoprotective protein C pathways and implications for 
stroke and neurological disorders. Trends Neurosci. Vol.34, No.4, pp. 198-209 
Part 5 
Role of TrkA Receptor in Inflammation 
 5 
Expression and Role of the  
TrkA Receptor in Pulmonary  
Inflammatory Diseases 
Véronique Freund-Michel1,2, Bernard Muller1,2 
 and Nelly Frossard3,4 
1INSERM U1045 “Centre de Recherche 
 Cardio-thoracique de Bordeaux”, Bordeaux 
2University Bordeaux Segalen, Bordeaux 
3UMR 7200 CNRS “Laboratoire d’Innovation 
 Thérapeutique”, Strasbourg 
4University of Strasbourg, Strasbourg 
France 
1. Introduction 
The nerve growth factor NGF belongs to the neurotrophin family and was described for the 
first time more than fifty years ago by Rita Levi-Montalcini and collaborators (Levi-
Montalcini et al., 1995; Levi-Montalcini & Hamburger, 1951), who showed its major role in 
neuronal growth and survival. NGF effects are mediated by activation of two receptor types: 
the low-affinity p75 receptor for neurotrophins (p75NTR) and the high-affinity tropomyosin-
related kinase A (TrkA) receptor (Freund-Michel & Frossard, 2008a). The p75NTR receptor 
belongs to the death receptor family and its activation by NGF at nanomolar concentrations 
leads either to pro- or anti-apoptotic signalling pathways. The p75NTR receptor is not 
selective for NGF as it can also bind pro-neurotrophins and the other neurotrophins at the 
same nanomolar concentrations (Chao, 2003). Inversely, the TrkA receptor is selective for 
NGF and belongs to the tyrosine-kinase receptor family. Its activation by NGF at picomolar 
concentrations activates signalling pathways inducing cell proliferation, differentiation and 
survival in particular through activation of phosphatidylinositol-3 kinase (PI3K), small 
protein G Ras, phospholipase C (PLC) and mitogen-activated protein kinases (MAPK) 
(Freund-Michel & Frossard, 2008a). 
The role of NGF in neuronal growth and survival has been widely studied and led to 
consider NGF as a promising therapeutic target in several pathologies of the nervous 
system, in particular neurodegenerative diseases (Prakash et al., 2010). In addition, many 
studies have suggested that NGF also plays the role of an inflammatory mediator, in 
particular in the lung (Freund-Michel & Frossard, 2008a). Indeed, numerous sources of 
NGF have been described in the lung, including infiltrated inflammatory cells, sensory 
nerves, and many lung structural cells such as fibroblasts, epithelial, endothelial, and 
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airway or pulmonary vascular smooth muscle cells (Ricci et al., 2004b). These cells have 
been shown to release more NGF in inflammatory conditions, and may thus participate in 
increased NGF levels observed in pulmonary inflammatory diseases. In parallel, many 
studies have shown an active role of NGF in pulmonary inflammation, airway sensory 
nerve plasticity, airway and vascular hyperreactivity and remodelling (Freund-Michel & 
Frossard, 2008a). Most of these NGF effects occur through activation of the TrkA receptor, 
thus highlighting the pivotal role played by this receptor in pulmonary inflammatory 
diseases.  
The aim of the present chapter is to describe the role of the TrkA receptor activated by NGF 
in pulmonary inflammatory diseases. We will first present the TrkA receptor by describing 
its discovery, its structure and activity as well as its major signalling pathways. We will then 
focus on the TrkA receptor in the lung, by describing its pulmonary expression and review 
its involvement in NGF-mediated effects in the lung. We will describe in particular how the 
TrkA receptor participates to NGF-induced inflammation, airway and vascular 
hyperreactivity and remodelling in the lung, focusing on two major pulmonary diseases: 
asthma and pulmonary hypertension. 
2. Presentation of the TrkA receptor 
The TrkA receptor belongs to the Trk receptor family, together with TrkB and TrkC 
receptors. Each Trk receptor binds with a picomolar affinity to a preferred ligand: NGF for 
TrkA, BDNF (brain-derived neurotrophic factor) and NT-4/5 (neurotrophin-4/5) for TrkB, 
and NT-3 (neurotrophin-3) for TrkC (Chao, 2003). However, some crosstalks have been 
described, in particular for NT-3 being able to bind TrkA and TrkB receptors but at higher 
concentrations (Ryden & Ibanez, 1996). 
2.1 Discovery of the TrkA receptor 
A proto-oncogene was identified in 1986 by Martin-Zanca and co-workers in human colon 
carcinomas (Martin-Zanca et al., 1986). This proto-oncogene, resulting from fusion between 
genes encoding for a tyrosine-kinase domain and a non muscular tropomyosin, was named 
NTRK or trk for « tropomyosin-related kinase ». Three isoforms were identified and named 
NTRK1 (or TRKA), NTRK2 (or TRKB) and NTRK3 (or TRKC), with proteins encoded by 
these genes named Trk (TrkA, TrkB and TrkC) (Martin-Zanca et al., 1986). Expression of Trk 
proteins was later also detected in thyroid carcinomas and other cancers such as melanomas 
or breast cancers, as well as in non cancer tissues, in particular in the nervous system (Greco 
et al., 1997). In 1991, the TrkA protein was identified as the high affinity receptor for NGF 
(Kaplan et al., 1991a; Klein et al., 1991). 
2.2 Structure of the TrkA receptor 
The human TrkA receptor is encoded by a gene of 23kb located on chromosome 1q21-q22 
(Weier et al., 1995). This gene contains 16 introns of 70bp to 3.3kb and 17 exons of 18 to 
394bp (Indo et al., 1997), with the 9 first exons encoding for the extracellular part of the 
receptor (Metsis, 2001). The TrkA protein contains 790 amino acids with a molecular weight 
of 140 kDa (Meakin & Shooter, 1992), and is composed of an intracellular domain containing 
a tyrosine-kinase intrinsic activity, a unique transmembrane helix, and an extracellular 
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domain dedicated to NGF binding (Wiesmann & de Vos, 2001). This extracellular domain is 
highly glycosylated, which is essential for activation of TrkA signalling pathways (Friedman 
& Greene, 1999). 
Alternative splicing leads to several isoforms of the TrkA receptor. TrkA I and TrkA II 
splice variants differ only in the presence or absence of a 6 amino acid sequence. 
However, even if TrkA II expression is restricted to the nervous system, whereas TrkA I is 
more ubiquitously expressed (Clary & Reichardt, 1994), no differences in NGF binding or 
in TrkA function have been identified between these two isoforms (Barker et al., 1993). 
More recently, a novel hypoxia-regulated TrkA III splice variant has also been described: 
this isoform is expressed on internal membranes (Tacconelli et al., 2005) and exhibits 
oncogenic activity (Farina et al., 2009). Finally, a metalloproteinase-dependent cleavage of 
TrkA extracellular domain has been described, with release of a soluble fragment whose 
function remains unknown (Cabrera et al., 1996). In parallel, this cleavage induces 
activation of TrkA intracellular kinase domain, thus providing a TrkA NGF-independent 
activation, which may contribute to TrkA-dependent effects in vivo (Diaz-Rodriguez et al., 
1999).  
2.3 Activation and signalling pathways of the TrkA receptor 
As classically described for other tyrosine-kinase receptors, NGF binds to the 
extracellular domain of the TrkA receptor and induces its dimerization thereby 
activating its intracellular tyrosine kinase domain (Kaplan et al., 1991b). Each kinase 
domain induces phosphorylation of three tyrosine residues (Y670, Y674 and Y675) on the 
contralateral kinase domain (Mitra, 1991), thus leading to enhancement of kinase activity 
and further phosphorylation of three other tyrosine residues outside the kinase domain 
(Y490, Y751 and Y785) (Stephens et al., 1994). These newly phosphorylated tyrosine 
residues are then recognized by proteins through their SH2 (Src homology domain 2) 
domains. The adapter protein Shc (Src homology 2-containing protein) interacts with the 
phosphorylated Y490 residue, phosphatidyl-inositol 3-kinase (PI3K) interacts with the 
phosphorylated Y751 residue, and phospholipase C (PLC) interacts with the 
phosphorylated Y785 residue, thereby initiating three main signalling pathways that 
have been widely studied in particular in neuronal cells (Skaper, 2008). However, some 
recent studies also show activation of these TrkA signalling pathways in non neuronal 
cells, and in particular in the airways (for reviews: Freund-Michel & Frossard, 2008a; 
Prakash et al., 2010). 
2.3.1 Ras/Raf pathway 
Shc intracellular binding to the TrkA receptor leads to phosphorylation of its tyrosine 
residues and further recognition by the adapter protein Grb-2 (growth factor receptor bound 
protein-2) through SH3 (Src homology domain 3) domains. Grb-2 then binds to the factor 
sos (factor son of sevenless) to induce recruitment of the small G protein Ras to the cell 
membrane and its activation (Segal & Greenberg, 1996). This translocation to the cell 
membrane enables Ras-induced activation of the Raf kinase and therefore phosphorylation 
of Raf and activation of the MAPK (mitogen-activated protein kinase) ERK1/2 
(extracellular-regulated protein kinase 1/2), leading to activation of survival mechanisms 
and proliferation (Freund-Michel et al., 2006). Concomitant activation of Rap1, another small 
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G protein, can potentiate Ras activation and enhance activation of the ERK1/2 pathway 
(York et al., 2000).  
2.3.2 PI3K pathway 
PI3K intracellular binding to the TrkA receptor leads to its phosphorylation and activation. 
PI3K then induces synthesis of phosphatidyl-inositol 3,4-bisphosphate that recruits PDK-1 
(phosphoinositide-dependent kinase-1) to the cell membrane and induces activation of PKB 
(protein-kinase B, also called Akt) (Ashcroft et al., 1999). PKB then leads to activation of 
gene transcription, either through activation of the small G protein Rac and the MAPK 
pathway (Kita et al., 1998; Yamaguchi et al., 2001), or through activation of the atypical PKC 
zeta in a MAPK-independent manner (Wooten et al., 1994). In addition, PKB can lead to 
activation of proteins belonging to the IAP (inhibitors of apoptosis) family that are involved 
in cell survival (Wiese et al., 1999). Finally, a Ras-dependent activation of PI3K has also been 
described, through direct interaction between Ras and PI3K in a complex also containing the 
adapter protein Gab-1 (Grb2-associated binder-1) after activation of Shc and Grb-2 
(Holgado-Madruga et al., 1997; Korhonen et al., 1999). 
2.3.3 PLC/PKC pathway 
PLC is activated by its interaction with the TrkA receptor and its phosphorylation by TrkA 
intrinsic kinase domains. PLC then induces cleavage of phosphatidyl inositol 4,5-
bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). DAG activates 
protein-kinase C (PKC) to activate the MAPK pathway, with in particular activation of JNK 
(c-jun N-terminal kinase) and p38 (Patapoutian & Reichardt, 2001). IP3 binds to its receptor 
localized on the endoplasmic reticulum and induces calcium release into the cell cytoplasm, 
thus contributing to PKC activation (Obermeier et al., 1993).  
2.4 Transactivation of the TrkA receptor by G protein-coupled receptors 
Neurotrophin-independent activation of Trk receptors, and in particular of the TrkA 
receptor, has been evidenced in rat neuronal cells after adenosine treatment (Lee & Chao, 
2001). Activation of the adenosine A2A receptor, a G protein-coupled receptor (GPCR), 
induces activation of a kinase belonging to the Src family that is then able to phosphorylate 
the TrkA receptor and activate the PI3K/PKB pathway (Lee & Chao, 2001; Lee et al., 2002a). 
This effect has also been evidenced with another GPCR agonist, the pituitary adenylate 
cyclase-activating peptide (PACAP), being able to induce TrkA transactivation and specific 
activation of the PI3K/PKB pathway in absence of NGF (Lee et al., 2002b). Since 
neuroprotective effects of adenosine and PACAP had been previously demonstrated, it has 
been suggested that this TrkA transactivation mechanism may contribute to these 
neuroprotective effects through activation of PI3K/PKB (Lee et al., 2002b). However more 
recent studies suggested that this TrkA transactivation mechanism occurred on newly 
synthesized TrkA receptors that were not already expressed at the cell membrane 
(Rajagopal et al., 2004). 
2.5 Trafficking of the TrkA receptor 
NGF activation of the TrkA receptor expressed on neurons can activate signalling pathways 
close to the nucleus through a specific mechanism called retrograde transport (Heerssen & 
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Segal, 2002). Once activated by NGF, the TrkA receptor is internalized, mainly through 
activation of three mechanisms:  clathrine-dependent internalization, caveolae-dependent 
internalization, or macroendocytosis (Philippidou et al., 2011; Zweifel et al., 2005). All these 
mechanisms are involved in TrkA internalization and depend i) on the cell type studied, ii) 
on the concentration of NGF, and iii) on the amplitude of the signal generated by TrkA 
activation (Zweifel et al., 2005). Once internalized, only a few number of TrkA receptors are 
transported close to the nucleus, using early endosomes characterized by expression of the 
small G protein Rab5 and its effector EEA1 (Early endosome antigen 1) (Delcroix et al., 
2003). TrkA retrograde transport is dependent upon activation of the PI3K-PKB pathway 
(Delcroix et al., 2003; Kuruvilla et al., 2000; York et al., 2000). Most of internalized TrkA 
receptors are either degraded through targeting to lysosomes (Jullien et al., 2002; Saxena et 
al., 2005) or to the proteasome after ubuquitination (Georgieva et al., 2011; Takahashi et al., 
2011), or recycled at the cell membrane (Chen et al., 2005). 
3. TrkA expression in the lung 
Neurotrophin expression was first described in the central and peripheral nervous systems, 
participating to nerve growth and survival through activation of Trk and p75NTR receptors. 
However, neurotrophins and their receptors were later also described in a variety of non-
neuronal tissues, and in particular in the lung (Lomen-Hoerth & Shooter, 1995). 
3.1 In vitro studies 
3.1.1 Inflammatory cells 
NGF expression, which was first reported in T lymphocytes (Ehrhard et al., 1993a), was later 
also described in a variety of inflammatory cells including B lymphocytes (Torcia et al., 
1996), mast cells (Leon et al., 1994), eosinophils (Solomon et al., 1998) and macrophages 
(Ricci et al., 2000b). Expression of the TrkA receptor was shown on mast cells (Tam et al., 
1997), Th2 lymphocytes (Ehrhard et al., 1993a; Lambiase et al., 1997), B lymphocytes (Torcia 
et al., 1996), eosinophils (Hahn et al., 2006; Nassenstein et al., 2003; Noga et al., 2002), 
monocytes and macrophages (Ehrhard et al., 1993b; Otten et al., 1994), and basophils (Burgi 
et al., 1996). 
3.1.2 Airway structural cells 
Many airway structural cells such as fibroblasts (Antonelli et al., 2005; Olgart & Frossard, 
2001), epithelial cells (Fox et al., 2001; Pons et al., 2001), airway smooth muscle cells (Freund 
et al., 2002), pulmonary endothelial and vascular smooth muscle cells (Freund-Michel et al., 
2009) are sources of NGF (Fig. 1). Investigation of TrkA expression on these cells showed 
TrkA expression in particular on pulmonary fibroblasts (Micera et al., 2001), airway smooth 
muscle cells (Dagnell et al., 2007; Freund-Michel et al., 2006; Freund-Michel & Frossard, 
2008b), airway epithelial cells (Othumpangat et al., 2009), and pulmonary endothelial and 
vascular smooth muscle cells (Freund-Michel et al., 2010) (Fig. 1).  
3.2 In vivo studies 
Expression of TrkA mRNA was initially evidenced in rat and human lung homogenates 
(Barbacid et al., 1991; Lomen-Hoerth &  Shooter, 1995). Expression of TrkA protein was then 
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shown by immunohistochemistry in isolated human alveolar macrophages (Ricci et al., 
2000b), in isolated extrapulmonary arteries (Ricci et al., 2000a), and was later also evidenced 
on human airway and vascular smooth muscles, on alveolar cells, on airway sensory nerves, 
as well as on infiltrated inflammatory cells, in particular macrophages, mast cells and 
lymphocytes (Kassel et al., 2001; Olgart Hoglund et al., 2002; Ricci et al., 2004b). Similar TrkA 

























Fig. 1. Expression of NGF and its receptors in human pulmonary vascular cells 
A) NGF protein levels (pg/ml) secreted after 24h by human pulmonary arterial smooth 
muscle cells (hPASMC) or human pulmonary arterial endothelial cells (hPAEC) in primary 
culture were assessed by ELISA in the culture cell supernatant. Data are means ± S.E.M. of 
n=3 experiments performed in triplicates with cells from two different donors. B) TrkA and 
p75NTR proteins were detected by Western blotting in cultured hPASMC or hPAEC from 
two different donors (D1 and D2), with rabbit polyclonal anti-human TrkA or p75NTR 
antibodies as specific protein bands of 140 and 75 kDa respectively. β-Actin probed in the 
same blots was used to control for protein loading. 
4. NGF effects in the lung mediated by activation of the TrkA receptor 
NGF is able to stimulate inflammatory cells infiltrated in the bronchial mucosa, promoting 
in particular their activation and survival in the airways (Freund-Michel & Frossard, 2008a). 
NGF also displays its role of growth factor on airway nerves, in particular on sensory 
airway nerves (Hoyle et al., 1998), and is able to stimulate other airway structural cells such 
as pulmonary fibroblasts or airway smooth muscle cells (Freund-Michel & Frossard, 2008a). 
Some of these effects involve activation of the TrkA receptor expressed on these cells  
(Fig. 2). 
 











































Fig. 2. NGF effects in the lung mediated via activation of the TrkA receptor 
NGF-induced activation of the TrkA receptor participates to attraction and activation of 
inflammatory cells in the lung and may therefore contribute to lung inflammation. The TrkA 
receptor is also expressed on lung structural cells and participates to NGF-induced effects 
that may contribute to altered reactivity and remodelling processes existing in pulmonary 
inflammatory diseases. 
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4.1 TrkA and inflammatory cells 
4.1.1 Mast cells 
In vitro, activation of the TrkA receptor by NGF induces granule formation in immature 
mast cells and therefore contributes to their differentiation (Kim et al., 2008). In addition, 
NGF is a chemotactic factor for mast cells through both MAPK and PI3K signalling 
pathways following TrkA activation (Sawada et al., 2000).  TrkA activation is also 
involved in NGF-induced degranulation of mast cells and mediators release such as for 
example chemokines (Ahamed et al., 2004), or serotonin (Kawamoto et al., 2002). Finally, 
NGF acts as a key factor to promote mast cell survival through TrkA-induced suppression 
of apoptosis (Kawamoto et al., 1995). In vivo, a correlation between NGF levels in 
bronchoalveolar lavage (BAL) fluids and the number of mast cells infiltrated in the 
bronchial mucosa has been evidenced in asthmatic patients after allergenic challenge 
(Kassel et al., 2001). Expression of TrkA receptors on these mast cells therefore suggests a 
role for this receptor in NGF-induced attraction and survival of these cells in the lung in 
vivo (Kassel et al., 2001).  
4.1.2 Basophils 
In vitro, NGF potentiates mediator release from human basophils as well as primes the cells 
to produce leukotriene C4, and these effects are TrkA-dependent (Burgi et al., 1996). NGF 
can also modulate IgE-mediated responses in human basophils, and these effects are 
enhanced on cells from allergic subjects (Sin et al., 2001). However, flow cytometry studies 
revealed no significant differences in TrkA receptor expression on basophils in this study 
(Sin et al., 2001). 
4.1.3 T and B cells 
Although various effects of NGF have been described on T lymphocytes, few studies have 
investigated the role of the TrkA receptor in these effects. Only one study by Ehrhard and 
co-workers clearly demonstrates involvement of the TrkA receptor in NGF-induced 
activation of T lymphocytes in vitro (Ehrhard et al., 1994). In vivo, NGF effects on T 
lymphocytes remain controversial, since two studies conducted in a mouse model of asthma 
failed to show NGF-related effects on T cells (Braun et al., 1998; Path et al., 2002). However, 
in a transgenic mouse tissue-specifically overexpressing NGF in the lung, increased 
numbers of T lymphocytes have been shown in the lung after allergenic challenge (Quarcoo 
et al., 2004). The role of NGF and its TrkA receptor on T lymphocytes in pulmonary 
inflammatory diseases needs therefore to be further clarified in vivo. 
NGF has been shown to induce proliferation of B lymphocytes in vitro, and this effect occurs 
through activation of the TrkA receptor and its signalling pathways involving PLC, PI3K 
and MAPK (Melamed et al., 1996). NGF-induced activation of the TrkA receptor also 
participates to B cell survival through  PI3K-dependent activation of PKC zeta (Kronfeld et 
al., 2002). In vivo, in mice lacking TrkA in non-neuronal tissues, all major immune system 
cell populations were present in normal numbers and distributions, excepted for B 
lymphocytes, demonstrating that endogenous NGF modulates B cell development through 
activation of the TrkA receptor (Coppola et al., 2004). Moreover, during allergic airway 
inflammation in the mouse in vivo, NGF contributes to B cell differentiation into plasma cells 
and activates the TrkA receptor to enhance plasma cell survival and production of 
immunoglobulins E (Abram et al., 2009).  
 




In vitro, eosinophil degranulation is promoted by NGF-induced activation of the TrkA 
receptor, inducing release of inflammatory mediators such as interleukin-4 (Noga et al., 
2002). In vitro NGF treatment of eosinophils from patients with allergic bronchial asthma 
increases viability of these cells, and this effect is correlated to increased expression of the 
TrkA receptor on eosinophils (Nassenstein et al., 2003). In addition, coculture of lung 
eosinophils with airway epithelial cells resulted in enhanced epithelial neurotrophin 
production, as well as in prolonged survival of eosinophils (Hahn et al., 2006). Complete 
inhibition of eosinophil survival in the presence of the TrkA kinase inhibitor K252a 
confirmed the important role of the TrkA receptor in eosinophil survival (Hahn et al., 2006).  
4.1.5 Monocytes / macrophages 
NGF induces TrkA activation in monocytes in vitro to trigger a respiratory burst, the major 
component of monocyte cytotoxic activity (Ehrhard et al., 1993b). Activation of the TrkA 
receptor by NGF also promotes monocytes survival (la Sala et al., 2000). TrkA transactivation 
mechanisms with GPCR ligands, recently evidenced in monocytes, contribute to pro-
inflammatory activities such as for example synthesis of reactive oxygen species (El Zein et al., 
2007, 2010). Expression of the TrkA receptor was shown to decrease during in vitro 
differentiation of monocytes to macrophages, suggesting a maturation-dependent regulation 
of TrkA expression in these cells (Ehrhard et al., 1993b). 
NGF was reported to activate macrophages in vitro in the process of inflammatory and 
immune actions, inducing phagocytosis, parasite killing, and production of inflammatory 
cytokines in a TrkA dependent-manner (Barouch et al., 2001; Susaki et al., 1996). In vivo, TrkA 
expression was reported on human alveolar macrophages (Ricci et al., 2004b; Ricci et al., 
2000b), and the TrkA receptor and its binding protein SH2-B participate to activation of 
alveolar macrophages in vivo in a guinea pig model of asthma (Li et al., 2009). 
4.1.6 Neutrophils 
In a murine model of rhinitis induced by toluene diisocyanate exposure, a massive increased 
number of neutrophils in the nasal mucosa correlates to increased levels of NGF (Wilfong & 
Dey, 2004 & 2005). Neutrophil infiltration was inhibited after in vivo pre-treatment with the 
TrkA kinase inhibitor K252a, thus showing the important role of the TrkA receptor on 
neutrophil attraction in the nasal mucosa (Wilfong & Dey, 2004). 
4.2 TrkA and airway structural cells 
A role for the TrkA receptor has been evidenced in NGF-induced effects on airway sensory 
nerves. In particular, NGF induces release of neuropeptides such as substance P by airway 
neurons, and this effect is TrkA-dependent (de Vries et al., 2006; Dinh et al., 2004). A similar 
effect has been reported in nasal sensory neurons (Wilfong & Dey, 2004). NGF induces 
proliferation of airway smooth muscle cells through activation of the TrkA receptor 
(Freund-Michel et al., 2006). We also showed that NGF multiple stimulation of these cells 
induce internalization and degradation of the TrkA receptor followed by upregulated re-
synthesis of functional TrkA receptors and increased proliferative effect (Freund-Michel & 
Frossard, 2008b). In ongoing studies, we have recently found that NGF induces proliferation 
and migration of human pulmonary endothelial and vascular smooth muscle cells in vitro, 
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and that these effects are inhibited by pre-treatment with the TrkA kinase inhibitor K252a, 
thus suggesting a role for the TrkA receptor in these NGF-mediated effects (Freund-Michel 



























































































Fig. 3. Involvement of the TrkA receptor in NGF-induced effects on human pulmonary 
vascular cells. 
Effect of NGF (0.1, 10 or 100 ng/ml) after 24h on A) human pulmonary arterial smooth muscle 
cells (hPASMC) or B) human pulmonary arterial endothelial cells (hPAEC) in primary culture. 
Cell proliferation was assessed by the BrdU technique and cell migration was evaluated by the 
Transwell assay. Data are presented as the maximal percentage of increased proliferation or 
migration compared to untreated control cells. NGF effect was evaluated in the presence or 
absence of the TrkA kinase inhibitor K252a (100nM, 30min pre-treatment followed by 24h 
concomitant treatment with NGF). ***: P<0.001 versus NGF alone with n=5 independent 
experiments performed in triplicates with cells from two different donors. 
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5. Role of the TrkA receptor in pulmonary inflammatory diseases 
Circulating NGF levels are increased in human allergic and inflammatory diseases (Bonini 
et al., 1996). A local increase in NGF secretion has also been evidenced in BAL fluid from 
asthmatic patients (Kassel et al., 2001; Olgart Hoglund et al., 2002). In addition, our ongoing 
studies show that pulmonary arteries from patients suffering from pulmonary hypertension 
secondary to chronic obstructive pulmonary diseases (COPD) secrete more NGF than 
pulmonary arteries from control donors (Freund-Michel et al., 2010). Asthma and 
pulmonary hypertension share in common three major features occurring either in airways 
or in pulmonary arteries: inflammation, tissue hyperreactivity and remodelling (Barnes, 
2010; Broide et al., 2011; Hassoun et al., 2009; Humbert, 2010).  Several in vitro and in vivo 
studies suggest that NGF may play a role in these three physiopathological mechanisms, in 
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and that these effects are inhibited by pre-treatment with the TrkA kinase inhibitor K252a, 
thus suggesting a role for the TrkA receptor in these NGF-mediated effects (Freund-Michel 



























































































Fig. 3. Involvement of the TrkA receptor in NGF-induced effects on human pulmonary 
vascular cells. 
Effect of NGF (0.1, 10 or 100 ng/ml) after 24h on A) human pulmonary arterial smooth muscle 
cells (hPASMC) or B) human pulmonary arterial endothelial cells (hPAEC) in primary culture. 
Cell proliferation was assessed by the BrdU technique and cell migration was evaluated by the 
Transwell assay. Data are presented as the maximal percentage of increased proliferation or 
migration compared to untreated control cells. NGF effect was evaluated in the presence or 
absence of the TrkA kinase inhibitor K252a (100nM, 30min pre-treatment followed by 24h 
concomitant treatment with NGF). ***: P<0.001 versus NGF alone with n=5 independent 
experiments performed in triplicates with cells from two different donors. 
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reduces interleukin-(IL-)4 and IL-5 cytokine levels (Nassenstein et al., 2006). Substance P is 
one of the neuropeptides released by airway sensory nerves that participates to neurogenic 
inflammation in asthma (Quarcoo et al., 2004). In vivo treatment with the TrkA kinase 
inhibitor K252a prevents the increase in substance P observed in a guinea pig model of 
asthma (de Vries et al., 2006). In vivo pre-treatment with TrkA blocking antibodies decreases 
IL-1 and IL-4 levels in the BAL fluid after allergen sensitization and challenge in the guinea 
pig (Li et al., 2009). Similar results are observed with TrkA blocking antibodies in a mouse 
model of asthma (Ni et al., 2010). Altogether, these results show a major role of NGF in 
airway inflammation through activation of its TrkA receptor. 
5.1.2 Pulmonary hypertension 
We recently showed that NGF stimulates secretion of inflammatory cytokines such as IL-1 
and tumor necrosis factor- from rat and human pulmonary arteries (Freund-Michel et al., 
2010). Moreover, in vivo treatment with anti-NGF blocking antibodies in animal models of 
pulmonary hypertension prevents the increased secretion of these inflammatory cytokines 
from diseased pulmonary arteries (Freund-Michel et al., unpublished data). Contribution of 
the TrkA receptor in these mechanisms remains to be determined, but our preliminary data 
support a role for NGF in the inflammatory mechanisms associated to pulmonary 
hypertension. 
5.2 NGF, TrkA and tissue hyperresponsiveness  
5.2.1 Asthma 
A role for NGF was reported in airway hyperresponsiveness (AHR) associated to asthma, 
since pre-treatment with anti-NGF blocking antibodies reduces AHR in various animal 
models of asthma (Braun et al., 1998; de Vries et al., 2006; Glaab et al., 2003). In addition, 
AHR is observed after in vitro NGF pre-treatment of guinea pig (de Vries et al., 2001), ferret 
(Wu & Dey, 2006) or human bronchi (Frossard et al., 2005). AHR is reduced in vivo after 
administration of a pan-Trk receptor decoy in a mouse model of asthma (Nassenstein et al., 
2006), or of the TrkA kinase inhibitor K252a in a guinea pig model of asthma (de Vries et al., 
2006), thus showing involvement of the TrkA receptor in NGF-induced AHR. 
5.2.2 Pulmonary hypertension 
In the systemic circulation, neurotrophins play a role in the control of vascular tone 
(Caporali & Emanueli, 2009), and a role for NGF has been suggested in systemic arterial 
hypertension (Sherer et al., 1998). Neurotrophins and their receptors are expressed on 
pulmonary arteries (Ricci et al., 2000a), and their expression is increased in the lung of 
spontaneously hypertensive rats (Ricci et al., 2004a). A role for neurotrophins in the control 
of the pulmonary arterial tone was recently proposed, through activation of the p75NTR 
receptor (Xu et al., 2008). BDNF and NT-3 induce relaxation of porcine pulmonary arterial 
rings, through activation of the endothelial nitric oxide synthase (Meuchel et al., 2011). 
Suppression of TrkB or TrkC expression via siRNA as well as functional blockade of p75NTR 
suggest a role of both Trk and p75NTR receptors in these effects (Meuchel et al., 2011). In our 
ongoing studies in rat or human pulmonary arteries, we show that NGF does not induce rat 
or human pulmonary arterial contraction or relaxation by itself. However, NGF pre-
treatment induces pulmonary arterial hyperresponsiveness to contractile agents such as 
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phenylephrine or prostaglandin F2 (Freund-Michel et al., 2010). Our preliminary data 
suggest that this effect may be due in part to activation of the TrkA receptors and increased 
intracellular calcium concentrations. These mechanisms are in accordance with the 
preliminary data recently described for BDNF and NT-3 by Prakash and co-workers 
(Prakash et al., 2010). Altogether, these results therefore suggest that neurotrophins, through 
activation of both Trk and p75NTR receptors, participate in both endothelial dysfunction and 
smooth muscle hyperreactivity observed in pulmonary hypertension. 
5.3 NGF, TrkA and tissue remodelling 
5.3.1 Asthma 
Airway remodelling in asthma is characterized by a sub-epithelial fibrosis with an increased 
proliferation of fibroblasts and a thickening of the basement membrane, 
hypervascularisation, sensory hyperinnervation, oedema, and hypertrophy and hyperplasia 
of the smooth muscle layer (Bara et al., 2010). In vitro, NGF activates the TrkA receptor to 
induce migration of pulmonary fibroblasts (Kohyama et al., 2002) and regulation of 
extracellular matrix synthesis (Khan et al., 2002; Takahashi et al., 2000). These results 
therefore suggest a role for the TrkA receptor in NGF-induced airway sub-epithelial fibrosis 
in vivo (Hoyle et al., 1998). We also reported that NGF induces proliferation of the airway 
smooth muscle through activation of the TrkA receptor and may therefore participate to 
hyperplasia of the smooth muscle layer in vivo (Freund-Michel et al., 2006). Activation of the 
TrkA receptor by NGF also stimulates vascular cells from other origins than the lung to 
induce migration and proliferation of endothelial cells (Cantarella et al., 2002; Dolle et al., 
2005; Lecht et al.,2010 ; Rahbek et al., 2005) as well as migration of vascular smooth muscle 
cells (Donovan et al., 1995; Kraemer et al., 1999). In addition, NGF stimulates angiogenesis in 
vivo through activation of the TrkA receptor (Cantarella et al., 2002; Caporali & Emanueli, 
2009). NGF is also able to stimulate synthesis of angiogenic factors such as vascular 
endothelial growth factor (VEGF) from various cells through activation of its TrkA receptor 
(Nakamura et al., 2011). Altogether, these results suggest that activation of the TrkA 
receptor participates to NGF-mediated hypervascularisation in the lung (Hoyle et al., 1998). 
5.3.2 Pulmonary hypertension 
Vascular remodelling in pulmonary hypertension is characterized by increased 
proliferation, decreased apoptosis and increased migration of pulmonary vascular cells 
(Humbert et al., 2004). NGF-induced activation of the TrkA receptor contributes to 
migration and proliferation of vascular cells from other origins than the lung and stimulates 
angiogenesis (see paragraph above). Our recent results show that NGF induces proliferation 
and migration of pulmonary vascular cells through activation of the TrkA receptor (see 
paragraph 4.2 and Fig. 3) (Freund-Michel et al., 2010). Therefore, our findings support a role 
for NGF and its TrkA receptor in pulmonary vascular remodelling in this disease. 
6. Therapeutic perspectives and conclusion 
In regard of the different results presented in this review, NGF seems to play a major role in 
altered inflammatory, remodelling and reactivity processes occurring in pulmonary 
inflammatory diseases such as asthma or pulmonary hypertension. The TrkA receptor is 
involved in many NGF effects in the lung and targeting NGF or its TrkA receptor may be a 
new therapeutic perspective in these diseases.  
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Outside the lung, blockade of NGF is of therapeutic interest in other areas, in particular in 
pain therapy (Hefti et al., 2006). Humanized monoclonal antibodies against NGF or against 
TrkA, as well as small molecules acting as TrkA antagonists or as TrkA kinase inhibitors 
have been developed and are currently under investigation (Ma et al., 2010; Martin et al., 
2011; McNamee et al., 2010; Ueda et al., 2010; Watson et al., 2008) (Fig. 5). In particular, 
tanezumab, a recombinant humanized monoclonal antibody against NGF, has been recently 
tested in clinical trials in osteoarthritic pain and chronic lower back pain and demonstrated 
good efficacy (Cattaneo, 2010; Lane et al., 2010).  Such strategies may be applied in the near 
future to target NGF or its receptors in pulmonary inflammatory diseases such as asthma or 
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Fig. 5. Potential therapeutic strategies to target the TrkA receptor in pulmonary 
inflammatory diseases. 
To trap circulating NGF and prevent its binding to the TrkA receptor, tools such as anti-
NGF blocking antibodies or soluble chimeric TrkA receptors have been developed. Other 
tools have been developed to target the TrkA receptor itself, either by blocking NGF binding 
to its extracellular part with antagonists or anti-TrkA antibodies, or by blocking TrkA kinase 
activity with kinase inhibitors. 
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1. Introduction  
Many scientific articles describe the pathogenesis of diseases that afflict the modern man 
(cancer, diabetes, obesity, degenerative diseases, etc.) as a slow common inflammatory 
process that is the basis of all these diseases. Therefore, we commonly speak of chronic 
inflammatory diseases (Allavena et al., 2008). The basis of this statement are the numerous 
experimental observations which show that these diseases are driven, from the earliest 
moments, by exchange between cells of tissues and organs of molecules that operate as 
messengers. These molecules, carrying biological messages of great importance, inform and 
lead a complex system of different cell types on what happens and towards which 
physiological and metabolic changes they are being carried. The chemical nature of these 
signaling molecules is diverse, but a group of them, the cytokines, is among the most 
important and studied inter-cellular messengers (Germano et al., 2008). We know the 
biological meaning of the signal of many of them, thus we can generally divide these 
molecules into two major classes: pro-inflammatory cytokines and anti-inflammatory 
cytokines. They are small proteins, quite numerous, more than about 100, expressed in very 
low amounts (pico and nano molar) and often short-lived, to cover specific information 
needs (Macarthur et al., 2004). 
The cells recognize these signals through appropriate receptors placed on their external 
membranes. However their study had some limitations due to the fact that (i) only those 
more abundant were studied, even if with very sensitive assays based on use of antibodies 
and fluorescence (ELISA); (ii) the receptors show pleiotropy, i.e. they have good affinity for 
various cytokines and hence the message can be brought by different cytokines; (iii) the 
biological significance of the message is known only for some of them, for example, it is not 
known which is the biological meaning carried out by the under-represented cytokines (the 
less concentrated ones at phenotypic level) and if the different messages are recognized by 
the receptor as only redundant or with diverse biological content (Colvin et al., 2004; 
Costantini et al., 2009; Trotta et al., 2009).  
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Recently, specific protein chips of considerable and improved sensitivity are being 
developed. They allow the simultaneous determination of different cytokines based on a 
fluorescence/laser/antibodies technology which uses microparticle beads (multiplex 
technology) that allows the analysis of tiny samples (few dozens of microliter) of serum, 
plasma, or cell cultures supernatant. Each bead set is coated with capture antibody specific 
for one analyte. The result is the most accurate, sensitive, and reproducible cytokine assay 
available. An important point of this technology is the ability to appreciate quantitatively 
also the presence of the under-represented cytokines (Capone et al., 2010; Costantini et al., 
2010a). The pattern of these cytokines, being part of the new global or holistic logic, which is 
used today in the “omics” approach to the study of biological phenomena, can be indicated 
as “cytokinome” (Costantini et al., 2010b). 
The fact is that the cytokines form an informative network, for some ways very similar to 
the Internet, that capillary connects, as knots to the network, cellular systems also different. 
The study of this network is important for understanding the evolution of the pathogenesis 
of many chronic inflammatory diseases. However, there are many questions that must still 
find the answer. In the case of chronic inflammatory diseases, which development in the 
time the whole pattern of cytokines shows? Their evolution in time begins in the same way 
and is common for all the diseases or is pathology correlated and addressed by different 
types or classes of cytokines? Which one is the cytokinome development during the disease? 
Answers to these and other questions are essential not only to be able to describe the 
cytokinome dynamics during the progression of chronic inflammatory diseases but, above 
all, to try to predict in large advance the prognosis of the disease. If this will be possible, we 
will be able to intervene with great advance in the early stages of the disease with much 
more chance of healing or of extending the duration and the expectations of life. 
Therefore, the review will focus on:  
 Role of the cytokines in chronic inflammatory diseases and cancers  
 Challenge and significance of the cytokinome profile 
 Hepatocarcinoma as an example of chronic inflammatory disease 
 Metabolic pathway analysis of significant genes in hepatoma cells 
 Evaluation of cytokines in HCC patients with HCV-related cirrhosis 
 Evaluation of cytokines in patients with chronic HCV or with HCV-related cirrhosis 
 The need of cytokinome data mining system for a predictive medicine for chronic 
inflammatory diseases  
 The need for structural studies of cytokine/receptor complex: the example of CXCL9, 
CXCL10 and CXCL11 chemokines and their membrane receptor CXCR3 
2. Role of the cytokines in chronic inflammatory diseases and cancers 
Inflammation is a physiologic process in response to acute tissue damage resulting from 
physical injury, ischemic injury, infection, exposure to toxins, chemical irritation, and/or 
wounding or other types of trauma (Lu et al., 2006; Philip et al., 2004); it is a protective 
attempt by the organism to remove the injurious stimuli as well as initiate the healing 
process for the tissue. At the very early stage of inflammation, the phagocytic cells are 
mainly involved: neutrophils are the first cells to migrate to the inflammatory sites under 
the regulation of molecules produced by rapidly responding macrophages and mast cells 
prestationed in tissues (Coussens & Werb, 2002). As the inflammation progresses, various 
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types of leukocytes, lymphocytes, and other inflammatory cells are activated and attracted 
to the inflamed site by a signaling network involving a great number of growth factors, 
cytokines, and chemokines (Coussens & Werb, 2002). All cells recruited to the inflammatory 
site contribute to tissue breakdown and are beneficial by strengthening and maintaining the 
defense against infection (Coussens & Werb, 2002). The resolution of inflammation also 
requires a rapid programmed clearance of inflammatory cells: neighboring macrophages, 
dendritic cells, and backup phagocytes do this job by inducing apoptosis and conducting 
phagocytosis (Savill et al., 2002). 
However, inflammation may become chronic either because an inflammatory stimulus 
persists or because of dysregulation in the control mechanisms that normally turn the 
process off. Recently, it has been suggested that inflammation associated with cancer is 
similar to that seen with chronic inflammation, which includes the production of growth 
and angiogenic factors that stimulate tissue repair, factors that can also promote cancer-cell 
survival, implantation, and growth (Philip et al., 2004; Macarthur et al., 2004; Balkwill and 
Mantovani, 2001). Interestingly, inflammation functions at all three stages of tumor 
development: initiation, progression and metastasis.   
Since many cancers arise from sites of infection, chronic irritation, and inflammation, it is 
now clear that the tumor microenvironment, which is largely orchestrated by 
inflammatory cells and cytokines (Fig. 1), is an indispensable participant in the neoplastic 
process altering not only the metabolic needs of the tissue, but also fostering DNA and 
protein damage, proliferation, survival, mutagenesis, migration and metastasis of 
malignant cells (Allavena et al., 2008). Indeed all tumors in the presence of stromal and 
infiltrating inflammatory cells are facilitated and helped to maintain these metastatic 
processes. Leukocytes, lymphocytes and other inflammatory cells are activated in this 
process and attracted to the inflamed site. Inflammation contributes to initiation by 
inducing the release of a variety of pro-inflammatory cytokines and chemokines and 
inflammatory enzymes as cyclo-oxygenases that alert the vasculature to release 
inflammatory cells and factors into the tissue milieu, thereby causing oxidative damage, 
DNA mutations, and other changes in the microenvironment, making it more conducive 
to cell transformation, increased survival and proliferation (Germano et al., 2008). We 
must not forget that many cytokines and chemokines are inducible by hypoxia which is a 
major physiological difference (Mancino et al., 2008). An important aspect of the tumor 
microenvironment is the cytokine mediated communication between the tumor and cells. 
Cytokines and chemokines have many activities that permit cell–cell communication 
locally at the tissue, with the outcome determined by cytokine concentration milieu and 
cell type (Germano et al., 2008). Current thinking is that activated immune cells provide 
both anti- and protumorigenic signals, thus representing targets to be harnessed or 
attacked for therapeutic advantage depending upon environmental and/or cellular 
context. Because the control of cytokine production is highly complex and multifactorial, 
the effects of cytokines are mediated through multiple regulatory networks. The intricate 
complexity of both cytokine networks clearly conceals the role that a single cytokine may 
play in the pathogenesis of the disease. It is therefore informative to investigate the 
immunopathogenesis of a disease process by analyzing multiple cytokines. In this way it 
is possible to provide a better understanding of the role of cellular, humoral and 
chemotactic immunity at a critical time in some cancer diseases and also in the treatment 
course of a correlated infection (Costantini et al., 2009). 
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Fig. 1. Relationship between inflammation, cytokines and cancer 
3. Challenge and significance of the cytokinome profile 
In order to understand the whole universe of human cytokines, the socalled cytokinome, 
according the “omics” system of definition, it needs to evaluate these proteins and analyse 
their complex network of interactions by which they regulate their own synthesis or that of 
their receptors, and antagonize or synergize with each other in many and often redundant 
ways (Costantini et al., 2010b). 
A major effort is the achievement of an efficient database that can collect together correct 
ontologies, algorithms and tools of analyses, structural and “omics” data of cytokines and 
their receptors, metabolic pathways, and the whole interactome. Another intriguing 
problem related to the cytokine family and their receptors is the pleiotropy existing in the 
cytokine system, where one cytokine is able to activate various receptors and many different 
cytokines activate the same receptor. When the frame of the whole cytokine network will be 
known, we will have the possibility to create best and more efficient drugs against the 
cancer, most probably able to interact with the receptors rather than directly with the 
cytokine molecules because of their pleiotropic effect. Another element of complexity in the 
cytokine network is introduced also by the fact that some genes encoding cytokines can give 
rise to variant forms of cytokines (isoforms) by means of alternative splicing, yielding 
molecules with slight structural differences but biologically significant changes of activities. 
This explains why it is always useful to analyze the gene expression profile correlated to the 
cytokines. In fact, previous studies have identified important mutations in some cancers, but 
they were primarily focused on a limited set of genes and, thus, provided a constrained 
view of the mutational spectrum. 
However, a correct and comprehensive understanding of cytokine functions can be obtained 
from simultaneous and coherent measurements of the serum concentrations of cytokines. 
This point raises the inherent difficulty of a simultaneous measurement of the cytokine 
concentrations to obtain correct internal ratios among the various molecules present in the 
same biological fluid due to the often large difference in concentrations spanning several 
magnitude orders. At present, it is possible to effectively characterize the serum levels of 
cytokines using a broad-spectrum bead based multiplex immunoassay. 
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In this complex interactions network, Systems Biology and/or Biologically Integrated 
Approaches are powerful tools to analyze as a whole, the enormous amount of data coming 
from the so-called "omics" disciplines (genomics, transcriptomics, proteomics) by 
computational methods and algorithms, in order to create an information body that allows 
us to have a comprehensive and integrated vision of the biological phenomenon under 
investigation. In fact, until the last century, the approach of biological science was to break 
down the object of study in its elementary parts and to study all the singular units in order 
to explain the life processes. This was a typical analytical and reductionist procedure, which 
allowed the understanding of almost all properties of molecular parts of living organisms, 
such as genes, proteins, metabolites, and was focused on the study of each single component 
of the system under consideration but was not able to predict the behavior of the systems as 
a whole. A system can be defined as a number of interacting elements existing within a 
boundary that is surrounded by an environment. Therefore, a complex system is able to 
create new properties from the interactions between its components, and also to interact and 
to respond with the external inputs. When the interactions between the parties are 
determined by the dynamical processes inducing the emerging properties like adaptability, 
self-organization and the ability to respond under disturbance, the system becomes 
complex. In this way these non linear interactions allow a number of possible several states 
and new emergent behaviors are not predictable from the simple sum of the component 
parts. These principles were applied to study the living organisms, the stock markets, the 
ecosystems and the flock of birds. In biology it’s necessary to study the living organism as a 
whole, and the laws of regarding the organizational forces of systems, which yet are not 
well known, but are essential to solve and to understand the collective phenomena and the 
framework for the functionality of the systems (Costantini et al., 2008). 
Therefore, all the data related to the cytokine evaluations can be analyzed and modeled 
computationally by using graphs or networks connecting the various data groups (related to 
gene and protein expression obtained by microarrays and by multiplex biometric ELISA-
based immunoassay) in terms of dynamic probabilistic maps of metabolic and/or 
physiological activities and/or pathogenetic pathways. Hence, the definition and evaluation 
of a human cytokinome is an important future tool to analyze the interaction network of 
cytokines both in healthy individuals and in patients affected from a cancer. Using these 
computational models it will be easier and immediate to understand and investigate how 
the regression of a chronic inflammation process, by acting on the cellular populations of 
cytokines, can block the progression of the cancer and how this knowledge can be an useful 
prognostic and diagnostic tool for clinicians. 
4. Hepatocellular carcinoma as an example of chronic inflammatory disease 
Hepatocellular carcinoma (HCC) accounts for >5% of all human cancers and for 80% - 90% 
of primary liver cancer. It is a major health problem worldwide being  the fifth most 
common malignancy in men and the eighth in women; the third most common cause of 
cancer-related death in the world. Moreover early diagnosis is uncommom and medical 
treatments are inadeguate (Altekruse et al., 2009). 
Yearly 550,000 people worldwide die for HCC, with a 2:1 ratio for men versus women. Its 
incidence is increasing dramatically, with marked variations among geographic areas (Jemal 
et al., 2007), racial and ethnic groups, environmental risk factors. The estimated annual 
number of HCC cases exceeds 700,000, with a mean annual incidence of 3-4% (Jemal et al., 
 
Inflammatory Diseases – A Modern Perspective 106 
 
 
Fig. 1. Relationship between inflammation, cytokines and cancer 
3. Challenge and significance of the cytokinome profile 
In order to understand the whole universe of human cytokines, the socalled cytokinome, 
according the “omics” system of definition, it needs to evaluate these proteins and analyse 
their complex network of interactions by which they regulate their own synthesis or that of 
their receptors, and antagonize or synergize with each other in many and often redundant 
ways (Costantini et al., 2010b). 
A major effort is the achievement of an efficient database that can collect together correct 
ontologies, algorithms and tools of analyses, structural and “omics” data of cytokines and 
their receptors, metabolic pathways, and the whole interactome. Another intriguing 
problem related to the cytokine family and their receptors is the pleiotropy existing in the 
cytokine system, where one cytokine is able to activate various receptors and many different 
cytokines activate the same receptor. When the frame of the whole cytokine network will be 
known, we will have the possibility to create best and more efficient drugs against the 
cancer, most probably able to interact with the receptors rather than directly with the 
cytokine molecules because of their pleiotropic effect. Another element of complexity in the 
cytokine network is introduced also by the fact that some genes encoding cytokines can give 
rise to variant forms of cytokines (isoforms) by means of alternative splicing, yielding 
molecules with slight structural differences but biologically significant changes of activities. 
This explains why it is always useful to analyze the gene expression profile correlated to the 
cytokines. In fact, previous studies have identified important mutations in some cancers, but 
they were primarily focused on a limited set of genes and, thus, provided a constrained 
view of the mutational spectrum. 
However, a correct and comprehensive understanding of cytokine functions can be obtained 
from simultaneous and coherent measurements of the serum concentrations of cytokines. 
This point raises the inherent difficulty of a simultaneous measurement of the cytokine 
concentrations to obtain correct internal ratios among the various molecules present in the 
same biological fluid due to the often large difference in concentrations spanning several 
magnitude orders. At present, it is possible to effectively characterize the serum levels of 
cytokines using a broad-spectrum bead based multiplex immunoassay. 
 
The Value of the Cytokinome Profile 107 
In this complex interactions network, Systems Biology and/or Biologically Integrated 
Approaches are powerful tools to analyze as a whole, the enormous amount of data coming 
from the so-called "omics" disciplines (genomics, transcriptomics, proteomics) by 
computational methods and algorithms, in order to create an information body that allows 
us to have a comprehensive and integrated vision of the biological phenomenon under 
investigation. In fact, until the last century, the approach of biological science was to break 
down the object of study in its elementary parts and to study all the singular units in order 
to explain the life processes. This was a typical analytical and reductionist procedure, which 
allowed the understanding of almost all properties of molecular parts of living organisms, 
such as genes, proteins, metabolites, and was focused on the study of each single component 
of the system under consideration but was not able to predict the behavior of the systems as 
a whole. A system can be defined as a number of interacting elements existing within a 
boundary that is surrounded by an environment. Therefore, a complex system is able to 
create new properties from the interactions between its components, and also to interact and 
to respond with the external inputs. When the interactions between the parties are 
determined by the dynamical processes inducing the emerging properties like adaptability, 
self-organization and the ability to respond under disturbance, the system becomes 
complex. In this way these non linear interactions allow a number of possible several states 
and new emergent behaviors are not predictable from the simple sum of the component 
parts. These principles were applied to study the living organisms, the stock markets, the 
ecosystems and the flock of birds. In biology it’s necessary to study the living organism as a 
whole, and the laws of regarding the organizational forces of systems, which yet are not 
well known, but are essential to solve and to understand the collective phenomena and the 
framework for the functionality of the systems (Costantini et al., 2008). 
Therefore, all the data related to the cytokine evaluations can be analyzed and modeled 
computationally by using graphs or networks connecting the various data groups (related to 
gene and protein expression obtained by microarrays and by multiplex biometric ELISA-
based immunoassay) in terms of dynamic probabilistic maps of metabolic and/or 
physiological activities and/or pathogenetic pathways. Hence, the definition and evaluation 
of a human cytokinome is an important future tool to analyze the interaction network of 
cytokines both in healthy individuals and in patients affected from a cancer. Using these 
computational models it will be easier and immediate to understand and investigate how 
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common malignancy in men and the eighth in women; the third most common cause of 
cancer-related death in the world. Moreover early diagnosis is uncommom and medical 
treatments are inadeguate (Altekruse et al., 2009). 
Yearly 550,000 people worldwide die for HCC, with a 2:1 ratio for men versus women. Its 
incidence is increasing dramatically, with marked variations among geographic areas (Jemal 
et al., 2007), racial and ethnic groups, environmental risk factors. The estimated annual 
number of HCC cases exceeds 700,000, with a mean annual incidence of 3-4% (Jemal et al., 
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2007). Most HCC cases (>80%) occur in either sub-Saharan Africa or in Eastern Asia (China 
alone accounts for more than 50% of the world’s cases) (Jemal et al., 2007). In the United 
States (US) HCC incidence is lower than other countries (0.3/100000) even if there has been 
a significant and alarming increase in the incidence of HCC in the US, from 1.3 in the late 
70s’ to 3 in the late 90s’, due to HCV infection. In 2008, 21370 new cases of HCC and 
intrahepatic bile duct cancer were estimated with 18410 deaths (Jemal et al., 2007). In 
Europe, Oceania and America, chronic hepatitis C and alcoholic cirrhosis are the main risk 
factors for HCC. The main risk factor for HCC development in patients with hepatitis C is 
the presence of cirrhosis. Among patients with hepatitis C and cirrhosis, the annual 
incidence rate of HCC ranges between 1-8%, being higher in Japan (4-8%) intermediate in 
Italy (2-4%) and lower in USA (1.4%) (Fassio, 2010). Analysis of mortality from HCC in 
Europe confirmed large variability, with high rates in France (6.79/100000) and Italy 
(6.72/100000) due to hepatitis C virus (HCV) during the 1960s and 1970s (Bosetti et al., 
2008). Southern Italy has the highest rates of HCC in Europe (Fusco et al., 2008).  
HCC is unique among cancers occurring mostly in patients with a known risk factor: ninety 
percent of HCCs develop in the context of chronic liver inflammation and cirrhosis 
(Altekruse et al., 2009). Hepatitis B (HBV) and C (HCV) viruses are the major cause of liver 
disease worldwide. Fortunately, the hepatitis B virus vaccine has resulted in a substantial 
decline in the number of new cases of acute hepatitis B among children, adolescents, and 
adults in western countries since the mid-1980s. This success is not duplicable for HCV 
where active or passive vaccination is not available yet. Therefore, the present and next 
future HCC history will be mainly related to HCV infection. The incidence of HCV infection 
is hard to quantify since it is often asymptomatic. The World Health Organization estimates 
that 3% of the world’s population - more than 170 million people - are chronically infected 
(3-4 million new infections every year). Therefore, a tremendous number of people are 
currently at elevated risk for HCC and its early diagnosis (when surgical intervention is 
possible) may significantly affect the patients prognosis (Ryder, 2003). 
However it is possible also a direct carcinogenesis by hepatitis viruses, without a cirrhotic 
step (Nash et al., 2010). In particular, it was reported that patients without cirrhosis were 
younger, survived longer than patients with cirrhosis (P < 0.0001) and had a better 5-year 
survival experience (Chiesa et al., 2000).  
In contrast to HBV, HCV does not integrate into the host genome and does not contain a 
reverse transcriptase. In particular, in the infected subjects both viruses trigger an immune-
mediated inflammatory response (hepatitis) that either clears the infection or slowly 
destroys the liver (Bowen & Walker, 2005).  
Effective HCV immunity is limited by the high variability of virion genome; HCV virions 
turn over rapidly (with a half-life of about 3 h), and up to about 1012 complete viruses are 
produced per day in an infected person (Ueno et al., 2009). About 80% of newly infected 
patients develop chronic infection; an estimated 10% to 20% will develop cirrhosis and 1-5% 
proceeds to end-stage liver cancer over a period of 20 to 30 years (Fig. 2). In the case of HCV, 
HCC is invariably observed as a complication of cirrhosis, whereas in the case of HBV HCC 
is often found in non-cirrhotic liver. Therefore, the hepatic fibrosis dramatically increase the 
incidence of HCC (Castello et al., 2010a). 
Many studies were conducted in the last years in regard to anti-HCV immune response. In 
fact, much attention has recently focused on regulatory T cells (Tregs) being able to secrete 
inhibitory cytokines such as IL-10 or TGF-, even if their contribution is yet unclear (Castello 
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et al., 2010b). Increased Treg cells were found in peripheral blood of HCV-infected patients 
(Boettler et al., 2005) as well as in the tumor microenvironment of HCC patients (Ormandi et 
al., 2005). The frequency of naturally arising CD4+CD25high+ Tregs in the periphery of HCV-
infected patients was reported to be higher than that in patients who resolved the infection 
or uninfected controls (Cabrera et al., 2004). TH1 cytokines are generally up-regulated in 
patients with HCC, resulting in higher levels of pro-inflammatory cytokines, as IL-1, IL-15, 
IL-18, TNF-, TNF-Rs, TNF-RI, TNF-RII, and IL-6 in comparison with healthy 
individuals (Huang et al., 1999). However, the intra/peri-tumoral cytokines levels are often 
different from the serum levels (Budhu & Wang, 2006). Higher serum IL-6 level was an 
independent risk factor for HCC development in female but not male chronic hepatitis C 
patients (Nakagawa et al., 2009). IL-10 was highly expressed in HCC tumors and serum, 
correlating with disease progression (Budhu & Wang, 2006). Budhu and Wang reviewed the 
association between cytokine abnormalities and HCC patients and found that a dominant 
TH2-like cytokine profile (IL-4, IL-8, IL-10, and IL-5) and a decrease in the TH1-like 
cytokines (IL-1, IL-1, IL-2, IL-12p35, IL-12p40, IL-15, TNF-, and IFN- was associated 
with the metastatic phenotype of disease (Budhu & Wang, 2006).  Thus, it has been 
hypothesized that TH1 cytokines are involved in tumor development, whereas TH2 
cytokines in tumor progression. Recently the cytokine concentrations have been evaluated 
in patients with HCC patients with HCV-related cirrhosis (Capone et al., 2010). 
 
 
Fig. 2. Evolution from HCV infection to HCC. 
5. Metabolic pathway analysis of significant genes in hepatoma cells 
The cytokinome study is an important step to our understanding of chronic inflammatory 
diseases because a global and dynamic knowledge of cellular signaling, at moment only 
static and mechanistic, will improve our ability to adequately read and understand the 
 
Inflammatory Diseases – A Modern Perspective 108 
2007). Most HCC cases (>80%) occur in either sub-Saharan Africa or in Eastern Asia (China 
alone accounts for more than 50% of the world’s cases) (Jemal et al., 2007). In the United 
States (US) HCC incidence is lower than other countries (0.3/100000) even if there has been 
a significant and alarming increase in the incidence of HCC in the US, from 1.3 in the late 
70s’ to 3 in the late 90s’, due to HCV infection. In 2008, 21370 new cases of HCC and 
intrahepatic bile duct cancer were estimated with 18410 deaths (Jemal et al., 2007). In 
Europe, Oceania and America, chronic hepatitis C and alcoholic cirrhosis are the main risk 
factors for HCC. The main risk factor for HCC development in patients with hepatitis C is 
the presence of cirrhosis. Among patients with hepatitis C and cirrhosis, the annual 
incidence rate of HCC ranges between 1-8%, being higher in Japan (4-8%) intermediate in 
Italy (2-4%) and lower in USA (1.4%) (Fassio, 2010). Analysis of mortality from HCC in 
Europe confirmed large variability, with high rates in France (6.79/100000) and Italy 
(6.72/100000) due to hepatitis C virus (HCV) during the 1960s and 1970s (Bosetti et al., 
2008). Southern Italy has the highest rates of HCC in Europe (Fusco et al., 2008).  
HCC is unique among cancers occurring mostly in patients with a known risk factor: ninety 
percent of HCCs develop in the context of chronic liver inflammation and cirrhosis 
(Altekruse et al., 2009). Hepatitis B (HBV) and C (HCV) viruses are the major cause of liver 
disease worldwide. Fortunately, the hepatitis B virus vaccine has resulted in a substantial 
decline in the number of new cases of acute hepatitis B among children, adolescents, and 
adults in western countries since the mid-1980s. This success is not duplicable for HCV 
where active or passive vaccination is not available yet. Therefore, the present and next 
future HCC history will be mainly related to HCV infection. The incidence of HCV infection 
is hard to quantify since it is often asymptomatic. The World Health Organization estimates 
that 3% of the world’s population - more than 170 million people - are chronically infected 
(3-4 million new infections every year). Therefore, a tremendous number of people are 
currently at elevated risk for HCC and its early diagnosis (when surgical intervention is 
possible) may significantly affect the patients prognosis (Ryder, 2003). 
However it is possible also a direct carcinogenesis by hepatitis viruses, without a cirrhotic 
step (Nash et al., 2010). In particular, it was reported that patients without cirrhosis were 
younger, survived longer than patients with cirrhosis (P < 0.0001) and had a better 5-year 
survival experience (Chiesa et al., 2000).  
In contrast to HBV, HCV does not integrate into the host genome and does not contain a 
reverse transcriptase. In particular, in the infected subjects both viruses trigger an immune-
mediated inflammatory response (hepatitis) that either clears the infection or slowly 
destroys the liver (Bowen & Walker, 2005).  
Effective HCV immunity is limited by the high variability of virion genome; HCV virions 
turn over rapidly (with a half-life of about 3 h), and up to about 1012 complete viruses are 
produced per day in an infected person (Ueno et al., 2009). About 80% of newly infected 
patients develop chronic infection; an estimated 10% to 20% will develop cirrhosis and 1-5% 
proceeds to end-stage liver cancer over a period of 20 to 30 years (Fig. 2). In the case of HCV, 
HCC is invariably observed as a complication of cirrhosis, whereas in the case of HBV HCC 
is often found in non-cirrhotic liver. Therefore, the hepatic fibrosis dramatically increase the 
incidence of HCC (Castello et al., 2010a). 
Many studies were conducted in the last years in regard to anti-HCV immune response. In 
fact, much attention has recently focused on regulatory T cells (Tregs) being able to secrete 
inhibitory cytokines such as IL-10 or TGF-, even if their contribution is yet unclear (Castello 
 
The Value of the Cytokinome Profile 109 
et al., 2010b). Increased Treg cells were found in peripheral blood of HCV-infected patients 
(Boettler et al., 2005) as well as in the tumor microenvironment of HCC patients (Ormandi et 
al., 2005). The frequency of naturally arising CD4+CD25high+ Tregs in the periphery of HCV-
infected patients was reported to be higher than that in patients who resolved the infection 
or uninfected controls (Cabrera et al., 2004). TH1 cytokines are generally up-regulated in 
patients with HCC, resulting in higher levels of pro-inflammatory cytokines, as IL-1, IL-15, 
IL-18, TNF-, TNF-Rs, TNF-RI, TNF-RII, and IL-6 in comparison with healthy 
individuals (Huang et al., 1999). However, the intra/peri-tumoral cytokines levels are often 
different from the serum levels (Budhu & Wang, 2006). Higher serum IL-6 level was an 
independent risk factor for HCC development in female but not male chronic hepatitis C 
patients (Nakagawa et al., 2009). IL-10 was highly expressed in HCC tumors and serum, 
correlating with disease progression (Budhu & Wang, 2006). Budhu and Wang reviewed the 
association between cytokine abnormalities and HCC patients and found that a dominant 
TH2-like cytokine profile (IL-4, IL-8, IL-10, and IL-5) and a decrease in the TH1-like 
cytokines (IL-1, IL-1, IL-2, IL-12p35, IL-12p40, IL-15, TNF-, and IFN- was associated 
with the metastatic phenotype of disease (Budhu & Wang, 2006).  Thus, it has been 
hypothesized that TH1 cytokines are involved in tumor development, whereas TH2 
cytokines in tumor progression. Recently the cytokine concentrations have been evaluated 
in patients with HCC patients with HCV-related cirrhosis (Capone et al., 2010). 
 
 
Fig. 2. Evolution from HCV infection to HCC. 
5. Metabolic pathway analysis of significant genes in hepatoma cells 
The cytokinome study is an important step to our understanding of chronic inflammatory 
diseases because a global and dynamic knowledge of cellular signaling, at moment only 
static and mechanistic, will improve our ability to adequately read and understand the 
 
Inflammatory Diseases – A Modern Perspective 110 
meaning in the early time of the information that cells exchange each other. The present 
technology supports this view from an experimental point of view by DNA and Protein 
microarrays. These techniques taken together can support a better knowledge of the 
relationships existing between genome behavior and related phenotypes (cytokines in this 
case) during the progression of a disease. More difficult is to correlate genomic and 
phenotypic levels by a logical analysis able to correlate the genes action with their products 
to extract useful biological information on the disease progression, such as changes in 
metabolic pathways or activation of new metabolic paths. In general, the knowledge of early 
metabolic changes during the first stages of an illness is an important moment to develop 
new more specific drugs by pharmacogenomics as well as to operate a metabolic repair by 
nutrigenomics. Probably this holistic view of the medicine is perhaps more expensive for the 
community but it is necessary to efficiently fight the numerous diseases of our time 
unfortunately founded on chronic inflammation.   
The global gene expression has been evaluated in HepG2 cells in comparison to normal 
human hepatocytes using Illumina microarray. In particular, cRNAs were hybridized to the 
HumanWG-6 Bead-Chip array which allows to assess the presence of more than 48,000 
transcripts (Whole Genome). Our metabolic pathway analysis aims at discovering 
modifications in and/or activation of new metabolic pathways involved into a perturbation 
of the hepatoma cell homeostasis. We have used a cluster analysis or “clustering” that is the 
assignment of a set of data or observations into subsets (called clusters) so that observations 
in the same cluster are similar. This is a method of analysis used also in bioinformatics to 
evaluate high-throughput genotyping platforms to build groups of genes with related 
expression patterns (also known as coexpressed genes). The algorithms we have used are 
hierarchical algorithms that find successive clusters using previously established clusters 
and create a hierarchy of clusters which may be represented by a hierarchical clustering 
dendrogram. The method builds the hierarchy from the individual elements by 
progressively merging clusters. In particular, hierarchical cluster analysis of genes showed 
the differential expression of genes in HepG2 cells respect to human hepatocytes used as 
healthy controls. 2646 genes were significantly down-regulated in HepG2 cells respect to the 
hepatocytes whereas a further 3586 genes were significantly up-regulated. Moreover, 
information on the biological functions of the genes that were significantly regulated was 
obtained by a pathway analysis. Pathways related to these genes were extracted from KEGG 
(Kyoto Encyclopedia of Genes and Genomes) (Ogata et al 1999), Pathway Interaction 
Database, and network for CXCL12 in Hepatocellular carcinoma is derived from the 
HCCnet  (Hepatocellular carcinoma network database) (Bing et al, 2010), which contains 
around 37811 protein-protein interactions from 13 individual datasets having 894 HCC 
samples containing 30.5%, 44.7 % and 18.7% of HCV infected, HBV infected and unknown 
factors respectively. Indeed a network of transcription factors that are extracted from 
microarray data and interact with EGFR gene is constructed by Cytoscape.  
Amongst the significantly up-regulated and down-regulated genes several chemokines and 
some transcription factors (CCL20, CCR6, CX3CL1, Grb2, p53, VCAN, C-MYC, CXCL12, 
SDC4 and Cyclin D1) were found. CCR6, being the receptor for the chemokine CCL20, is 
expressed on inactivated memory T-cells, on some dendritic cells and also on Th17 cells. 
Some studies suggest the involvement of the CCL20/CCR6 system in the carcinogenesis and 
progression of human HCC (Rubie et al., 2006). CCR6 is implicated in the Chemokine 
signaling pathway and cytokine–cytokine receptor interaction as obtained from Kegg 
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(Kyoto encyclopedia of genes) (Ogata et al 1999). In particular, CCL20 interacts with VCAN 
gene (Fig. 3) which encodes for the Versican protein that plays a role in angiogenesis, 
inflammation. This protein prevents the growth of cancerous tumors and regulates the 
activity of several growth factors, which control a diverse range of processes important for 
cell growth. Moreover elevated levels of Versican have been reported in most malignancies, 
including brain tumors, melanomas, lymphomas and breast cancers, prostate, colon, lung, 
pancreas, endometrium, and ovary (Miranda et al., 2011; Kusumoto et al., 2010). CCR6 and 
CCL20 are known to interact with Versican in the HCC network. This protein was found to 
be upregulated in HCC patients correlated to Hepatitis B Virus and was indicated as a 
possible candidate for mediating tumor progression and proliferation in liver and more 
importantly visual impairment (Paraneoplastic syndrome) associated with HCC patients 
correlated to HBV. 
 
 
Fig. 3. VCAN Network where the genes are shown by circle and proteins by stars. Different 
colors: red, up-regulated one; light green, down-regulated one; blue, bidirection-regulated 
one; grey, not high confident HCC-related one; dark green, genes with selected function 
info; purple, genes with selected pathway info. 
The CXCR4/CXCL12 axis is up-regulated in HCC and participates in HCC cell proliferation. 
Upon interaction with SDC4 (Syndecan 4), being a heparan sulfate proteoglycans, these 
proteins function as key regulators of cell signaling via their interactions with multiple 
growth and angiogenic factors, and promote an aggressive tumor phenotype (Sanderson et 
al, 2010). CXCL12/SDC4  makes a complex with O Phospho L Tyrosine and upon complex 
formation it can be hypothesized that it provides stability to p53 protein avoiding cancerous 
sitations as shown in various cancer cell lines like cervical cancer and lung cancer Renal and 
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Lung cancer (Sanderson et al, 2010). CXCL12 is found to trans-activating Epidermal growth 
factor receptor (EGFR) (Porcile,C et al ,2005), that is considered as an important signaling 
hub where different proliferative and survival signals converge. It is highly evident that 
EGFR has most important roles to play for controlling signaling cascades from extracellular 
regions. In particular, the interaction network of EGFR with transcription factors can 
provide much needed insights to multi factor governing HCC. There were found numerous 
up- and down- regulated transcription factors interacting with EGFR from microarray data 
(Fig. 4) and they can produce actions in invasion and metastatis state of the cells and induce 




Fig. 4. Interactions of EGFR with de-regulated genes of our microarray data. The down-
expressed genes are reported in red, those up-regulated in green and in yellow those no 
expressed. 
Moreover, between the important factors that are governing HCC there is also CX3CL1 
(Fractalkine), being a chemokine with both chemoattractant and cell-adhesive functions. 
Under specific inflammatory conditions, it could regulate the attractions of CX3CR1 
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bearing cells to tumor site either providing antitumor responses or either pathogenic 
angiogenesis (Deleterious effects) (Turner et al, 2010). When CX3CL1 is expressed in the 
tumor, it appears to recruit cytotoxic T cells and NK cells to the tumor site and its 
expression level is found to correlate with the density of Tumor Infiltrating Lymphocytes 
(TILs) in some cancers (Ohta et al ,2005).  
In addition to these chemokines, Grb2 is also one of the most important upregulated 
proteins in HCC that was found to be functioning in number of pathways involved in 
cancer. In particular, Grb2 recruits SOS (exchange protein) for the activating RAS that 
operates as a molecular switch between MEK and ERK (MAPK) which in nucleus acts on 
numerous important transcriptions factors like STAT 3 and  the expression of STAT3 
regulates genes including BCL-x1, CYCLIN D1 and c-MYC which involve in cell apoptosis 
and cell cycle progression (Sun et al.,2008). In IL6 mediated signaling events, GRB2 interacts 
with some proteins like FOS and JUN, that are both down regulated in HCC and 
importantly transcriptional activity of JUN is attenuated and sometimes antagonized by 
JUNB. This activation takes place in chemically induced murine liver tumours and HCCs of 
humans, suggesting oncogenic function for this gene in liver tumors of mammals with 
HSP70 that exhibits regulatory functions of c-JUN, ERK and the JNK pathway, thus  
inhibiting cell apoptosis (Lee et al., 2005). Moreover, Grb2 plays a specific role in EGF-
stimulated EGFR internalization (e.g. receptor sorting, vesicle budding/pinching or vesicle 
transport (Yamazaki et al., 2002).  
From KEGG, other two pathways are found to be deregulated in HCC metastasis, i.e. P53 
and MAPK pathways. TP53 plays an important role on regulation of apoptosis and cell cycle 
arrest and external environment factors or agents are implicated in the development of HCC 
in correlation with P53, including nutrition, diabetes, oral infection, oral contraceptive, 
alcohol consumption and some trace elements such as Selenium (Irmak et al., 2003; Wei et 
al., 2001). A second pathway, which is deregulated in metastatis, is MAPK pathway that is 
considered to control the most of the activities related to HCC condition by activating 
around 90 transcription factors although tyrosine kinase inhibitor Sorafenib is used as 
potential inhibitor of MAPK pathway by inhibiting RAF in HCC and Renal carcinoma 
(Cabrera et al., 2011). 
6. Evaluation of cytokines in HCC patients with HCV-related cirrhosis 
The serum levels of 50 different cytokines, chemokines and growth factors were evaluated 
in patients affected by HCC with chronic HCV-related hepatitis and liver cirrhosis using 
multiplex biometric ELISA-based immunoassay (Capone et al., 2010). The HCC patients 
showed a different secretion profile of these proteins compared to healthy controls. Greater 
amounts of IL-1α, IL-3, IL-12p40, IL-6, IL-8, IL-10, CCL27, CXCL10, CXCL1, IFN-α2, M-CSF, 
GM-CSF, CXCL9, β-NGF, SCF, SCGF-β, CXCL12, TNF-β were secreted by the HCC patients. 
No correlation was observed between serum levels and patients age/gender or between 
patients with a solitary tumour and those with multiple tumours. In particular, the attention 
was focused only on the proinflammatory molecules (IL-1α, IL-6, IL-8, IL-12p40, GM-CSF, 
CCL27, CXCL1, CXCL9, CXCL10, CXCL12, β-NGF) that were found to be significantly 
increased in HCC patients compared to healthy controls. The significantly increased serum 
levels of IL-6 and IL-8 found in HCC patients agreed with data reported in other studies 
(Ataseven et al., 2006; Burger et al., 2006). In particular, IL-8 levels measured in HCC 
patients were found to be increased, and correlated significantly with large tumor size (> 5 
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GM-CSF, CXCL9, β-NGF, SCF, SCGF-β, CXCL12, TNF-β were secreted by the HCC patients. 
No correlation was observed between serum levels and patients age/gender or between 
patients with a solitary tumour and those with multiple tumours. In particular, the attention 
was focused only on the proinflammatory molecules (IL-1α, IL-6, IL-8, IL-12p40, GM-CSF, 
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levels of IL-6 and IL-8 found in HCC patients agreed with data reported in other studies 
(Ataseven et al., 2006; Burger et al., 2006). In particular, IL-8 levels measured in HCC 
patients were found to be increased, and correlated significantly with large tumor size (> 5 
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cm) suggesting that IL-8 may be involved in disease progression and might prove to be both 
a useful marker of tumor invasiveness and an independent prognostic factor for HCC 
patients (Burger et al., 2006, Capone et al., 2010).  
 
 
Fig. 5. Protein hierarchy assessed by a computational clustering analysis. More specifically, 
the length of branches indicates, in inverse proportion, the similarity of protein 
concentrations, and the scale of protein intensity is indicated by the different colors: over-
expressed cytokines, chemokines and growth factors in red, lower values in grey, and 
values equal to zero in black. 
Since IL-8 and IL-6 concentrations correlated significantly with large tumor size (p-value < 
0.05 and R > 0.83), this confirmed the clinical significance of IL-6 as a prognostic factor of 
cancer and, in particular, its association with the development of HCC (Łukaszewicz et al., 
2007; Wong et al., 2009; Nakagawa et al., 2009). Indeed, CXCL10 levels correlated both with 
any tumour size and with transaminase levels suggesting that it could be used as marker of 
liver inflammation status and cancer progression. CXCL12 is known to play a role both in 
pathogenesis by promoting tumor growth and malignancy, and in the HCC metastatic 
network by recruiting endothelial cell tumor progenitors (Liu et al., 2008; Burns et al., 2006; 
Kryczek et al., 2007). Recently, some papers have suggested that β-NGF was involved in 
cancer growth and metastasis and was detected in diseased liver tissues; in fact this protein 
has been suggested to be involved in chronic inflammation leading to cancer (Rasi et al., 
2007). The correlation evaluation between the concentrations of over-expressed pro-
inflammatory molecules measured in HCC patients showed that β-NGF correlated with IL-
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1α, IL-12p40, CCL27, CXCL1 and CXCL12. This was confirmed by the related computational 
clustering analysis which shows that the molecules cluster in two groups, as demonstrated 
by branches joining them. In particular, β-NGF was grouped with the proteins indicated 
above (Fig. 5). Therefore, it is possible to suggest that a panel composed of β-NGF and these 
five proteins may be useful for diagnostic/prognostic purposes. 
In conclusion, this approach showed that some pro-inflammatory molecules were 
significantly up-regulated in these patients, and highlighted the complexity of the 
cytokine network in this disease. Moreover, this suggests the need to monitor these 
proteins in order to define a profile that could characterize patients with HCC or to help 
identify useful markers. In fact, this could lead to better definition of the disease state, and 
to an increased understanding of the relationships between chronic inflammation and 
cancer (Capone et al., 2010). 
7. Evaluation of cytokines in patients with chronic HCV or with HCV-related 
cirrhosis 
The serum concentrations of a panel of 30 cytokines, chemokines and growth factors were 
evaluated in patients with chronic inflammation (HC) and liver cirrhosis (LC), and in 
healthy donors by multiplex biometric ELISA-based assays (Costantini et al., 2010a). The 
molecules that showed different serum levels in patients respect to healthy controls are 
reported in Table 1.  
 
  HC vs controls LC vs controls 
IL-1a 0.0196* 0.0077** 
IL-1b <0.0001*** <0.0001*** 
IL-2R 0.0355* 0.0053** 
IL-6 0.0032** 0.0024** 
IL-8 0.0004*** 0.0001*** 
CXCL1 0.0076** 0.0034** 
CXCL9 0.0004*** 0.0002*** 
CXCL10 0.0015** 0.0003*** 
CXCL12 0.0364* 0.0443* 
MIF 0.04* 0.0033** 
b-NGF 0.0008*** 0.0002*** 
HGF   0.0028** 
Table 1. P values obtained for all significant molecules in HC and LC patients respect to 
controls using the nonparametric Mann-Whitney U test. 
Greater amounts of IL-1α, IL-1, IL-2R, IL-6, IL-8, CXCL1, CXCL9, CXCL10, CXCL12, MIF, 
and -NGF were secreted by both HC and LC patients.  
In particular, in the chronic inflammation and liver cirrhosis patients the same proteins were 
increased and the only difference was related to HGF being resulted significant and up-
regulated only in the patients with liver cirrhosis and not in those with chronic 
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1α, IL-12p40, CCL27, CXCL1 and CXCL12. This was confirmed by the related computational 
clustering analysis which shows that the molecules cluster in two groups, as demonstrated 
by branches joining them. In particular, β-NGF was grouped with the proteins indicated 
above (Fig. 5). Therefore, it is possible to suggest that a panel composed of β-NGF and these 
five proteins may be useful for diagnostic/prognostic purposes. 
In conclusion, this approach showed that some pro-inflammatory molecules were 
significantly up-regulated in these patients, and highlighted the complexity of the 
cytokine network in this disease. Moreover, this suggests the need to monitor these 
proteins in order to define a profile that could characterize patients with HCC or to help 
identify useful markers. In fact, this could lead to better definition of the disease state, and 
to an increased understanding of the relationships between chronic inflammation and 
cancer (Capone et al., 2010). 
7. Evaluation of cytokines in patients with chronic HCV or with HCV-related 
cirrhosis 
The serum concentrations of a panel of 30 cytokines, chemokines and growth factors were 
evaluated in patients with chronic inflammation (HC) and liver cirrhosis (LC), and in 
healthy donors by multiplex biometric ELISA-based assays (Costantini et al., 2010a). The 
molecules that showed different serum levels in patients respect to healthy controls are 
reported in Table 1.  
 
  HC vs controls LC vs controls 
IL-1a 0.0196* 0.0077** 
IL-1b <0.0001*** <0.0001*** 
IL-2R 0.0355* 0.0053** 
IL-6 0.0032** 0.0024** 
IL-8 0.0004*** 0.0001*** 
CXCL1 0.0076** 0.0034** 
CXCL9 0.0004*** 0.0002*** 
CXCL10 0.0015** 0.0003*** 
CXCL12 0.0364* 0.0443* 
MIF 0.04* 0.0033** 
b-NGF 0.0008*** 0.0002*** 
HGF   0.0028** 
Table 1. P values obtained for all significant molecules in HC and LC patients respect to 
controls using the nonparametric Mann-Whitney U test. 
Greater amounts of IL-1α, IL-1, IL-2R, IL-6, IL-8, CXCL1, CXCL9, CXCL10, CXCL12, MIF, 
and -NGF were secreted by both HC and LC patients.  
In particular, in the chronic inflammation and liver cirrhosis patients the same proteins were 
increased and the only difference was related to HGF being resulted significant and up-
regulated only in the patients with liver cirrhosis and not in those with chronic 
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inflammation. In particular, HGF is a multifunctional growth factor that regulates growth 
and cell motility, exerts mitogenic effects on hepatocytes and epithelial cells and plays 
diverse roles in organ development, tissue regeneration, and tumor progression (Gentile et 
al., 2008). Moreover, it is implicated with IL-6, IL-8 and IL-1 in the hepatic stellate cell 
activation pathway.  
However, numerous reports have examined the relationship between HGF and either the 
facilitation or suppression of HCC occurrence and have suggested that this growth factor 
could be used as index of cellular growth and of HCC development in liver cirrhosis 
patients (Yagamamim et al., 2002). In fact, it is interesting that the amount of this 
molecule was significantly different in liver cirrhosis patients in respect to both healthy 
controls and chronic inflammation patients and that its concentration in HCC patients 
was higher than in liver cirrhosis patients. This means that HGF increased in the 
progression of chronic inflammation leading to liver cirrhosis and cancer and can be 
used for predicting the occurrence of HCC in chronic HCV-related liver diseases 
(Costantini et al., 2010a). 
7.1 Chronic inflammation versus liver cirrhosis patients 
Since IL-1α, IL-1, IL-2R, IL-6, IL-8, CXCL1, CXCL9, CXCL10, CXCL12, MIF, and -NGF 
were increased in both HC and LC patients in respect to healthy control subjects, their 
mean concentrations were compared by t-test. Fig. 6 shows that the concentrations of all 
the proteins and, in particular, IL-8, CXCL9 and  -NGF were higher (with p<0.05) in 
patients with liver cirrhosis than in those with chronic inflammation. Afterwards, 
comparing the serum levels of all cytokines, chemokines and growth factors in HC and 
LC patients respect to those in HCC patients tested in our recent paper (Capone et 
al.,2010) is resulted that the mean concentrations of all molecules resulted higher in HCC 
patients than in those with liver cirrhosis. This indicates that the expression of these pro-
inflammatory molecules tends to increase in the chronic inflammation progression 
leading to liver cirrhosis and HCC and, thus, their evaluation could be used for 
prognostic studies. The serum levels of statistically significant cytokines, chemokines and 
growth factors in the HC and LC patients were correlated with clinical data by using the 
Pearson correlation coefficient. In chronic inflammation patients IL-1, IL-2R, MIF and -
NGF showed a significant correlation with a positive correlation coefficient between them 
and with the transaminase values, that were higher in these patients than in healthy 
controls. Therefore these proteins can be considered as index of immune activation. In 
particular, these results agreed with literature data reporting that IL-1 and IL-2R 
participate in the progression from liver injury to fibrosis (Zekri et al., 2010) and that β-
NGF is involved in liver cancer growth and metastasis and can be used as an index of 
chronic infection leading to LC and HCC (Gieling et al., 2009). Indeed, this work 
suggested for the first time a role of MIF in HCV-related chronic inflammation patients 
because an increased serum MIF was reported only in HBV patients (Kimura et al., 2006). 
Moreover, CXCL1, CXCL9, CXCL10 and HFG in liver cirrhosis patients showed a 
significant correlation and, in details, a positive correlation coefficient between them and 
a negative correlation coefficient with the albumin values, that were lower in these 
patients respect to controls. Concerning that HGF resulted the only molecule that was 
statistically different between HC and LC patients, these data suggested that the four 
proteins could be useful for diagnostic/prognostic purposes. 
 




Fig. 6. Mean concentrations of significant cytokines, chemokines and growth factors in 
healthy control subjects (light grey) and in chronic inflammation (yellow) and liver cirrhosis 
(pink) patients. 
7.2 Chronic inflammation patients with different fibrosis stages 
After the classification of their fibrosis stage of chronic inflammation by F Ishak index 
(Costantini et al., 2010a), the patients were divided in three different subgroups 
corresponding to F2, F3 and F4 stages and their mean concentrations of significant 
molecules in three groups compared by t-test. No relevant difference was found between 
chronic inflammation patients with F3 and F4 fibrosis grade because they corresponded to 
two already advanced fibrosis stages. Comparing F2 and F4 patients the concentrations of 
IL-2R, IL-6, IL-8, CXCL9, CXCL10, CXCL12 and MIF were found statistically higher (with 
p<0.05) in chronic inflammation patients with F4 fibrosis grade in respect to F2 fibrosis 
grade (Costantini et al., 2010a). These data agreed with a recent paper reporting that 
CXCL9 and CXCL10 were significantly elevated in patients with advanced fibrosis 
(Zeremski et al. 2009). 
In conclusion these results suggested that i) IL-2R, IL-6, IL-8, CXCL9, CXCL10, CXCL12 and 
MIF could be markers of the progression of chronic hepatitis C leading to liver cirrhosis by 
increasing fibrosis and ii) HGF, being over-expressed only in liver cirrhosis patients, could 
be index of fibrosis progression versus liver cirrhosis. 
However this work indicated the need of cytokinome data mining system for a predictive 
medicine, and suggested the utility to integrate all the cytokine data in a network and to 
make drug design studies on the chemokines resulted significant in the progression from 
chronic inflammation to HCC. 
 
Inflammatory Diseases – A Modern Perspective 116 
inflammation. In particular, HGF is a multifunctional growth factor that regulates growth 
and cell motility, exerts mitogenic effects on hepatocytes and epithelial cells and plays 
diverse roles in organ development, tissue regeneration, and tumor progression (Gentile et 
al., 2008). Moreover, it is implicated with IL-6, IL-8 and IL-1 in the hepatic stellate cell 
activation pathway.  
However, numerous reports have examined the relationship between HGF and either the 
facilitation or suppression of HCC occurrence and have suggested that this growth factor 
could be used as index of cellular growth and of HCC development in liver cirrhosis 
patients (Yagamamim et al., 2002). In fact, it is interesting that the amount of this 
molecule was significantly different in liver cirrhosis patients in respect to both healthy 
controls and chronic inflammation patients and that its concentration in HCC patients 
was higher than in liver cirrhosis patients. This means that HGF increased in the 
progression of chronic inflammation leading to liver cirrhosis and cancer and can be 
used for predicting the occurrence of HCC in chronic HCV-related liver diseases 
(Costantini et al., 2010a). 
7.1 Chronic inflammation versus liver cirrhosis patients 
Since IL-1α, IL-1, IL-2R, IL-6, IL-8, CXCL1, CXCL9, CXCL10, CXCL12, MIF, and -NGF 
were increased in both HC and LC patients in respect to healthy control subjects, their 
mean concentrations were compared by t-test. Fig. 6 shows that the concentrations of all 
the proteins and, in particular, IL-8, CXCL9 and  -NGF were higher (with p<0.05) in 
patients with liver cirrhosis than in those with chronic inflammation. Afterwards, 
comparing the serum levels of all cytokines, chemokines and growth factors in HC and 
LC patients respect to those in HCC patients tested in our recent paper (Capone et 
al.,2010) is resulted that the mean concentrations of all molecules resulted higher in HCC 
patients than in those with liver cirrhosis. This indicates that the expression of these pro-
inflammatory molecules tends to increase in the chronic inflammation progression 
leading to liver cirrhosis and HCC and, thus, their evaluation could be used for 
prognostic studies. The serum levels of statistically significant cytokines, chemokines and 
growth factors in the HC and LC patients were correlated with clinical data by using the 
Pearson correlation coefficient. In chronic inflammation patients IL-1, IL-2R, MIF and -
NGF showed a significant correlation with a positive correlation coefficient between them 
and with the transaminase values, that were higher in these patients than in healthy 
controls. Therefore these proteins can be considered as index of immune activation. In 
particular, these results agreed with literature data reporting that IL-1 and IL-2R 
participate in the progression from liver injury to fibrosis (Zekri et al., 2010) and that β-
NGF is involved in liver cancer growth and metastasis and can be used as an index of 
chronic infection leading to LC and HCC (Gieling et al., 2009). Indeed, this work 
suggested for the first time a role of MIF in HCV-related chronic inflammation patients 
because an increased serum MIF was reported only in HBV patients (Kimura et al., 2006). 
Moreover, CXCL1, CXCL9, CXCL10 and HFG in liver cirrhosis patients showed a 
significant correlation and, in details, a positive correlation coefficient between them and 
a negative correlation coefficient with the albumin values, that were lower in these 
patients respect to controls. Concerning that HGF resulted the only molecule that was 
statistically different between HC and LC patients, these data suggested that the four 
proteins could be useful for diagnostic/prognostic purposes. 
 




Fig. 6. Mean concentrations of significant cytokines, chemokines and growth factors in 
healthy control subjects (light grey) and in chronic inflammation (yellow) and liver cirrhosis 
(pink) patients. 
7.2 Chronic inflammation patients with different fibrosis stages 
After the classification of their fibrosis stage of chronic inflammation by F Ishak index 
(Costantini et al., 2010a), the patients were divided in three different subgroups 
corresponding to F2, F3 and F4 stages and their mean concentrations of significant 
molecules in three groups compared by t-test. No relevant difference was found between 
chronic inflammation patients with F3 and F4 fibrosis grade because they corresponded to 
two already advanced fibrosis stages. Comparing F2 and F4 patients the concentrations of 
IL-2R, IL-6, IL-8, CXCL9, CXCL10, CXCL12 and MIF were found statistically higher (with 
p<0.05) in chronic inflammation patients with F4 fibrosis grade in respect to F2 fibrosis 
grade (Costantini et al., 2010a). These data agreed with a recent paper reporting that 
CXCL9 and CXCL10 were significantly elevated in patients with advanced fibrosis 
(Zeremski et al. 2009). 
In conclusion these results suggested that i) IL-2R, IL-6, IL-8, CXCL9, CXCL10, CXCL12 and 
MIF could be markers of the progression of chronic hepatitis C leading to liver cirrhosis by 
increasing fibrosis and ii) HGF, being over-expressed only in liver cirrhosis patients, could 
be index of fibrosis progression versus liver cirrhosis. 
However this work indicated the need of cytokinome data mining system for a predictive 
medicine, and suggested the utility to integrate all the cytokine data in a network and to 
make drug design studies on the chemokines resulted significant in the progression from 
chronic inflammation to HCC. 
 
Inflammatory Diseases – A Modern Perspective 118 
8. The need of cytokinome data mining system for a predictive medicine 
The progressive increase in electronically stored clinical data is opening the possibility of 
carrying out large-scale studies aimed to discover correlations between new research data 
and related diseases. For these reasons, many relational databases have implemented data 
mining techniques (Harrison, 2008) that have been described as the ‘extraction of implicit, 
previously unknown and potentially useful information’, such as associations and 
correlations between data elements from large repositories of data (Lee & Siau, 2001). 
However, the scientific community needs clinical laboratory databases to collect medical 
data related to diseases progression and therapy response. In the last years, particular 
attention has been focused on the protein class comprising cytokines, chemokines and 
growth factors, because they play a crucial role in promoting angiogenesis, metastasis and 
subversion of adaptive immunity. Since the control of cytokine production is highly 
complex and multifactorial, their effects are mediated through multiple regulatory 
networks. The intricate complexity of these networks clearly conceals the role that a single 
cytokine may play in the pathogenesis of the disease. Therefore, it is more informative to 
investigate the immunopathogenesis of a disease process by analyzing a multiple panel of 
cytokines (Costantini et al., 2009). Utilizing a bead-based broad-spectrum multiplex 
immunoassay, it is possible not only to evaluate the serum levels of those cytokines 
ensemble that effectively correlate with the progression of the disease activity but also to 
define the immunomodulatory effects of a therapy even after months of treatment (Sato et 
al., 2009; Ozturk et al., 2009; Capone et al., 2010). This indicates that the definition and 
evaluation of a human cytokinome represents an important future tool to analyze the 
interaction network of cytokines both in healthy individuals and in patients affected by 
different diseases. In fact, it will permit one to understand and investigate how the 
regression of a chronic inflammation process, by acting on the cellular populations of 
cytokines, can block the progression of a cancer and, therefore, it can be a useful prognostic 
and diagnostic tool for clinicians. 
For these reasons, a portal with user-friendly interfaces, which can be used both by 
physicians and researchers not only to collect and to correlate clinical data and serum levels 
of cytokines but also to know quickly what cytokines, chemokines or growth factors are 
significant in the progression state of a given disease, represents an important and useful 
tool for clinical prognosis and therapy studies. 
Recently it has been developed a software named CDMS (Clinical Data Mining Software) 
and accessible at the URL: http://www.cro-m.eu/CDMS/ to collect clinical data and serum 
levels of many cytokines, chemokines and growth factors evaluated on healthy subjects and 
patients affected by different diseases (i.e. chronic hepatitis C and HCC) using multiplex 
immunoassays (Evangelista et al., 2010). Moreover, some statistical tools were implemented 
to correlate significatively clinical and experimental data and to quickly compare 
standardized cytokinome profile of a patient against a whole data bank that collects 
cytokinome data from some different diseases. CDMS allows certified users to access some 
of its services on the basis of their privileges. In detail, physicians and researchers can access 
the patient administration and statistical analysis sections, and all other authorized figures 
can access only statistical analysis section. In the patient administration section, there are 
case histories of patients with information related to their diagnosis, biological analyses as 
well as clinical data, and evaluations of 50 cytokine concentrations. Moreover, for the same 
patients, it is possible to insert the cytokine profiles evaluated at different times to compare 
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and evaluate results at different stages of the disease. In the statistical analysis section, the 
user can select the disease, filter the patients on the basis of gender, age and experiment date 
and select the most appropriate tool to perform the statistical analysis. In particular, we 
have implemented: (i) median, mean, variance, standard deviation, min and max values for 
the selected protein; (ii) t-test value related to the comparison between cytokine 
concentrations in control group and patients; (iii) Pearson correlation between different 
cytokines with related graph; (iv) Pearson correlation between each cytokine and some 
clinical data (i.e. tumor size) with related graph. CDMS represents the first ‘user-friendly’ 
tool that can be used by researchers as well as physicians and clinicians to significatively 
correlate clinical data and cytokine profiles and to identify what cytokines can be significant 
for the examined disease at a given time. Using its available statistical tools, it has been 
possible to identify the cyto-chemokines pattern involved in the chronic inflammation 
processes versus HCC and to verify that IL-8 correlated significantly with large tumor size 
(>5 cm), and it can be used both as a useful marker of tumor invasiveness and as an 
independent prognostic factor for HCC patients (Capone et al., 2010; Evangelista et al. 2010). 
Therefore, this tool can be a useful support to develop a reliable predictive medicine and to 
improve or discover new predictive relationships among data groups. 
9. The need for structural studies of cytokine/receptor complex: The example 
of CXCL9, CXCL10 and CXCL11 chemokines and their membrane receptor 
CXCR3 
The data obtained on sera of patients with chronic inflammation (HC), liver cirrhosis (LC) 
and HCC suggested the utility to make drug design studies on three CXCL9, CXCL10 and 
CXCL11 chemokines for obtaining molecules able to block the progression of fibrotic 
damage in chronic inflammation patients leading to liver cirrhosis and, then, to HCC 
(Costantini et al., 2010a).  
CXCL9, CXCL10 and CXCL11 are members of a family of small (8–10 kDa) proteins, the 
chemokines (or chemoattractant cytokines). They play a key role in immune and 
inflammatory responses by promoting recruitment and activation of different 
subpopulations of leukocytes, hence they have important proinflammatory and immune 
modulatory functions (Booth et al., 2002). CXCL9 as well as do CXCL10  and CXCL11 
binds and activates the same receptor CXCR3 (chemokine (C-X-C motif) receptor 3) 
(Booth et al., 2004).  
CXCR3 is mainly expressed on activated T and Natural Killer (NK) cells (Zeremski et al., 
2007). While CXCL11, CXCL10, and CXCL9 are agonists for CXCR3, they can also act as 
antagonists for CCR3 (Loetscher et al. 2001). Tumor cells aberrantly express chemokines 
and/or chemokine receptors, and the interaction of chemokine ligand-receptor pairs is 
increasingly implicated as a mediator of tumor growth and metastasis. In particular, CXCR3 
has now been identified in a variety of malignant cells, including melanoma, breast and 
prostate carcinomas, neuroblastoma, and a subset of B cell lymphomas (Colvin et al., 2004). 
CXCL9 and CXCL10 may promote the recruitment of lymphocytes to HCC and released 
from the HCC cells may induce lymphocyte infiltration. Ruehlmann et al. (2001) suggested 
that the expression of CXCL9 and CXCL10 might lead to lymphocytic infiltration into HCC, 
and gene therapy with these CXC chemokines may be effective for patients with HCC. 
Hrnce, during the past few years, several studies have demonstrated a pathogenenetic role 
of CXCR3 and its ligands in human inflammatory diseases suggesting the involvement of 
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and evaluate results at different stages of the disease. In the statistical analysis section, the 
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CXCL11 chemokines for obtaining molecules able to block the progression of fibrotic 
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of CXCR3 and its ligands in human inflammatory diseases suggesting the involvement of 
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various segments of their sequences. Therefore, the blockade of CXCR3 interactions with its 
ligands in vivo has been suggested as a possible therapeutic goal for the treatment of these 
disorders (Xanthou et al. 2003). Recently the three-dimensional structure of CXCL9 and 
CXCR3 has been simulated (Trotta et al., 2009). Successively, also the CXCL9/CXCR3 
complex (Fig. 7) has been modelled in comparison to CXCL10/CXCR3 and CXCL11/CXCR3 
complexes in order to evaluate in details the interaction residues involved in the formation 
of the complexes and their properties as important structural features to be used for drug 
design (Trotta et al., 2009).  
 
 
Fig. 7. 3D model of CXCL9/CXCR3 complex where CXCR3 is reported with green ribbon 
but CXCL9 with cyan ribbon. In details, the loops of the interaction regions are evidenced 
(i.e. N-terminal, loop1, loop 2 and loop3 of the receptor are shown in red, yellow, blue and 
magenta, respectively, and N-terminal and N-loop of the chemokine in orange and grey, 
respectively).  
Three chemokines resulted always to interact with their receptor by N-terminal region and 
N-loop but the receptor by N-terminal region and three extracellular loops according to 
precedent studies (Xanthou et al. 2003). Moreover the analysis of three complexes showed 
that the N-loop of all three chemokines was essential for binding the N-terminal region of 
CXCR3 in agreement to Clark-Lewis et al. (2003) whereas the loop 1 of CXCR3 was essential 
to bind only CXCL11 and CXCL10 as well as indicated by Xanthou et al. 2003.  The analysis 
of the physical-chemical properties of residues present in these regions in CXCR3 
highlighted that: i) N-terminal, loop1 and loop 2 contained some aromatic residues (Phe, Tyr 
and Trp); ii) N-terminal presented three negatively charged residues (3 Glu), loop2 one 
(Asp) but loop 3 three (2 Asp and 1 Glu) and iii) both loop 2 and loop 3 had two positively 
charged residues (2 Arg).These data suggested that the predominant interaction between 
CXCR3 and its ligands was on electrostatic basis and was favored also from the presence of 
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positively charged residues located in N-terminal region of three chemokines (i.e. three in 
CXCL9 and CXCL11 and two in CXCL10). Moreover, the presence of aromatic residues 
stabilized mainly the interaction between CXCR3 and CXCL11, having two Phe residues in 
N-terminal and might play an important role to favour the stacking interactions with 
putative drugs and organic compounds. 
Therefore the study of the structural basis of the CXCR3 receptor-ligand system through the 
modeling of three complexes CXCL9/CXCR3, CXCL10/CXCR3, and CXCL11/CXCR3 has 
evidenced the interaction regions between three chemokines and CXCR3 (Trotta et al., 2009). 
The related analysis of the physico-chemical properties of residues in these regions 
suggested that the predominant interaction between CXCR3 and its ligands was on 
electrostatic basis and favored by the presence of positively charged residues located in the 
N-terminal region of the three chemokines. The comparison of the three complexes showed 
that CXCR3 had the highest affinity for CXCL11 in terms of binding energy and higher 
number of H-bonds, of salt bridges and of interaction residues (Trotta et al., 2009). Since the 
in silico modelling provided a time- and cost-effective tool for the screening of molecules as 
well as for designing of novel molecules of desired activity, it was possible to focus the 
attention on CXCL11. Therefore, in order to develop putative antagonists to CXCR3, a 
peptide, derived from the N-terminal region of CXCL11, has been synthesized. Preliminary 
results of this study, taken as a whole, indicated that this peptide may be regarded as a 
small molecule that, opportunely modified, could represent a good model for an antagonist 
to CXCR3. Hence, further studies are currently underway to design analogs of this peptide 
to optimize its physico-chemical properties and to improve the electrostatic and stacking 
interactions with CXCR3 for novel therapeutic approaches. 
10. Conclusion  
Over the past several years, there has been a renaissance of research into connection 
between inflammation and cancer. The inflammation can play a role in tumor suppression 
by stimulating an antitumor immune response, but more often, under certain conditions, it 
appears to stimulate tumor development (Mantovani et al., 2008). The intensity and nature 
of the inflammation could explain this apparent contradiction. In fact, the inflammation may 
become chronic when the inflammatory stimulus persists. However, it has been suggested 
that inflammation associated with cancer is similar to that seen with chronic inflammation, 
which includes the production of growth and angiogenic factors that stimulate tissue repair, 
factors that can also promote cancer-cell survival, implantation, and growth (Allavena et al., 
2008). Thus immune response can promote anticancer effects or carcinogenesis and tumor 
growth (Mantovani et al., 2008). Cytokines are among molecules that play an important role 
in the evolution of these processes. In fact, they are proteins that are expressed before and 
during the inflammatory process and play a key role at the various disease levels so that 
they can be considered as specific markers of cancer and of its specific evolutive steps 
(Capone et al., 2010; Costantini et al., 2010a).  
The studying model chosen in this chapter is the hepatocellular carcinoma (HCC) that 
represents a major health problem worldwide being the fifth most common malignancy in 
men and the eighth in women and the third most common cause of cancer-related death in 
the world. Indeed its incidence is increasing dramatically, with marked variations among 
geographic regions, racial and ethnic groups, relatively to the exposure documented 
environmental risk factors (Castello et al., 2010a, 2010b). In particular, Southern Italy has the 
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positively charged residues located in N-terminal region of three chemokines (i.e. three in 
CXCL9 and CXCL11 and two in CXCL10). Moreover, the presence of aromatic residues 
stabilized mainly the interaction between CXCR3 and CXCL11, having two Phe residues in 
N-terminal and might play an important role to favour the stacking interactions with 
putative drugs and organic compounds. 
Therefore the study of the structural basis of the CXCR3 receptor-ligand system through the 
modeling of three complexes CXCL9/CXCR3, CXCL10/CXCR3, and CXCL11/CXCR3 has 
evidenced the interaction regions between three chemokines and CXCR3 (Trotta et al., 2009). 
The related analysis of the physico-chemical properties of residues in these regions 
suggested that the predominant interaction between CXCR3 and its ligands was on 
electrostatic basis and favored by the presence of positively charged residues located in the 
N-terminal region of the three chemokines. The comparison of the three complexes showed 
that CXCR3 had the highest affinity for CXCL11 in terms of binding energy and higher 
number of H-bonds, of salt bridges and of interaction residues (Trotta et al., 2009). Since the 
in silico modelling provided a time- and cost-effective tool for the screening of molecules as 
well as for designing of novel molecules of desired activity, it was possible to focus the 
attention on CXCL11. Therefore, in order to develop putative antagonists to CXCR3, a 
peptide, derived from the N-terminal region of CXCL11, has been synthesized. Preliminary 
results of this study, taken as a whole, indicated that this peptide may be regarded as a 
small molecule that, opportunely modified, could represent a good model for an antagonist 
to CXCR3. Hence, further studies are currently underway to design analogs of this peptide 
to optimize its physico-chemical properties and to improve the electrostatic and stacking 
interactions with CXCR3 for novel therapeutic approaches. 
10. Conclusion  
Over the past several years, there has been a renaissance of research into connection 
between inflammation and cancer. The inflammation can play a role in tumor suppression 
by stimulating an antitumor immune response, but more often, under certain conditions, it 
appears to stimulate tumor development (Mantovani et al., 2008). The intensity and nature 
of the inflammation could explain this apparent contradiction. In fact, the inflammation may 
become chronic when the inflammatory stimulus persists. However, it has been suggested 
that inflammation associated with cancer is similar to that seen with chronic inflammation, 
which includes the production of growth and angiogenic factors that stimulate tissue repair, 
factors that can also promote cancer-cell survival, implantation, and growth (Allavena et al., 
2008). Thus immune response can promote anticancer effects or carcinogenesis and tumor 
growth (Mantovani et al., 2008). Cytokines are among molecules that play an important role 
in the evolution of these processes. In fact, they are proteins that are expressed before and 
during the inflammatory process and play a key role at the various disease levels so that 
they can be considered as specific markers of cancer and of its specific evolutive steps 
(Capone et al., 2010; Costantini et al., 2010a).  
The studying model chosen in this chapter is the hepatocellular carcinoma (HCC) that 
represents a major health problem worldwide being the fifth most common malignancy in 
men and the eighth in women and the third most common cause of cancer-related death in 
the world. Indeed its incidence is increasing dramatically, with marked variations among 
geographic regions, racial and ethnic groups, relatively to the exposure documented 
environmental risk factors (Castello et al., 2010a, 2010b). In particular, Southern Italy has the 
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highest rates of HCC in Europe (Fusco et al., 2008). HCC derives from a long clinical history 
in patients with HCV or HBV infection. In fact, about 80% of newly infected patients 
develop chronic infection; an estimated 10% to 20% will develop cirrhosis and 1% to 5% 
advance to end-stage liver cancer (HCC) over a period of 20 to 30 years (Fig. 1). 
Recently the serum levels of many cytokines have been evaluated by a broad spectrum 
bead-based multiplex immunoassay both in patients with chronic HCV or with HCV-related 
cirrhosis and in patients with HCC patients with HCV-related cirrhosis. These studies have 
evidenced that some interleukins and chemokines (Fig. 5 and 6) are putative markers of the 
progression of chronic hepatitis C leading to liver cirrhosis by increasing fibrosis and can be 
used as templates for designing new drugs able to block the progression of the 
inflammatory processes (Capone et al., 2010; Costantini et al., 2010a).  
However, all the data related to the cytokine evaluations should be modeled 
computationally by using graphs or networks connecting the various data groups in terms 
of dynamic probabilistic maps of metabolic and/or physiological activities and/or 
pathogenetic pathways. In fact only in this way it is possible to define the human 
cytokinome that can be an useful tool to analyze the interaction network of cytokines both in 
healthy individuals and in patients affected from HCC (Costantini et al., 2010b). Therefore, 
CDMS represents the first ‘user-friendly’ tool that can be used by researchers as well as 
physicians and clinicians to significatively correlate clinical data and cytokine profiles and to 
identify what cytokines can be significant for the examined disease at a given time 
(Evangelista et al., 2010). However further studies will regard the opening of the data sets to 
other diseases and the implementation of other statistical tools and classification methods to 
improve or  to discover new predictive relationships among data groups. 
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During past decades the relationship between dentistry and internal medicine has been 
intensely debated. Current evidence suggests that inflammation due to periodontal 
infections may not be limited to the immediate oral environment but can have systemic 
effects. Clinical, epidemiological and molecular studies have demonstrated significant 
association between periodontitis and various diseases, such as coronary heart disease, 
atherosclerosis, bacterial pneumonia, diabetes mellitus and low birth weight. Individuals 
with periodontal infections have elevated concentrations of circulating inflammatory 
markers, disease severity directly correlates with serum concentrations of inflammatory 
markers, and treatment of periodontal infection can lower markers of systemic 
inflammatory dysfunction within 2–6 months. 
Various hypotheses, including common susceptibility, systemic inflammation, direct 
bacterial infection and cross-reactivity, or molecular mimicry, between bacterial antigens 
and self-antigens, have been postulated to explain these relationships. In this scenario, the 
association of periodontal disease with systemic diseases has set the stage for introducing 
the concept of periodontal medicine. 
At present it is generally agreed on that oral status is connected with systemic health, since 
poor oral health may occur concomitantly with more serious underlying diseases and/or it 
may predispose to other systemic diseases. The pioneering approach of periodontal 
medicine has helped to renew attention on the theory of focal infection and the deepening of 
the relationship between chronic periodontitis and systemic health. 
In recent years, chronic periodontitis has been proposed as a risk factor for pancreatic 
cancer. Chronic periodontitis might promote pancreatic carcinogenesis, by means of 
systemic inflammation, or alternatively, through increased production of carcinogens, 
namely nitrosamines. 
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The aim of the present study was to investigate pancreatic tissue for the potential presence 
of periodontopathogenic microorganisms.  
2. Periodontal diseases 
Periodontal diseases are a group of bacterial inflammatory diseases of the supporting tissues 
of the teeth (gingiva, periodontal ligament, cementum and alveolar bone). Periodontal diseases 
include two general conditions based on whether there is attachment or bone loss: gingivitis 
and periodontitis. Gingivitis is considered a reversible form of the disease, and generally 
involves inflammation of the gingival tissues without loss of connective tissue attachment. 
Gingivitis is the most common and prevalent form of periodontal disease among children and 
adolescents. The incidence and severity increase from childhood to adolescence, reaching a 
peak prevalence of 80% at 11-13 years of age. The progression from gingivitis to periodontitis 
is characterized by periodontal pocket development, which favours further plaque 
accumulation and a shift in its qualitative composition. Thereafter, as the severity of gingivitis 
decreases, chronic periodontitis measured by attachment loss becomes dominant and 
continues to increase in severity with age. Periodontitis is a chronic infection involving 
destruction of tooth-supporting tissues, including the periodontal ligament and alveolar socket 
support of the teeth. Periodontal disease can affect one tooth or many teeth and, if left 
untreated, can lead to tooth loss, particularly in adults. It is the most common dental condition 
in adults, and is also one of the most common chronic inflammatory diseases affecting a 
majority of the population throughout the world. Some of the clinical signs include bleeding 
on probing, deep pockets, recession and tooth mobility. Progressive changes from healthy 
gums to necrotizing periodontitis are given in Figures 1 to 5. 
 
 
Fig. 1. Healthy gums 
 
 
Fig. 2. Gingivitis 
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2.1 Classification of periodontal diseases 
2.1.1 Chronic periodontitis 
Chronic periodontitis is the most common form of periodontitis in adults, but can occur at 
any age. Progression of attachment loss usually occurs slowly, but periods of exacerbation 
with rapid progression, or periods of remission can occur. The rate of disease progression 
may be influenced by local (subgingivally placed fillings or crowns, tooth caries…) and/or 
systemic conditions (diabetes mellitus, pregnancy, puberty, leukemia…) that alter the 
normal host response to bacterial plaque. The severity of disease can be described as slight, 
moderate, or severe, based on the level of destruction.  
 
 
Fig. 3. Gingivitis 
 
 
Fig. 4. Periodontitis 
2.1.2 Aggressive periodontitis 
Aggressive periodontitis (previously Juvenile Periodontitis) is characterized by rapid 
attachment loss and bone destruction in the absence of significant accumulations of plaque 
and calculus. (Tonetti&Mombelly, 1999) This form of periodontitis usually affects young 
individuals, often during puberty, from 10-30 years of age, with genetic predisposition. The 
bacteria most often associated with aggressive periodontitis is Aggregatibacter 
actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans). Aggressive 
periodontitis can occur as localized or generalized forms. The localized form usually affects 
first molar and incisor sites. The generalized form usually involves at least three teeth other 
than first molars and incisors.  
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2.1.3 Periodontitis as a manifestation of systemic diseases 
Periodontitis as a manifestation of systemic diseases may be associated with diabetes, 
several hematological (acquired, familial, and cyclic neutropenias, leukemias) and genetic 
disorders (Down’s syndrome, certain types of Ehlers-Danlos syndrome, Papillon-Lefevre 
syndrome, Cohen syndrome and hypophosphatasia). The mechanisms by which all of these 
disorders affect the health of periodontium are not fully understood, but it is speculated that 
these diseases can alter host defense mechanisms and upregulate inflammatory responses, 
resulting in progressive periodontal destruction.  
2.1.4 Necrotizing periodontal diseases 
Necrotizing periodontal diseases (necrotizing gingivitis, necrotizing periodontitis and 
necrotizing stomatitis) are the most severe inflammatory periodontal disorders caused by 
plaque bacteria. These lesions are commonly observed in individuals with systemic 
conditions such HIV infection, malnutrition and immunosuppression. Clinical 
characteristics of necrotizing periodontal diseases may include but are not limited to 
ulcerated and necrotic papillary and marginal gingiva covered by a yellowish and grayish 
slough or pseudomembrane, blunting and cratering of papillae, bleeding on provocation or 
spontaneous bleeding, pain, and fetid breath. These diseases may be accompanied by fever, 
malaise, and lymphadenopathy, although these characteristics are not consistent.  
 
 
Fig. 5. Necrotizing periodontitis 
These diseases appear to have multiple etiologies, microbial and immunological being the 
two most studied. The primary microbial factor contributing to disease is a shift in the 
content of the oral microflora, while the primary immunological factor is the destructive 
host inflammatory response.  
2.2 Microbial etiology of periodontal disease  
As many as 700 different species of bacteria that colonize the oral cavity can affect the 
delicate balance of host-bacterial interactions leading to disease. Periodontal infection is 
initiated by specific invasive oral pathogens that colonize dental plaque biofilms on the 
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tooth root surface. No one knows how many bacterial species, ribotypes, and serotypes 
coexist in the dental plaque, but the number is very large. With the advent of PCR 
technologies, many new uncultivable species are being identified. 
The onset and progression of periodontal disease is attributed to the presence of elevated 
levels of a consortium of pathogenic bacteria within the gingival crevice. The plaque is 
divided into two distinct types based on the relationship of the plaque to the gingival 
margin, i.e., supragingival plaque and subgingival plaque. The supragingival plaque is 
dominated by facultative Streptococcus and Actinomyces species, whereas the subgingival 
plaque harbors an anaerobic gram-negative flora dominated by uncultivable spirochetal 
species. It is this gram-negative flora that has been associated with periodontal disease. 
Since many of its members derive some of their nutrients from the gingival crevicular fluid, 
a tissue transudate that seeps into the periodontal area, it is possible that their overgrowth is 
a result of the inflammatory process (Loe et al., 1965). 
The disease is a chronic low grade infection involving mainly Gram-negative anaerobic 
bacteria. There is a clear evidence for the pathogenic role of Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia in periodontal 
disease development and a reasonably strong evidence exists for the pathogenic role in 
certain forms of periodontal disease of some other microorganisms such as Prevotella 
intermedia, Fusobacterium nucleatum, Campylobacter rectus, Eikenella corrodens etc (Brajovic et 
al., 2010; Milicevic et al, 2008). A number of gram-negative rods and spirochetes are putative 
periodontal pathogens, but these organisms may also be present, although in smaller 
concentrations, in healthy patients.  
Although the plaque is essential for the initiation of periodontal diseases, the majority of the 
destructive processes associated with these diseases are due to an excessive host response to 
the bacterial challenge. Periodontal bacteria possess a plethora of virulence factors that, 
upon interaction with host cells, induce the production of inflammatory mediators at the 
gingival level. 
2.3 Host inflammatory response to bacterial challenge 
The fundamental question in regard to periodontal pathology is whether the host is 
responding to the nonspecific overgrowth of bacteria on the tooth surfaces (inflammatory 
disease) or to the overgrowth of a limited number of species which produce biologically 
active molecules that are particularly proinflammatory or antigenic (infection). 
There is a distinction between the way the host responds to the supragingival plaque and its 
response to the subgingival plaque. The response to the supragingival plaque has been 
thoroughly studied in the experimental gingivitis model described below, whereas the 
response to the subgingival plaque remains under investigation. Does the host respond to 
the subgingival plaque as if it were an overgrowth of a bacterial community in which many 
members produce substances, such as LPS, that are particularly bioactive if they enter the 
gingival tissue? Or does it respond to a plaque in which certain members produce more 
biologically active molecules, such as butyric acid (Niederman al., 1997) or hydrogen sulfide 
(Ratcliff&Johnson, 1999), per cell or possess unique proteases, such as are found in P. 
gingivalis and Treponema denticola, which can degrade host molecules, creating a 
proinflammatory effect (Kuramitsu, 1998)? In either case, although bacteria are involved, it 
is not the scenario of a typical infection, as the offending bacteria generally remain outside 
the body, attached to the tooth. 
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Fig. 6. A) Histology of normal gingiva; B) Accumulation of Gram positive and Gram 
negative bacteria and bacterial toxins; C) Basement membrane and tissue destruction 
leading to epithelial ulcerations. 
In periodontal disease the inflammatory response causes tissue resistance to bacterial 
invasion but also provides mechanisms that contribute to tissue damage. Acute 
inflammatory cells, such as mast cells, macrophages, Langerhans cells, and 
polymorphonuclear leukocytes, combine their action to form a potent antibacterial defense 
mechanism. However the initial signs of gingival inflammation (swelling, redness, bleeding 
on probing) are nothing but the tissue-destructive aspects of the activity of these cells. 
Neutrophils function to control the bacterial assault by phagocytosis but also secrete matrix 
metalloproteinases (MMP), which are the agents responsible for collagen loss in the tissues. 
These latent collagenolytic enzymes can be converted to active forms by proteases and 
reactive oxygen species in the inflammatory environment, giving rise to elevated levels of 
interstitial collagenase in the inflammed gingival tissue. The resulting attachment loss 
deepens the sulcus, or depression, formed where the gingival tissues contact the tooth 
surface, thereby creating the periodontal pocket. By definition, this loss of attachment 
converts gingivitis to periodontitis. The depth of the pocket reflects an inflammatory 
response that causes both the swelling of the gingival tissues at the top of the pocket and the 
loss of collagen attachment of the tooth to the alveolar bone at the bottom of the pocket. 
Good oral hygiene can reduce the inflammatory swelling, but the attachment loss and 
accompanying bone loss is thought to be irreversible. In established periodontal disease, 
there is also a chronic inflammatory change, with B cells and T cells adding to the 
antibacterial spectrum. These cells also have capacity to release cytokines, which may 
induce the synthesis of arachidonate metabolites (especially PGE2), and to stimulate 
macrophages and osteoclasts to release hydrolases and collagenases, which are responsible 
for loss of collagen and bone. The interaction of bacterial antigens with peripheral dendritic 
cells leads to the generation of systemic antibody, whereas interaction with local B cells 
leads to production of local antibody. Antibody specific to many of the periodontal 
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microorganisms is essential for phagocytosis. Complement components also may contribute 
to efficient bacterial phagocytosis. The production of interleukin-1β (IL-1β), tumor necrosis 
factor alpha (TNF-α), and prostaglandin E2 (PGE2) in response to bacterial 
lipopolysaccharides (LPS) leads to bone resorption through osteoclast activation, 
proliferation, and differentiation. Each patient with dental plaque has a complex balance 
between these protective and damaging scenarios that results either in a slowly progressive 
loss of attachment (periodontitis) or in a restriction of tissue inflammation to the peripheral 
tissues (gingivitis).    
2.4 Treatment of periodontal disease  
Various treatment modalities, such as the traditional debridement procedures (scaling and 
root planning), surgery (Kwan et al., 1998; Lekovic et al., 1997, 1998a, 1998b, 2001a, 2001b, 
2003, 2005; Camargo et al., 1998, 2000, 2002, 2005) and various antimicrobial regimens were 
introduced for the treatment of periodontal disease. 
Traditional treatments reflect the premise that periodontal disease is due to the nonspecific 
overgrowth of any and all bacteria on the tooth surfaces and that the magnitude of the 
bacterial overgrowth on the teeth can be controlled by professional cleaning of the teeth at 
regular intervals. If these accumulations are not removed, various bacterial by-products and 
their cellular components such as LPS, antigens, or enzymes can provoke an inflammatory 
response in the gingival tissue. Undisturbed plaques often become calcified, forming dental 
calculus or tartar, which, if formed below the gingival margin, is often difficult to remove 
from the root surfaces without some form of surgical access. 
This type of periodontal treatment which is considered to be the standard treatment, is 
based on the premise that if the bacterial overgrowth in dental plaque can be continuously 
suppressed by mechanical debridement, gingival and periodontal health will be maintained. 
It is the basis of the “plaque control” programs of organized dentistry and dentifrice 
manufacturers; as a public health effort, this approach has been very successful. 
3. Oral-systemic relationship 
In the last decade, the possible association between oral and systemic health has been 
highlighted in numerous reports. Apart from the seeding infection as a direct consequence 
of transient bacteraemia, such oral-systemic interactions and outcomes could be due to 
other, indirect reasons, such as metastatic inflammation as a result of circulating 
macromolecular complexes and/or metastatic injury due to soluble toxins and bacterial 
lipopolysaccharide. It has become increasingly clear that the oral cavity can act as the site of 
origin for dissemination of pathogenic organisms to distant body sites, especially in 
immunocompromised hosts such as patients suffering from malignancies, diabetes, or 
rheumatoid arthritis or having corticosteroid or other immunosuppressive treatment. A 
number of epidemiological studies have suggested that oral infection, especially marginal 
and apical periodontitis, may be a risk factor for systemic diseases. 
3.1 Transient bacteraemia 
In common inflammatory conditions such as gingivitis and chronic periodontitis, which are 
precipitated by the buildup of plaque biofilms, the periodontal vasculature proliferates and 
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Fig. 6. A) Histology of normal gingiva; B) Accumulation of Gram positive and Gram 
negative bacteria and bacterial toxins; C) Basement membrane and tissue destruction 
leading to epithelial ulcerations. 
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response that causes both the swelling of the gingival tissues at the top of the pocket and the 
loss of collagen attachment of the tooth to the alveolar bone at the bottom of the pocket. 
Good oral hygiene can reduce the inflammatory swelling, but the attachment loss and 
accompanying bone loss is thought to be irreversible. In established periodontal disease, 
there is also a chronic inflammatory change, with B cells and T cells adding to the 
antibacterial spectrum. These cells also have capacity to release cytokines, which may 
induce the synthesis of arachidonate metabolites (especially PGE2), and to stimulate 
macrophages and osteoclasts to release hydrolases and collagenases, which are responsible 
for loss of collagen and bone. The interaction of bacterial antigens with peripheral dendritic 
cells leads to the generation of systemic antibody, whereas interaction with local B cells 
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microorganisms is essential for phagocytosis. Complement components also may contribute 
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lipopolysaccharides (LPS) leads to bone resorption through osteoclast activation, 
proliferation, and differentiation. Each patient with dental plaque has a complex balance 
between these protective and damaging scenarios that results either in a slowly progressive 
loss of attachment (periodontitis) or in a restriction of tissue inflammation to the peripheral 
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overgrowth of any and all bacteria on the tooth surfaces and that the magnitude of the 
bacterial overgrowth on the teeth can be controlled by professional cleaning of the teeth at 
regular intervals. If these accumulations are not removed, various bacterial by-products and 
their cellular components such as LPS, antigens, or enzymes can provoke an inflammatory 
response in the gingival tissue. Undisturbed plaques often become calcified, forming dental 
calculus or tartar, which, if formed below the gingival margin, is often difficult to remove 
from the root surfaces without some form of surgical access. 
This type of periodontal treatment which is considered to be the standard treatment, is 
based on the premise that if the bacterial overgrowth in dental plaque can be continuously 
suppressed by mechanical debridement, gingival and periodontal health will be maintained. 
It is the basis of the “plaque control” programs of organized dentistry and dentifrice 
manufacturers; as a public health effort, this approach has been very successful. 
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origin for dissemination of pathogenic organisms to distant body sites, especially in 
immunocompromised hosts such as patients suffering from malignancies, diabetes, or 
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and apical periodontitis, may be a risk factor for systemic diseases. 
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dilates, providing an even greater surface area that facilitates the entry of microorganisms 
into the bloodstream. Often, these bacteraemias are short-lived and transient, with the 
highest intensity limited to the first 30 min after a trigger episode. On occasions, this may 
lead to seeding of microorganisms in different target organs, resulting in subclinical, acute, 
or chronic infections. Yet there are a number of other organs and body sites that may be 
affected by focal bacteremic spread from the oral cavity. Based on the current evidence, it is 
likely that bacteria may enter into the bloodstream from oral niches through a number of 
mechanisms and a variety of portals. First, and most commonly, when there is tissue trauma 
induced by procedures such as periodontal probing, scaling, instrumentation beyond the 
root apex, and tooth extractions, a breakage in capillaries and other small blood vessels that 
are located in the vicinity of the plaque biofilms may lead to spillage of bacteria into the 
systemic circulation. As stated above, dissemination of oral microorganisms into the 
bloodstream is common, and less than 1 minute after an oral procedure, organisms from the 
infected site may have reached the heart, lungs, and peripheral blood capillary system. 
There are more than 1013 microbes on all surfaces of the body, yet the underlying tissues and 
the bloodstream are usually sterile. In the oral cavity there are several barriers to bacterial 
penetration from dental plaque into the tissue: a physical barrier composed of the surface 
epithelium; defensins, which are host-derived peptide antibiotics, in the oral mucosal 
epithelium; an electrical barrier that reflects the difference between the host cell and the 
microbial layer; an immunological barrier of antibody-forming cells; and the 
reticuloendothelial system (phagocyte barrier). Under normal circumstances, these barrier 
systems work together to inhibit and eliminate penetrating bacteria. When this state of 
equilibrium is disturbed by an overt breach in the physical system (e.g., trauma), the 
electrical system (i.e., hypoxia), or immunological barriers (e.g., through neutropenia, AIDS, 
or immunosuppressant therapy), microorganisms can propagate and cause both acute and 
chronic infections with increased frequency and severity. With normal oral health and 
dental care, only small numbers of mostly facultative bacterial species gain access to the 
bloodstream. However, with poor oral hygiene, the numbers of bacteria colonizing the teeth, 
especially supragingivally, could increase 2- to 10-fold and thus possibly introduce more 
bacteria into tissue and the bloodstream, leading to an increase in the prevalence and 
magnitude of bacteraemia. 
Obviously, a higher microbial load would facilitate such dissemination, as it is known that 
individuals with poor oral hygiene are at a higher risk of developing bacteraemias during 
oral manipulative procedures. Innate microbial factors may play a role in the latter 
phenomenon, as only a few species are detected in experimental bacteraemias despite the 
multitude of diverse bacteria residing within the periodontal biofilm. Species that are 
commonly found in the bloodstream have virulence attributes that could be linked to 
vascular invasion. Of particular note are attributes such as endothelial adhesion of 
Streptococcus spp., degradation of intercellular matrices by Porphyromonas gingivalis, and 
impedance of phagocytic activity by Aggregatibacter actinomycetemcomitans and Fusobacterium 
nucleatum. As opposed to the more than 700 bacterial species that inhabit the oral cavity, 
relatively fewer species have been isolated from blood cultures for odontogenic 
bacteraemias. Phylogenetic studies of the oral microbiome have shown that a large 
proportion of the oral bacteria comprise the genus Streptococcus (Van Dyke et al., 1982.). In a 
number of controlled clinical trials, streptococci were the predominant organisms isolated, 
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ranging from 40 to 65% of isolates. The highest incidence of bacteraemia results from tooth 
extractions. Periodontal manipulations are also shown to produce a long-lasting (30 min) 
bacteraemia. This is probably a reflection of the bacterial load and tissue trauma or 
associated inflammation at these niches. Other oral procedures are not as significant, at least 
for individuals with healthy oral cavities. Routine oral hygiene measures such as brushing 
or flossing are unlikely to cause a significant degree of bacteraemia, but sporadic cleaning 
after accumulation of a heavy plaque load should be considered a potential risk factor for a 
bacteremic state. 
3.2 Mechanisms linking oral infection to secondary nonoral diseases 
Three mechanisms or pathways linking oral infections to secondary systemic effects have 
been proposed. These are metastatic spread of infection from the oral cavity as a result of 
transient bacteraemia, metastatic injury from the effects of circulating oral microbial toxins, 
and metastatic inflammation caused by immunological injury induced by oral 
microorganisms. 
3.2.1 Metastatic infection 
As previously discussed, oral infections and dental procedures can cause transient 
bacteraemia. The microorganisms that gain entrance to the blood and circulate throughout 
the body are usually eliminated by the reticuloendothelial system within minutes 
(transient bacteraemia) and as a rule lead to no other clinical symptoms than possibly a 
slight increase in body temperature. However, if the disseminated microorganisms find 
favorable conditions, they may settle at a given site and, after a certain time lag, start to 
multiply. 
3.2.2 Metastatic injury 
Some gram-positive and gram-negative bacteria have the ability to produce diffusible 
proteins, or exotoxins, which include cytolytic enzymes and dimeric toxins. The exotoxins 
have specific pharmacological actions and are considered the most powerful and lethal 
poisons known (51). Conversely, endotoxins are part of the outer membranes released after 
cell death. Endotoxin is compositionally a lipopolysaccharide (LPS) that, when introduced 
into the host, gives rise to a large number of pathological manifestations. LPS is 
continuously shed from periodontal gram-negative rods during their growth in vivo. 
3.2.3 Metastatic inflammation 
Soluble antigen may enter the bloodstream, react with circulating specific antibody, and 
form a macromolecular complex. These immunocomplexes may give rise to a variety of 
acute and chronic inflammatory reactions at the sites of deposition. 
4. Periodontitis affects susceptibility to systemic disease 
In a recent review article, Page proposed that periodontitis may affect the host’s 
susceptibility to systemic disease in three ways: by shared risk factors, by subgingival 
biofilms acting as reservoirs of gram-negative bacteria, and through the periodontium 
acting as a reservoir of inflammatory mediators. 
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penetration from dental plaque into the tissue: a physical barrier composed of the surface 
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reticuloendothelial system (phagocyte barrier). Under normal circumstances, these barrier 
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dental care, only small numbers of mostly facultative bacterial species gain access to the 
bloodstream. However, with poor oral hygiene, the numbers of bacteria colonizing the teeth, 
especially supragingivally, could increase 2- to 10-fold and thus possibly introduce more 
bacteria into tissue and the bloodstream, leading to an increase in the prevalence and 
magnitude of bacteraemia. 
Obviously, a higher microbial load would facilitate such dissemination, as it is known that 
individuals with poor oral hygiene are at a higher risk of developing bacteraemias during 
oral manipulative procedures. Innate microbial factors may play a role in the latter 
phenomenon, as only a few species are detected in experimental bacteraemias despite the 
multitude of diverse bacteria residing within the periodontal biofilm. Species that are 
commonly found in the bloodstream have virulence attributes that could be linked to 
vascular invasion. Of particular note are attributes such as endothelial adhesion of 
Streptococcus spp., degradation of intercellular matrices by Porphyromonas gingivalis, and 
impedance of phagocytic activity by Aggregatibacter actinomycetemcomitans and Fusobacterium 
nucleatum. As opposed to the more than 700 bacterial species that inhabit the oral cavity, 
relatively fewer species have been isolated from blood cultures for odontogenic 
bacteraemias. Phylogenetic studies of the oral microbiome have shown that a large 
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ranging from 40 to 65% of isolates. The highest incidence of bacteraemia results from tooth 
extractions. Periodontal manipulations are also shown to produce a long-lasting (30 min) 
bacteraemia. This is probably a reflection of the bacterial load and tissue trauma or 
associated inflammation at these niches. Other oral procedures are not as significant, at least 
for individuals with healthy oral cavities. Routine oral hygiene measures such as brushing 
or flossing are unlikely to cause a significant degree of bacteraemia, but sporadic cleaning 
after accumulation of a heavy plaque load should be considered a potential risk factor for a 
bacteremic state. 
3.2 Mechanisms linking oral infection to secondary nonoral diseases 
Three mechanisms or pathways linking oral infections to secondary systemic effects have 
been proposed. These are metastatic spread of infection from the oral cavity as a result of 
transient bacteraemia, metastatic injury from the effects of circulating oral microbial toxins, 
and metastatic inflammation caused by immunological injury induced by oral 
microorganisms. 
3.2.1 Metastatic infection 
As previously discussed, oral infections and dental procedures can cause transient 
bacteraemia. The microorganisms that gain entrance to the blood and circulate throughout 
the body are usually eliminated by the reticuloendothelial system within minutes 
(transient bacteraemia) and as a rule lead to no other clinical symptoms than possibly a 
slight increase in body temperature. However, if the disseminated microorganisms find 
favorable conditions, they may settle at a given site and, after a certain time lag, start to 
multiply. 
3.2.2 Metastatic injury 
Some gram-positive and gram-negative bacteria have the ability to produce diffusible 
proteins, or exotoxins, which include cytolytic enzymes and dimeric toxins. The exotoxins 
have specific pharmacological actions and are considered the most powerful and lethal 
poisons known (51). Conversely, endotoxins are part of the outer membranes released after 
cell death. Endotoxin is compositionally a lipopolysaccharide (LPS) that, when introduced 
into the host, gives rise to a large number of pathological manifestations. LPS is 
continuously shed from periodontal gram-negative rods during their growth in vivo. 
3.2.3 Metastatic inflammation 
Soluble antigen may enter the bloodstream, react with circulating specific antibody, and 
form a macromolecular complex. These immunocomplexes may give rise to a variety of 
acute and chronic inflammatory reactions at the sites of deposition. 
4. Periodontitis affects susceptibility to systemic disease 
In a recent review article, Page proposed that periodontitis may affect the host’s 
susceptibility to systemic disease in three ways: by shared risk factors, by subgingival 
biofilms acting as reservoirs of gram-negative bacteria, and through the periodontium 
acting as a reservoir of inflammatory mediators. 
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4.1 Shared risk factors 
Factors that place individuals at high risk for periodontitis may also place them at high risk 
for systemic diseases such as cardiovascular disease. Among the environmental risk factors 
and indicators shared by periodontitis and systemic diseases, such as cardiovascular 
disease, are tobacco smoking, stress, aging, race or ethnicity, and male gender. Studies 
demonstrating genetic factors shared by periodontitis, cardiovascular disease, preterm 
labor, and osteoporosis have not yet been performed but may be fruitful. 
4.2 Subgingival biofilms 
Subgingival biofilms constitute an enormous and continuing bacterial load. They present 
continually renewing reservoirs of LPS and other gram-negative bacteria with ready access 
to the periodontal tissues and the circulation. Systemic challenge with gram-negative 
bacteria or LPS induces major vascular responses, including an inflammatory cell infiltrate 
in the vessel walls, vascular smooth muscle proliferation, vascular fatty degeneration, and 
intravascular coagulation. LPS upregulates expression of endothelial cell adhesion 
molecules and secretion of interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-a), and 
thromboxane, which results in platelet aggregation and adhesion, formation of lipidladen 
foam cells, and deposits of cholesterol and cholesterol esters. 
4.3 Periodontium as cytokine reservoir 
The proinflammatory cytokines TNF-a, IL-1b, and gamma interferon as well as 
prostaglandin E2 (PGE2) reach high tissue concentrations in periodontitis. The 
periodontium can therefore serve as a renewing reservoir for spillover of these mediators, 
which can enter the circulation and induce and perpetuate systemic effects. IL-1b favors 
coagulation and thrombosis and retards fibrinolysis. IL-1, TNF-a, and thromboxane can 
cause platelet aggregation and adhesion, formation of lipidladen foam cells, and deposition 
of cholesterol. These same mediators emanating from the diseased periodontium may also 
account for preterm labor and low-birth-weight infants (Page,  1998). 
5. Cardiovascular disease 
Cardiovascular disease and periodontal disease are both chronic inflammatory diseases. 
Numerous cross-sectional and longitudinal epidemiological studies have provided evidence 
that there is an association between periodontitis and elevated risk for cardiovascular 
disease. A number of systematic reviews and meta-analyses have described the relationship 
between periodontal infection and cardiovascular disease, and have suggested that 
periodontitis may contribute to cardiovascular disease and stroke in susceptible subjects. 
It is well accepted that hyperlipidemia is a risk factor for coronary heart disease. Recent 
studies have shown an association between periodontitis and elevated atherogenic lipid 
fraction levels and  or decreased anti-atherogenic lipid fraction levels. Most of these were 
cross-sectional studies, and it is still unclear whether there is a causal relationship between 
periodontitis and hyperlipidemia. Improvement of serum lipid profiles after periodontal 
treatment may indicate a causal relationship between periodontitis and hyperlipidemia, and 
may suggest the possibility of reducing the risk of coronary heart disease by effective 
periodontal intervention. 
C-reactive protein is an important marker for systemic inflammation, and has been 
consistently found to be elevated in patients with coronary syndromes. Recently, evidence 
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has accumulated demonstrating the association between periodontitis and C-reactive 
protein. The serum C-reactive protein concentration is increased in systemically healthy 
subjects with periodontitis. Numerous studies indicate that periodontal intervention 
therapy may decrease the C-reactive protein-associated cardiovascular disease risk. 
Many cytokines play a role in the pathogenesis of both coronary heart disease and 
periodontitis. These include interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor-a, 
intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-selectin. Some intervention 
studies have indicated that periodontal therapy can reduce the levels of these pro-inflammory 
cytokines, and thus periodontal treatment may lower the cardiovascular disease risk. 
Numerous studies of different design and rigor have provided statistical evidence for an 
association between periodontal disease and cardiovascular disease, raising the possibility 
that periodontal disease is a risk factor for cardiovascular disease. There are several 
proposed mechanisms (Fig. 1) by which periodontal disease may trigger pathways leading 
to cardiovascular disease through direct and indirect effects of oral bacteria. First, evidence 
indicates that oral bacteria such as Streptococcus sanguis and Porphyromonas gingivalis induce 
platelet aggregation, which leads to thrombus formation. These organisms have a collagen-
like molecule, the platelet aggregation- associated protein, on their surface. Furthermore, 
one or more periodontal pathogens have been found in 42% of the atheromas studied in 
patients with severe periodontal disease (Zambon, 1998). The second factor in this process 
could be an exaggerated host response to a given microbial or LPS challenge, as reflected in 
the release of high levels of proinflammatory mediators such as PGE2, TNF-a, and IL-1b. 
These mediators have been related to interindividual differences in the T-cell repertoire and 
the secretory capacity of monocytic cells. Typically, peripheral blood monocytes from these 
individuals with the hyperinflammatory monocyte phenotype secrete 3- to 10-fold-greater 
amounts of these mediators in response to LPS than those from normal monocyte 
phenotype individuals. Patients with certain forms of periodontal disease, such as early-
onset periodontitis and refractory periodontitis, possess a hyperinflammatory monocyte 
phenotype. A third mechanism possibly involves the relationship between bacterial and 
inflammatory products of periodontitis and cardiovascular disease. LPS from periodontal 
organisms being transferred to the serum as a result of bacteraemias or bacterial invasion 
may have a direct effect on endothelia so that atherosclerosis is promoted (Pesonen et al., 
1981). LPS may also elicit recruitment of inflammatory cells into major blood vessels and 
stimulate proliferation of vascular smooth muscle, vascular fatty degeneration, intravascular 
coagulation, and blood platelet function. These changes are the result of the action of 
various biologic mediators, such as PGs, ILs, and TNF-a on vascular endothelium and 
smooth muscle. Fibrinogen and WBC count increases noted in periodontitis patients may be 
a secondary effect of the above mechanisms or a constitutive feature of those at risk for both 
cardiovascular disease and periodontitis (Kweider et al., 1993).  
If so, periodontal disease, because it is both preventable and treatable, becomes a modifiable 
risk factor for cardiovascular disease. However, if periodontal disease is primarily due to the 
overgrowth of bacteria in the dental plaque, all individuals would need preventive 
treatment, since all individuals form dental plaque. 
5.1 Atherosclerosis 
Atherosclerosis has been defined as a progressive disease process that involves large- to 
medium-sized muscular and large elastic arteries. The advanced lesion is the atheroma, 
 
Inflammatory Diseases – A Modern Perspective 
 
140 
4.1 Shared risk factors 
Factors that place individuals at high risk for periodontitis may also place them at high risk 
for systemic diseases such as cardiovascular disease. Among the environmental risk factors 
and indicators shared by periodontitis and systemic diseases, such as cardiovascular 
disease, are tobacco smoking, stress, aging, race or ethnicity, and male gender. Studies 
demonstrating genetic factors shared by periodontitis, cardiovascular disease, preterm 
labor, and osteoporosis have not yet been performed but may be fruitful. 
4.2 Subgingival biofilms 
Subgingival biofilms constitute an enormous and continuing bacterial load. They present 
continually renewing reservoirs of LPS and other gram-negative bacteria with ready access 
to the periodontal tissues and the circulation. Systemic challenge with gram-negative 
bacteria or LPS induces major vascular responses, including an inflammatory cell infiltrate 
in the vessel walls, vascular smooth muscle proliferation, vascular fatty degeneration, and 
intravascular coagulation. LPS upregulates expression of endothelial cell adhesion 
molecules and secretion of interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-a), and 
thromboxane, which results in platelet aggregation and adhesion, formation of lipidladen 
foam cells, and deposits of cholesterol and cholesterol esters. 
4.3 Periodontium as cytokine reservoir 
The proinflammatory cytokines TNF-a, IL-1b, and gamma interferon as well as 
prostaglandin E2 (PGE2) reach high tissue concentrations in periodontitis. The 
periodontium can therefore serve as a renewing reservoir for spillover of these mediators, 
which can enter the circulation and induce and perpetuate systemic effects. IL-1b favors 
coagulation and thrombosis and retards fibrinolysis. IL-1, TNF-a, and thromboxane can 
cause platelet aggregation and adhesion, formation of lipidladen foam cells, and deposition 
of cholesterol. These same mediators emanating from the diseased periodontium may also 
account for preterm labor and low-birth-weight infants (Page,  1998). 
5. Cardiovascular disease 
Cardiovascular disease and periodontal disease are both chronic inflammatory diseases. 
Numerous cross-sectional and longitudinal epidemiological studies have provided evidence 
that there is an association between periodontitis and elevated risk for cardiovascular 
disease. A number of systematic reviews and meta-analyses have described the relationship 
between periodontal infection and cardiovascular disease, and have suggested that 
periodontitis may contribute to cardiovascular disease and stroke in susceptible subjects. 
It is well accepted that hyperlipidemia is a risk factor for coronary heart disease. Recent 
studies have shown an association between periodontitis and elevated atherogenic lipid 
fraction levels and  or decreased anti-atherogenic lipid fraction levels. Most of these were 
cross-sectional studies, and it is still unclear whether there is a causal relationship between 
periodontitis and hyperlipidemia. Improvement of serum lipid profiles after periodontal 
treatment may indicate a causal relationship between periodontitis and hyperlipidemia, and 
may suggest the possibility of reducing the risk of coronary heart disease by effective 
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which consists of elevated focal intimal plaques with a necrotic central core containing lysed 
cells, cholesterol ester crystals, lipid-laden foam cells, and surface plasma proteins, 
including fibrin and fibrinogen. In the last few years there were an increasing number of 
reports dealing with the possible relationship between atherosclerosis and periodontitis, as 
well as between chronic coronary heart disease and periodontitis (Fien et al., 2005; Ford et 
al., 2006; Pucar et al., 2007; Spahr et al., 2006). Arteries have been thoroughly explored for 
the presence of periodontopathogens and a variety of oral microorganisms have been found 
lodged in arterial walls.  
 
 
Fig. 7. Coronary artery with stable atheroma. Inflammation and necrosis have replaced the 
smooth muscle but there is a dense layer of collagen next to lumen (arrows) 
 
 
Fig. 8. Circulating oral bacteria have peptides that cause platelet aggregation (arrows) 
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There are sufficient data to consider that A.actimomycetamcomitans, P. gingivalis and P. 
intermedia have the ability to invade host cells including epithelium and endothelium 
evading the neutrophil clearance; in this way periodontal pathogens can penetrate the 
epithelial barrier of the periodontal tissues and get systemic spreading through the blood 
stream. By this dynamic, periodontal pathogens can infect directly the vascular 
endothelium, and atherosclerotic plaques, causing inflammation and plaque instability up to 
an acute myocardial ischemia. Moreover, periodontal pathogens produce a variety of 
virulence factors (e.g. adhesions, portliness, haemolysins, membrane vesicles and LPS) that 
have deleterious effects on vascular system, resulting in platelet aggregation and adhesion, 
formation of lipid-laden foam cells and deposits of cholesterol, all factors contributing to the 
formation of atheroma. 
Endothelial dysfunction is a fundamental step in the development of atherosclerosis, and 
can be measured by several methods, including flow-mediated dilatation of the brachial 
artery. Endothelial dysfunction as determined by measurement of brachial flow-mediated 
dilatation is considered to be a good predictor of cardiovascular outcomes (Roquer et al., 
2009). 
Periodontal disease is associated with endothelial dysfunction as measured by brachial 
flow-mediated dilatation. Endothelial function has been reported to be significantly lower in 
patients with periodontitis than in control subjects. In addition, endothelial dysfunction in 
hypertensive patients with periodontitis is more severe compared to hypertensive patients 
without periodontitis (Higashi et al., 2009). Recently, endothelial function was evaluated in 
healthy and periodontitis patients with coronary artery disease (Higashi et al., 2008). The 
results showed that endothelial function was significantly lower in the periodontitis group 
with coronary artery disease than in the nonperiodontitis group with coronary artery 
disease. These results suggest that periodontitis is a contributor to endothelial dysfunction, 
and hence could increase the risk of cardiovascular disease. Based on current evidence, 
periodontal therapy can improve endothelial dysfunction in periodontitis patients whether 
they are systemically healthy or have hypertension. This further confirms the causal 
association between periodontitis and endothelial dysfunction. As endothelial dysfunction 
is associated with an adverse prognosis for atherosclerosis and cardiovascular disease, 
periodontal intervention therapy may bring benefits to patients with periodontitis by 
improving endothelial function, thus reducing the risk of cardiovascular disease. However, 
this requires further study. 
6. Diabetes mellitus  
Recent findings indicate that oral health may influence systemic health, and that this may be 
a bi-directional relationship for some conditions. This is particularly true for the relationship 
between periodontal disease and diabetes mellitus. The inter-relationship between 
periodontal disease and diabetes mellitus provides an example of a cyclic association,  
whereby a systemic disease predisposes the individual to oral infections, and, once the oral 
infection is established, it exacerbates the systemic disease. 
The inflammatory response in the periodontal tissues in response to challenge by dental 
biofilm is complex and involves networks of cytokines functioning in synergy. The 
inflammatory response is characterized by localized production of various inflammatory 
markers and enzymes, such as C-reactive proteins, cytokines (interleukin-1b, interleukin- 6, 
tumor necrosis factor α), prostanoids (prostaglandin E2) and matrix metalloproteinases. 
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These increased secretions of inflammatory cytokines contribute to bone loss in 
periodontitis. The balance between the protective host factors and microbial challenge is 
greatly influenced by environmental and genetic factors that have an impact on the 
immuno-inflammatory response of the host. Alterations in immunologically active 
molecules as a result of diabetes may alter the levels of cytokines in the periodontium, 
which accelerates progression of the disease. This is the scientific basis for the increased 
susceptibility to periodontal disease seen in diabetics. 
Patients with diabetes exhibited greater periodontal breakdown in response to dental 
biofilm; however, this depended on the degree of glycemic control (Arrieta-Blanco et al., 
2003; Bastard et al., 2006). The highest levels of gingivitis were seen in diabetic patients with 
poor glycemic control (Mealey, 2006). Clinical and epidemiological studies have reported a 
higher prevalence and increased severity of periodontal disease in diabetic patients 
compared with non-diabetic controls (Ciancola et al., 1982; Collin et al., 1998; Safkan-
Seppala et at., 1992). Studies have shown that diabetes carries a threefold increased risk of 
periodontitis compared to non-diabetic individuals (Lo¨e et al., 1978; Sclossman et al., 1990). 
Alveolar bone loss is enhanced in these individuals, resulting in a more persistent 
inflammatory response in diabetics. This leads to greater attachment loss and impaired 
formation of new bone (Liu et al., 2006). In addition, Lo¨e (Lo¨e, 1993) described 
periodontitis as the 6th complication of diabetes, together with retinopathy, nephropathy, 
neuropathy, macrovascular diseases and altered wound healing. The complications of 
diabetes are related to long-term elevation of blood glucose concentrations 
(hyperglycaemia) that results in the formation of advanced glycation end-products (AGEs). 
The accumulation of AGEs increases the intensity of the immune-inflammatory response to 
different pathogens, because inflammatory cells such as monocytes and macrophages have 
receptors for AGEs with consequent increased production of IL-1β and TNF-α. The AGEs-
enriched gingival tissue has greater vascular permeability, greater breakdown of collagen 
fibers and accelerated destruction of both non-mineralized connective tissue and bone 
occurs. Diabetes can also cause damage of neutrophil adhesion, chemotaxis and 
phagocytosis, making patients more susceptible to periodontal destruction. The effects of 
the hyperglycemic state include the inhibition of osteoblastic proliferation and collagen 
production. Several studies indicated that diabetes is associated with an increased 
prevalence, extent and severity of chronic periodontitis. Other studies have suggested that 
the presence of periodontal infection may be linked to poor metabolic control of diabetes 
(Southerland et al., 2005). Treatment of periodontal disease can alter glycemic control, and 
early intervention and treatment of periodontitis may help to prevent the long-term 
complications of diabetes, thereby having an impact on mortality. 
7. Bacterial pneumonia  
Pneumonia is an infection of pulmonary parenchyma caused by a wide variety of infectious 
agents, including bacteria, fungi, parasites, and viruses. Pneumonia can be a life-threatening 
infection, especially in the old and immunocompromised patient, and is a significant cause 
of morbidity and mortality in patients of all ages. Most commonly, bacterial pneumonia 
results from aspiration of oropharyngeal flora into the lower respiratory tract, failure of host 
defense mechanisms to eliminate them, multiplication of the microorganisms, and 
subsequent tissue destruction. It is likely that most pathogens first colonize the surfaces of 
the oral cavity or pharyngeal mucosa before aspiration. These pathogens can colonize from 
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an exogenous source or emerge following overgrowth of the normal oral flora after 
antibiotic treatment. Common potential respiratory pathogens (PRPs) such as Streptococcus 
pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae can colonize the oropharynx 
and be aspirated into the lower airways. Other species thought to comprise the normal oral 
flora, including A. actinomycetemcomitans and anaerobes such as P. gingivalis and 
Fusobacterium species, can also be aspirated into the lower airways and cause pneumonia. 
Pneumonia can result from infection by anaerobic bacteria. Dental plaque would seem to be 
a logical source of these bacteria, especially in patients with periodontal disease. Such 
patients harbor a large number of subgingival bacteria, particularly anaerobic species. 
Among the oral bacterial species implicated in pneumonia are A. actinomycetemcomitans, 
Actinomyces israelii, Capnocytophaga spp., Eikenella corrodens, Prevotella intermedia, and 
Streptococcus constellatus. A study has shown that individuals with respiratory disease have 
significantly higher oral hygiene index scores than subjects without respiratory disease.  
8. Low birth weight  
Pregnancy can influence gingival health. Changes in hormone levels during pregnancy 
promote an inflammation termed pregnancy gingivitis. This type of gingivitis may occur 
without changes in plaque levels. Oral contraceptives may also produce changes in gingival 
health. Some birth control pill users have a high gingival inflammation level but a low 
plaque level. Birth control pills may cause changes such as alteration of the 
microvasculature, gingival permeability, and increased synthesis of estrogen. 
Oral infections also seem to increase the risk for or contribute to low birth weight in 
newborns. Low birth weight, defined as a birth weight of <2,500 g, is a major public health 
problem in both developed and developing countries. As a remote gram-negative infection, 
periodontal disease may have the potential to affect pregnancy outcome. During pregnancy, 
the ratio of anaerobic gram-negative bacterial species to aerobic species increases in dental 
plaque in the second trimester. The gram-negative bacteria associated with progressive 
disease can produce a variety of bioactive molecules that can directly affect the host. One 
microbial component, LPS, can activate macrophages and other cells to synthesize and 
secrete a wide array of molecules, including the cytokines IL-1b, TNF-a, IL-6, and PGE2 and 
matrix metalloproteinases. If they escape into the general circulation and cross the placental 
barrier, they could augment the physiologic levels of PGE2 and TNF-a in the amniotic fluid 
and induce premature labor. 
Human case-control studies have demonstrated that women who have low-birth-weight 
infants as a consequence of either preterm labor or premature rupture of membranes tend to 
have more severe periodontal disease than mothers with normal- birth-weight infants. In a 
recent case-control study, 48 case-control subjects had their gingival crevicular fluid (GCF) 
levels of PGE2 and IL-1b measured to determine whether mediator levels are related to 
current pregnancy outcome. In addition, the levels of four periodontal pathogens were 
measured by using microbespecific DNA probes. The results indicate that GCF PGE2 levels 
are significantly higher in mothers of preterm low-birthweight infants than in mothers of 
normal-birth-weight infants (controls). These data suggest a dose-response relationship for 
increased GCF PGE2 as a marker of current periodontal disease activity and decreasing 
birth weight. Four organisms associated with mature plaque and progressing periodontitis, 
Bacteroides forsythus, P. gingivalis, A. actinomycetemcomitans, and Treponema denticola, are 
 
Inflammatory Diseases – A Modern Perspective 
 
144 
These increased secretions of inflammatory cytokines contribute to bone loss in 
periodontitis. The balance between the protective host factors and microbial challenge is 
greatly influenced by environmental and genetic factors that have an impact on the 
immuno-inflammatory response of the host. Alterations in immunologically active 
molecules as a result of diabetes may alter the levels of cytokines in the periodontium, 
which accelerates progression of the disease. This is the scientific basis for the increased 
susceptibility to periodontal disease seen in diabetics. 
Patients with diabetes exhibited greater periodontal breakdown in response to dental 
biofilm; however, this depended on the degree of glycemic control (Arrieta-Blanco et al., 
2003; Bastard et al., 2006). The highest levels of gingivitis were seen in diabetic patients with 
poor glycemic control (Mealey, 2006). Clinical and epidemiological studies have reported a 
higher prevalence and increased severity of periodontal disease in diabetic patients 
compared with non-diabetic controls (Ciancola et al., 1982; Collin et al., 1998; Safkan-
Seppala et at., 1992). Studies have shown that diabetes carries a threefold increased risk of 
periodontitis compared to non-diabetic individuals (Lo¨e et al., 1978; Sclossman et al., 1990). 
Alveolar bone loss is enhanced in these individuals, resulting in a more persistent 
inflammatory response in diabetics. This leads to greater attachment loss and impaired 
formation of new bone (Liu et al., 2006). In addition, Lo¨e (Lo¨e, 1993) described 
periodontitis as the 6th complication of diabetes, together with retinopathy, nephropathy, 
neuropathy, macrovascular diseases and altered wound healing. The complications of 
diabetes are related to long-term elevation of blood glucose concentrations 
(hyperglycaemia) that results in the formation of advanced glycation end-products (AGEs). 
The accumulation of AGEs increases the intensity of the immune-inflammatory response to 
different pathogens, because inflammatory cells such as monocytes and macrophages have 
receptors for AGEs with consequent increased production of IL-1β and TNF-α. The AGEs-
enriched gingival tissue has greater vascular permeability, greater breakdown of collagen 
fibers and accelerated destruction of both non-mineralized connective tissue and bone 
occurs. Diabetes can also cause damage of neutrophil adhesion, chemotaxis and 
phagocytosis, making patients more susceptible to periodontal destruction. The effects of 
the hyperglycemic state include the inhibition of osteoblastic proliferation and collagen 
production. Several studies indicated that diabetes is associated with an increased 
prevalence, extent and severity of chronic periodontitis. Other studies have suggested that 
the presence of periodontal infection may be linked to poor metabolic control of diabetes 
(Southerland et al., 2005). Treatment of periodontal disease can alter glycemic control, and 
early intervention and treatment of periodontitis may help to prevent the long-term 
complications of diabetes, thereby having an impact on mortality. 
7. Bacterial pneumonia  
Pneumonia is an infection of pulmonary parenchyma caused by a wide variety of infectious 
agents, including bacteria, fungi, parasites, and viruses. Pneumonia can be a life-threatening 
infection, especially in the old and immunocompromised patient, and is a significant cause 
of morbidity and mortality in patients of all ages. Most commonly, bacterial pneumonia 
results from aspiration of oropharyngeal flora into the lower respiratory tract, failure of host 
defense mechanisms to eliminate them, multiplication of the microorganisms, and 
subsequent tissue destruction. It is likely that most pathogens first colonize the surfaces of 
the oral cavity or pharyngeal mucosa before aspiration. These pathogens can colonize from 
 
Periodontal Inflammation as Risk Factor for Pancreatic Diseases 
 
145 
an exogenous source or emerge following overgrowth of the normal oral flora after 
antibiotic treatment. Common potential respiratory pathogens (PRPs) such as Streptococcus 
pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae can colonize the oropharynx 
and be aspirated into the lower airways. Other species thought to comprise the normal oral 
flora, including A. actinomycetemcomitans and anaerobes such as P. gingivalis and 
Fusobacterium species, can also be aspirated into the lower airways and cause pneumonia. 
Pneumonia can result from infection by anaerobic bacteria. Dental plaque would seem to be 
a logical source of these bacteria, especially in patients with periodontal disease. Such 
patients harbor a large number of subgingival bacteria, particularly anaerobic species. 
Among the oral bacterial species implicated in pneumonia are A. actinomycetemcomitans, 
Actinomyces israelii, Capnocytophaga spp., Eikenella corrodens, Prevotella intermedia, and 
Streptococcus constellatus. A study has shown that individuals with respiratory disease have 
significantly higher oral hygiene index scores than subjects without respiratory disease.  
8. Low birth weight  
Pregnancy can influence gingival health. Changes in hormone levels during pregnancy 
promote an inflammation termed pregnancy gingivitis. This type of gingivitis may occur 
without changes in plaque levels. Oral contraceptives may also produce changes in gingival 
health. Some birth control pill users have a high gingival inflammation level but a low 
plaque level. Birth control pills may cause changes such as alteration of the 
microvasculature, gingival permeability, and increased synthesis of estrogen. 
Oral infections also seem to increase the risk for or contribute to low birth weight in 
newborns. Low birth weight, defined as a birth weight of <2,500 g, is a major public health 
problem in both developed and developing countries. As a remote gram-negative infection, 
periodontal disease may have the potential to affect pregnancy outcome. During pregnancy, 
the ratio of anaerobic gram-negative bacterial species to aerobic species increases in dental 
plaque in the second trimester. The gram-negative bacteria associated with progressive 
disease can produce a variety of bioactive molecules that can directly affect the host. One 
microbial component, LPS, can activate macrophages and other cells to synthesize and 
secrete a wide array of molecules, including the cytokines IL-1b, TNF-a, IL-6, and PGE2 and 
matrix metalloproteinases. If they escape into the general circulation and cross the placental 
barrier, they could augment the physiologic levels of PGE2 and TNF-a in the amniotic fluid 
and induce premature labor. 
Human case-control studies have demonstrated that women who have low-birth-weight 
infants as a consequence of either preterm labor or premature rupture of membranes tend to 
have more severe periodontal disease than mothers with normal- birth-weight infants. In a 
recent case-control study, 48 case-control subjects had their gingival crevicular fluid (GCF) 
levels of PGE2 and IL-1b measured to determine whether mediator levels are related to 
current pregnancy outcome. In addition, the levels of four periodontal pathogens were 
measured by using microbespecific DNA probes. The results indicate that GCF PGE2 levels 
are significantly higher in mothers of preterm low-birthweight infants than in mothers of 
normal-birth-weight infants (controls). These data suggest a dose-response relationship for 
increased GCF PGE2 as a marker of current periodontal disease activity and decreasing 
birth weight. Four organisms associated with mature plaque and progressing periodontitis, 
Bacteroides forsythus, P. gingivalis, A. actinomycetemcomitans, and Treponema denticola, are 
 
Inflammatory Diseases – A Modern Perspective 
 
146 
detected at higher levels in mothers of preterm low-birth-weight infants than in controls. 
These data suggest that biochemical measures of maternal periodontal status and oral 
microbial burden are associated with preterm birth and low birth weight. 18.2% of preterm 
low-birth-weight babies may result from periodontal disease— a previously unrecognized 
and clinically important risk factor for preterm birth and low birth weight. The association 
between periodontal disease and low birth weight may reflect the patient’s altered immune-
inflammatory trait that places the patient at risk for both conditions. 
Thus, periodontitis may be a marker for preterm delivery susceptibility as well as a potential 
risk factor. Indeed, the data from animal models suggest that even if periodontal disease is 
not the primary cause of prematurity, in a subset of patients it may serve as a contributor to 
the condition. Currently, there is insufficient evidence to link chronic periodontitis to 
specific adverse pregnancy outcomes. 
9. Cancer associated with chronic inflammation  
Various sudies confirmed that malignancies may arise from areas of infection and 
inflammation, simply as part of the normal host response. Indeed, there is a growing body 
of evidence that many malignancies are initiated by infections (Kuper et al., 2000; Sachter et 
al., 2002). Persistent infections within the host induce chronic inflammation. Leukocytes and 
other phagocytic cells induce DNA damage in proliferating cells, through their generation of 
reactive oxygen and nitrogen species that are produced normally by these cells to fight 
infection. These species react to form peroxynitrite, a mutagenic agent (Maeda &Akaike, 
1998). Hence, repeated tissue damage and regeneration of tissue, in the presence of highly 
reactive nitrogen and oxygen species released from inflammatory cells, interacts with DNA 
in proliferating epithelium resulting in permanent genomic alterations such as point 
mutations, deletions, or chromosomal rearrangements. 
More recently, a link between periodontal disease and cancer has been suggested. The 
scientific rationale behind the proposed association is that inflammation is a major factor in 
both periodontal disease and cancer.  
Oral cancer, gingival squamous cell carcinoma in particular, has been known to mimic 
advanced periodontal disease in clinical appearance showing similar symptoms of swelling, 
bleeding, tooth mobility, deep periodontal pockets, and bone destruction. Many cases have 
been reported of gingival squamous cell carcinoma presenting clinically similar to 
inflammatory periodontal or periodontal/endodontic lesions. Cases of other types of cancer 
mistaken for periodontal disease such as metastatic pancreatic cancer and osteogenic 
sarcoma have also been reported. These examples hint that a similar underlying mechanism 
may be responsible for both periodontal disease and cancer. 
9.1 Cancers and periodontal disease 
Several hypotheses are of interest in the potential etiology of a link between, periodontal 
disease and cancer. 
9.1.1 Alteration of the oral flora 
It has been suggested that carcinogenic metabolic by-products of periodontal disease might 
account for the relationship between the two diseases. When considering gastric cancers, it 
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had been argued that the mechanism of increased cancer risk may be an increased 
production of nitrosamines in situations of poor oral hygiene and that these by-products 
may function as gastro-intestinal organ specific carcinogens. Nitrosamines have been linked 
to cancers of the stomach and esophagus. Helicobacter pylori infection also plays a role in 
stomach cancers (Zarić et al, 2009). Other microorganisms have been studied as well as 
potential carcinogenic agents. There is also evidence that some strains of candidiasis have 
been seen at higher frequency in oral cancer patients. Viruses may also play a role. A 
suggestion has been made that increased periodontal disease may be associated with 
infection with cytomegalovirus and/or Epstein-Barr Virus 1 with mixed results. EBV of 
course has been linked to cancer including lymphoma and nasopharyngeal carcinoma. 
9.1.2 Increase in systemic circulatory inflammatory markers 
The presence of inflammatory cells and mediators such as chemokines, cytokines, and 
prostaglandins represent indicators associated with tumors. Also, the immune response 
mounted to a chronic periodontal infection has been proposed as a potential carcinogenic 
etiologic factor. Also of interest is the relationship between the pro-inflammatory 
expression of the receptor for advanced glycation end products (RAGE) and esophageal, 
gastric, colon, biliary, pancreatic, and prostate cancers. RAGE has been shown to play a 
role in the inflammatory processes of oral infections including periodontal disease. There 
are several obstacles in accurately determining a relationship between, periodontal 
disease and cancer.  
9.1.3 Confounding factors 
Smoking appeared to be the main confounding factor among these studies, especially for 
cancers strongly linked to tobacco use such as lung cancer. Other potential confounding 
factors are socio-economic status, diabetes, age, gender and ethnicity, along with 
genetics.  
9.2 Chronic periodontitis as a risk factor for pancreatic cancer 
Cancer of the pancreas is a rapidly fatal tumor. Smoking is the only well-documented 
modifiable risk factors for this cancer, although data suggest that diabetes, obesity and 
insulin resistance are also risk factors. Alcohol consumption is not an established risk factor 
for pancreatic cancer, but there is a strong association between alcohol consumption and 
chronic pancreatitis, and the latter has been associated with a higher risk for pancreatic 
cancer. 
Although viral infections have been strongly associated with cancers, several bacteria can 
promote or initiate abnormal cell growth by evading the immune system or suppressing 
apoptosis. Since periodontitis is a chronic oral bacterial infection, few authors have 
suggested a possible positive association between periodontitis and pancreatic cancer. 
Chronic periodontitis might promote pancreatic carcinogenesis, by means of systemic 
inflammation, or alternatively, through increased production of carcinogens, namely 
nitrosamines. Nitrosamines and gastric acidity have been suggested as factors that have an 
important role in pancreatic cancer, and tooth loss that occurs through poor dental hygiene 
may be a marker for more deleterious gastrointestinal flora and, consequently, greater 
endogenous nitrosation. In fact, endogenous formation of nitrosamines in the oral cavity in 
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It has been suggested that carcinogenic metabolic by-products of periodontal disease might 
account for the relationship between the two diseases. When considering gastric cancers, it 
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had been argued that the mechanism of increased cancer risk may be an increased 
production of nitrosamines in situations of poor oral hygiene and that these by-products 
may function as gastro-intestinal organ specific carcinogens. Nitrosamines have been linked 
to cancers of the stomach and esophagus. Helicobacter pylori infection also plays a role in 
stomach cancers (Zarić et al, 2009). Other microorganisms have been studied as well as 
potential carcinogenic agents. There is also evidence that some strains of candidiasis have 
been seen at higher frequency in oral cancer patients. Viruses may also play a role. A 
suggestion has been made that increased periodontal disease may be associated with 
infection with cytomegalovirus and/or Epstein-Barr Virus 1 with mixed results. EBV of 
course has been linked to cancer including lymphoma and nasopharyngeal carcinoma. 
9.1.2 Increase in systemic circulatory inflammatory markers 
The presence of inflammatory cells and mediators such as chemokines, cytokines, and 
prostaglandins represent indicators associated with tumors. Also, the immune response 
mounted to a chronic periodontal infection has been proposed as a potential carcinogenic 
etiologic factor. Also of interest is the relationship between the pro-inflammatory 
expression of the receptor for advanced glycation end products (RAGE) and esophageal, 
gastric, colon, biliary, pancreatic, and prostate cancers. RAGE has been shown to play a 
role in the inflammatory processes of oral infections including periodontal disease. There 
are several obstacles in accurately determining a relationship between, periodontal 
disease and cancer.  
9.1.3 Confounding factors 
Smoking appeared to be the main confounding factor among these studies, especially for 
cancers strongly linked to tobacco use such as lung cancer. Other potential confounding 
factors are socio-economic status, diabetes, age, gender and ethnicity, along with 
genetics.  
9.2 Chronic periodontitis as a risk factor for pancreatic cancer 
Cancer of the pancreas is a rapidly fatal tumor. Smoking is the only well-documented 
modifiable risk factors for this cancer, although data suggest that diabetes, obesity and 
insulin resistance are also risk factors. Alcohol consumption is not an established risk factor 
for pancreatic cancer, but there is a strong association between alcohol consumption and 
chronic pancreatitis, and the latter has been associated with a higher risk for pancreatic 
cancer. 
Although viral infections have been strongly associated with cancers, several bacteria can 
promote or initiate abnormal cell growth by evading the immune system or suppressing 
apoptosis. Since periodontitis is a chronic oral bacterial infection, few authors have 
suggested a possible positive association between periodontitis and pancreatic cancer. 
Chronic periodontitis might promote pancreatic carcinogenesis, by means of systemic 
inflammation, or alternatively, through increased production of carcinogens, namely 
nitrosamines. Nitrosamines and gastric acidity have been suggested as factors that have an 
important role in pancreatic cancer, and tooth loss that occurs through poor dental hygiene 
may be a marker for more deleterious gastrointestinal flora and, consequently, greater 
endogenous nitrosation. In fact, endogenous formation of nitrosamines in the oral cavity in 
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individuals with poor oral hygiene is due to elevated levels of nitrate-reducing oral bacteria, 
including H. pylori. The association between H. pylori infection and pancreatic cancer was 
investigated, but this association could not be confirmed. 
A recent study has also suggested positive association between periodontitis and pancreatic 
cancer risk. Myeloperoxidase and superoxide dismutase help to regulate inflammation and 
are found to be elevated in periodontitis, and polymorphisms of these genes have been 
associated with elevated pancreatic cancer risk. 
10. Methods  
10.1 Patients 
Pancreatic tissue specimens were obtained from patients undergoing surgery for ANP (40) 
and for PC (20) at the Surgical Clinic of the Medical Center of Serbia. The research protocol 
received institutional evaluation and approval (Ethical Committee of the School of 
Dentistry, Belgrade). Periodontal evaluation was performed in the hospital, a day before 
planned surgical procedures, and included assessment of pocket depth (PD in mm) and 
clinical attachment loss (CAL in mm) at six points of every present tooth (mesio-buccal, 
mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). The clinical parameters 
were evaluated with a periodontal probe (XP 23/UNC-15). All measurements were 
performed by a single periodontist (A.P.). Chronic periodontitis was defined by the 
presence of at least 4 non-adjacent teeth with sites CAL≥4mm and PD≥5mm (Okuda et al., 
2001). All patients that had been taking antibiotics in the previous three months and/or 
received periodontal treatment were excluded.  
12 pancreas specimens obtained during autopsies performed at the Institute of Pathology, 
School of Medicine, University of Belgrade were also included in the study and used as 
controls. The cause of death was not related to pancreas. 
Immediately after being taken, the specimens were frozen at -20 C until further 
processing. 
10.2 Bacterial DNA detection by PCR 
Tissue specimens were treated with proteinase K at 56°C for 30 minutes, followed by 10 
minutes of proteinase K inactivation at 95°C and 5 minutes centrifugation in a microfuge to 
pellet cell debris. 
The PCR was performed in volumes of 25 l containing PCR/Mg++ buffer, 0.2 mM of each 
dNTP, 0.2 M of each primer, 0.5 U Taq DNA polymerase and 3-5 l of template DNA 
containing supernatant. 
The amplification was performed in a DNA Thermal Cycler (Hybaid) programmed at 94°C 
(5 minutes) followed by 35 cycles at 94°C (1 min), annealing temperatures adequate for each 
primer pair (1 min) and extension at 72°C (1 minute 30 seconds) plus a final extension at 
72°C (5 min). The PCR amplified fragments were visualized in an 8% polyacrylamide gel 
stained with ethidium bromide, on an ultraviolet transilluminator.  
Peridontopathogens were detected by means of primer specific PCR. The list of primers, the 
annealing temperatures as well as the length of the products are given in Table 1. P. 
gingivalis and A. actinomycetemcomitans were amplified in the same multiplex PCR reaction, 
whilst T. Forshytia and P. Intermedia were coamplified in another multiplex reaction. E. 
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corrodens was amplified separately. Specimens of subgingival dental plaque, positive for 
those microorganisms were used as positive controls. For the negative control, DNA sample 
was omitted and replaced by water. 
 





AGA GTT TGA TCC TGG CTC AG 
CAA TAC TCG TAT CGC CCG TTA TTC 55 460 bp 
Aggregatibacter 
actinomycetemcomitans
AGA GTT TGA TCC TGG CTC AG 
CAC TTA AAG GTC CGC CTA CGT GC 55 600 bp 
Tannerella forsythia AGA GTT TGA TCC TGG CTC AG GTA GAG CTT ACA CTA TAT CGC AAA CTC CTA 53 840 bp 
Prevotella intermedia AGA GTT TGA TCC TGG CTC AG GTT GCG TGC ACT CAA GTC CGC C 53 660 bp 
Eikenella corrodens CTA ATA CCG CAT ACG TCC TAA G CTA CTA AGC AAT CAA GTT GCC C 53 800 bp 
Table 1. Primer sequences, annealing temperatures and size of obtained PCR products used 
for the detection of tested bacteria 
11. Results  
All 60 patients included in the study were diagnosed as chronic generalized periodontitis 
with a mean value of PD 3.12±0.35mm and CAL 2.79±0.82mm. 
A total of 72 specimens have been tested for the presence of 5 different 
periodontopathogens. The result was considered to be positive if a band of expected size 
was present on the gel. There was no attempt of sequencing the PCR products or 
quantifying the infectious agents by real-time PCR. 7 out of 40 specimens of acute 
necrotizing pancreatitis were positive for the presence of: E. corrodens (3 cases), A. 
actinomycetemcomitans (1 case), P. intermedia (1 case), T. forsythia (3 cases, Fig. 9), and T. 
forsythia and P. intermedia simultaneously (1 case). In one specimen of pancreatic cancer P. 
intermedia could be detected. Interestingly, two control specimens obtained from cadavers 
(cause of death was liver cirrhosis) harbored oral microorganisms. 
 
 
Fig. 9. Polyacrylamide gel electrophoresis showing bands that represent the product of PCR 
amplification corresponding to Tannerella forsythia 
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corrodens was amplified separately. Specimens of subgingival dental plaque, positive for 
those microorganisms were used as positive controls. For the negative control, DNA sample 
was omitted and replaced by water. 
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Data on tissue specimen origin and PCR findings are summarized in Table 2. 
 
Tissue no Pg Aa Pi Tf Ec 
ANP 40  1 2 2 3 
PC 20   1   
NP 12   1 1  
Table 2. The presence of periodontal pathogens in pancreatic tissue. ANP - acute necrotizing 
pancreatitis, PC - pancreatic cancer, NP - normal pancreatic tissue obtained post-mortem, Pg 
– Porphyromonas ginivalis, Aa – Aggregatibacter actinomycetemcomitans, Pi – Prevotella 
intermedia, Tf - Tannerella forsythia, Ec – Eikenella corroden 
12. Conclusion  
To the best of our knowledge, this is the first time that E. corrodens, A. actinomycetemcomitans, 
P. intermedia and B. forsythia have been described in ANP. Even though it is for some time 
obvious that periodontal pathogens can enter the circulation, causing transient bacteraemia, 
there were no systematic assessments of potential association between oral bacteria and 
extraoral infections. Although Eikenella species, for instance, have been shown to cause 
endocarditis and intraabdominal infection, they are considered a very rare etiological agent 
(Danzinger et al., 1994; Watkin et al., 2002). Interestingly, we found E. corrodens in three 
cases of acute necrotizing pancreatitis. Four other cases of ANP harbored other periodontal 
pathogens.  
Bacterial infections are usual complications in patients with acute pancreatitis but they 
typically include Salmonella, Campylobacter, Escherichia coli, Pseudomonas aeruginosa etc (Garg 
et al., 2001; Reimund et al., 2008). Generally, acute pancreatitis is not the primary 
manifestation of these infections. The presence of dental plaque bacteria in our cases of ANP 
does not exclude the simultaneous occurrence of other pathogens.  
Bacterial translocation which can be defined as the passage of intestinal microbes through 
the mucosa to internal organs is doubtlessly an important cause of pancreas infection. 
Nonetheless, other infection routes and infection sources should be considered as well, and 
the presence of periodontal microorganisms in ANP substantiates the hypothesis of 
alternative paths. Multiple risk factors of bacterial spreading, including surgery, tumour 
metastasis in the abdomen, compromising local anatomy and circulation, etc., are known to 
exist. Presumably, from abdominal aorta, where they can be found, oral bacteria are capable 
of reaching the main arteries supplying pancreas. Their presence in pancreatic tissue could 
be tentatively explained by compromised local circulation. The finding of bactDNA in two 
control pancreatic specimens, in which the cause of death was a non-pancreatic disease 
(cirrhosis), may be due to some contamination during autopsy. Infections in patients with 
cirrhosis are frequent and varied and their spreading in the peritoneum cannot be ruled out 
(Frances et al., 2008). In the present study, liver tissue has not been tested for the presence of 
periodontopathogens. 
The finding of only one case positive for P. intermedia in the pancreatic cancer group does 
not support the concept of direct oral bacteria involvement in the pathogenic processes, in 
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the same way as seen in atherosclerosis. On the other hand, pancreatic cancer has been 
previously related to different bacterial infections. Namely, Helicobacter DNA was detected 
in a very high percentage of pancreatic tumors and surrounding tissue (Nilson et al., 2006; 
Stolzenberg et at., 2001). As Helicobacter pylori is also frequently encountered in the oral 
cavity of individuals with periodontal disease (Souto et al., 2008, Zarić et al., 2009), its 
occurrence in the present cases of pancreatic cancer is very probable. A rising body of 
evidence supports the view on microbially induced and inflammation-driven malignancies 
(Engels et al., 2008; Lochhead&El-Omar, 2008; Michaud, 2007). 
Two large cohort studies looked at a link between pancreatic cancer and history of 
periodontal disease and found a significant association between the two (Michaud et al., 
2007, 2008). According to the authors periodontal disease might be a marker of a susceptible 
immune system or might directly affect cancer risk. Hujoel  found a significant association 
between pancreatic cancer and periodontitis measured by examination but again had a 
relatively small number of cases within their cohort. The results published by Michaud on 
increased incidence of pancreatic cancer among patients with periodontal disease could 
suggest a possible involvement of periodontopathogens in pancreatic cancer. Our study 
does not really confirm it, or at least does not point to direct, local contribution of oral 
microorganisms to the pathogenic process. Their role may be considered in terms of 
infection and chronic inflammation with systemic effect. 
The presence of periodontopathogens in various arteries, however, is an important finding. 
It means that oral microorganisms have theoretically the possibility to migrate to organs 
distant from their primary reservoir-the oral cavity, and invade them. Whether it will result 
in clinical or subclinical pathological changes remains uncertain. 
In periodontitis, periodontal pathogens and their products, as well as inflammatory 
mediators produced in periodontal tissues, might enter the bloodstream and contribute to 
the global inflammatory burden, causing systemic effects and/or contributing to systemic 
diseases. Several bacteria can promote or initiate abnormal cell growth by evading the 
immune system or suppressing apoptosis. Since periodontitis is a chronic oral bacterial 
infection, few authors have suggested a possible positive association between 
periodontitis and pancreatic cancer. To our knowledge, this is the first study which 
demonstrated the presence of periodontal bacteria in pancreatic tissue. Relatively low 
percentage of positive findings in our study does not represent a reliable proof of a link 
between periodontopathogens and pancreatic diseases. This might be explained by the 
fact that destruction of periodontal tissues in our study group was not extensive. Further 
researches to confirm association between periodontitis and pancreatic diseases are 
required. 
Epidemiological research (cross-sectional and longitudinal studies) can identify 
relationships but not causation. If some types of periodontal disease merely constitute an 
oral component of a systemic disorder or have etiological features in common with systemic 
diseases, periodontal and systemic diseases might frequently occur together without having 
a cause effect relationship (Slots, 1998). Medical community should be aware of the potential 
negative effects of periodontal infections on systemic health. First of all, periodontal 
infections must be recognized and treated, and then a regular oral care must be maintained. 
Nevertheless, with information accessible at the moment, it seems justified to state that good 
oral health is important to maintain good general health. 
 
Inflammatory Diseases – A Modern Perspective 
 
150 
Data on tissue specimen origin and PCR findings are summarized in Table 2. 
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cases of acute necrotizing pancreatitis. Four other cases of ANP harbored other periodontal 
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(cirrhosis), may be due to some contamination during autopsy. Infections in patients with 
cirrhosis are frequent and varied and their spreading in the peritoneum cannot be ruled out 
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not support the concept of direct oral bacteria involvement in the pathogenic processes, in 
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the same way as seen in atherosclerosis. On the other hand, pancreatic cancer has been 
previously related to different bacterial infections. Namely, Helicobacter DNA was detected 
in a very high percentage of pancreatic tumors and surrounding tissue (Nilson et al., 2006; 
Stolzenberg et at., 2001). As Helicobacter pylori is also frequently encountered in the oral 
cavity of individuals with periodontal disease (Souto et al., 2008, Zarić et al., 2009), its 
occurrence in the present cases of pancreatic cancer is very probable. A rising body of 
evidence supports the view on microbially induced and inflammation-driven malignancies 
(Engels et al., 2008; Lochhead&El-Omar, 2008; Michaud, 2007). 
Two large cohort studies looked at a link between pancreatic cancer and history of 
periodontal disease and found a significant association between the two (Michaud et al., 
2007, 2008). According to the authors periodontal disease might be a marker of a susceptible 
immune system or might directly affect cancer risk. Hujoel  found a significant association 
between pancreatic cancer and periodontitis measured by examination but again had a 
relatively small number of cases within their cohort. The results published by Michaud on 
increased incidence of pancreatic cancer among patients with periodontal disease could 
suggest a possible involvement of periodontopathogens in pancreatic cancer. Our study 
does not really confirm it, or at least does not point to direct, local contribution of oral 
microorganisms to the pathogenic process. Their role may be considered in terms of 
infection and chronic inflammation with systemic effect. 
The presence of periodontopathogens in various arteries, however, is an important finding. 
It means that oral microorganisms have theoretically the possibility to migrate to organs 
distant from their primary reservoir-the oral cavity, and invade them. Whether it will result 
in clinical or subclinical pathological changes remains uncertain. 
In periodontitis, periodontal pathogens and their products, as well as inflammatory 
mediators produced in periodontal tissues, might enter the bloodstream and contribute to 
the global inflammatory burden, causing systemic effects and/or contributing to systemic 
diseases. Several bacteria can promote or initiate abnormal cell growth by evading the 
immune system or suppressing apoptosis. Since periodontitis is a chronic oral bacterial 
infection, few authors have suggested a possible positive association between 
periodontitis and pancreatic cancer. To our knowledge, this is the first study which 
demonstrated the presence of periodontal bacteria in pancreatic tissue. Relatively low 
percentage of positive findings in our study does not represent a reliable proof of a link 
between periodontopathogens and pancreatic diseases. This might be explained by the 
fact that destruction of periodontal tissues in our study group was not extensive. Further 
researches to confirm association between periodontitis and pancreatic diseases are 
required. 
Epidemiological research (cross-sectional and longitudinal studies) can identify 
relationships but not causation. If some types of periodontal disease merely constitute an 
oral component of a systemic disorder or have etiological features in common with systemic 
diseases, periodontal and systemic diseases might frequently occur together without having 
a cause effect relationship (Slots, 1998). Medical community should be aware of the potential 
negative effects of periodontal infections on systemic health. First of all, periodontal 
infections must be recognized and treated, and then a regular oral care must be maintained. 
Nevertheless, with information accessible at the moment, it seems justified to state that good 
oral health is important to maintain good general health. 
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1. Introduction 
Polyunsaturated fatty acids and their metabolites are crucial to the physiologic and 
pathophysiologic processes in inflammation. The balance between n-6 and n-3 
polyunsaturated fatty acids in body tissues is a key to regulating the inflammatory reaction 
and preventing exacerbated inflammation in inflammatory disorders. Altering fatty acid 
type and their composition in phospholipids through diet supplements for beneficial 
outcomes in disease has been of major interest to the community. The sources of 
polysaturated fatty acid include de novo synthesis, essential fatty acids obtained from the 
diet, elongation and desaturation to obtain fatty acids of longer chain length by tissues.  
The types of fatty acids being esterified in membrane phospholipids provide a characteristic 
fatty acid composition of the phospholipids which can dictate the characteristics of the 
inflammatory response depending on the types of metabolites of polyunsaturated fatty 
acids formed through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways, either 
promoting or inhibiting the inflammatory process, by controlling intracellular signalling 
pathways, such as PKC, MAP kinases, PI3 kinase etc 
While focusing on the use of n-3 polyunsaturated fatty acids in treating rheumatoid 
arthritis, cardiovascular diseases and asthma, it is highlighted that such treatments are at a 
‘cross road’ because of poor understanding of the field of lipidomics and in 
supplementation approaches in those with various illnesses, including inflammatory 
diseases. 
2. Sources of arachidonic acid and other fatty acids 
Fatty acids in the body can be obtained by de novo synthesis in tissues, through the diet or 
from the hydrolysis of membrane phospholipids. Human beings can synthesize fatty acids 
up to 16:0 (palmitate) de novo from acetyl coenzyme, by a series of cycles of sequential 
condensation, reduction, dehydration and reduction. The chain is elongated by two carbon 
atoms per cycle. 16:0 is then elongated to 18:0 (stearate) and desaturated to yield 18:1n-9 
 8 
Polyunsaturated Fatty Acids  
and Inflammatory Diseases 
Antonio Ferrante and Charles Hii 
Department of Immunopathology 
SA Pathology at Women’s and Children’s Hospital 
Discipline of Paediatrics, University of Adelaide, 
School of Pharmacy and Medical Science 
University of South Australia 
 Australia 
1. Introduction 
Polyunsaturated fatty acids and their metabolites are crucial to the physiologic and 
pathophysiologic processes in inflammation. The balance between n-6 and n-3 
polyunsaturated fatty acids in body tissues is a key to regulating the inflammatory reaction 
and preventing exacerbated inflammation in inflammatory disorders. Altering fatty acid 
type and their composition in phospholipids through diet supplements for beneficial 
outcomes in disease has been of major interest to the community. The sources of 
polysaturated fatty acid include de novo synthesis, essential fatty acids obtained from the 
diet, elongation and desaturation to obtain fatty acids of longer chain length by tissues.  
The types of fatty acids being esterified in membrane phospholipids provide a characteristic 
fatty acid composition of the phospholipids which can dictate the characteristics of the 
inflammatory response depending on the types of metabolites of polyunsaturated fatty 
acids formed through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways, either 
promoting or inhibiting the inflammatory process, by controlling intracellular signalling 
pathways, such as PKC, MAP kinases, PI3 kinase etc 
While focusing on the use of n-3 polyunsaturated fatty acids in treating rheumatoid 
arthritis, cardiovascular diseases and asthma, it is highlighted that such treatments are at a 
‘cross road’ because of poor understanding of the field of lipidomics and in 
supplementation approaches in those with various illnesses, including inflammatory 
diseases. 
2. Sources of arachidonic acid and other fatty acids 
Fatty acids in the body can be obtained by de novo synthesis in tissues, through the diet or 
from the hydrolysis of membrane phospholipids. Human beings can synthesize fatty acids 
up to 16:0 (palmitate) de novo from acetyl coenzyme, by a series of cycles of sequential 
condensation, reduction, dehydration and reduction. The chain is elongated by two carbon 
atoms per cycle. 16:0 is then elongated to 18:0 (stearate) and desaturated to yield 18:1n-9 
 
Inflammatory Diseases – A Modern Perspective 
 
160 
(oleate). Alternatively, 16:0 is desaturated to 16:1n-9 (palmitoleate) and elongated to 18:1n-9. 
A variety of longer chain fatty acids can be derived from 18:1n-9 by a combination of 
elongation and desaturation reactions. However, mammalian cells are unable to perform 
these reactions because they do not express the enzymes, 12 and 15 desaturases to 
introduce double bonds at carbon atoms beyond C-9. Consequently, mammalian cells 
cannot synthesise 18:2n-6 (linoleic) and 18:3n-3 (α-linolenate). These fatty acids, required by 
the animal but cannot be synthesised endogenously, are therefore considered as essential 
fatty acids and are obtained from the diet. The essential fatty acids serve as starting points 
for the synthesis of longer chain fatty acids such as 20:4n-6 (arachidonic acid, AA) and the n-
3 fatty acids 20:5n-3 (eicosapentaenoic acid, EPA) and 22:6n-3 (docosahexaenoic acid, DHA)  
by elongation and desaturation through the action of elongases and desaturases (e.g 6, 5 
and 4). AA is derived from 18:2n-6 while EPA and DHA are derived from 18:3n-3. 
Dietary fatty acids can be obtained from animal meats, fish, green vegetables, and from oils 
derived from the above. They mainly occur as triacylglycerols. Essential fatty acids are 
found in abundance in green leafy vegetables and the seeds of most plants. The n-3 fatty 
acids EPA and DHA are abundant in marine oils and fish rich diets are another source of 
these fatty acids. Grain-fed animals are rich in AA (Simopoulos, 1991). 
3. Transport and uptake of fatty acids 
Following absorption by the intestine, the fatty acids are transported to tissues where they 
may be utilized immediately or stored. At least four types of vehicles have been shown to be 
involved in their transportation: (i) chylomicrons, where dietary triacylglycerol is carried in 
protein-coated lipid droplets and transported to the whole body from the intestine; (ii) 
ketone bodies (acetoacetate and -hydroxybutyrate) and (iii) very low density lipoprotein 
(VLDL), which are responsible for transporting fatty acids, processed by or synthesised in 
the liver, to either adipose tissue for storage, or to various tissues to be used for cell 
structure and metabolism and (iv) as non-esterified fatty acid. Triacylglycerol in the blood is 
enzymatically hydrolysed by lipases, such as lipoprotein lipases, on the surface of 
endothelial cells. The released free fatty acids become bound to serum fatty acid binding 
protein eg. albumin, type IV fatty acid transporter, which carries the released fatty acids in 
the blood stream to appropriate tissue sites. The free fatty acids in the extracellular fluid 
continuously exchange with the intracellular fatty acids which are released by the action of 
phospholipase A2. This process is called intracellular fatty acid turnover (McGarry, 1993). 
How fatty acids are taken up by cells remains unclear. It has been proposed that fatty acids 
firstly become dissociated from albumin and then bind to a fatty acid transporter protein in 
the plasma membrane or a flip flop mechanism. A fatty acid translocase (FAT) with 
homology to CD36 has also been reported to be involved in the transport of long chain fatty 
acids (Bonen et al, 2002). There is evidence that fatty acids can also enter cells by a flip flop 
mechanism (Kamp et al, 2003). These two modes of fatty acid uptake need not be mutually 
exclusive. Once inside the cell, fatty acids are transported to various intracellular sites by the 
cytosolic fatty acid binding protein (FABP, 14-15 kDa) where they interact with appropriate 
proteins/structures to evoke cellular responses (Spector, 1992; Poirrier et al, 1996). The 
precise mechanism by which fatty acids are taken up by neutrophils is still poorly defined. 
However, it has been demonstrated that the ability of a fatty acid to partition into the 
neutrophil plasma membrane is not sufficient to evoke superoxide production (Steinbeck et 
al, 1991). Similarly, the observation that saturated fatty acids (lacking biological actions) 
have a greater ability to partition into the plasma membrane of cytotoxic T lymphocyte than 
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cis unsaturated fatty acids, is inconsistent with their biological activity being totally caused 
by membrane partitioning of a fatty acid (Anel et al, 1993). 
4. Arachidonic acid and its metabolites are central to the development of 
inflammatory reactions  
AA is an important promoter of physiologic processes of body tissue and organs. AA and its 
metabolites can act as an intercellular signalling molecule as well as intracellular secondary 
signalling molecule  (Ferrante et al. 2005). The role of this fatty acid and its products in 
autoimmune and allergic inflammation has also been abundantly described and 
appreciated, such that AA and pathways involved in its metabolism have been the targets of 
medications. The resolution of inflammation initiated through the release of AA from 
cellular membrane phospholipids is important and where its generation persists, this 
reaction evolves into a chronic and debilitating condition. The main pathways for its 
metabolism have been the lipoxygenase (LOX) and cyclooxygenase (COX) enzymes. 
AA and its metabolites can be generated at several cellular points. Apart from production at 
local tissues, be these immune cells or barrier cells such as endothelial cells, epithelial cells 
etc, the infiltrating cells, particular leukocytes, provide a rich source of these mediators of 
inflammation. Thus it is not surprising that the lipids influence several key functions of 
leukocytes which include, chemotaxis, oxygen radical generation, granule enzyme release 
and cytokine production (Ferrante et al, 2005). 
AA may control inflammation through several activities. AA per se has been shown to cause 
cellular activation independently of its metabolism via the LOX and COX pathways 
(Ferrante et al, 2005). The generation of several metabolites such as LTB4 and PGE2 gives the 
system a potent inflammatory potential. 
5. Release of AA from the cellular phospholipid pools and the generation of 
eicosanoids  
Cellular activation leads to the activation of Phospholipase A2 (PLA2) and the release of 
AA from the sn-2 position of the phospholipids (Balsinde et al, 2002). This activation can 
be brought about by many different types of agonists acting usually via a cell surface 
receptor. This includes intercellular signalling molecules such as cytokines which are 
involved in inflammatory responses in both the context of physiologic and 
pathophysiologic states.  
Amongst the various structurally different forms of the PLA2 is the cytosolic (cPLA2α, 
Group IVA), believed to play an important role in eicosanoids production (Kita et al, 2006; 
Ghosh et al, 2006). Submicromolar concentrations of Ca++ promotes the translocation of 
cPLA2 from the cytosol to the perinuclear membrane where it becomes activated by MAP 
kinases (Lin et al, 1993; Nemenoff et al, 1993). There it causes preferential hydrolysis of AA-
containing phospholipids, releasing AA to become available to downstream enzymes 
including LOX and COX, important in production of leukotrienes and prostaglandins (Fig 
1). Its importance has been concluded from studies showing that mice deficient in 
cPLA2were not susceptible to allergy induced brocho-constriction, airway hyper-
responsiveness, as well as adult respiratory distress syndrome (Wu et al, 2010). Mice 
deficient in cPLA2α were also protected from experimental autoimmune encephalomyelitis 
(Marusic et al, 1995). 
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Fig. 1. Outline of the metabolism of arachidonic acid, eicosapentaenoic acid and 
docosahexaenoic acid by the lipoxygenases and cyclooxygenases. LOX, lipoxygenase; COX, 
cyclooxygenase; HPETE, hydroperoxyeicosatetraenoic acid; HPEPE, 
hydroperoxypentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HEPE, 
hydroxypentaenoic acid; LT, leukotrienes; TX, thromboxane; PG, prostaglandin; LX, lipoxin; 
HpDHA, hydroperoxyDHA. 
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Cell activation leads to the generation of AA-derived eicosanoids (Fig 1). The main ones  are 
divided into three groups, leukotrienes (LTs), prostaglandins (PGs) and lipoxins (LXs). Their 
biological properties give rise to a regulatory network of inflammation, having both an 
effect on cells of the immune system, macrophages, T cells, neutrophils as well as non-
immune cells such as endothelial cells. While the metabolism of AA via the LOX and COX 
pathways is considered to be inflammatory, it is also evident that some products may 
exhibit anti-inflammatory properties. 
It is clear from several studies that different eicosanoids are generated at different times of 
an acute inflammatory response (Serhan, 2005; Serhan et al, 2008). Hence, prostaglandins 
and leukotrienes are rapidly generated, whereas the lipoxins, also produced from AA, are 
generated later with the onset of the resolution phase. During acute inflammation, activation 
of cPLA2 results in the conversion of the released AA by 5-LOX and COX to leukotrienes 
such as LTB4, a potent neutrophil activator and chemoattractant, and proinflammatory 
prostaglandins which control local blood flow, vascular dilation and permeability changes 
needed for leukocyte adhesion, diapedesis, and recruitment. The prostaglandins initiate a 
number of responses relevant in inflammation (i.e., vasoconstriction, vascular permeability 
changes, pain, vasodilation and edema). However, the production of prostaglandins such as 
PGE2 and PGD2 which possess proinflammatory properties, also signals the end of the 
inflammatory response by activating the transcriptional regulation of 15-LOX in neutrophils 
that initiates an eicosanoid class switch from a proinflammatory profile to a resolving 
profile, including the generation of EPA- and DHA-derived resolvins and/or protectins. In 
murine models, resolution of acute inflammation is accompanied by the appearance in 
exudates of EPA and DHA, which follows the appearance of non-esterified AA. Indeed, 
leukotrienes (potent chemoattractants) are deactivated and the transcriptional regulation of 
enzymes required for LX and resolvin production is activated. (Serhan, 2005; Serhan et al, 
2008). The combined actions of 5-LOX, 12-LOX and 15-LOX lead to the generation of 
lipoxins such as LTA4, resolvins and/or protectins. These mediators have anti-inflammatory 
and pro-resolving activities.  
6. Biological properties of eicosanoids 
The cellular actions of the LTB4 and cysteinyl leukotrienes (cysLTs), LTC4, LTD4 and 
LTE4, occur through their binding to specific G protein-coupled receptors found on 
responsive tissues e.g., smooth muscle and inflammatory cells of the immune system 
e.g., neutrophils. The distribution of receptors for LTs on various cell types are 
summarised in Table 1 (Okunishi et al, 2011). Two receptors for cysLTs have been well 
characterised, CysLt1 and CysLt2. LTD4 has high affinity and LTE4 has low affinity for 
these receptors. But other receptors are being recognised for CysLTs which includes a 
specific receptor for LTE4 (Maekawa et al, 2008). 
LTB4 has two receptors, a high affinity, BLT1 and lower affinity, BLT2 (Yokomizo et al, 
2000). Notably BLT1 is expressed predominantly on leukocytes (Table 1). The biological role 
of BLT2 requires further studies. LTB4 is recognised for its potent chemoattractant properties 
for neutrophils. It also activates other neutrophil responses such as respiratory burst 
(oxygen radical production) and degranulation. As indicated by the expression of BLT1 on 
other leukocytes, apart from neutrophils (Table 1), LTB4 activates also macrophages, 
eosinophils, T cells and dendritic cells (DCs). 
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Cell-type BLT1 CysLT1 CysLT2 
Macrophages  + ±# ± 
Dendritic cells + + ? 
B cells ? + ? 
CD4 + T cells + + ? 
CD8 + T cells + ?# ? 
Neutrophils + + + 
Eosinophils + + + 
Basophils + + + 
Mast Cells + + + 
Airway smooth muscle cells + + ? 
Endothelial cells + + + 
Table 1. Leukotriene receptor expression. (+), positive; (+), negligible; (?), not determined; 
(#) up-regulation upon cell activation (adapted from Okunishi et al, 2011) 
The action of PGs is through the rhodopsin-like 7-transmembrane-spanning G protein-
coupled receptors. These prostanoid receptors subfamily consists of 8 members 
EP1/EP2/EP3/EP4 bind PGE2, DP/CRTH2 bind PGD2, FP binds PGF2α, IP binds PGI2, TP 
binds TXA2 (Table 2). The CRTH2 receptor is expressed on Th2 lymphocytes and a member 
of the fMLF receptor superfamily (Ricciotti and FitzGerald, 2011).  
7. Eicosanoids and inflammation 
7.1 Leukotrienes 
Inflammation, whether physiologic or pathophysiologic, is manifested by the accumulation 
of leukocytes and plasma leakage into the tissue site. The leukotrienes form a major family 
of the inflammatory mediators generated which significantly contributes to the process. 
LTB4 through its chemotactic properties for several cell types including neutrophils and T 
cells, causes infiltration and accumulation of leukocytes at inflammatory foci. LTB4 increases 
vascular permeability of post capillary venules. The ability of LTs to activate DCs has 
indicated a role in antigen presentation and T cell sensitisation. Relevant to this action is the 
finding that LTs are produced through the innate immune response, where the various 
pattern recognition receptors (e.g., Toll-like receptors, TLRs) are expressed on different cell 
types (Alvarez et al, 2010). Thus LTs may play important roles in the adaptive immune 
response at an early phase. 
 
Prostaglandin 
Class Receptor subtype Type of cells/tissues 
PGE2 EP1, EP2, EP3, EP4 Brain, kidneys, VSMCs, platelets
PGD2 DP, CRTH2 Mast cells, brain, airways, Th2 lymphocytes 
PGF2a FPA, FPB Uterus, airways, VSMCs, eyes
PGI2 IP-IP, IP-TPa Endothelium, VSMCs, platelets, kidney, brain 
TxA2 TPa, TPb Platelets, VSMCs, macrophages, kidney 
Table 2. Expression of prostanoid receptors (adapted from Ricciotti and FitzGerald, 2011). 
VSMC ; vascular smooth muscle cells 
The role of LTs has been established as a key mediator in several inflammatory diseases, 
both in experimental and clinical settings. This includes asthma and allergic rhinitis (Dahlen, 
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2006; Peter-Golden & Henderson, 2007). Their importance extends to the pathophysiology of 
atherosclerosis and progression of cancer. 
7.2 Prostaglandins 
PGE2 is involved in all the signs of inflammation; redness, swelling and pain (Ricciotti & 
Fitzgerald, 2011), through its effects on arterial dilation, increased permeability of the 
microvasculature, peripheral sensory nervous and central sites within the spinal cord and 
brain. PGE2 acts via one of its receptors, EP1 to EP4. Using KO mice deficient in these 
receptors, it has been appreciated that they play important roles in hyperalgesia (PGE2-EP1), 
paw swelling in collagen-induced arthritis (EP2, EP4), Carrageenan-induced paw 
oedema/pleurisy (EP2, EP3), IL-6 production and joint destruction in RA and anti-
inflammatory effects of PGE2 as seen in allergic inflammation. 
The regulation of various cell types by PGE2 occurs through the expression of different EP 
receptors. PGE2 exerts an anti-inflammatory effect on functions of neutrophils, macrophages 
and natural killer cells, the cell-types which underpin the innate immune response (Harris et 
al. 2002). PGE2 also exerts regulatory actions on macrophages, DCs, T and B cells which may 
manifest itself as either inflammatory or anti-inflammatory actions. Examples are regulation 
of DC cytokine profiles and Th1 or Th2 lymphocyte development (Egan et al, 2004). 
Engagement of  EP4 by PGE2 in DCs and T cells promotes differentiation to Th1 and also 
Th17 lymphocytes (Yao et al, 2009). Other ways that PGE2 regulates the immune response is 
through its role in the development of DCs with a migratory phenotyping to promote 
homing to drain lymph nodes (Kabashima et al, 2003; Legler et al, 2006), as well as 
upregulating the expression of co-stimulatory molecules on these cells (Krause et al, 2009). 
In an anti-inflammatory manner, PGE2 suppresses Th1 cell development, B cell function and 
IgE-driven inflammatory response (Roper et al, 1995; Harris et al, 2002). 
PGI2 has potent vasodilator actions and is known to be important in regulation of 
cardiovascular homeostasis. The eicosanoid is an inhibitor of platelet aggregation, leukocyte 
adhesion and vascular smooth muscle cell proliferation (Gryglewski, 2008; Kawabe et al, 
2010). Mice deficient in receptors for PGI2 show an abrogation of the ability of PGI2 to 
potentiate the bradykinin-induced microvascular permeability and a substantially reduced 
carrageenan-induced paw oedema (Murata et al, 1997). Other actions of PGI2 involving the 
IP receptors is an allergic inflammation where it may suppress the Th2-mediated lung 
inflammation (Jaffar et al, 2002).  
PGD2 has inflammatory and homeostatic properties. Thus while in the brain it regulates 
sleep and various other central nervous activities, it has inflammatory function particularly 
in atropic conditions. The eicosanoid promotes broncho- constriction and airways 
neutrophil infiltration, typical of allergic asthma (Hardy et al, 1984; Emery et al, 1980; 
Fujitani et al, 2002). The DP1 and DP2/CRTH2 receptors bind PGD2 with similar high 
affinity and both are responsible for the pro-inflammatory responses. Effects caused by 
PGD2 are dictated by the differential expression of these receptors in tissues such as the 
expression of DP1 receptors in bronchial epithelium is believed to promote the production 
of cytokines and chemokines which recruit eosinophils and lymphocytes in airway 
inflammation and hyperreactivity associated with asthma (Kabashima & Narumiya, 2003). 
Using mice  deficient in DP1 receptors the role of PGD2 and the receptor in airway 
hyperreactivity and Th2-mediated lung inflammation has been documented in animal 
models (Matsuoka et al. 2000). The use of DP1 antagonists in animal models supports a role 
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Cell-type BLT1 CysLT1 CysLT2 
Macrophages  + ±# ± 
Dendritic cells + + ? 
B cells ? + ? 
CD4 + T cells + + ? 
CD8 + T cells + ?# ? 
Neutrophils + + + 
Eosinophils + + + 
Basophils + + + 
Mast Cells + + + 
Airway smooth muscle cells + + ? 
Endothelial cells + + + 
Table 1. Leukotriene receptor expression. (+), positive; (+), negligible; (?), not determined; 
(#) up-regulation upon cell activation (adapted from Okunishi et al, 2011) 
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7. Eicosanoids and inflammation 
7.1 Leukotrienes 
Inflammation, whether physiologic or pathophysiologic, is manifested by the accumulation 
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Prostaglandin 
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VSMC ; vascular smooth muscle cells 
The role of LTs has been established as a key mediator in several inflammatory diseases, 
both in experimental and clinical settings. This includes asthma and allergic rhinitis (Dahlen, 
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2006; Peter-Golden & Henderson, 2007). Their importance extends to the pathophysiology of 
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paw swelling in collagen-induced arthritis (EP2, EP4), Carrageenan-induced paw 
oedema/pleurisy (EP2, EP3), IL-6 production and joint destruction in RA and anti-
inflammatory effects of PGE2 as seen in allergic inflammation. 
The regulation of various cell types by PGE2 occurs through the expression of different EP 
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in atropic conditions. The eicosanoid promotes broncho- constriction and airways 
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affinity and both are responsible for the pro-inflammatory responses. Effects caused by 
PGD2 are dictated by the differential expression of these receptors in tissues such as the 
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Using mice  deficient in DP1 receptors the role of PGD2 and the receptor in airway 
hyperreactivity and Th2-mediated lung inflammation has been documented in animal 
models (Matsuoka et al. 2000). The use of DP1 antagonists in animal models supports a role 
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for the receptor in antigen-induced microvascular permeability and ovalbumin (OVA)-
induced airway hyperreactivity. Reports have also suggested that the DP2/CRTH2 
receptors contribute to inflammatory reactions by controlling cell traffic and the effect of 
function of leukocytes in which it is expressed, Th2 cells, mast cells and eosinophils. An 
increase in its expression has been shown to be associated with some forms of atopic 
dermatitis. However inflammation in other contexts may be inhibited by PGD2-DP1 
receptor where inhibition of DC migration affects T cell proliferation and cytokine 
production (Hammad et al, 2003).  
TXA2 is highly unstable and its activity is mediated mainly through the TP receptor. Studies 
regarding the role of this receptor in physiologic and pathophysiologic responses show that 
its involved in platelet adhesion and aggregation, activation of endothelial inflammatory 
response and contraction/proliferation of smooth muscle cells (Nakahata, 2008). 
8. Arachidonic acid and metabolites in inflammatory disorders 
AA and its metabolites have been shown to play major roles in the pathogenesis of several 
inflammatory conditions (Table 3). Three inflammatory conditions, asthma, rheumatoid 
arthritis and atherosclerosis, will be used to demonstrate the interest and the importance of 
AA and its metabolites in  such diseases/conditions. 
8.1 Asthma 
Arachidonic acid and eicosanoids have been long recognised to play a key role in asthma 
pathophysiology. The hallmark of this condition is airway inflammation and 
hyperresponsiveness. The importance of the enzyme responsible for releasing AA from 
membrane phospholipids, PLA2 has been established using pharmacological inhibitors and 
more recently genetically modified mice. Bronchoalveolar lavage fluid of asthmatics 
contains increased amounts of secretory phospholipase A2 (sPLA2) and increased activity 
compared to controls (Triggiani et al, 2009; Chilton et al, 1996; Bowton et al, 1997). Particular 
interest has centred on group X sPLA2 as this was responsible for most of the activity 
(Hallstrand et al., 2011). Levels of this sPLA2 correlated with eicosanoid release, severity of 
asthma and airway inflammation (Hallstrand et al., 2011). Further studies have suggested 
that group X sPLA2 functions in asthma pathogenesis through the release of cysLTs which 
are involved in airway inflammation and hyperresponsiveness. Mice genetically deficient in 
group X sPLA2 showed a marked reduction of asthma induced with OVA, manifested as 
decreased interstitial oedema, and the accumulation of eosinophils and T cells into the lung 
(Henderson et al, 2007). The Th2 cytokine levels were also decreased in the deficient mice as 
were the eicosanoids, PGE2, PGD2, LTB4, and cysLTs (LTC4, LTD4, LTE4) (Henderson et al, 
2007). Using knock-in mice with human group X sPLA2, it was demonstrated that this could 
restore the airway inflammation (Henderson et al., 2011). The important role of the high 
affinity LTB4 receptor BLT1 also supports the role of LTs in pathogenesis of asthma 
(Watanabe et al, 2009).  
8.2 Rheumatoid arthritis 
AA derived eicosanoids have been shown to play a major role in the pathogenesis of RA. In 
a murine model of  arthritis, a role for cPLA2α was examined using the inhibitor, 
pyrroxyphine (Tai et al, 2010). There was an increase in cPLA2α activity which correlated 
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with arthritis severity. Both bone destruction and incidence of arthritis was reduced by the 
inhibitor. Such effects correlated also with an inhibition of the production of eicosanoids and 
COX-2 induction. 
The importance of eicosanoids in inflammatory arthritis can also be seen from studies with 
mice which were deficient in either the BLT1 receptor or the low affinity BLT2 receptor. In 
the collagen-induce arthritis model, BLT1 was found to mediate the disease. Thus, BLT1-/- 
mice were completely protected and so were the BLT1-/-/BLT2-/- double knockout mice 
(Shao et al, 2006). Because the BLT1-/- mice were completely protected, the authors were not 
able to determine the contribution of BLT2. This was addressed by Mathis et al (2010) who 
reported that BLT2-/- mice showed reduced incidence and severity of disease in an 
autoantibody-induced arthritis model. Note that while the BLT2 receptor is a low affinity 
receptor for LTB4, it is in fact a high affinity receptor for the COX-1 derived 12(S)-
hydroxyheptadeca-5Z, 8E, 10E-trienoic acid. BTL2 is considered a model target for treating 
this inflammatory condition. 
Prostaglandins levels are elevated in synovial fluid and synovial membranes of RA patients 
and are believed to play a role in fluid extravasations and pain in synovial tissue, as well as 
articular cartilage erosion. COX-2 is present in high and COX-1 in smaller amounts in RA 
synovial tissue. Selective COX-2 inhibitors (e.g. celecoxib, valdecoxib and rofecoxib) have 
been used to treat inflammation in RA patients, although some (e.g. valdecoxib and 
rofecoxib) have been withdrawn owing to increased risk of heart attack and stroke in users 
(James et al, 2007). The presence of the metabolites of AA in RA patients’ synovial fluid has 
been outlined (Grignani et al, 1996). When compared with patients with artherosis 
(degenerative joint disease), the levels of LTB4, LTC4 and 6-keto-PGF1 were significantly 
higher in RA patients. 
8.3 Cardiovascular disease and atheroosclerosis  
The 5-LOX/LT pathway has been implicated in the development of cardiovascular disease 
(CVD) based on studies of human genetic variation (polymorphisms in the genes that code 
for 5-LOX or its activating protein, 5-LO-activating protein (FLAP)) and in animals, leading 
to the hypothesis that this pathway promotes atherosclerosis, abdominal aortic aneurysm, 
and myocardial infarction/reperfusion injury. Much of this is based on the known effects of 
LTs on leucocyte chemotaxis, vascular inflammation and enhanced permeability, and 
subsequent tissue/matrix degeneration. Data from a series of studies that involved genetic 
or pharmacological inhibition of either LT biosynthesis (5-LOX, FLAP, LTA4 hydrolase, 
LTC4 synthase) or the LT receptors, have painted a complex picture of 5-LOX/LT 
participation in cardiovascular disease, which is further complicated by marked differences 
between mice and humans (reviewed by Poeckel and Funk, 2010). Added to this is another 
layer of complexity imposed by the cytokine network specific to a particular pathological 
condition which impacts on the expression level and hence, the contribution of 5-LOX to the 
overall disease state. Nevertheless, current data suggest roles for 5-LOX in the early/acute 
stages of atherosclerosis in mice and humans, but only in the advanced stage of the human 
pathology. Hence, LTB4 and CysLT are likely to play critical roles in the early phase of 
atherosclerosis through their influence on leukocyte recruitment, smooth muscle cell 
proliferation, migration of endothelial cells (properties of LTB4) and inflammatory cell 
recruitment, coronary artery constriction and endothelial cell activation (properties of 
CysLT). In the advanced phase, LTB4 may affect plaque stability, and the expression of other 
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2007). Using knock-in mice with human group X sPLA2, it was demonstrated that this could 
restore the airway inflammation (Henderson et al., 2011). The important role of the high 
affinity LTB4 receptor BLT1 also supports the role of LTs in pathogenesis of asthma 
(Watanabe et al, 2009).  
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AA derived eicosanoids have been shown to play a major role in the pathogenesis of RA. In 
a murine model of  arthritis, a role for cPLA2α was examined using the inhibitor, 
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with arthritis severity. Both bone destruction and incidence of arthritis was reduced by the 
inhibitor. Such effects correlated also with an inhibition of the production of eicosanoids and 
COX-2 induction. 
The importance of eicosanoids in inflammatory arthritis can also be seen from studies with 
mice which were deficient in either the BLT1 receptor or the low affinity BLT2 receptor. In 
the collagen-induce arthritis model, BLT1 was found to mediate the disease. Thus, BLT1-/- 
mice were completely protected and so were the BLT1-/-/BLT2-/- double knockout mice 
(Shao et al, 2006). Because the BLT1-/- mice were completely protected, the authors were not 
able to determine the contribution of BLT2. This was addressed by Mathis et al (2010) who 
reported that BLT2-/- mice showed reduced incidence and severity of disease in an 
autoantibody-induced arthritis model. Note that while the BLT2 receptor is a low affinity 
receptor for LTB4, it is in fact a high affinity receptor for the COX-1 derived 12(S)-
hydroxyheptadeca-5Z, 8E, 10E-trienoic acid. BTL2 is considered a model target for treating 
this inflammatory condition. 
Prostaglandins levels are elevated in synovial fluid and synovial membranes of RA patients 
and are believed to play a role in fluid extravasations and pain in synovial tissue, as well as 
articular cartilage erosion. COX-2 is present in high and COX-1 in smaller amounts in RA 
synovial tissue. Selective COX-2 inhibitors (e.g. celecoxib, valdecoxib and rofecoxib) have 
been used to treat inflammation in RA patients, although some (e.g. valdecoxib and 
rofecoxib) have been withdrawn owing to increased risk of heart attack and stroke in users 
(James et al, 2007). The presence of the metabolites of AA in RA patients’ synovial fluid has 
been outlined (Grignani et al, 1996). When compared with patients with artherosis 
(degenerative joint disease), the levels of LTB4, LTC4 and 6-keto-PGF1 were significantly 
higher in RA patients. 
8.3 Cardiovascular disease and atheroosclerosis  
The 5-LOX/LT pathway has been implicated in the development of cardiovascular disease 
(CVD) based on studies of human genetic variation (polymorphisms in the genes that code 
for 5-LOX or its activating protein, 5-LO-activating protein (FLAP)) and in animals, leading 
to the hypothesis that this pathway promotes atherosclerosis, abdominal aortic aneurysm, 
and myocardial infarction/reperfusion injury. Much of this is based on the known effects of 
LTs on leucocyte chemotaxis, vascular inflammation and enhanced permeability, and 
subsequent tissue/matrix degeneration. Data from a series of studies that involved genetic 
or pharmacological inhibition of either LT biosynthesis (5-LOX, FLAP, LTA4 hydrolase, 
LTC4 synthase) or the LT receptors, have painted a complex picture of 5-LOX/LT 
participation in cardiovascular disease, which is further complicated by marked differences 
between mice and humans (reviewed by Poeckel and Funk, 2010). Added to this is another 
layer of complexity imposed by the cytokine network specific to a particular pathological 
condition which impacts on the expression level and hence, the contribution of 5-LOX to the 
overall disease state. Nevertheless, current data suggest roles for 5-LOX in the early/acute 
stages of atherosclerosis in mice and humans, but only in the advanced stage of the human 
pathology. Hence, LTB4 and CysLT are likely to play critical roles in the early phase of 
atherosclerosis through their influence on leukocyte recruitment, smooth muscle cell 
proliferation, migration of endothelial cells (properties of LTB4) and inflammatory cell 
recruitment, coronary artery constriction and endothelial cell activation (properties of 
CysLT). In the advanced phase, LTB4 may affect plaque stability, and the expression of other 
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components of the 5-LOX pathway such as BLT1, BLT2, FLAP, LTA4 synthase, CysLT1 and 
CysLT2 are up-regulated (reviewed by Poeckel and Funk, 2010). 
The action of LTs in various stages of atherosclerosis development has been reviewed (Back, 
2009). The role of LTB4 in the lipid retention and modification stage is  seen by the finding 
that targeting BLT1 receptor decreases the accumulation of lipids and the infiltration of 
foam cells. The early development of intimal hyperplasia appears also to be influenced by 
cysLTs and LTB4. Targeting their receptors most likely inhibits intimal hyperplasia with 
respect to endothelial dysfunction. Cys-LTs have been suggested to play a role in both 
endothelium relaxation and constriction. The discovery, that endothelial cells express the BLT1 
receptor during atherosclerosis (Back et al., 2005) has also implicated LTB4 in causing the 
changes on the endothelium. The disease progresses into recruitment of leukocytes in the 
vascular wall and the formation of atherosclerotic plaque. Most likely the macrophages 
continue to be the centre point of this development, through their ability to produce LTs , such 
as LTB4 and exacerbate the inflammation at atherosclerotic lesions. This draws in T cells which 
can stimulate macrophages to generate more LTB4, leading to a vicious cycle, perhaps halted 
by anti-LT treatments (Back, 2008). Upon rupture of the fibrous cap there is exposure to the 
blood elements with the consequences of platelet activation and thrombotic occlusion. To date 
there is only indirect evidence for a role of LTs where it has been shown that 5-LOX is located 
in areas where matrix metalloproteinases are present and which are responsible for rupture. 
Plaque in the coronary cerebral arteries will lead to myocardial ischemia and cerebral 
ischemia, respectively. In myocardial ischemia the role of LTs has been controversial from 
suggestions of a major, no role and even to possibly protective role (Back, 2009; Adamek et al., 
2007). In contrast, in cerebral ischemia, the importance of LTs has been acknowledged. LT 
synthesis inhibitors and  cysLT receptor antagonists limited the damage in animal models. 
9. Omega 3 polyunsaturated fatty acids 
Supplementation with n-3 fatty acids is of interest because of its potential benefits in treating 
a range of human diseases and conditions (Table 3). In particular, it is well appreciated that 
increasing the ratio of n-3 over n-6 polyunsaturated fatty acids in membrane phospholipids 
in patients experiencing inflammation has benefits (Simopoulos, 1991). Thus, fatty acid diet 
manipulations have been used in treating a wide variety of diseases/conditions including 
those which have an autoimmune and allergic base. While the mechanisms governing the 
beneficial effects of certain types of polyunsaturated fatty acids in different types of diseases 
is likely to vary, it is well appreciated that altering the types of polyunsaturated fatty acids 
in diets can modify the immune response. This is thought to be the major mechanism by 
which polyunsaturated fatty acids exert their protective effects in inflammatory and 
autoimmune disorders (Calder, 2010).  
High n-3 fatty acid intake for four months significantly increased the general score and 
sigmoidoscope score of active ulcerative colitis patients compared with a placebo diet 
(Simopoulos, 1991; Greenfield et al., 1993). The effects were maintained for three months 
after the fatty acid treatment was discontinued. In a human gingival inflammation model, 
28-day treatment with EPA and DHA (1.8g/day) markedly reduced the gingival index in 
interdental papilla (Campan et al., 1996). Dietary supplementation with fish oil fatty acids in 
conjunction with conventional treatment (cyclosporin) in psoriasis patients has been shown 
to improve the skin lesions and decrease the nephrotoxicity of cyclosporin (Simopoulos, 
1991). In the treatment of RA, the beneficial effects of fish oil are pronounced and  
 
 












Systemic lupus erythematosus 
Cystic fibrosis 
Type 1 diabetes 
Chronic obstructive pulmonary disease 
Table 3. Inflammation-based conditions which appear to benefit from n-3 polyunsaturated 
fatty acid or fish oil supplementation (adapted from Calder et al, 2010) 
reproducible in both animal models and in human trials. It has been shown that feeding 
mice with EPA and DHA, reduces the incidence and severity of type II collagen-induced 
experimental arthritis (Leslie et al, 1985). Another study demonstrated that n-3 fatty acids 
given in the form of krill oil or fish oil caused a significant reduction in arthritis score and 
hind paw swelling in a collagen-induced arthritis model (Ierna et al., 2010). Dietary 
supplementation with n-3 polyunsaturated fatty acids in RA patients shows  significant 
relief of joint pain and swelling, and the duration of morning stiffness. This has led to a 
reduction in requirement for nonsteroidal anti-inflammatory drugs (NSAIDs), with some 
patients able to discontinue NSAIDs while receiving n-3 fatty acid supplements (Kremer et 
al., 1995; Sperling, 1991). A recent clinical study of -linolenic acid (GLA, 18:3n-6) dietary 
manipulation in RA patients also showed evidence of the alleviation of disease activity 
(Zurier et al., 1996). Many recent studies have shown that production of 
immunological/inflammatory mediators can also be regulated by polyunsaturated fatty 
acids. Diets rich in n-3 polyunsaturated fatty acids significantly reduce the production of the 
pro-inflammatory cytokines, tumour necrosis factor, interleukin-1 and interleukin-2, as 
well as the lipid mediator, platelet activating factor (Sperling, 1991; Endres, 1989; Williams 
et al., 1996) and this could account for some of their anti-inflammatory properties. However 
it has recently been appreciated, through meta analysis, that the use of these fatty acids in 
the human disease is uncertain (James et al., 2010). These investigators have proposed that 
fish oil may be of benefit in RA because it may overcome the cardiovascular risk of non-
steroidal anti-inflammatory agents. 
Supplementation with n-3 fatty acids also decreases the symptoms of dysmenorrhoea, a 
prostaglandin-mediated condition in adolescents. After a two month treatment with fish oil, 
a significant reduction in the Cox Menstrual Symptom Scale was found compared with a 
placebo diet, probably due to alteration of the prostanoid profile by the high n-3 fatty acid 
intake (Harel et al., 1996; Deutch, 1995). Essential fatty acids play an important role in brain 
and retinal development which mainly occurs during the latter half of pregnancy and the 
postnatal stage. The growth of fetal brain acquires approximately 21g/wk of DHA during 
the last trimester of pregnancy. Fatty acids are transported from the maternal circulation 
across the placenta and fetal blood-brain barrier into the central nervous system. A 
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in diets can modify the immune response. This is thought to be the major mechanism by 
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steroidal anti-inflammatory agents. 
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a significant reduction in the Cox Menstrual Symptom Scale was found compared with a 
placebo diet, probably due to alteration of the prostanoid profile by the high n-3 fatty acid 
intake (Harel et al., 1996; Deutch, 1995). Essential fatty acids play an important role in brain 
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deficiency of essential fatty acids during pregnancy leads to a reduced level of DHA in the 
newborn, which is related to a reduction in slow-wave sleep and impaired vision in these 
infants. Dietary supplementation of n-3 fatty acids to pregnant women and increasing the 
amount of DHA in infant formula are beneficial for early neurological development and 
improve the visual recognition in preterm and term infants (Gibson et al., 1996; Connor et 
al., 1996; Uauy et al., 1996). It has also been shown that diets rich in n-3 fatty acids can 
prevent premature labor and preeclampsia (Olsen & Secher, 1990). Dietary n-3 fatty acids 
also reduce the severity and frequency of relapses in patients suffering from multiple 
sclerosis (Bates, 1990).  
Recent work has shown that n-3 fatty acid supplements modify allergic disease 
development in young children. A systematic review of reports on the effects of n-3 fatty 
acid supplementation during pregnancy and lactation on the risk of developing childhood 
allergic diseases and asthma, concluded that supplementation during pregnancy but not 
during lactation decreases childhood asthma and allergy (Klemens et al, 2011; Kremmyda et 
al, 2009). Thus, fish oil supplements when given to pregnant women with a history of 
allergic diseases gave rise to significant protection against infant allergy development. This 
was associated with reduced cord blood IL-13 (Klemens et al, 2011). The difference between 
supplementation  during pregnancy versus in infancy and childhood and the development 
of eczema, hay fever and asthma has also been highlighted (Calder et al, 2010). Interestingly 
both the susceptibility and the protection afforded by the n-3 supplements were associated 
with the levels of protein kinase C  (PKC) in cord blood T cells and how those cells mature 
into Th1 and Th2 cytokine pattern producers. Low PKC expression in the cord blood T 
cells of an infant increases the risk of development of allergic diseases in childhood (Prescott 
et al, 2007). In another population study of bronchial inflammation induced by grass pollen 
allergy challenge showed that the ratio of n-3: n-6 fats were significantly lower for the 
asthmatics than in healthy subjects (Kitz et al, 2010). 
Obese adolescents appear to benefit from n-3 fatty acid supplementation, shown to improve 
vascular function and cause a reduction in vascular inflammation (Dangardt et al., 2010). 
Furthermore EPA has been shown to be incorporated into advanced atherosclerotic plaques 
(Cawood et al, 2010). The higher EPA content in the plaque is associated with reduced 
plaque inflammation and increased plaque stability (Cawood et al, 2010, Calder & Yaqoob, 
2010). There was a reduction in foam cells, T cells and expression of metalloproteinases. In 
an animal model of atherosclerosis, employing the apoE-deficient mouse, combination of 
extra virgin oil and fish oil gave rise to protection by a mechanism of anti-thrombotic, anti-
hypertriglyceridemic and anti-oxidant (Eilertsen et al., 2011)  
The long chain, n-3 polyunsaturated fatty acids, EPA and DHA, are also substrates for the 
LOX and COX. It is evident that the metabolites of EPA and DHA display several means by 
which they can contribute to the regulatory network of lipid mediators; by replacing the 
highly inflammatory products of AA; having anti-inflammatory activity per se and 
displaying inflammation resolving abilities by having cell protection activity. The ability of 
the LOX and COX systems to generate fatty acid metabolites with substantially lower 
proinflammatory activity than the AA-derived eicosanoids has provided the basis for 
classical strategies to manipulate the inflammatory reaction. For example, increasing the 
ratio of n-3 to n-6 in membrane phospholipids of leukocytes reduces the production of 
inflammatory eicosanoids in favour of metabolites with markedly reduced or those which 
lack proinflammatory activity. Thus diets which contain high levels of the n-3 fatty acids, 
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EPA and DHA or their precursors have been used as ways of decreasing inflammatory 
reactions and relieving the symptoms of these diseases (Simopoulos, 1991).  
The EPA metabolised through COX and LOX pathways leads to the generation of 3-series 
PGs and TXs, and 5-series LTs (Fig 1). These products have some thousand fold less 
inflammatory activity than the 2-series PGs and 4-series LTs derived from AA. Thus the 
release of EPA from the sn-2 position of the membrane phospholipids will lead to an 
increased production of 3-series PGs and 5-series LTs following cell activation. This is 
believed to be a major mechanism of the beneficial effects of EPA/fish oil supplementation 
of patients with inflammatory diseases such as RA (James et al., 2010). In another 
development in the lipid mediator network, more recent work has characterised the 
generation of another class of inflammation regulators, the aspirin-triggered resolvins. This 
involves COX-2 aspirin triggered metabolism of EPA and further action of the 5-LOX, 
leading to the generation of the E-series resolvins, E1 and E2 (Fig 1) (Serhan et al., 2008). 
These molecules are highly potent in inhibiting neutrophil infiltration and in resolving the 
inflammatory reaction. Aspirin also triggers the generation of the D – series aspirin-
triggered resolvins, RvD1, D2, D3, D4, D5, D6 which are generated from DHA, involving 
COX-2 and the 5-LOX. DHA metabolism via the 15-LOX and other reactions leads to the 
release also of these resolvins (Fig 1). DHA can also be oxidised via the 15-LOX to protectin 
D1. This metabolite inhibits neutrophil and T cell migration, airway inflammation, NF-B 
activation, COX-2 induction and TLR macrophage activation. Protectin D1/neuroprotectin 
D1 is known for its neuroprotective properties (Serhan et al., 2008). It reduces brain ischemia 
and reperfusion injury, kidney ischemic injury and has anti-fibrotic activity. 
10. Concluding remarks 
Polyunsaturated fatty acids play critical roles in physiologic and pathophysiologic processes 
involving the immune system. While these have the ability to alter cellular responses as free 
fatty acids, most interest is on the properties of the array of metabolic products which they 
generate. These form a regulatory network which either down- or up-regulates the 
inflammatory reaction. A major effort continues to be made on the need to achieve an 
appropriate balance of n-6:n-3 fatty acids in tissues. The levels and ratios of these fatty acids 
is considered to regulate immune cell function through an effect on cell membrane fluidity, 
cell membrane structure, the expression of functional cell surface receptors and the types of 
oxidized products formed. Eicosanoid generation appears to be central to the inflammatory 
process by influencing the activities of many cell types, T cells, macrophages, neutrophils, 
eosinophils, DCs, endothelial cells, epithelial cells and smooth muscle cells. The 
characteristics of the inflammatory response is dependent on the concentrations and types 
of eicosanoids generated as well as the types of eicosanoid receptors expressed on the cell, 
which can vary dramatically from cell-type to cell-type. Both exogeneous and endogenous 
stimuli promote the activation of phospholipase A2, the release of the polyunsaturated fatty 
acids from the phopholipids and their metabolism via the LOX and COX pathways. While 
most of the products formed from AA metabolism are highly proinflammatory, a number of 
these can also have a dampening effect on the inflammatory response. However, it is 
evident that the elicitation of a highly pro-inflammatory reaction is offset by the presence of 
n-3 fatty acids, EPA and DHA. These are metabolised into the low inflammatory, 5-series 
LTs and 3-series PGs, and anti-inflammatory products, the E-series resolvins/D-series 
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resolvins and neuroprotective lipids, protectins. Because of the diversity of the array of 
eicosanoids and other fatty acid products generated, there is still much to be discovered on 
how this network of fatty acid metabolites promote and inhibit the inflammatory response. 
The time-dependent production of the different types of eicosanoids during various phases 
of the reaction could explain the types of inflammatory reactions we see, for example 
resolving and not resolving. The free fatty acids and their metabolic products also govern 
the synthesis of inflammatory mediators such as cytokines, which are targets for anti-
inflammatory medications. Current evidence underscores the importance of phospholipase 
A2 and eicosanoids in the pathogenesis of inflammatory conditions, including asthma, 
rheumatoid arthritis and atherosclerosis. In contrast to the view of AA as a promoter of 
inflammation, n-3 fatty acids are considered as an attractive approach for anti-inflammatory 
therapy. However, while there is convincing in vitro data and data from animal models of 
an anti-inflammatory action of n-3 fatty acids in these diseases, results from human studies 
remain unconvincing or at best only small benefits are achieved. This is likely to reflect still 
our poor understanding of the actions of these fats when taken as dietary supplements and 
obviously further and more appropriate clinical trials have been suggested (Fritsche, 2006).  
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1. Introduction 
The definition of asthma is constantly being modified and redefined. New knowledge 
derived from molecular biology and applied immunology is very valuable in interpreting 
how the airway becomes diseased. At the same time, new biomarkers useful for monitoring 
patients and detecting inflammatory airway disease are being identified. Currently, patients 
whose condition is included in the spectrum of inflammatory airway diseases may be 
reassessed and placed into subgroups so that the biotypes, or endotypes (disease) and 
phenotypes (patients), form new paradigms to delineate and integrate applied knowledge to 
this complex and heterogeneously-expressed disease. The definition of asthma and different 
ways of understanding the disease undergo constant review. 
2. Asthma defined as an inflammatory airway disease 
The definition of asthma may be established using a set of characteristics that are clinical 
(recurrent episodes of wheezing and dyspnea), pathophysiological (variability in airflow), 
or immunological (chronic inflammation) (Global Initiative for Astma [GINA], 2009; British 
Thoracic Society Scottish Intercollegiate Guidelines Network [BTSSIGN], 2008). They may 
be found in patients or heterogeneous groups of patients who share these symptoms to a 
greater or lesser extent. Depending on the emphasis placed on a more specific predominant 
feature of airway dysfunction, the ‘nominalist’ view of the concept of asthma is more 
relevant. On the other hand, if several features are examined together to make the diagnosis, 
the more 'essentialist' aspect of the specific airway disease stands out [GINA, 2009; BTSSIGN 
2008]. Thus, both definitions must be kept in mind when dealing with asthma, and 
determining an objective system of measurement for the quantifiable aspects that that make 
up either definition is required [Hargreave & Nair, 2009]. For decades, different methods to 
quantify and measure the various components of asthma (symptoms, spirometry, maximum 
peak flow, bronchial provocation) have been used in situations of good health or illness, 
highlighting the complexity involved in studying, functionally, both the normal and altered 
airway. Not all the defining characteristics of asthma are present in all patients; moreover, 
they vary greatly and are often irregular in a single patient. The therapeutic response may 
also be different depending on the specific pathophysiological characteristics that are 
predominately found [Lotvall et al., 2011]. Therefore, the classification of asthma severity by 
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daily medication regimen and response to treatment, as well as the different strategies and 
recommendations for managing patients with difficult to control asthma are essentially 
needed in clinical practice [Holgate & Polosa, 2006]; otherwise they are limited. New 
methods based on statistical physics and fluctuation analysis can be a new strategy for 
assessing and predicting the risk of progression of asthma [Frey & Suki, 2008], but 
monitoring of airway diseases also requires focus on foundations of the modern biology. 
Therefore, the application of new technological advancements and the disciplines applied to 
the study of inflammation, as well as the incorporation of new markers for diagnosis and 
the monitoring of patients affected by asthma, inspires optimism in the challenge to find a 
better conceptual understanding of asthma using a dynamic approach that continuously 
changes and at the same time is more significant than that achieved by mere verification.  
In this chapter, specific aspects of the new contributions to the monitoring of asthma and the 
new research using defined groups of patients to study interrelated heterogeneous aspects 
of asthma will be described and discussed. These new contributions have modified the 
approach to grouping and reclassifying characteristics that are clinical, pathophysiological 
and biological as a whole, and allow for a new definition of asthma in terms of 'phenotypes' 
and 'endotypes' [Anderson, 2008a; Wenzel, 2006]. Although the addition of these new terms 
to the definition of asthma may be seen as a conceptual breakthrough, caution must be 
exercised. For example, new biological knowledge about the pathogenic understanding of 
inflammatory airway disease (IAD) requires further investigation in many aspects, 
including how it differs from phenotypes in chronic obstructive pulmonary disease (COPD) 
[Barnes, 2008], as well as in children [Spycher, 2010]. Hence, a major challenge in the field of 
respiratory disease today is how to adapt the definition of asthma to new scientific 
developments. The verification of objective 'biotypes', in terms of the development of 
asthma and the patients in whom they are observed, is an important conceptual advance, 
provided better clinical management for each patient is achieved so that the relative 
uniqueness of each patient with asthma can be better understood, both by the physician and 
the patients themselves. However, in order to define 'phenotypes' specific to patients or 
subgroups of patients in addition to the specific pathogenic 'endotypes' that identify them 
(in other words, how asthma patients become ill), it is necessary to thoroughly identify their 
defining characteristics. They must therefore be measured and grouped biologically and 
clinically in a differentiated way, even if certain aspects of the illness are the same [Lotvall et 
al., 2011; Moore et al., 2010].  
Today's objective biological measures and markers used to better understand these biotypes 
are the central focus of this chapter. 
3. Monitoring the airway and monitoring asthma in particular 
There are a number of methods available for identifying different aspects related to the 
natural evolution of IAD. The contribution of each aspect is determined by providing 
appropriate measures and robust parameters that meet consistent methodological 
determinants, such as the standardization of the method used, the availability of reference 
values, the reproducibility of findings, and above all the application of research findings to 
clinical practice and the global management of patients whose situation is well-defined as 
well as homogeneous patients or groups of subjects. Not all biological measures studied in 
recent years have managed to become routinely added as a parameter with clinical value in 
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the management of patients. Furthermore, those used routinely provide specific and limited 
information only. Therefore, current research being conducted focuses more on the 
inflammatory aspects of the lung, rather than the classical or clinical function, because it is 
the central pathogenic mechanism of the disease in the airway [Fabbri et al., 2005]. Severity 
and control disease assessment requires a multidimensional practical approach including an 
inflammatory view, as was previously confirmed by some authors [Fitzpatrick et al. 2011a; 
Haldar et al., 2008]. 
Technological advancements brought about by modern molecular biology and innovative 
micron analysis technology applied to the study of inflammation and the pathways of 
oxidative, lipid, or nitric stress, for example, can allow for a better identification and 
definition of new parameters, inflammatory profiles, and biomarkers that are more sensitive 
and specific for predicting the state of progression of IAD, differences in poor outcomes, and 
the type of anti-inflammatory treatment best suited to manage a particular patient or patient 
group. 
This section briefly discusses the most relevant parameters used in clinical practice for the 
monitoring of asthma, especially the most recent parameters that contribute greatly to the 
overall management of patients and other more promising parameters, from the perspective 
derived by direct measurement and monitoring of inflammatory activity. 
3.1 Global systems of measurement for airway disease  
From a clinical point of view, patients are typically monitored through the measurement of 
the symptoms present, questionnaires on the degree of control of the disease [Curtis et al., 
1997] or the impact on quality of life related to health [Juniper et al., 2004], 
pathophysiological parameters such as the degree of bronchial obstruction [FEV1 or PEF] 
[Miller, 2005], and variability [Reddel, 2006] or the degree of bronchial hyper-reactivity, both 
specific and nonspecific [Anderson, 2008b, Cockcroft & Davis 2006; Crapo et al., 2000; Sont 
et al., 1999; Sterk et al., 1993]. Each of these are more or less direct methods of measuring the 
clinical impact of inflammatory diseases of the airways, providing complementary 
information to diagnostic and therapeutic management [Fuhlbrigge, 2004; Gibson & Powell, 
2004; Taylor et al., 2008] and, to a lesser degree, clinical interpretation [Frey & Suki, 2008]. 
They have become absolutely necessary and indispensable for the classification of the 
patient's and establishment of control disease. In terms of study, testing of the whole 
response of the total airway implies knowing several pathogenic mechanisms of disease 
[Bousquet et al., 2000; Leuppi et al., 2001]. Understanding how control of the severity or 
clinical evolution of the disease is developed retains some specific limitations that result in 
advantages and disadvantages. For example, the main advantage of studying bronchial 
hyper-responsiveness to histamine or methacholine challenge is the high negative predictive 
value of the test [Luks et al., 2010]. On the contrary, its presence and the severity observed 
indicate functional impairment of the airway.  This may be interpretable in either a 
physiological (dysfunction, with or without an associated inflammatory basal profile) or 
pathological context (chronic inflammation, injury, mucosal or submucosal remodelling), 
which may or may not be modified by treatment once established [Hargreave et al., 1981; 
Rosi et al., 1999; Sont et al., 1999; van Essen-Zandvliet et al., 1994]. Recent advances in the 
clinical use of substances, such as adenosine or mannitol, provide additional data on the 
association between bronchial hyper-responsiveness, as measured by these indirect stimuli, 
and markers of inflammation [Polosa et al., 2000; Rutgers et al., 2000].  
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Other findings arising from the current radiological spectrum of diseases of the airway also 
provide useful data to study dynamic airway inflammation, expressed as the degree of 
trapped air and bronchial wall thickness [Gupta et al., 2010].  
It is therefore possible to say that although the parameters and measurements discussed in 
this section can be applied to both asthma and COPD in order to achieve better clinical 
management, its meaning and clinical interpretation are often heterogeneous or variable 
depending on the patient, the therapy administered at the time of measurement, and the 
spectrum of IADs identified in the subject, both initially and over time [Avital et al., 1995; 
Dima et al., 2010]. Discrimination of all the spectrum of obstructive airway diseases is the 
goal to achieve at present time.   
3.2 Direct systems of injury and repair measurement in pulmonary biology 
The pathology of the airway has a clearly inflammatory pathophysiological basis, although 
the role this plays, both in the short term and in the long term, in the biological continuum 
of integrity, dysfunction, injury, and repair continues to undergo constant research. 
Traditionally, the gold standard in inflammatory activity has been to use various 
measurements and markers, both inflammatory and those of oxidative stress, obtained 
invasively by bronchial biopsy and bronchoalveolar lavage [Bergeron et al., 2007; Brasier et 
al., 2010; Hallstrand et al., 2011]. Although various parameters and histological patterns of 
inflammation have been identified with these techniques, many of them are shared by the 
anatomopathological spectrum of IAD. This causes ambiguity, both in the various 
pathogenic contexts in which pathophysiological interpretation is difficult and, 
consequently, non-pathognomonic situations in which discrimination regarding asthma or 
COPD occurs. Only some of these findings have demonstrated applicability to clinical care 
and a certain ability to differentiate or discriminate between the inflammatory pathogenic 
states of an underlying pathologic lesion, as in the study of bronchial remodelling [Sont et 
al., 1999; Sont et al., 2003], or the prevalence of the cellular profile of bronchial infiltration, 
as in the case of life-threatening asthma [Mauad et al., 2004; Mauad et al., 2008]. 
Furthermore, both techniques also have some significant limitations when carried out 
routinely. The first is that only one compartment of the airway is represented unless both 
procedures are done at the same time. The second limitation is the invasiveness of the 
procedure. This is an obstacle when routinely performed on the patient, despite the fact 
that these methods have been standardized and allow for a better visualization of the type 
of inflammation and anatomical injury caused by IAD in certain patients. They are also 
useful in studying the pathogenic mechanisms involved, as well as classifying and 
identifying the stage of disease [Fabbri et al., 2003; Fabbri et al., 2005; Moore et al., 2011], 
but the requirements of the procedure do not make them suitable for routine monitoring 
of the patient and are therefore generally reserved today for the systematic study of 
inflammation in pulmonary biology research.  
The new semi-invasive methods, such as induced sputum, or non-invasive methods, such as 
the measurement of nitric oxide, condensation, or exhaled temperature, provide new and 
useful data directly from the airway that may be used in the classification of IADs and the 
management of patients [Popov, 2011]. Some markers derived from blood samples can also 
be used in assessing inflammatory disease and its systemic impact. These include eosinophil 
cationic proteins, as well as cationic peroxidase and leucotriens [Koh et al., 2007; 
Rabinovitch, 2007], but other novel systemic blood biomarkers are also promising [Verrills 
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et al., 2011]. The most important contributions of non-invasive methods currently used to 
measure inflammation of the airway and the most promising research being carried out 
with new applied technologies in molecular biology and immunology are discussed below. 
3.2.1 Induced sputum 
This semi-invasive technique is used to obtain a representative sample of bronchial 
secretions in the airway. Some methodological variations in the induction procedure may 
produce samples from a more central or peripheral compartment of the airway, providing 
versatility in IAD screening in terms of both central and peripheral orientation. This is 
characterized as such because the differential inflammatory profile obtained is reproducible 
and can be correctly interpreted in a clinical context. However, this is not the case in the 
study of the various markers of inflammation and oxidative stress obtained from the 
supernatant, which have strict methodological considerations and limitations in the 
interpretation of results [Nicholas, 2009]. Bearing this in mind, induced sputum has become 
the gold standard non-invasive method for measuring bronchial cell inflammation and for 
certain soluble markers that are identifiable and of specific dilution [Bakakos, 2011; 
Djukanovic 2004]. The standardization of the method and procedure, adequate safeness of 
the technique, good toleration by the patient, ease of use, and the obtainment of reference 
values have made it an essential technique in the study of complex patients who require the 
characterization of the bronchial inflammatory pattern in order to be managed correctly 
[Djukanovic, 2002]. The current characterization of the endotypes and phenotypes of 
patients with inflammatory airway disease, based on inflammatory cell patterns [Balzar et 
al., 2011; Haldar et al., 2008], and the combination of different biomarkers, such as those 
derived from 'esputoma' [Gray et al., 2008; Nicholas, 2006] and oxidative stress [Louhelainen 
et al., 2008a; Louhelainen et al., 2008b], 15-lipoxygenase pathway [Chu, et al., 2002], 
gluthation oxidation [Fitzpatrick et al., 2011b] or genetics and protein identification [Baines 
et al., 2011; Hastie et al, 2010] make sputum an indisputable protagonist in the new 
definition of phenotypes, the classification of patients with asthma and COPD [Fabbri et al., 
2003; Fatj et al., 2009; Louis et al., 2002; Wang et al., 2011], the therapeutic management of 
these patients, the prediction of therapeutic response [Green et al., 2002; Jayaram et al., 2006, 
Caramori et al., 2005], and the evaluation of efficacy in the most recent anti-inflammatory 
molecules [Haldar et al, 2009; Pavord et al. 2009, van Rensen et al. 2009]. Currently, new 
techniques in molecular biology may be applied to the study of sputum in order to study the 
expression shown in the cellular response of certain subtypes of cell lines, as found for 
example, by studying toll-like cell receptors or local innate immunity measured by flow 
cytometry [Lay et al, 2011], or those derived from cell cultures [Bettiol et al., 2002], the 
cellular response to markers of cell migration [Dent et al., 2004], or even those obtained from 
the analysis of proteomics traces or esputoma [Park & Rim, 2011; Nicholas & Djukanovic, 
2009], as well as the genome [Baines et al., 2011; Bisgaard et al., 2011]. 
3.2.2 The exhaled fraction determined singularly or in combination 
The use of exhaled markers capable of reflecting a clinically useful measurement of the 
inflammation and oxidative stress present in the airway currently involves bronchial nitric 
oxide (NO) as the main marker [Barnes et al., 2010]. This measurement is reproducible and 
the method has been standardized [ATS/ERS, 2005]. Because its concentration is dependent 
on the flow and the source of production, a compartmental model of alveolar or bronchial 
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Other findings arising from the current radiological spectrum of diseases of the airway also 
provide useful data to study dynamic airway inflammation, expressed as the degree of 
trapped air and bronchial wall thickness [Gupta et al., 2010].  
It is therefore possible to say that although the parameters and measurements discussed in 
this section can be applied to both asthma and COPD in order to achieve better clinical 
management, its meaning and clinical interpretation are often heterogeneous or variable 
depending on the patient, the therapy administered at the time of measurement, and the 
spectrum of IADs identified in the subject, both initially and over time [Avital et al., 1995; 
Dima et al., 2010]. Discrimination of all the spectrum of obstructive airway diseases is the 
goal to achieve at present time.   
3.2 Direct systems of injury and repair measurement in pulmonary biology 
The pathology of the airway has a clearly inflammatory pathophysiological basis, although 
the role this plays, both in the short term and in the long term, in the biological continuum 
of integrity, dysfunction, injury, and repair continues to undergo constant research. 
Traditionally, the gold standard in inflammatory activity has been to use various 
measurements and markers, both inflammatory and those of oxidative stress, obtained 
invasively by bronchial biopsy and bronchoalveolar lavage [Bergeron et al., 2007; Brasier et 
al., 2010; Hallstrand et al., 2011]. Although various parameters and histological patterns of 
inflammation have been identified with these techniques, many of them are shared by the 
anatomopathological spectrum of IAD. This causes ambiguity, both in the various 
pathogenic contexts in which pathophysiological interpretation is difficult and, 
consequently, non-pathognomonic situations in which discrimination regarding asthma or 
COPD occurs. Only some of these findings have demonstrated applicability to clinical care 
and a certain ability to differentiate or discriminate between the inflammatory pathogenic 
states of an underlying pathologic lesion, as in the study of bronchial remodelling [Sont et 
al., 1999; Sont et al., 2003], or the prevalence of the cellular profile of bronchial infiltration, 
as in the case of life-threatening asthma [Mauad et al., 2004; Mauad et al., 2008]. 
Furthermore, both techniques also have some significant limitations when carried out 
routinely. The first is that only one compartment of the airway is represented unless both 
procedures are done at the same time. The second limitation is the invasiveness of the 
procedure. This is an obstacle when routinely performed on the patient, despite the fact 
that these methods have been standardized and allow for a better visualization of the type 
of inflammation and anatomical injury caused by IAD in certain patients. They are also 
useful in studying the pathogenic mechanisms involved, as well as classifying and 
identifying the stage of disease [Fabbri et al., 2003; Fabbri et al., 2005; Moore et al., 2011], 
but the requirements of the procedure do not make them suitable for routine monitoring 
of the patient and are therefore generally reserved today for the systematic study of 
inflammation in pulmonary biology research.  
The new semi-invasive methods, such as induced sputum, or non-invasive methods, such as 
the measurement of nitric oxide, condensation, or exhaled temperature, provide new and 
useful data directly from the airway that may be used in the classification of IADs and the 
management of patients [Popov, 2011]. Some markers derived from blood samples can also 
be used in assessing inflammatory disease and its systemic impact. These include eosinophil 
cationic proteins, as well as cationic peroxidase and leucotriens [Koh et al., 2007; 
Rabinovitch, 2007], but other novel systemic blood biomarkers are also promising [Verrills 
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et al., 2011]. The most important contributions of non-invasive methods currently used to 
measure inflammation of the airway and the most promising research being carried out 
with new applied technologies in molecular biology and immunology are discussed below. 
3.2.1 Induced sputum 
This semi-invasive technique is used to obtain a representative sample of bronchial 
secretions in the airway. Some methodological variations in the induction procedure may 
produce samples from a more central or peripheral compartment of the airway, providing 
versatility in IAD screening in terms of both central and peripheral orientation. This is 
characterized as such because the differential inflammatory profile obtained is reproducible 
and can be correctly interpreted in a clinical context. However, this is not the case in the 
study of the various markers of inflammation and oxidative stress obtained from the 
supernatant, which have strict methodological considerations and limitations in the 
interpretation of results [Nicholas, 2009]. Bearing this in mind, induced sputum has become 
the gold standard non-invasive method for measuring bronchial cell inflammation and for 
certain soluble markers that are identifiable and of specific dilution [Bakakos, 2011; 
Djukanovic 2004]. The standardization of the method and procedure, adequate safeness of 
the technique, good toleration by the patient, ease of use, and the obtainment of reference 
values have made it an essential technique in the study of complex patients who require the 
characterization of the bronchial inflammatory pattern in order to be managed correctly 
[Djukanovic, 2002]. The current characterization of the endotypes and phenotypes of 
patients with inflammatory airway disease, based on inflammatory cell patterns [Balzar et 
al., 2011; Haldar et al., 2008], and the combination of different biomarkers, such as those 
derived from 'esputoma' [Gray et al., 2008; Nicholas, 2006] and oxidative stress [Louhelainen 
et al., 2008a; Louhelainen et al., 2008b], 15-lipoxygenase pathway [Chu, et al., 2002], 
gluthation oxidation [Fitzpatrick et al., 2011b] or genetics and protein identification [Baines 
et al., 2011; Hastie et al, 2010] make sputum an indisputable protagonist in the new 
definition of phenotypes, the classification of patients with asthma and COPD [Fabbri et al., 
2003; Fatj et al., 2009; Louis et al., 2002; Wang et al., 2011], the therapeutic management of 
these patients, the prediction of therapeutic response [Green et al., 2002; Jayaram et al., 2006, 
Caramori et al., 2005], and the evaluation of efficacy in the most recent anti-inflammatory 
molecules [Haldar et al, 2009; Pavord et al. 2009, van Rensen et al. 2009]. Currently, new 
techniques in molecular biology may be applied to the study of sputum in order to study the 
expression shown in the cellular response of certain subtypes of cell lines, as found for 
example, by studying toll-like cell receptors or local innate immunity measured by flow 
cytometry [Lay et al, 2011], or those derived from cell cultures [Bettiol et al., 2002], the 
cellular response to markers of cell migration [Dent et al., 2004], or even those obtained from 
the analysis of proteomics traces or esputoma [Park & Rim, 2011; Nicholas & Djukanovic, 
2009], as well as the genome [Baines et al., 2011; Bisgaard et al., 2011]. 
3.2.2 The exhaled fraction determined singularly or in combination 
The use of exhaled markers capable of reflecting a clinically useful measurement of the 
inflammation and oxidative stress present in the airway currently involves bronchial nitric 
oxide (NO) as the main marker [Barnes et al., 2010]. This measurement is reproducible and 
the method has been standardized [ATS/ERS, 2005]. Because its concentration is dependent 
on the flow and the source of production, a compartmental model of alveolar or bronchial 
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origin of exhaled nitric oxide has been developed in order to study of the origin of the 
alteration and the lung injury, situating it at a more central or peripheral level in the airway 
[Puckett et al., 2010]. This model allows the production variability within the spectrum of 
IAD and the anti-inflammatory modulation produced by the therapy administered to be 
studied in depth. While this method is certainly advantageous when carrying out clinical 
monitoring within a timeframe because of its non-invasivity, it may only be used in 
certain patients, i.e. those in whom the main source of NO has been identified as a clearly 
modifiable and dependent element of the course of inflammation with therapeutic anti-
inflammatory management, or for the screening of type of activated inflammation 
[Anderson et al., 2011]. The use of NO in the research of no homogeneously selected 
patients leads to a clinically confusing interpretation in terms of its identification and 
therefore must be considered limited or biased under these circumstances [Dweik et al., 
2010]. In addition, certain methodological considerations conditioned by the design of NO 
research studies regarding the cut-off used to make a management decision must be taken 
into account during diagnosis and treatment, i.e. conditioning the patient management 
strategy based on the levels of NO [Gibson, 2009; Quaedvlieg et al., 2009; Schleich et al., 
2009; Schneider et al., 2009]. 
Other exhaled markers of the bronchial airway, such as the detection of carbon monoxide 
and other volatile hydrocarbon compounds, products of lipid peroxidation, have also 
been studied [Antczak et al., 2011]. However, a definitive standardization of methods for 
immediate application in a clinical context has not been achieved. Similarly, the 
measurement of exhaled temperature increase at the start of breathing with regard to the 
reference point marked during the entire period of measurement of the increase is 
associated with the presence of active inflammation and airway remodelling [Paredi, 
2005]. This also occurs with the measurement of bronchial blood flow, estimated by mass 
spectrometry using the Fick principle, and the calculation of the dilution of exhaled 
acetylene [the initial concentration inhaled is known]. Both methods may have their place 
in the spectrum of non-invasive monitoring of bronchial inflammation if the optimal 
exhaled flow is standardized methodologically for the purpose of measurement [Paredi & 
Barnes, 2010]. 
The identification of different volatile compounds produced by oxidative stress, nitrosative 
stress, inflammation and metallic elements, and obtained from the exhaled condensate has 
also been possible through the use of chromatography and mass spectrometry [Corradi et al. 
2007; Corradi et al, 2010]. Some of these compounds may be considered biomarkers in 
clinical practice [Baraldi et al., 2009 Kostikas et al., 2008; Loukides et al, 2011], such as pH 
determination [Kostikas et al., 2011; Antus et al, 2010]. However, it is necessary to simplify 
the instrumentation of the procedure for routine use in clinical practice. The standardization 
of methodology and applicability to clinical practice of other compounds under 
investigation as potential biomarkers has yet to be sufficiently achieved due, among other 
things, to certain limitations, such as contamination of condensate compounds of the mouth 
(especially if concomitant oral inflammation occurs), difficulty in calculating the optimal 
dilution of the selected parameter, or instability, volatility, and interaction of the mixture of 
soluble compounds that can take place during this process [Horvàth et al. 2005]. 
Comparisons with other biomarkers obtained and already standardized are needed to 
establish the utility of the different compounds of exhaled condensate, especially if 
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performed one by one [Baraldi et al., 2009]. However, recent specific phenotypes of asthma 
patients, like aspirin intolerant asthmatics can be identified [Sanak et al, 2011]. 
Calculating the nasal exhaled fraction may be useful for the study and diagnosis of primary 
ciliary dyskinesia and is virtually abolished in this disease [Horváth et al., 2003]. On the 
contrary nasal NO levels are higher in rhinitis [Struben et al., 2006] 
3.2.3 The multiple molecular studies of biological lung samples, or systemic samples, 
significant to pulmonary disease  
Since the detection of a single marker of inflammation or oxidative stress does not identify a 
specific inflammatory disease of the airway as defined today, but rather proves the 
heterogeneity of inflammatory conditions and diseases of the airway, current research on 
biological markers focuses on a combination of identifying patterns of proteins and volatile 
compounds that can be identified by molecular marks or traces they contain. At the 
molecular level, many omic compounds (proteomic, metabolomic, genomic) may be 
identified. Within the field of respiratory medicine, these compounds will remain an enigma 
until the wealth of empirical molecular information is organized and interpreted, free of a 
priori hypotheses, and the subsequent translation to clinical practice can be carried out. Such 
information would have the great advantage of producing a custom 'fingerprint' of 
inflammation during a specific time point in the evolution of the disease process in a 
particular patient. The correct interpretation of molecular information will allow the 
clinician to identify and predict the patient and disease biotypes (phenotype and endotype), 
the severity of the inflammatory process in progress, the clinical evolution, the type of 
treatment to be applied, the response to the therapy administered, and the prognosis for 
each individual patient [Crameri, 2005; Vijverberg et al., 2011]. The new molecular 
application technology based on bioinformatics, cluster analysis, and artificial intelligence 
algorithms that are being developed at present provide all this information for the purpose 
of prediction and interpretation at a biological level. This is useful in understanding the new 
biology of systems integration [Perpiñá, 2010; Scott et al., 2007; Thaler & Hanson, 2005]. The 
following is a description of the research currently being conducted. 
First, chromatography and mass spectrometry have been used to identify hundreds of 
volatile exhaled organic compounds originating from the metabolic pathways involved in 
pulmonary biology. However, their use as biomarkers with a clinical application is still 
under study [Freidrich, 2009]. Secondly, the addition of other specific technology for 
determining the spectrum of metabolites, proteins or organic compounds in different 
biological samples (cellular, fluid, or gas) in blood, sputum, or bronchoalveolar lavage, and 
developed on line, such as the application a multiple set of nanosensors (arrays) or the 
application of high-resolution nuclear magnetic resonance, has achieved rapid progress in 
identifying potential profiles and patterns of disease-specific biomarkers. For example, 
different patterns of compounds originating in breathing and exhaled breath evaluated by 
the so-called electronic nose identify molecules of different size, volume and dipole [Lewis, 
2004]. These patterns have shown good sensitivity and discrimination capabilities for this 
combination and may be as helpful as those already described for the identification of 
certain odours, producing an odoriferous mark or smellprint. This would specifically identify 
the type of inflammation present and could be useful in the differential diagnosis of specific 
IADs [Dragonieri et al., 2007] in addition to the particular diagnostic and therapeutic 
strategies for each patient. 
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origin of exhaled nitric oxide has been developed in order to study of the origin of the 
alteration and the lung injury, situating it at a more central or peripheral level in the airway 
[Puckett et al., 2010]. This model allows the production variability within the spectrum of 
IAD and the anti-inflammatory modulation produced by the therapy administered to be 
studied in depth. While this method is certainly advantageous when carrying out clinical 
monitoring within a timeframe because of its non-invasivity, it may only be used in 
certain patients, i.e. those in whom the main source of NO has been identified as a clearly 
modifiable and dependent element of the course of inflammation with therapeutic anti-
inflammatory management, or for the screening of type of activated inflammation 
[Anderson et al., 2011]. The use of NO in the research of no homogeneously selected 
patients leads to a clinically confusing interpretation in terms of its identification and 
therefore must be considered limited or biased under these circumstances [Dweik et al., 
2010]. In addition, certain methodological considerations conditioned by the design of NO 
research studies regarding the cut-off used to make a management decision must be taken 
into account during diagnosis and treatment, i.e. conditioning the patient management 
strategy based on the levels of NO [Gibson, 2009; Quaedvlieg et al., 2009; Schleich et al., 
2009; Schneider et al., 2009]. 
Other exhaled markers of the bronchial airway, such as the detection of carbon monoxide 
and other volatile hydrocarbon compounds, products of lipid peroxidation, have also 
been studied [Antczak et al., 2011]. However, a definitive standardization of methods for 
immediate application in a clinical context has not been achieved. Similarly, the 
measurement of exhaled temperature increase at the start of breathing with regard to the 
reference point marked during the entire period of measurement of the increase is 
associated with the presence of active inflammation and airway remodelling [Paredi, 
2005]. This also occurs with the measurement of bronchial blood flow, estimated by mass 
spectrometry using the Fick principle, and the calculation of the dilution of exhaled 
acetylene [the initial concentration inhaled is known]. Both methods may have their place 
in the spectrum of non-invasive monitoring of bronchial inflammation if the optimal 
exhaled flow is standardized methodologically for the purpose of measurement [Paredi & 
Barnes, 2010]. 
The identification of different volatile compounds produced by oxidative stress, nitrosative 
stress, inflammation and metallic elements, and obtained from the exhaled condensate has 
also been possible through the use of chromatography and mass spectrometry [Corradi et al. 
2007; Corradi et al, 2010]. Some of these compounds may be considered biomarkers in 
clinical practice [Baraldi et al., 2009 Kostikas et al., 2008; Loukides et al, 2011], such as pH 
determination [Kostikas et al., 2011; Antus et al, 2010]. However, it is necessary to simplify 
the instrumentation of the procedure for routine use in clinical practice. The standardization 
of methodology and applicability to clinical practice of other compounds under 
investigation as potential biomarkers has yet to be sufficiently achieved due, among other 
things, to certain limitations, such as contamination of condensate compounds of the mouth 
(especially if concomitant oral inflammation occurs), difficulty in calculating the optimal 
dilution of the selected parameter, or instability, volatility, and interaction of the mixture of 
soluble compounds that can take place during this process [Horvàth et al. 2005]. 
Comparisons with other biomarkers obtained and already standardized are needed to 
establish the utility of the different compounds of exhaled condensate, especially if 
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performed one by one [Baraldi et al., 2009]. However, recent specific phenotypes of asthma 
patients, like aspirin intolerant asthmatics can be identified [Sanak et al, 2011]. 
Calculating the nasal exhaled fraction may be useful for the study and diagnosis of primary 
ciliary dyskinesia and is virtually abolished in this disease [Horváth et al., 2003]. On the 
contrary nasal NO levels are higher in rhinitis [Struben et al., 2006] 
3.2.3 The multiple molecular studies of biological lung samples, or systemic samples, 
significant to pulmonary disease  
Since the detection of a single marker of inflammation or oxidative stress does not identify a 
specific inflammatory disease of the airway as defined today, but rather proves the 
heterogeneity of inflammatory conditions and diseases of the airway, current research on 
biological markers focuses on a combination of identifying patterns of proteins and volatile 
compounds that can be identified by molecular marks or traces they contain. At the 
molecular level, many omic compounds (proteomic, metabolomic, genomic) may be 
identified. Within the field of respiratory medicine, these compounds will remain an enigma 
until the wealth of empirical molecular information is organized and interpreted, free of a 
priori hypotheses, and the subsequent translation to clinical practice can be carried out. Such 
information would have the great advantage of producing a custom 'fingerprint' of 
inflammation during a specific time point in the evolution of the disease process in a 
particular patient. The correct interpretation of molecular information will allow the 
clinician to identify and predict the patient and disease biotypes (phenotype and endotype), 
the severity of the inflammatory process in progress, the clinical evolution, the type of 
treatment to be applied, the response to the therapy administered, and the prognosis for 
each individual patient [Crameri, 2005; Vijverberg et al., 2011]. The new molecular 
application technology based on bioinformatics, cluster analysis, and artificial intelligence 
algorithms that are being developed at present provide all this information for the purpose 
of prediction and interpretation at a biological level. This is useful in understanding the new 
biology of systems integration [Perpiñá, 2010; Scott et al., 2007; Thaler & Hanson, 2005]. The 
following is a description of the research currently being conducted. 
First, chromatography and mass spectrometry have been used to identify hundreds of 
volatile exhaled organic compounds originating from the metabolic pathways involved in 
pulmonary biology. However, their use as biomarkers with a clinical application is still 
under study [Freidrich, 2009]. Secondly, the addition of other specific technology for 
determining the spectrum of metabolites, proteins or organic compounds in different 
biological samples (cellular, fluid, or gas) in blood, sputum, or bronchoalveolar lavage, and 
developed on line, such as the application a multiple set of nanosensors (arrays) or the 
application of high-resolution nuclear magnetic resonance, has achieved rapid progress in 
identifying potential profiles and patterns of disease-specific biomarkers. For example, 
different patterns of compounds originating in breathing and exhaled breath evaluated by 
the so-called electronic nose identify molecules of different size, volume and dipole [Lewis, 
2004]. These patterns have shown good sensitivity and discrimination capabilities for this 
combination and may be as helpful as those already described for the identification of 
certain odours, producing an odoriferous mark or smellprint. This would specifically identify 
the type of inflammation present and could be useful in the differential diagnosis of specific 
IADs [Dragonieri et al., 2007] in addition to the particular diagnostic and therapeutic 
strategies for each patient. 
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4. The future of targeted and individualized biological respiratory therapy 
The new concept of biotypes (endotypes and phenotypes) of IAD is transforming the 
definition of asthma to the point where it will soon be possible to obtain a more accurate 
simplification of what is understood today as asthma in order to better adapt to patient 
management and the clinical reality. However, the definition of asthma that currently exists 
is complex and will remain so, despite continuous modification and rehabilitation, given 
that although the heterogeneity of the IAD is better understood and the subtypes of the 
disease and patient subgroups are better classified, the multifactorial and dynamic aspects 
of the biological responses involved make applying reductionist criteria very difficult. It is 
therefore necessary to maintain a flexible and mentally versatile attitude that is as dynamic 
as biology itself. This attitude will facilitate the understanding of respiratory medicine of the 
future, which in turn will affect therapeutic management. This approach may be considered 
the cornerstone of individualized therapy for respiratory patients. It will aid in the 
progressive incorporation of biopharmaceuticals capable of regulating or altering 
inflammatory pathways, the remodelling process and the smooth muscle response. Both 
strategies are complementary and briefly commented. 
First, the action and biological and immunological mechanisms will modulate the degree of 
response obtained at the molecular level and will result clinically in a very specific action. 
Being able to have these modulating biopharmaceuticals will be crucial and improve the 
quality of life for patients with IAD and asthma [Adock et al., 2008; Casale & Stokes, 2008]. 
However, the availability of these drugs will lead to a major challenge at the clinical level 
that they will be reflected in trying to establish well-defined therapeutic indications to 
ensure safe, efficient, and cost-effective use. Some examples of modulating 
biopharmaceuticals in the context of eosinophilic inflammation that have been used in 
patients with poor control and greater severity of symptoms are those that interfere with the 
biological action of IgE, IL-5 or TNF. The attainment of adequate control and improvement 
of outcome in these patients is a sign of success in the development of new molecules, such 
as the monoclonal antibodies, mepolizumab, etarnercept or omalizumab [Holgate et al, 
2011; Pavord et al., 2010; Pelaia et al., 2011]. Other biological modulating drugs acting at the 
neutrophilic, mast o lymphocite cells or other relevant molecules in the pathways and the 
inflammatory response, are being tested for the purpose of incorporation into the 
therapeutic arsenal available for IAD [Chung & Marwick, 2010, Barnes, 2009]. 
Pharmacogenetics and understanding of innate immunty pathways are promising areas of 
research to discover determined mechanisms and specific molecules to reverse the altered 
inflammatory response [Caramori et al., 2004; Kanagaratham et al., 2011; Gupta & Agrawal, 
2010; Slager, 2010].  
Second, the important thing to considering the therapy of releaving symptoms in the 
asthma clinic course is the understanding of the mechanical obstruction in the airways 
and the air-trapping compensatory consequence [Sorkness et al., 2008]. New long-acting 
smooth muscle relaxant molecules are been incorporated alone or in combination to the 
inhaler therapy [Cazzola et al., 2011; Chung et al., 2009; Kiyokawa  et al., 2011; Postma et 
al., 2011], but recent knowing of the genetics of airway smooth muscle points out a new 
strategies to develop asthma targeted molecules [Hai, 2008]. Another specific therapy 
focus on smooth muscle of the airways, like bronchial thermoplasty, is still under 
evaluation [Thompson et al., 2011]. 
 




Inflammatory diseases of the airway, and asthma in particular, are complex and 
heterogenous, both in terms of the biological expression of inflammation they produce and 
in terms of the 'biotypes' (endotypes and phenotypes) that can be objectively translated from 
this condition. New information provided by new technology applied to modern molecular 
biology and immunology requires the current concept and definition of asthma to be 
modified and adapted. The attainment of this important progressive scientific knowledge 
can help to address how and why this condition occurs and may contribute to a better 
understanding of the classification of each asthma patient, the proper diagnosis of the type 
of asthma presented, the monitoring approach, the personalized treatment required, and the 
method to determine prognosis. A wide spectrum of biomarkers is currently being 
incorporated as clinically useful parameters. What remains is to gradually adapt them to 
comprehensive of multidimensional approaches and medical procedures, and establish the 
appropriate indications and clinical applications in respiratory disease. 
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4. The future of targeted and individualized biological respiratory therapy 
The new concept of biotypes (endotypes and phenotypes) of IAD is transforming the 
definition of asthma to the point where it will soon be possible to obtain a more accurate 
simplification of what is understood today as asthma in order to better adapt to patient 
management and the clinical reality. However, the definition of asthma that currently exists 
is complex and will remain so, despite continuous modification and rehabilitation, given 
that although the heterogeneity of the IAD is better understood and the subtypes of the 
disease and patient subgroups are better classified, the multifactorial and dynamic aspects 
of the biological responses involved make applying reductionist criteria very difficult. It is 
therefore necessary to maintain a flexible and mentally versatile attitude that is as dynamic 
as biology itself. This attitude will facilitate the understanding of respiratory medicine of the 
future, which in turn will affect therapeutic management. This approach may be considered 
the cornerstone of individualized therapy for respiratory patients. It will aid in the 
progressive incorporation of biopharmaceuticals capable of regulating or altering 
inflammatory pathways, the remodelling process and the smooth muscle response. Both 
strategies are complementary and briefly commented. 
First, the action and biological and immunological mechanisms will modulate the degree of 
response obtained at the molecular level and will result clinically in a very specific action. 
Being able to have these modulating biopharmaceuticals will be crucial and improve the 
quality of life for patients with IAD and asthma [Adock et al., 2008; Casale & Stokes, 2008]. 
However, the availability of these drugs will lead to a major challenge at the clinical level 
that they will be reflected in trying to establish well-defined therapeutic indications to 
ensure safe, efficient, and cost-effective use. Some examples of modulating 
biopharmaceuticals in the context of eosinophilic inflammation that have been used in 
patients with poor control and greater severity of symptoms are those that interfere with the 
biological action of IgE, IL-5 or TNF. The attainment of adequate control and improvement 
of outcome in these patients is a sign of success in the development of new molecules, such 
as the monoclonal antibodies, mepolizumab, etarnercept or omalizumab [Holgate et al, 
2011; Pavord et al., 2010; Pelaia et al., 2011]. Other biological modulating drugs acting at the 
neutrophilic, mast o lymphocite cells or other relevant molecules in the pathways and the 
inflammatory response, are being tested for the purpose of incorporation into the 
therapeutic arsenal available for IAD [Chung & Marwick, 2010, Barnes, 2009]. 
Pharmacogenetics and understanding of innate immunty pathways are promising areas of 
research to discover determined mechanisms and specific molecules to reverse the altered 
inflammatory response [Caramori et al., 2004; Kanagaratham et al., 2011; Gupta & Agrawal, 
2010; Slager, 2010].  
Second, the important thing to considering the therapy of releaving symptoms in the 
asthma clinic course is the understanding of the mechanical obstruction in the airways 
and the air-trapping compensatory consequence [Sorkness et al., 2008]. New long-acting 
smooth muscle relaxant molecules are been incorporated alone or in combination to the 
inhaler therapy [Cazzola et al., 2011; Chung et al., 2009; Kiyokawa  et al., 2011; Postma et 
al., 2011], but recent knowing of the genetics of airway smooth muscle points out a new 
strategies to develop asthma targeted molecules [Hai, 2008]. Another specific therapy 
focus on smooth muscle of the airways, like bronchial thermoplasty, is still under 
evaluation [Thompson et al., 2011]. 
 




Inflammatory diseases of the airway, and asthma in particular, are complex and 
heterogenous, both in terms of the biological expression of inflammation they produce and 
in terms of the 'biotypes' (endotypes and phenotypes) that can be objectively translated from 
this condition. New information provided by new technology applied to modern molecular 
biology and immunology requires the current concept and definition of asthma to be 
modified and adapted. The attainment of this important progressive scientific knowledge 
can help to address how and why this condition occurs and may contribute to a better 
understanding of the classification of each asthma patient, the proper diagnosis of the type 
of asthma presented, the monitoring approach, the personalized treatment required, and the 
method to determine prognosis. A wide spectrum of biomarkers is currently being 
incorporated as clinically useful parameters. What remains is to gradually adapt them to 
comprehensive of multidimensional approaches and medical procedures, and establish the 
appropriate indications and clinical applications in respiratory disease. 
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1. Introduction  
Acyl-CoA Thioesterases (ACOTs) perform a wide range of cellular functions by catalysing 
the thiolytic cleavage of activated fatty acyl-CoAs. Substrates of ACOTs include short to 
long-chain acyl-CoAs as well as a range of methyl-branched, and dicarboxylic bile acid-
CoAs (M. C. Hunt & Alexson, 2008). Expression of ACOTs have been detected in both 
prokaryotes and eukaryotes with expression in higher organisms being detected in cytosol, 
mitochondria, peroxisomes and endoplasmic reticulum (J. Yamada, 2005).  
Within the ACOT enzyme family, one member in particular, ACOT7 has recently been 
identified as playing a role inflammation through the production of arachidonic acid (AA). 
It was recently proposed that ACOT7-mediated AA production may provide a 
complementary source of AA to the well characterised phospholipase A2 (PLA2) pathway 
(Satoru Sakuma, Usa, & Fujimoto, 2006); see Table 1 for review of Acot substrate specificity. 
Evidence for these observations was through experimental data showing that ACOT7 
possessed high substrate specificity for AA-CoA; the gene encoding ACOT7 was highly 
expressed in macrophages and up-regulated when stimulated by lipopolysaccharide (LPS); 
and that over-expression of the enzyme lead to an increase in prostaglandin production. 
Together, these observations highlight a novel role of ACOT7 in inflammation through the 
production of arachidonic acid from the thiolytic cleavage of activated polyunsaturated 
omega-6 fatty acid C20:4-CoA (Forwood et al., 2007). 
2. Cellular production of arachidonic acid (C20:4) 
Arachidonic acid has a number of important cellular roles, namely in cell signalling, 
regulation of metabolic and signalling enzymes, and inflammation.  Despite its importance, 
its methods of cellular production are not fully understood.  The most well characterised 
cellular pathway for arachidonic acid involves its release from membrane phospholipids via 
the action of PLA2, an enzyme responsible for the catalysis and hydrolysis of phospholipids 
at the sn-2 position (Sakuma et al, 2006) (see Figure 1).  
Expression of PLA2 is regulated according to the requirement for arachidonic acid and well 
understood. Rapid activation of PLA2 is achieved via posttranslational modification,  and 
enzyme activity is activated by phosphorylation (controlled by mitogen-activated protein), 
while prolonged expression is regulated at a transcriptional level by cytokines and growth 
factors such as macrophage colony stimulating factor, tumor necrosis stimulating factor- 
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Acot Homologue Preferred acyl-CoA substrate 
Acot1 Lauroyl and palmitoyl-CoA 
Acot2 Lauroyl and palmitoyl-CoA 
Acot3 Palmitoyl-CoA  
Acot4 Succinyl-CoA  
Acot5 Decanoyl-CoA  
Acot6 Not determined 
Acot7 Arachidonoyl-CoA 
Acot8 Bile acids  
Acot9 Myristoyl-CoA  
Acot10 Myristoyl-CoA  
Acot11 Not determined 
Acot12 Acetyl-CoA 
Acot13 Aromatic acyl-CoAs 
Table 1. Substrate specificities for acyl-coA thioesterases. 
alpha and glucocorticoid (Jiang et al., 2001; Satoru Sakuma, et al., 2006). While PLA2 is well 
known for its role in generating AA from the cleavage of the acyl bond of membrane 
phospholipids in a range of cell types, several lines of evidence have recently developed to 
suggest that PLA2 may not be solely responsible for controlling AA levels. For example, it 
was shown that AA-CoA can supply AA for prostaglandin (PG) synthesis (S. Sakuma et al., 
1994), and that a novel enzymatic pathway exists whereby thioesterase cleavage of AA-CoA 
is responsible for supplying free AA to be utilised in the synthesis of prostaglandins (S. 
Sakuma, et al., 1994). A similar mechanism has also been described for controlling cellular 
levels of AA where it was demonstrated that AA levels were under the control of competing 
actions of an acyl-CoA thioesterase and synthetase, independent of the classical PLA2 
cascade (Maloberti et al., 2005). In further support of these observations, when competition 
on AA levels were reduced through inhibition of an AA acyl-CoA synthetase (ACS; the 
opposite reaction that is catalysed by Acot7), substantial increases in PG levels were 
observed (Castilla et al., 2004); and moreover, in an independent study, overexpression of an 
acyl-CoA synthetase was been shown to cause a marked increase in synthesis of AA-CoA, 
increased 20:4 incorporation into membrane phospholipids, reduced cellular levels of 
unesterified 20:4, and reduced secretion of prostaglandin E2 (PGE2) while inhibition of the 
ACS resulted in increased release of PGE2 (Golej et al., 2011). Thus, it is emerging that 
inflammation is a complex cellular process, and PLA2 is unlikely to be the sole enzymatic 
pathway responsible for regulating AA levels, typically kept low due to the potent 
biological actions of the eicosanoids (Flesch, Schonhardt, & Ferber, 1989; Irvine, 1982), and 
that complementary pathways exist to contribute to AA generation and synthesis of 
eicosanoid inflammatory mediators during an immune response. That ACOT7 is 
abundantly expressed in macrophages and upregulated during an immune response; has 
high specificity for AA-CoA; and its over-expression in LPS-simulated macrophages cause 
 
Role of ACOT7 in Arachidonic Acid Production and Inflammation 205 
an increase in prostaglandin production, is consistent with the role of ACOT7 in 
inflammation through the production of AA-derived inflammatory mediators.  
 
 
Fig. 1. The cellular pathway of arachidonic acid release involves the phospholipaseA2, and 
other AA-producing pathways. 
2.1 Role of arachidonic acid in inflammation 
Cellular production of arachidonic acid is utilized in a range of pathways, including the 
generation of potent mediators to initiate an inflammatory response. Two well characterised 
pathways important in inflammation include the cyclooxygenase (COX) and 5-
Lipoxygnease pathways, and involve the conversion of arachidonic acid into prostanoids 
(prostaglandins, thromboxans), and leukotrienes respectively. The prostanoids include a 
range of arachidonic acid-derived metabolites that function to maintain body homeostasis 
by acting in a paracrine and autocrine fashion on cells within the vicinity of their release and 
are targets for the anti-inflammatory drugs including aspirin and derivatives. They typically 
exert their effect through activation of cell surface specific G-protein coupled receptors 
(GPCR), of which there are several subtypes for each prostanoid: PGD receptor (DP); PGE 
receptors EP1, EP2, EP3 and EP4 subtypes; PGF receptor (FP); PGI receptor (IP); and TX 
receptor (TP). There is also a receptor found on Th2 cells (CRTH2) that reacts to PGD2 but 
belongs to the chemokine receptor family (Narumiya, 2009; Wang, Honn, & Nie, 2007).  
Prostanoid production is increased during the inflammation response, particularly during 
acute inflammation, prior to the recruitment of leukocytes. There are a number of different 
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Prostanoid production is increased during the inflammation response, particularly during 
acute inflammation, prior to the recruitment of leukocytes. There are a number of different 
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prostanoids produced from the COX pathway, including prostaglandin (PG) D2, 
prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2α), prostacyclin (PGI2) and thromboxane 
(TX) A2 (Narumiya, 2009). Gilroy et al. found that PGE2 levels are raised only during the 
initial phases of inflammation whilst PGD2 becomes the predominant prostanoid during the 
final stages of the inflammatory response (Gilroy et al., 1999; Tilley, Coffman, & Koller, 
2001). 
5-lipoxygenase utilises free arachidonic acid in conjunction with 5-lipoxygenase activating-
protein (FLAP), the 5-lipoxygenase activating protein, to catalyse the oxygenation of 
arachidonic acid into hydroperoxy-eicosatetraenoic acid (HPETE). FLAP selectively 
transfers arachidonic acid to 5-lipoxygenase and enhances the sequential oxygenation of this 
substrate to produce 5(S)-hydroperoxyeicosatetraenoic acid (5HpETE), as well as 
dehydration of arachidonic acid to leukotriene A4 (LTA4). LTA4 can then be exported from 
the cell and undergo transcellular metabolism or be converted into either the pro-
inflammatory LTB4 or into a cysteinyl leukotrienes (cysLTs) LTC4, LTD4 or LTE4. The 
cysteinyl leukotrienes are a family of bronchoconstrictive, vasoconstrictive pro-
inflammatory molecules. The primary signalling method for these leukotrienes is the 
activation of GPCRs on cell surfaces, namely BLT1 and BLT2 forLTB4, and CysLT1 and 
CysLT2 for CysLT’s. Leukotrienes are thought to play a role in innate immune defence as 
well as a role in antimicrobial host defence. Importantly, they have been shown to play a 
role in respiratory diseases, such as asthma, allergies, such as anaphylaxis (Ferreira et al., 
2008), as well as cardiovascular disease (Evans, Ferguson, Mosley, & Hutchinson, 2008). 
Cytochrome P450 is thought to act on endogenous arachidonic acid converting it into epoxy-
eicosatrienoic acids (EETs) (Piomelli, 2000). Although found primarily in the liver 
cytochrome P450 has also been detected in a number of different tissues such as lungs, 
kidney, skin, adrenal cortex and brain tissues. The implications of P450 in the brain were 
demonstrated by Nicholson & Renton (2005) by removing astrocytes from rat brains and 
demonstrating that levels of P450 are modulated by inflammation using LPS stimulation.  
Peroxisome-proliferator-activated receptors (PPARs) α and γ regulate the transcription of 
target genes through agonist binding to the ligand-binding domain (LBD) of these genes. 
PPARα plays a role in fatty acid regulation, through modulating the expression of target 
genes, and are characterised by a high lipid catabolic activity. Jiang et al. (2001) found that 
clofibrate, which activates PPARα, up-regulates the expression of cPLA2 and COX-2 in 
preadipocytes. PPARγ has been shown to play a role in the regulation of differentiation of 
preadipocytes into adipocytes. It was found by Murakami et al. (2001) that fatty acyl-CoA’s 
function as antagonists for PPARα and PPARγ. 
3. Acyl-CoA thioesterase activity 
Acyl-CoA’s perform a wide range of important cellular functions, serving as primary 
substrates for fatty acid degradation and lipid synthesis as well as regulators of cellular 
mechanisms such as ion fluxes, vesicle trafficking, protein phosphorylation and gene 
expression (see Figure 2 for domain organisation of Acot family members).  
Most recently, the action of a specific enzyme within the ACOT enzyme family was 
demonstrated to act on arachidonoyl-CoA, and therefore possibly play a role in arachidonic 
acid production for the generation of prostanoids and leukotrienes.  This is achieved by 
cleaving the thioester bond of activated C20:4-CoA in the general reaction described in 
Figure 3. 
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Fig. 2. Domain organisation of Acots. 
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Fig. 2. Domain organisation of Acots. 
 









Fig. 3. ACOTs hydrolyse acyl-CoA esters to form free fatty acids and CoASH 
3.1 Activity of ACOT7 
It has been demonstrated that ACOT7 cleaves arachidonoyl-CoA to release CoA as CoASH 
and the free fatty acid arachidonic acid. Arachidonic acid is the precursor for a number of  
eicanosoids that enable the activation of macrophages (Kirkby, Roman, Kobe, Kellie, & 
Forwood, 2010), and it has been shown that ACOT7 expression is upregulated in 
macrophages in the presence of LPS and colony-stimulating factor 1 (CSF-1) (2007). It is 
from this data that the putative role of ACOT7 in inflammation was recognised. As shown 
in figure 4 below, ACOT7 may provide an alternative pathway for inflammation to the well 
characterised PLA2-mediated pathway and a possible target for a new class of anti-
inflammation therapies. 
Fujita et al. (2011) found that levels of both cytosolic and mitochondrial ACOT7 within 
mammalian heart muscle increase in response to a high fat diet, and induce inflammation. 
The increased levels of ACOT7 are in response to the increasing levels of acyl-CoA 
imported across the mitochondrial membranes from the cytosol via the action of carnitine 
plamitoyltransferase (CPT). This mechanism is thought to reduce the “lipotoxic” effects of 
insulin resistance which leads to contractile dysfunction of the heart as the cells 
accumulate proinflammatory molecules such as acyl-CoA, diacylglycerol and ceramide 
(Fujita, et al., 2011).  
ACOT7 is also known as brain acyl-CoA hydrolase (BACH) and has been purified from the 
brain cytosol of rats and humans and is believed to be responsible for acyl-CoA hydrolytic 
activity in the brain. Given the highly toxic nature of long chain acyl-CoA’s, as a detergent, 
the activity of ACOT7 within the brain may be to reduce the levels of these within neurons 
(Kuramochi et al., 2002). Furthermore  Takagi et al. (2006) found that ACOT7 is expressed in 
mouse testis and may play a role in spermatogenesis. The results of this research suggest 
that the regulation of ACOT7 occurs at a posttranscriptional level or that the rate of turnover 
in the testis is higher than in the brain. The level of ACOT7 protein was higher in the brain 
than the testis however the mRNA level was higher in the adult testis than the brain. The 
physiological significance of ACOT7 within the testis has not been determined however it is 
thought to scavenge cytosolic free long-chain acyl-CoA’s.  
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Fig. 4. Classical pathway of inflammation with role of ACOT7 in arachidonic acid 
production.  
4. Structure of ACOT7 
Structural insights into the function of ACOT7 have recently been undertaken through the 
cloning and high-level recombinant expression of ACOT7. Pioneering characterisation of 
ACOT7 was undertaken by Yamada et al. (1994) through the isolation and purification of rat 
liver, however high level over-expression and isolation of the enzyme required cloning of 
cDNA into bacterial expression vectors (Broustas, Larkins, Uhler, & Hajra, 1996; Junji 
Yamada et al., 1999). Serek et al. (2006) elucidated the structure of the C-terminal of the 
ACOT7 protein purified from Mus musculis by crystallising the C-terminal domain and 
analysing the high resolution structure using X-Ray diffraction techniques. From this data it 
was identified that the C-terminal domain of ACOT7 exists in a hexameric form. Forwood et 
al (2007) isolated and expressed both the N- and C-terminals of ACOT7. These domains 
were then separately crystallised and the resulting structures (in 1.8 and 2.5 Å resolution 
respectively) were superimposed to determine the structure of the full length ACOT7. 
Within the hexamer of Acot7 β-sheets from each domain form a semicontinuous antiparallel 
barrel with 25% of Acot7 residues involved in interdomain contacts (see Figure 5).  
 









Fig. 3. ACOTs hydrolyse acyl-CoA esters to form free fatty acids and CoASH 
3.1 Activity of ACOT7 
It has been demonstrated that ACOT7 cleaves arachidonoyl-CoA to release CoA as CoASH 
and the free fatty acid arachidonic acid. Arachidonic acid is the precursor for a number of  
eicanosoids that enable the activation of macrophages (Kirkby, Roman, Kobe, Kellie, & 
Forwood, 2010), and it has been shown that ACOT7 expression is upregulated in 
macrophages in the presence of LPS and colony-stimulating factor 1 (CSF-1) (2007). It is 
from this data that the putative role of ACOT7 in inflammation was recognised. As shown 
in figure 4 below, ACOT7 may provide an alternative pathway for inflammation to the well 
characterised PLA2-mediated pathway and a possible target for a new class of anti-
inflammation therapies. 
Fujita et al. (2011) found that levels of both cytosolic and mitochondrial ACOT7 within 
mammalian heart muscle increase in response to a high fat diet, and induce inflammation. 
The increased levels of ACOT7 are in response to the increasing levels of acyl-CoA 
imported across the mitochondrial membranes from the cytosol via the action of carnitine 
plamitoyltransferase (CPT). This mechanism is thought to reduce the “lipotoxic” effects of 
insulin resistance which leads to contractile dysfunction of the heart as the cells 
accumulate proinflammatory molecules such as acyl-CoA, diacylglycerol and ceramide 
(Fujita, et al., 2011).  
ACOT7 is also known as brain acyl-CoA hydrolase (BACH) and has been purified from the 
brain cytosol of rats and humans and is believed to be responsible for acyl-CoA hydrolytic 
activity in the brain. Given the highly toxic nature of long chain acyl-CoA’s, as a detergent, 
the activity of ACOT7 within the brain may be to reduce the levels of these within neurons 
(Kuramochi et al., 2002). Furthermore  Takagi et al. (2006) found that ACOT7 is expressed in 
mouse testis and may play a role in spermatogenesis. The results of this research suggest 
that the regulation of ACOT7 occurs at a posttranscriptional level or that the rate of turnover 
in the testis is higher than in the brain. The level of ACOT7 protein was higher in the brain 
than the testis however the mRNA level was higher in the adult testis than the brain. The 
physiological significance of ACOT7 within the testis has not been determined however it is 
thought to scavenge cytosolic free long-chain acyl-CoA’s.  
 
Role of ACOT7 in Arachidonic Acid Production and Inflammation 209 
 
Fig. 4. Classical pathway of inflammation with role of ACOT7 in arachidonic acid 
production.  
4. Structure of ACOT7 
Structural insights into the function of ACOT7 have recently been undertaken through the 
cloning and high-level recombinant expression of ACOT7. Pioneering characterisation of 
ACOT7 was undertaken by Yamada et al. (1994) through the isolation and purification of rat 
liver, however high level over-expression and isolation of the enzyme required cloning of 
cDNA into bacterial expression vectors (Broustas, Larkins, Uhler, & Hajra, 1996; Junji 
Yamada et al., 1999). Serek et al. (2006) elucidated the structure of the C-terminal of the 
ACOT7 protein purified from Mus musculis by crystallising the C-terminal domain and 
analysing the high resolution structure using X-Ray diffraction techniques. From this data it 
was identified that the C-terminal domain of ACOT7 exists in a hexameric form. Forwood et 
al (2007) isolated and expressed both the N- and C-terminals of ACOT7. These domains 
were then separately crystallised and the resulting structures (in 1.8 and 2.5 Å resolution 
respectively) were superimposed to determine the structure of the full length ACOT7. 
Within the hexamer of Acot7 β-sheets from each domain form a semicontinuous antiparallel 
barrel with 25% of Acot7 residues involved in interdomain contacts (see Figure 5).  
 
Inflammatory Diseases – A Modern Perspective 210 
 
Fig. 5. Structure of full-length Acot7 showing monomer and trimer arrangement. 
Wedged between the two monomers that make up the protomer are six CoA molecules, 
making contacts with residues from each domain. Opposite this binding site is a large 
hydrophobic tunnel, conserved within thioesterases that may be involved in the fatty-acid 
recognition and release. The individual domains are inactive when in homomeric 
complexes however when combined the activity can be restored to half that of the wild 
type enzyme. The arrangement of the N- and C-domains within ACOT7 and the 
positioning of the CoA molecules within the N-domain suggest that the full molecule 
contains three copies each of two distinct active sites in ACOT7. There are two potential 
active sites within ACOT7 (sites I and II, see Figure 6); these were determined via 
sequence analysis of mammalian ACOT7s.  To assess the role that each of these active 
sites play in catalysis each residue was mutated to Ala and the recombinant mutant 
enzymes were isolated and the activity of the mutant residues determined. The mutations 
in site I resulted in dramatic reductions in catalytic activity, whereas the analogous 
mutations in site II did not affect activity. These findings demonstrated that site II were 
not directly involved in catalysis. Furthermore the introduction of the key catalytic 
residues from site I into site II resulted in a four-fold increase in catalytic activity when 
compared with the wild-type Acot7. Thus, Acot7 (structures of each domain presented in 
figure 7) is believed to contain a “half-of-sites” activity, which may regulate the enzyme 
by placing an upper limit on enzyme efficiency and allows the cell to regulate the cellular 
concentrations of AA-CoA and arachidonic acid.  
 
Role of ACOT7 in Arachidonic Acid Production and Inflammation 211 
5. Genetic regulation of ACOTs   
The acyl-CoA thioesterase gene (ACOT) family encodes for two specific types of enzyme, 
acyl-CoA thioesterase type I and type II, which are determined by differences in structure 
and sequence. These two types catalyse similar reactions but share no similarity in structure 
or function, demonstrating that they are analogous and not homologous. They are an 
example of convergent evolution, whereby two molecules have evolved to fill the same need 
within the cell. Type I ACOT proteins are members of the α/β hydrolase fold enzyme 
superfamily. This superfamily also includes a number of esterase-activity-inhibiting 
enzymes such as carboxyl-esterase’s and lipases. This group is comprised of only four genes; 
ACOT1, ACOT2, ACOT4 and ACOT6. These proteins share a high degree of sequence 
homology, all forming an 80 kilobase gene cluster on chromosome 14q24.3, demonstrating 
that they have arisen as a result of gene duplication.  Within the mouse and rat orthologues 
there is a similar phenomenon; Acot1, Acot2, Acot3, Acot4, Acot5 and Acot6 are clustered on 
chromosomes 12 D3 within the mouse and 6q31 within the rat. This can be seen in figure 8 
below which also demonstrates the cellular compartments in which each is expressed 
(Brocker, Carpenter, Nebert, & Vasiliou, 2010).  
Type II ACOTs are members of the ‘hot dog’ fold enzyme superfamily. The type II ACOTs 
are far less related than the type I ACOTs. There is only one type II ACOT that does not 
contain a double ‘hot dog’ domain suggesting that they may have evolved as a gene 
duplication event, allowing for the accommodation of bulky substrates. Type II ACOTs 
show highly divergent sequences making evolutionary comparisons difficult without three-
dimensional structures, as structural interaction conservation does not directly correspond 
with residue conservation. Within the mouse genome there is an additional type II ACOT, 
known as Acot10, which shares 95% mRNA identity with ACOT9. The other seven type II 
ACOT genes are highly conserved among human, mouse and rat indicating that they were 
all present in the ancestor preceding mammalian radiation (Brocker, et al., 2010; M. C. Hunt 
& Alexson, 2008; Kirkby, et al., 2010).  
5.1 Expression and regulation of ACOT7 
The ACOT7 enzyme is highly conserved, exhibiting greater than 95% sequence homology 
at the amino acid level between human, mice and rats (Kuramochi et al., 2002). 
Transcription start sites for ACOT7 were characterised by Takagi et al. in 2004 and shown 
to encode a 43kDa subunit, located in the cytosol; and six isoforms comprised of 50kDa 
subunits, expressed at trace levels and located in the mitochondria. Independent studies 
have confirmed that the ACOT7 gene can generate up to seven different protein isoforms 
as can be seen below in figure 6 (J. Yamada, 2005). The human ACOT7 gene consists of 13 
exons, with the first four of these able to be used as first exons. The most well 
characterised of the ACOT7 isoforms, ACOT7a, is derived from the sequence 
corresponding to transcription initiation at exon 2 (M. Hunt et al., 2007; Kirkby, et al., 
2010).   
Expression of ACOT7 has been detected in the developing mouse embryo brain as early as 
embryonic 11.5 days although in very low concentrations and increases until day seven 
following birth. Thereafter the level declined until day 28 following birth when it reached 
a steady state which was about 70% of its highest expression (on day 7) and identical to  
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Fig. 6. Active sites of Acot7: Active site I is comprised of Asn24 from the N-domain and 
Asp213 from the C-domain; the analogous site (later determined to be inactive) is comprised 
of Glu39 from the N-domain and Thr198 from the C-domain 
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Fig. 7. (A) (B) Quaternary structure of Acot7 (N terminus) and C terminus respectively 
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Fig. 7. (A) (B) Quaternary structure of Acot7 (N terminus) and C terminus respectively 
 










Fig. 8. Full length Acot7 demonstrating the N terminus domain (in green) and C terminus 
domain (in purple) 
levels recorded at birth. The expression of ACOT7 was located only in cells committed to 
neuronal lineage, and continues to be expressed in these cells resulting in the high 
expression of ACOT7 in the adult brain (Junji Yamada, Kuramochi, Takagi, & Suga,  
2004). 
Research by Takagi, Suto, Suga & Yamada (2005) showed that ACOT7 gene expression is 
regulated by Sterol Regulatory Element-Binding Proteins (SREBPs). SREBPs form a few 
transcription factors which play a critical role in the regulation of cholesterol and fatty acids. 
Within the cell SREBPs are located in the membrane, to enter the nucleus they undergo 
proteolytic cleavage and their N-terminals are released as nSREBPs. Within the nucleus 
SREBPs bind to the sterol regulatory element (SRE) of target genes. The BACH gene 
promoter region contains two SRE motifs providing a binding partner for nSREBPs 
stimulating the production of cDNA of Acot7 (Takagi, et al., 2005).  
 








Fig. 9. The type I acyl-CoA thioesterase gene cluster is found on chromosome 14q24.3 in the 




Fig. 10. Structural organisation of the human BACH gene, exons are designated by blue 
boxes and introns by red segments, adapted from Yamada et al. (2005) 
6. Conclusion 
Inflammation is a complex immune response that involves the production of eicosanoids via 
AA. The cellular role of ACOT7 has been extended to include the cleavage of 
arachidonoyl:CoA to yield arachidonic acid, and therefore may provide a mechanism for the 
supply of arachidonic acid from intracellular arachidonoyl-CoA. This is supported by a 
number of lines of evidence: ACOT7 is highly expressed in macrophages and upregulated 
by proinflammatory stimuli; the preferred substrate of ACOT7 is arachidonoyl-CoA and the 
reaction product is the central precursor for lipid inflammatory mediators; and finally, over-
expression of ACOT7 in activated macrophages increases prostaglandin production.  Thus, 
ACOT7 is able to complement the well-characterised PLA2 AA-producing pathway, and 
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may play a role in inflammation by producing sufficient levels of AA for eicosanoid 
production.  
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1. Introduction 
Inflammatory Bowel Disease (IBD) is a disorder of the gastrointestinal tract that is 
characterised by chronic inflammation, with high incidence in Westernised countries 
(Yamamoto et al., 2009). Long-chain n-3 polyunsaturated fatty acids (PUFA), in particular 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are purported to be 
important for maintaining health and protection against disease (Connor, 2000). They 
exhibit beneficial effects with respect to cardiovascular diseases, rheumatoid arthritis, 
inflammatory diseases and neurodegenerative illnesses (Wahrburg, 2004). PUFA can 
modulate the inflammatory response (Calder, 2008) and could therefore be an important 
factor in the course of IBD. Several studies have tested the anti-inflammatory potential of 
pure n-3 PUFA extracts, fish oil and whole fish, however, the results of these studies are 
inconsistent (effects of dietary n-3 PUFA on animal models of colitis reviewed in Calder, 
2008; effects of dietary n-3 PUFA in intervention studies with IBD patients reviewed in 
Ferguson et al., 2010). Nevertheless, experimental evidence (Knoch et al., 2009) has shown 
potential anti-inflammatory effects of dietary EPA supplementation, a nutrient which is 
found in high levels in salmon. Furthermore, New Zealand IBD patients recorded a higher 
tolerance to salmon compared with other foods on the basis of a food frequency 
questionnaire (Triggs et al., 2010) and salmon has shown beneficial effects for patients with 
mild IBD (Grimstad et al., 2011). Various factors play a role in the development of IBD, 
however, the focus of this review is the effect of dietary n-3 PUFA and n-3 PUFA-rich food 
such as salmon. 
2. Background 
2.1 Inflammation in inflammatory bowel disease 
The inflammatory response is the beginning of an immunological process and is necessary 
to protect the body against invading pathogens and toxins. The response is typified by 
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activation/production of at least the following four classes of active molecules (Chapkin et 
al., 2009): (i) adhesions molecules (e.g. vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and E-selectin) on the surface of endothelial 
cells, allowing leukocyte binding and subsequent diapedesis; (ii) inflammatory cytokines 
(e.g. tumor necrosis factor alpha (TNFα), interleukin (IL) 1, IL6 and IL8); (iii) arachidonic 
acid (AA)-derived eicosanoids; and (iv) inflammatory mediators (e.g. platelet activating 
factor). The activation/production of these molecules must be ordered and controlled to 
avoid excessive damage to host tissue and chronic inflammatory disorders (Calder, 2006). 
This defect in resolving inflammation and returning the target tissue back to homeostasis 
is a hallmark of IBD (Chapkin et al., 2009). While the rate of new cases of IBD is beginning 
to stabilise in high-incidence areas, including northern Europe and North America, 
countries with traditionally low occurrence rates (e.g. southern Europe, Asia and 
developing countries) are reporting an increased rate of new patients (Loftus, 2004). 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two most common forms of IBD 
and although the two forms have distinctive characteristics, they share many common 
symptoms and can be difficult to distinguish clinically (Lee & Buchman, 2009; Teitelbaum 
& Allan Walker, 2001). The aetiology of IBD is largely unknown, but it is generally 
accepted that genetic factors and the environment play a role (Ferguson, 2010; Hanauer, 
2006; Lee & Buchman, 2009). Furthermore, the tolerance of the mucosal immune system to 
the commensal intestinal microbiota is disrupted and dysregulation of the immune 
system occurs (Duchmann et al., 1995). 
Observations in twin studies have highlighted that susceptibility to IBD, in particular CD, is 
inherited (Bouma & Strober, 2003). The genetics of IBD is complex and it is suggested that 
variations in key genes, for example single-nucleotide polymorphisms (SNPs), play a role. 
SNPs are genetic variations in the DNA sequence, whereby only a single nucleotide is 
changed. Approximately seven million common SNPs have been found across the human 
population (Hinds et al., 2005). While only a few of these may have a functional effect (Stover, 
2006), some variations can affect health or even cause disease (Lee & Buchman, 2009). 
Currently, 99 susceptibility loci/genes are known to contribute susceptibly to IBD (Lees et al., 
2011). One of the first susceptibility loci was found to be a polymorphism of the caspase 
recruitment domain family member 15 (CARD15) gene, which encodes the protein nucleotide-
binding oligomerization domain 2 (NOD2) (Hugot et al., 1996; Hugot et al., 2001).  
Environmental factors such as dietary changes, smoking, oral contraceptives, appendectomy 
and stress can affect the development of IBD (Krishnan & Korzenik, 2002; Loftus, 2004). In 
the last three decades, the incidence of IBD in Japan has increased sharply, correlating with 
changes in dietary preferences towards a Western-type diet (Yamamoto et al., 2009). This 
implies that dietary choice is an important factor in the development of IBD. The lipid 
profile of Western-type diets features excessive amounts of saturated fats and n-6 PUFA, but 
a deficiency of n-3 PUFA. This imbalance leads to an altered n-6/n-3 ratio, which may 
promote the pathogenesis of many diseases including IBD (Simopoulos, 2008). Thus 
increasing the n-3 PUFA intake and lowering the ratio of n-6/n-3 PUFA in the diet may 
reduce the risk of developing chronic diseases.  
The molecular mechanisms underlying the interaction of nutrients including n-3 PUFA with 
an individual’s genome are very complex, and also poorly understood (Stover, 2006; Weaver 
et al., 2009). To improve the understanding of these gene-diet interactions, the field of 
nutrigenomics has evolved with the aim of developing a personalised strategy for health 
maintenance or disease treatment (Ferguson, 2010). In nutrigenomics research, nutrients are 
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considered signalling molecules that can target the cellular sensor system and therefore 
subsequently influence gene expression, protein expression and metabolite production 
(Subbiah, 2008). These dietary signals can cause changes in the organism, tissue or single 
cells and subsequently influence homeostasis (Müller & Kersten, 2003).  
2.2 Dietary intake of lipids 
2.2.1 Fatty acids 
Fatty acids form the major component of dietary fats, and dietary sources range from free 
fatty acids to phospholipids, sterols and triacylglycerol (TG) (Ratnayake & Galli, 2009). The 
term fatty acid describes a carboxylic acid with an aliphatic chain that can be saturated or 
unsaturated. The degree of un-saturation is addressed by the number of double bonds 
between the carbon atoms of a fatty acid. A fatty acid that contains two or more double 
bonds between the carbon atoms is classified as polyunsaturated, while monounsaturated 
fatty acids (MUFA) contain only one double bond. The classification into n-3 and n-6 PUFA 
is based on the position of the first double bond, starting from the terminal methyl end. In 
general, short-chain unsaturated fatty acids refer to 19 or fewer carbon atoms, long-chain to 
20-24 carbon atoms and very-long-chain to 25 or more. The reactivity of fatty acids increases 
with double bonds; therefore, saturated fatty acids are more stable and have a longer shelf 
life than unsaturated ones (Ratnayake & Galli, 2009). 
The dietary intake of lipids is predominately through TG, which is the vast majority of lipid 
found in vegetable oils and animal fats (Ratnayake & Galli, 2009). TG are characterised by a 
glycerol backbone connected to three molecules of fatty acids (sn-1, sn-2 and sn-3, starting 
from the top of the glycerol), whereby the three hydroxyl groups from the glycerol backbone 
form an ester bond with the carboxyl groups from fatty acids (Fahy et al., 2005). 
Nutritionally, the distribution of fatty acids over the three sn-positions changes biological 
activity and absorption pattern, whereas the composition of sn-2 is of importance due to 
facilitated absorption (Ratnayake & Galli, 2009). In Atlantic salmon, the TG in the depot fat 
comprise ~70% DHA on sn-2 position, whereas EPA is nearly randomly distributed (40% on 
sn-2) (Aursand et al., 1995). In order to be absorbed by the gastrointestinal tract lining, TG 
need to be digested, i.e. broken down into smaller components (Ratnayake & Galli, 2009). 
The small intestine is the main site for fat digestion, where the pancreatic lipase hydrolyses 
TG at sn-1 and sn-3 position, yielding final products of 2-monoacylglycerols and free fatty 
acids (Mu & Porsgaard, 2005). Free fatty acids are directly absorbed through the intestinal 
wall and 2-monoacylglycerols form micelles that further diffuse to the epithelial cells, where 
they leave the micelles and enter epithelial cells by diffusion. In the enterocytes, they are 
transported to the endoplasmic reticulum in association with a fatty acid binding protein 
(FABP) and are re-synthesised to TG. Newly synthesized TG are transported out of the 
enterocyte and enter the bloodstream via the lymph vessels in the form of chylomicrons. In 
the bloodstream, the TG of the chylomicrons are hydrolysed to free fatty acids and glycerol 
that then pass through the capillary walls to be used by cells as the major substrates for 
energy production and storage (Ratnayake & Galli, 2009). Some fatty acids (e.g. DHA, EPA 
and AA) have additional roles in modulating the structural and functional properties of cells 
(Galli & Calder, 2009). 
2.2.2 Fatty acid metabolism 
Due to its abundance in food, many human populations over-consume n-6, but 
consequently lack long-chain n-3 PUFA (Calder, 2006; Ratnayake & Galli, 2009), resulting in 
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considered signalling molecules that can target the cellular sensor system and therefore 
subsequently influence gene expression, protein expression and metabolite production 
(Subbiah, 2008). These dietary signals can cause changes in the organism, tissue or single 
cells and subsequently influence homeostasis (Müller & Kersten, 2003).  
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fatty acids to phospholipids, sterols and triacylglycerol (TG) (Ratnayake & Galli, 2009). The 
term fatty acid describes a carboxylic acid with an aliphatic chain that can be saturated or 
unsaturated. The degree of un-saturation is addressed by the number of double bonds 
between the carbon atoms of a fatty acid. A fatty acid that contains two or more double 
bonds between the carbon atoms is classified as polyunsaturated, while monounsaturated 
fatty acids (MUFA) contain only one double bond. The classification into n-3 and n-6 PUFA 
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20-24 carbon atoms and very-long-chain to 25 or more. The reactivity of fatty acids increases 
with double bonds; therefore, saturated fatty acids are more stable and have a longer shelf 
life than unsaturated ones (Ratnayake & Galli, 2009). 
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found in vegetable oils and animal fats (Ratnayake & Galli, 2009). TG are characterised by a 
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sn-2) (Aursand et al., 1995). In order to be absorbed by the gastrointestinal tract lining, TG 
need to be digested, i.e. broken down into smaller components (Ratnayake & Galli, 2009). 
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(FABP) and are re-synthesised to TG. Newly synthesized TG are transported out of the 
enterocyte and enter the bloodstream via the lymph vessels in the form of chylomicrons. In 
the bloodstream, the TG of the chylomicrons are hydrolysed to free fatty acids and glycerol 
that then pass through the capillary walls to be used by cells as the major substrates for 
energy production and storage (Ratnayake & Galli, 2009). Some fatty acids (e.g. DHA, EPA 
and AA) have additional roles in modulating the structural and functional properties of cells 
(Galli & Calder, 2009). 
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Due to its abundance in food, many human populations over-consume n-6, but 
consequently lack long-chain n-3 PUFA (Calder, 2006; Ratnayake & Galli, 2009), resulting in 
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an n-6/n-3 ratio of ~10:1 to 20-25:1, which may promote the pathogenesis of many diseases 
including inflammatory disorders (Simopoulos, 1991). Whereas humans evolved on a diet 
with a ratio of ~1:1 (Simopoulos, 2008), a ratio of 4:1 is recommended as optimal (Wall et al., 
2010), but this may vary with disease state (Simopoulos, 2008). It has been suggested that 
lowering the n-6/n-3 ratio in the diet should be achieved by increasing the amount of n-3 
PUFA rather than by simply reducing n-6 PUFA, which may reduce the risk of developing 
chronic diseases (Camuesco et al., 2005; Simopoulos, 2008). The long-chain PUFA AA, EPA 
and DHA are supplied to tissues from dietary sources, either via direct supplementation or 
via the consumption of the precursor PUFA linoleic acid (LA; n-6 pathway) and α-linolenic 
acid (ALA; n-3 pathway). LA and ALA cannot be synthesised in the human body, but can be 
metabolised to longer-chain fatty acids. This conversion of LA and ALA occurs via several 
elongation and desaturation steps (Fig. 1), with competition for the same enzymes on both 
pathways (Calder & Yaqoob, 2009). LA, the parent fatty acid on the n-6 PUFA pathway, is 
metabolised to AA, whereas ALA on the n-3 PUFA pathway is metabolised to EPA and 
further to DHA. However, as the conversion of ALA to EPA is limited and further 
conversion to DHA is even lower (Burdge & Calder, 2005; Garg et al., 2006), direct DHA and 
EPA supplementation is more effective than de-novo synthesis in increasing long-chain n-3 
PUFA concentrations in the cell membrane (Hamilton et al., 2005). 
3. Putative mechanisms of action 
Long-chain PUFA are taken up by inflammatory cells and incorporated into membrane 
phospholipids (Leslie, 2004). Membrane phospholipids of inflammatory cells from humans 
consuming Western-type diets possess a relatively high amount (>20%) of n-6 PUFA, 
whereas long-chain n-3 PUFA represent less than 1% of fatty acids (Calder, 2006). The result  
 
 
Fig. 1. Metabolism of n-6 and n-3 PUFA from precursor fatty acids (Wall et al., 2010) 
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is an unbalanced n-6/n-3 ratio which can promote a pro-inflammatory phenotype. The 
dietary intake of foods rich in EPA and DHA results in membrane replacement of n-6 PUFA 
in a time and dose-dependent manner, which may contribute to anti-inflammatory effects 
(Calder, 2009). How an elevated dietary intake of n-3 PUFA exerts its beneficial effects is not 
fully understood, but the putative mechanisms of action of n-3 PUFA are illustrated in Fig. 
2. These include alterations in (i) cell membrane lipid bi-layer composition; (ii) gene 
expression; and (iii) lipid mediator metabolism (Chapkin et al., 2009). The overall 
physiological outcome depends on several factors, for example, the quantity and chemistry 
of the fat ingested, the cells present, cell-specific fatty acid metabolism (oxidative pathways, 
kinetics, and competing reactions) or the nature of the stimulus (Calder et al., 2009; Jump & 
Clarke, 1999). However, the different effects of DHA versus EPA are not well studied 
(Chapkin et al., 2009). 
Lipid rafts are complex micro-domains in the cell membrane that appear to serve as 
platforms for receptor-mediated signal transduction (Calder & Yaqoob, 2007; Chapkin et al., 
2009). When incorporated into cell membrane phospholipids, n-3 PUFA can increase 
membrane fluidity (Li et al., 2005), however, lipid rafts are far more sensitive to the 
incorporation of n-3 PUFA than non-raft domains (Rockett et al., 2011). A modulation of the 
lipid composition in rafts is associated with altered signalling pathways (Li et al., 2005; 
Schley et al., 2007; Stulnig et al., 2001).  
 
 
Fig. 2. Putative mechanism of action of PUFA. These include alterations in lipid mediator 
synthesis, gene expression, lipid composition in cell membrane and signal transduction 
(Chapkin et al., 2009) 
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Dietary n-3 PUFA can be transported into the cell via passive diffusion or active protein-
mediated transport (Bordoni et al., 2006), depending on the chain size. Longer-chain fatty 
acids are actively transported via fatty acid transport proteins (FATP) 1-6 and/or CD36  
(Bordoni et al., 2006; Heimerl et al., 2006). Inside the cell, n-3 PUFA can give rise to the 
anti-inflammatory lipid mediators resolvins and protectins (Serhan et al., 2008) and in 
turn competitively inhibit the production of mainly pro-inflammatory eicosanoids from 
AA. Furthermore, alterations in gene expression by n-3 PUFA can be mediated by 
interaction with transcription factors. For example, the activation of peroxisome 
proliferator-acitvated receptors (PPARs) can suppress nuclear factor-kappaB (NFκB) 
translocation and thereby inhibit the expression levels of pro-inflammatory cytokine 
genes (e.g. IL1 or TNFα) (Chapkin et al., 2009). 
3.1 The formation of lipid mediators from fatty acids  
Lipid mediators including eicosanoids, resolvins and protectins are regulators of 
inflammation and are generated from long-chain PUFA (Fig. 1) (Calder, 2009). The 
biological activity and potency of lipid mediators is dependent on the PUFA substrate. The 
n-6 PUFA AA gives rise to several eicosanoids (e.g. series-2 prostaglandins and 
thromboxanes, series-4 leukotrienes), hydroperoxy- and hydroxy-eicosatetraenoic 
derivatives and lipoxins. The majority of eicosanoids derived from AA are pro-
inflammatory; however, prostaglandin E2 and lipoxin have been shown to exert anti-
inflammatory effects (Calder, 2008). EPA is the substrate for the anti-inflammatory 
eicosanoids and resolvins (e.g. series-3 prostaglandins and thromboxanes and series-5 
leukotrienes) and hydroperoxy- and hydroxy-eicosapentaenoic derivatives. DHA gives rise 
to anti-inflammatory and pro-resolution mediators (e.g. resolvins and neuroprotectin) (Wall 
et al., 2010). The enzymes which catalyse these conversions are at least two cyclooxygenase 
(COX) and several lipoxygenase (LOX) enzymes (Calder et al., 2009), thus an elevated n-3 
PUFA intake can lead to competitive inhibition of eicosanoid production from AA. 
Consequently, the pattern of lipid mediator production can be modulated towards a 
decrease in mainly pro-inflammatory eicosanoids from n-6 PUFA and an increase in anti-
inflammatory resolvins from EPA and DHA (Calder, 2008; Calder, 2009). 
3.2 Modulation of gene expression by polyunsaturated fatty acids  
As well as altering lipid mediator synthesis, dietary fatty acids can affect gene expression 
and subsequently influence metabolism, growth and cell differentiation (Jump & Clarke, 
1999). The mechanisms for these influences may be via intermediate molecules (e.g. 
transcription factors, nuclear hormone receptors and lipid secondary messengers) that 
subsequently alter gene expression, or a direct interaction with target genes (Deckelbaum et 
al., 2006). The expression levels of genes encoding several key proteins involved in 
inflammation, lipid metabolism and energy utilisation have been identified to be modulated 
by n-3 PUFA (Deckelbaum et al., 2006).    
3.2.1 Gene expression changes underlying intestinal inflammation 
Differences in gene expression and metabolic pathways underlying intestinal inflammation 
can be characterised when inflamed colon tissue from interleukin-10 gene-deficient (Il10–/–) 
mice is compared to colon tissue from healthy control mice. The gene expression levels in 
Il10–/– mice on a control diet were mainly increased in the inflammatory and immune 
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response pathway, with pro-inflammatory genes encoding cytokines (e.g. Il1β and TNFα) or 
chemokine receptors (e.g. Ccr5) as examples (Table 2) (Knoch et al., 2009). Decreased 
expression levels were observed for genes involved in fatty acid metabolism and xenobiotic 
metabolism (Table 1) (Knoch et al., 2009). The decreased expression levels of genes 
associated with fatty acid oxidation may have a role in disease progression (Knoch et al., 
2009) and have also been observed in colon tissue of IBD patients (Heimerl et al., 2006). 
Decreased mRNA levels of genes involved in xenobiotic metabolism were observed in Il10–/– 
mice. Detoxification and biotransformation alter xenobiotics, i.e. foreign compounds (Jakoby 
& Ziegler, 1990), and a dysfunction of these mechanisms exposes enterocytes to toxic 
luminal antigens (Langmann & Schmitz, 2006), promoting local injury (Sartor, 1995) and 
contributing to the pathophysiology of IBD (Crotty, 1994; Langmann & Schmitz, 2006). 
Expression levels of genes encoding tight junction proteins were decreased in colon tissue of 
Il10–/– mice (Knoch et al., 2009). Tight junctions are intercellular barriers that regulate the  
transport of large molecules between the intestinal epithelial cells (Balda et al., 1992) and a 
dysfunction leads to impaired intestinal integrity and increased permeability (‘leaky gut’) 
(Forster, 2008). A non-invasive method to assess intestinal permeability is the urinary 
measurement after an oral dose of sugar probes, for example sucralose, mannitol and 
lactulose (Arrieta et al., 2006; Farhadi et al., 2003). In Il10–/– mice, it was found that the ratio 
of lactulose/mannitol, a marker of small intestinal barrier permeability, was increased 
compared to control mice (Arrieta et al., 2009). The urinary excretion of sucralose, which 
indicates colonic damage, was also increased in Il10–/– mice. 
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Table 1. Selected genes and their associated pathways that are down-regulated in the Il10–/– 
mouse model, compared to wild-type (WT) mice, and the effects of polyunsaturated fatty acids 
in mouse models of intestinal inflammation (Table constructed with information from (A) Knoch 
et al., 2009; (B) Knoch et al., 2010a; (C) Reiff et al., 2009). (*) indicates a non-significant change. 
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translocation and thereby inhibit the expression levels of pro-inflammatory cytokine 
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Table 1. Selected genes and their associated pathways that are down-regulated in the Il10–/– 
mouse model, compared to wild-type (WT) mice, and the effects of polyunsaturated fatty acids 
in mouse models of intestinal inflammation (Table constructed with information from (A) Knoch 
et al., 2009; (B) Knoch et al., 2010a; (C) Reiff et al., 2009). (*) indicates a non-significant change. 
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Table 2. Selected genes and their associated pathways that are up-regulated in the Il10–/– 
mouse model, compared to wild-type (WT) mice, and the effects of polyunsaturated fatty 
acids in mouse models of intestinal inflammation (Table constructed with information from 
(A) Cho et al., 2011; (B) Knoch et al., 2009; (C) Knoch et al., 2010a; (D) Knoch et al., 2010b; (E) 
Reiff et al., 2009). (*) indicates a non-significant change. 
3.2.2 Modulation of gene expression by polyunsaturated fatty acids  
PUFA-enriched diets were partly able to reduce expression levels of genes associated with 
inflammation (Table 1 and Table 2) (Cho et al., 2011; Deckelbaum et al., 2006; Knoch et al., 
2009; Knoch et al., 2010a; Knoch et al., 2010b; Reiff et al., 2009). As illustrated in Table 1, 
expression levels of the PPARα gene were increased by EPA-enriched diets. This is 
supported by a study in a pig model of IBD, where dietary LA increased colonic PPARγ 
gene expression levels and dietary n-3 PUFA activated PPARδ (Bassaganya-Riera & 
Hontecillas, 2006). In this study (Bassaganya-Riera & Hontecillas, 2006), the onset of 
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experimental IBD was either delayed (PPARγ activation) or colonic regeneration and clinical 
remission accelerated (PPARδ activation). The expression levels of the gene encoding for the 
S100a8 protein, associated with neutrophil activation (Ryckman et al., 2003), was increased 
in UC patients compared to healthy subjects (Dieckgraefe et al., 2000). Its expression level 
was also increased in mice with experimental colitis compared to healthy mice; DHA- and 
AA-enriched diets were able to reduce increased S100a8 gene expression levels in Il10–/– 
mice, however, EPA-enriched diets were not (Cho et al., 2011; Knoch et al., 2009).  
The transcription factors NFκB and PPARs are reported to be modulated in inflammatory 
states and by dietary PUFA (Calder, 2008; Chapkin et al., 2009; Wall et al., 2010). NFκB is a 
regulator of the inflammatory response and oxidative stress (Hassan et al., 2010) and its 
activation is triggered by extracellular inflammatory stimuli, followed by translocation of 
NFκB to the nucleus and an increase in expression levels of genes associated with 
inflammation (e.g. the cytokines IL1, IL6 or TNFα) (Calder, 2008). Fatty acids and 
eicosanoids are natural ligands of PPARs. When activated by ligand binding, PPARs 
dimerise with the retinoid X receptor (RXR) and the dimer subsequently binds to specific 
response elements (PPREs) within promoter regions of target genes, thus modulating 
transcription of the genes (Berger & Moller, 2002). The three isotypes PPARα, PPARβ/γ and 
PPARδ are encoded by different genes and exhibit broad, isotype-specific tissue expression 
patterns (Michalik et al., 2006). PPARγ activity can be inhibited by TNFα which 
consequently is associated with the pathogenesis of inflammation (Ye, 2008). PPARα was 
shown to be an important transcriptional regulator in the small intestine (Buenger et al., 
2007) and reduced NFκB gene expression levels (Knoch et al., 2009). DHA and EPA are 
natural ligands of PPARα and its activation can trigger fatty acid oxidation, thus a 
deficiency in PPARα resulted in a dysfunction of hepatic fatty acid uptake and oxidation in 
an animal model (Lee & Kim, 2010).     
3.3 Modulation of protein expression by polyunsaturated fatty acids  
The analysis of gene expression explains only a part of the observed phenotype, as the 
increase or decrease of expression levels of a gene that code for a certain protein does not 
necessarily result in changed protein abundance (Ideker et al., 2001). Several influences, 
including the degradation of mRNA, post-translational modifications and the rate of 
degradation of the protein, can affect protein abundance. While there is published 
research on the effects of fatty acids on gene expression, there is less data available on its 
effects on protein expression. Proteomic analysis for IBD patients exists (Shkoda et al., 
2007; Zhao et al., 2011) and has identified distinctive patterns in protein expression 
compared to healthy subjects. The studies showed that the biological processes 
inflammatory response and oxidative stress, signal transduction, energy generation 
including lipid metabolism and cell apoptosis were influenced (Shkoda et al., 2007; Zhao 
et al., 2011). How n-3 PUFA can influence protein expression in Il10–/– mice should 
therefore provide further insights into the putative molecular mechanisms behind the 
observed phenotypical changes between Il10–/– and control mice. 
4. The role of foods in IBD 
Minor components in foods such as antioxidants or PUFA are necessary for several 
processes in the human body (Visioli et al., 2003). The use of pure extracts of these 
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Reiff et al., 2009). (*) indicates a non-significant change. 
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experimental IBD was either delayed (PPARγ activation) or colonic regeneration and clinical 
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et al., 2011). How n-3 PUFA can influence protein expression in Il10–/– mice should 
therefore provide further insights into the putative molecular mechanisms behind the 
observed phenotypical changes between Il10–/– and control mice. 
4. The role of foods in IBD 
Minor components in foods such as antioxidants or PUFA are necessary for several 
processes in the human body (Visioli et al., 2003). The use of pure extracts of these 
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components has occasionally been promoted and the effects of these single nutrients have 
been reviewed. For example, curcumin (a polyphenolic compound found in some foods 
such as the spice turmeric), reduced histological signs of colonic inflammation and the 
expression levels of genes in pro-inflammatory pathways in a mouse model of IBD (Nones 
et al., 2009). The influences of dietary PUFA supplementation on mice with chronic colitis 
were studied by Knoch et al. (2009; 2010a) and Roy et al. (2007). The results of these 
experiments showed mild anti-inflammatory effects for both n-3 and n-6 PUFA, the former 
via the activation of a PPARα transcription factor. However, single nutrients may exert 
different protective effects than whole foods which provide these components. Possible anti-
inflammatory features of extracted long-chain n-3 PUFA (Calder, 2009; Knoch et al., 2009; 
Knoch et al., 2010a; Roy et al., 2007) may function differently when in a food matrix (Kris-
Etherton & Hill, 2008). Dietary n-3 PUFA can be ingested as highly purified extracts of 
single n-3 PUFA, fish oil (mixture of PUFA) or marine fish (nutrient package and rich in n-3 
PUFA). One of the advantages in the consumption of whole fish is nutritional diversity, 
which favours possible synergistic effects (He, 2009; Rudkowska et al., 2010). 
4.1 The benefits of dietary fish intake 
Compared to other foods, marine fish (especially salmon and tuna) are naturally rich in 
long-chain n-3 PUFA (Mozaffarian, 2006). Early evidence of potential health benefits of fish 
was found in the dietary habits of Greenland Eskimos (Bang et al., 1976). The food 
consumed by Eskimos is mostly of marine origin and provides high amounts of long-chain 
n-3 PUFA including EPA and DHA. An important correlation between dietary fish intake 
and a lower risk of coronary atherosclerotic diseases was found (Bang et al., 1976).  
Long-chain n-3 PUFA accumulates in fish through the food chain (Sargent, 1997). The basis 
of the food chain is marine phytoplankton, which synthesises long-chain n-3 PUFA by 
conversion of LA to ALA (Hamilton et al., 2005). The uptake of phytoplankton by marine 
zooplankton leads to the accumulation of n-3 PUFA in the phospholipids of cellular 
membranes and through the ingestion of zooplankton, n-3 PUFA accumulates in fish. In 
general, deep water fish including salmon, herring, mackerel or tuna are classified as oily 
fish, with the main fat storage being the flesh. The lipid reserves of lean fish, for example 
cod, haddock or whiting, are in the liver. Cod liver is therefore a rich source of n-3 PUFA, as 
well as the fillets of salmon, herring etc. (Sargent, 1997). The n-3 PUFA content in fish varies 
with species, age, size, reproduction stage, season, geographical location and diet (Larsen et 
al., 2010).  
The advantage of whole fish consumption compared to supplements is nutritional diversity. 
A common problem in IBD is malnutrition, caused by for example poor dietary intake or 
impaired nutrient absorption (O'Sullivan & O'Morain, 2006). Fish could compensate for the 
micronutrient deficiencies and provide a mechanism to elevate the levels of several minerals 
and vitamins. Of particular clinical relevance are deficiencies in calcium, vitamin D and B12, 
folate (Goh & O'Morain, 2003), zinc (Hendricks & Walker, 1988) and vitamin B6 (Saibeni et 
al., 2003), which are all contained in fish (Sidhu, 2003). Several of these micronutrients were 
able to suppress inflammation in rodents with experimental colitis. For example, vitamin E 
protected the rat colon from oxidative stress, which is associated with inflammation 
(González et al., 2001). Oxidised PUFA can activate transcription factors such as NFκB and 
subsequently trigger pro-inflammatory gene expression, whereby vitamin E as an 
antioxidant compound in salmon might prevent oxidation and in turn NFκB activation 
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(Calder et al., 2009). The supplementation of vitamin D and calcium showed protective 
effects in Il10–/– mice (associated with TNFα pathway) (Zhu et al., 2005) and selenium 
protected rats with experimental colitis (Tirosh et al., 2007). Furthermore, fish is also an 
excellent source of amino acids, such as taurine, arginine and glutamine, which may 
contribute to anti-inflammatory effects (He, 2009; Rudkowska et al., 2010).  
A positive association of salmon with IBD has been identified among New Zealand CD 
patients (Triggs et al., 2010). 446 patients rated food items and their effects on disease 
symptoms. No single food item was considered beneficial in all cases, however a small 
number of foods were frequently perceived to be beneficial, including white fish, salmon 
and tuna. These results indicated that salmon was perceived to be one of the most beneficial 
foods for those patients. Furthermore, intervention studies involving patients with active 
CD showed a favourable influence of salmon on IBD. After 8 weeks of a dietary intake of 
600 g Atlantic salmon per week, the clinical colitis activity index was improved and the n-
3/n-6 ratio increased (Grimstad et al., 2011). Another study (Pot et al., 2010) revealed that 
after 6 months, patients with previous colorectal adenomas or non-active UC showed 
partially decreased inflammation markers. The patients consumed either fatty (farmed 
salmon) or lean fish (Icelandic cod) in 2 x 150 g portions per week. Interestingly, the 
consumption of cod (lean fish) showed the same results as the salmon group, suggesting 
that not only oily fish, but also lean fish can exert anti-inflammatory effects (Pot et al., 2010). 
4.2 Whole foods vs. supplements 
Bioavailability is defined as “the proportion of a drug or other substance which enters the 
circulation when introduced into the body and so is able to have an active effect”(Oxford 
Dictionaries, 2010). Dietary n-3 PUFA can be provided by fatty fish, fish oil capsules or via  
foods enriched with n-3 PUFA (e.g. milk and meat)  (Kitessa et al., 2001; Knowles et al., 2004; 
Ponnampalam et al., 2002), however its bioavailability may differ between these formats. 
Fish intake may increase the bioavailability of n-3 PUFA because: (i) the ingestion of whole 
foods is followed by a more effective activation of digestion/absorption in the intestine 
compared to capsules (Elvevoll et al., 2006; Galli & Calder, 2009; Visioli et al., 2003); (ii) 
lipids in fish are mostly in form of TG, with n-3 PUFA mostly in position sn-2, which 
facilitates absorption (Aursand et al., 1995; Ratnayake & Galli, 2009); and (iii) the 
bioavailability of EPA is improved when co-ingested with a high-fat meal (Lawson & 
Hughes, 1988a). Human studies have found that the n-3 PUFA within salmon are more 
efficient at increasing n-3 PUFA levels in serum and plasma compared to fish oil capsules 
(Elvevoll et al., 2006; Visioli et al., 2003). However, this contrasts to results from Arterburn et 
al. (2008), who found that algal-oil capsules and cooked salmon are nutritionally equivalent 
sources of DHA, thus representing an alternative to fish. The results of these studies 
(Arterburn et al., 2008; Elvevoll et al., 2006; Visioli et al., 2003) may depend on several 
factors, for example genetic differences in the individual subjects, but also on the oxidation 
rate of n-3 PUFA in capsules or differences in encapsulation (e.g. hard vs. soft gelatine 
capsules) (Ferguson et al., 2010).   
5. Limitations 
Dietary recommendations of two servings of fish per week require unlimited sources of fish. 
However, wild-caught fish are finite and some species are already classified as over-fished 
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such as the spice turmeric), reduced histological signs of colonic inflammation and the 
expression levels of genes in pro-inflammatory pathways in a mouse model of IBD (Nones 
et al., 2009). The influences of dietary PUFA supplementation on mice with chronic colitis 
were studied by Knoch et al. (2009; 2010a) and Roy et al. (2007). The results of these 
experiments showed mild anti-inflammatory effects for both n-3 and n-6 PUFA, the former 
via the activation of a PPARα transcription factor. However, single nutrients may exert 
different protective effects than whole foods which provide these components. Possible anti-
inflammatory features of extracted long-chain n-3 PUFA (Calder, 2009; Knoch et al., 2009; 
Knoch et al., 2010a; Roy et al., 2007) may function differently when in a food matrix (Kris-
Etherton & Hill, 2008). Dietary n-3 PUFA can be ingested as highly purified extracts of 
single n-3 PUFA, fish oil (mixture of PUFA) or marine fish (nutrient package and rich in n-3 
PUFA). One of the advantages in the consumption of whole fish is nutritional diversity, 
which favours possible synergistic effects (He, 2009; Rudkowska et al., 2010). 
4.1 The benefits of dietary fish intake 
Compared to other foods, marine fish (especially salmon and tuna) are naturally rich in 
long-chain n-3 PUFA (Mozaffarian, 2006). Early evidence of potential health benefits of fish 
was found in the dietary habits of Greenland Eskimos (Bang et al., 1976). The food 
consumed by Eskimos is mostly of marine origin and provides high amounts of long-chain 
n-3 PUFA including EPA and DHA. An important correlation between dietary fish intake 
and a lower risk of coronary atherosclerotic diseases was found (Bang et al., 1976).  
Long-chain n-3 PUFA accumulates in fish through the food chain (Sargent, 1997). The basis 
of the food chain is marine phytoplankton, which synthesises long-chain n-3 PUFA by 
conversion of LA to ALA (Hamilton et al., 2005). The uptake of phytoplankton by marine 
zooplankton leads to the accumulation of n-3 PUFA in the phospholipids of cellular 
membranes and through the ingestion of zooplankton, n-3 PUFA accumulates in fish. In 
general, deep water fish including salmon, herring, mackerel or tuna are classified as oily 
fish, with the main fat storage being the flesh. The lipid reserves of lean fish, for example 
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protected the rat colon from oxidative stress, which is associated with inflammation 
(González et al., 2001). Oxidised PUFA can activate transcription factors such as NFκB and 
subsequently trigger pro-inflammatory gene expression, whereby vitamin E as an 
antioxidant compound in salmon might prevent oxidation and in turn NFκB activation 
 
The Effects of n-3 Polyunsaturated Fatty Acid-Rich Salmon on Inflammatory Bowel Diseases 
 
231 
(Calder et al., 2009). The supplementation of vitamin D and calcium showed protective 
effects in Il10–/– mice (associated with TNFα pathway) (Zhu et al., 2005) and selenium 
protected rats with experimental colitis (Tirosh et al., 2007). Furthermore, fish is also an 
excellent source of amino acids, such as taurine, arginine and glutamine, which may 
contribute to anti-inflammatory effects (He, 2009; Rudkowska et al., 2010).  
A positive association of salmon with IBD has been identified among New Zealand CD 
patients (Triggs et al., 2010). 446 patients rated food items and their effects on disease 
symptoms. No single food item was considered beneficial in all cases, however a small 
number of foods were frequently perceived to be beneficial, including white fish, salmon 
and tuna. These results indicated that salmon was perceived to be one of the most beneficial 
foods for those patients. Furthermore, intervention studies involving patients with active 
CD showed a favourable influence of salmon on IBD. After 8 weeks of a dietary intake of 
600 g Atlantic salmon per week, the clinical colitis activity index was improved and the n-
3/n-6 ratio increased (Grimstad et al., 2011). Another study (Pot et al., 2010) revealed that 
after 6 months, patients with previous colorectal adenomas or non-active UC showed 
partially decreased inflammation markers. The patients consumed either fatty (farmed 
salmon) or lean fish (Icelandic cod) in 2 x 150 g portions per week. Interestingly, the 
consumption of cod (lean fish) showed the same results as the salmon group, suggesting 
that not only oily fish, but also lean fish can exert anti-inflammatory effects (Pot et al., 2010). 
4.2 Whole foods vs. supplements 
Bioavailability is defined as “the proportion of a drug or other substance which enters the 
circulation when introduced into the body and so is able to have an active effect”(Oxford 
Dictionaries, 2010). Dietary n-3 PUFA can be provided by fatty fish, fish oil capsules or via  
foods enriched with n-3 PUFA (e.g. milk and meat)  (Kitessa et al., 2001; Knowles et al., 2004; 
Ponnampalam et al., 2002), however its bioavailability may differ between these formats. 
Fish intake may increase the bioavailability of n-3 PUFA because: (i) the ingestion of whole 
foods is followed by a more effective activation of digestion/absorption in the intestine 
compared to capsules (Elvevoll et al., 2006; Galli & Calder, 2009; Visioli et al., 2003); (ii) 
lipids in fish are mostly in form of TG, with n-3 PUFA mostly in position sn-2, which 
facilitates absorption (Aursand et al., 1995; Ratnayake & Galli, 2009); and (iii) the 
bioavailability of EPA is improved when co-ingested with a high-fat meal (Lawson & 
Hughes, 1988a). Human studies have found that the n-3 PUFA within salmon are more 
efficient at increasing n-3 PUFA levels in serum and plasma compared to fish oil capsules 
(Elvevoll et al., 2006; Visioli et al., 2003). However, this contrasts to results from Arterburn et 
al. (2008), who found that algal-oil capsules and cooked salmon are nutritionally equivalent 
sources of DHA, thus representing an alternative to fish. The results of these studies 
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factors, for example genetic differences in the individual subjects, but also on the oxidation 
rate of n-3 PUFA in capsules or differences in encapsulation (e.g. hard vs. soft gelatine 
capsules) (Ferguson et al., 2010).   
5. Limitations 
Dietary recommendations of two servings of fish per week require unlimited sources of fish. 
However, wild-caught fish are finite and some species are already classified as over-fished 
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(Naylor et al., 2000). Producing farmed fish in aquacultures may not be sustainable long-
term. Apart from water pollution or habitat destruction, aquacultures require large inputs of 
wild fish for feed (Jenkins et al., 2009; Naylor et al., 2000). For example, the production of 
one kilogram of farmed fish, raised on feeds fortified with fish meal and oil, requires 
approximately three kilograms of wild fish (Naylor et al., 2000). To lower fish input in feed, 
n-3 PUFA-rich fish oil was replaced by n-3 PUFA-deficient vegetable oil. However, this 
resulted in lower levels of n-3 PUFA in salmon flesh, which would therefore not serve the 
purpose of increasing DHA and EPA in the human diet. 
For those who do not wish to consume fish, enrichment of foods which are not naturally 
rich in long-chain n-3 PUFA is an option (Bermingham et al., 2008; Calder & Yaqoob, 
2009; Whelan et al., 2009). These include n-3 PUFA-enriched eggs, meat (Knowles et al., 
2004; Ponnampalam et al., 2002) or milk (Kitessa et al., 2001) that can be produced by 
bio-fortification (feeding the animal n-3 PUFA-rich feeds) or post-harvest modification of 
foods (n-3 PUFA-rich oils into foods) (Bermingham et al., 2008; Whelan et al., 2009). 
However in most cases, fish oils are used for elevating the n-3 PUFA levels. In order to 
reduce pressure on wild fish stocks, it is important to find an alternative source of n-3 
PUFA. A possible solution could be DHA-rich algal oil, which is considered as plant-
derived, thus also appropriate for vegetarians for direct supplementation (Whelan & 
Rust, 2006). 
Evidence for the protective effects of n-3 PUFA is inconsistent, possibly due to various 
factors (Ferguson et al., 2010). In vitro models can not mimic the complexity of an entire 
organism, which makes the use of animal models necessary. However, disease pathogenesis 
differs across animal models, thus making it difficult to compare results (Hegazi et al., 2003; 
Hegazi et al., 2006). Diets enriched with n-3 PUFA which are fed to animals differ in their 
sources and range from highly purified extracts of single PUFA (i.e. DHA or EPA) to fish oil 
and marine fish. Although these sources generally represent an excess of n-3 PUFA, 
bioavailability might change with the form provided (e.g. free fatty acids, ethyl esters, TG or 
embedded in a food matrix) (Lawson & Hughes, 1988b). Additionally, the time point of 
supplying the PUFA diets may be an important factor for the outcome of the study 
(Ramakers et al., 2008). As a preventive approach, the feeding of diets prior to colitis 
induction could exert different effects when compared with a therapeutic approach, in 
which the diets are fed when colitis is already present (Ramakers et al., 2008). An 
important factor is the dose of the supplemented n-3 PUFA. Trebble et al. (2003) 
demonstrated that the production of the pro-inflammatory cytokines TNFα and IL6 by 
cells appear to follow a ‘U-shaped’ dose response when n-3 PUFA supplementation was 
present. In this study, the supplementation of dietary fish oil in healthy humans resulted 
in a significantly decreased TNFα and IL6 production of the peripheral blood 
mononuclear cells at the lowest level (0.3 g n-3 PUFA per day). A maximum inhibition 
was observed at intermediate levels (1.0 g n-3 PUFA per day), but the least inhibition at 
highest supplementation levels (2.0 g n-3 PUFA per day). Thus, the dose of the dietary n-3 
PUFA may considerably influence the outcome of n-3 PUFA supplementation studies 
(Trebble et al., 2003). A possible explanation for the observations might be found in the 
molecular mechanisms by which n-3 PUFA influences cell function, i.e. altered eicosanoid 
synthesis, signal transduction or gene expression. It is hypothesised that those 
mechanisms have maximum effects at different intake levels of n-3 PUFA and thus a ‘U-
shaped’ dose–response curve results (Trebble et al., 2003).  
 




Fish is high in protein, low in saturated fat and it provides high amounts of n-3 PUFA (He, 
2009). Therefore, as part of a healthy lifestyle, fish should be consumed at least twice per 
week, and one of these servings should be oily fish (Kris-Etherton & Hill, 2008; Scientific 
Advisory Committee on Nutrition/Committee on Toxicity, 2004). The underlying molecular 
mechanisms by which salmon-containing diets influence intestinal inflammation are not 
well known. In Il10–/– mice, pure EPA can reduce colon inflammation and regulate gene and 
protein expression involved in various pathways (Knoch et al., 2009), leaving a unique 
dietary signature. A genome-wide approach can be applied with the use of ‘omics’-
technologies – transcriptomics (gene expression analysis) and proteomics (protein 
expression analysis) – to identify metabolic pathways and key gene/protein regulatory 
‘hubs’ which are responsive to n-3 PUFA-enriched diets, and through which anti-
inflammatory effects are exerted. A metabolomic approach can be used to identify 
metabolites in mouse urine and plasma samples that are influenced by the n-3 PUFA-
enriched diets. These metabolites could serve as biomarkers for future human clinical 
intervention studies to assess the effect of these diets non-invasively. Future studies need to 
determine if the dietary intake of salmon is more beneficial than fish oil (mixture of n-3 
PUFA) or single n-3 PUFA (i.e. DHA or EPA). Further, if the intake of fish has anti-
inflammatory effects, can these be attributed to DHA or EPA, a combination, or synergistic 
effects with other nutrients?  
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(Ramakers et al., 2008). As a preventive approach, the feeding of diets prior to colitis 
induction could exert different effects when compared with a therapeutic approach, in 
which the diets are fed when colitis is already present (Ramakers et al., 2008). An 
important factor is the dose of the supplemented n-3 PUFA. Trebble et al. (2003) 
demonstrated that the production of the pro-inflammatory cytokines TNFα and IL6 by 
cells appear to follow a ‘U-shaped’ dose response when n-3 PUFA supplementation was 
present. In this study, the supplementation of dietary fish oil in healthy humans resulted 
in a significantly decreased TNFα and IL6 production of the peripheral blood 
mononuclear cells at the lowest level (0.3 g n-3 PUFA per day). A maximum inhibition 
was observed at intermediate levels (1.0 g n-3 PUFA per day), but the least inhibition at 
highest supplementation levels (2.0 g n-3 PUFA per day). Thus, the dose of the dietary n-3 
PUFA may considerably influence the outcome of n-3 PUFA supplementation studies 
(Trebble et al., 2003). A possible explanation for the observations might be found in the 
molecular mechanisms by which n-3 PUFA influences cell function, i.e. altered eicosanoid 
synthesis, signal transduction or gene expression. It is hypothesised that those 
mechanisms have maximum effects at different intake levels of n-3 PUFA and thus a ‘U-
shaped’ dose–response curve results (Trebble et al., 2003).  
 




Fish is high in protein, low in saturated fat and it provides high amounts of n-3 PUFA (He, 
2009). Therefore, as part of a healthy lifestyle, fish should be consumed at least twice per 
week, and one of these servings should be oily fish (Kris-Etherton & Hill, 2008; Scientific 
Advisory Committee on Nutrition/Committee on Toxicity, 2004). The underlying molecular 
mechanisms by which salmon-containing diets influence intestinal inflammation are not 
well known. In Il10–/– mice, pure EPA can reduce colon inflammation and regulate gene and 
protein expression involved in various pathways (Knoch et al., 2009), leaving a unique 
dietary signature. A genome-wide approach can be applied with the use of ‘omics’-
technologies – transcriptomics (gene expression analysis) and proteomics (protein 
expression analysis) – to identify metabolic pathways and key gene/protein regulatory 
‘hubs’ which are responsive to n-3 PUFA-enriched diets, and through which anti-
inflammatory effects are exerted. A metabolomic approach can be used to identify 
metabolites in mouse urine and plasma samples that are influenced by the n-3 PUFA-
enriched diets. These metabolites could serve as biomarkers for future human clinical 
intervention studies to assess the effect of these diets non-invasively. Future studies need to 
determine if the dietary intake of salmon is more beneficial than fish oil (mixture of n-3 
PUFA) or single n-3 PUFA (i.e. DHA or EPA). Further, if the intake of fish has anti-
inflammatory effects, can these be attributed to DHA or EPA, a combination, or synergistic 
effects with other nutrients?  
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